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ABSTRACT
Cancer is the second leading cause of death in the developed world. However despite 
significant advances in chemotherapy during the latter half of the 20th Century, the 
impact on mortality has been modest. There is therefore a profound need for the 
identification of novel strategies to treat cancer. The DNA replication licensing 
pathway, which co-ordinates the decision to initiate DNA replication, has recently 
emerged as a potential anti-cancer target. The early dysregulation of the replication 
licensing machinery during tumourigenesis suggests that agents targeting this 
pathway may have high efficacy in tumour cells. However, the response of normal 
cells to such agents must also be considered.
Here I show that withdrawal of cells from the mitotic cell cycle into the out-of-cycle 
states of quiescence and differentiation is tightly coupled to down-regulation of the 
DNA replication licensing machinery. Importantly, stem/progenitor cells of self- 
renewing tissues display an unlicensed replication phenotype. These results indicate 
that normal out-of-cycle functional, differentiated and stem/progenitor cell 
populations will be refractory to agents targeting the replication licensing machinery. 
Rapidly proliferating normal cell populations can suffer severe genotoxic and 
cytotoxic damage in response to chemotherapy. Here I show that inhibition of origin 
licensing in normal proliferating cells invokes the reversible activation of a putative 
origin licensing checkpoint which stalls cells in G1 until the block to origin licensing 
is removed, thereby protecting cells from damage. In contrast, transformed cells 
respond to inhibition of origin licensing by inducing apoptosis, suggesting that origin 
licensing inhibitors may represent highly specific cancer killing agents.
Finally, I have utilised a cell-free DNA replication and chromatin-binding assay to 
analyse the biochemical properties of two potential lead compounds: the endogenous 
origin licensing repressor geminin and a viral pathogen HPV1 E4. Collectively, these 
studies reinforce the concept that the inhibition of DNA replication licensing 
represents a novel chemotherapeutic strategy to combat cancer.
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CHAPTER ONE 
INTRODUCTION
Over the past decade our understanding of the biological, genetic and molecular 
aspects of neoplastic disease has vastly increased. A plethora of studies have 
established that the underlying event in tumour formation and progression, the 
acquisition of the capacity for uncontrolled growth, results from multiple activating 
and inactivating mutations which uncouple the checkpoint pathways regulating 
transition through the cell cycle and the signalling transduction pathways 
coordinating mitogenic and anti-proliferative signals. However these advances 
arguably so far have not translated into greatly improved therapeutic strategies for 
the treatment of cancer and although some progress has been made, the impact on 
mortality rates has been modest and the 'magic bullet' of chemotherapy still remains 
elusive.
The complex, branched and often redundant nature of signalling pathways regulating 
transition through the cell cycle ensures that dysregulation can occur through a 
variety of different mutations at all levels of signal transduction and that the genetic 
status of malignant cells covers a very broad spectrum, with subgroups of single 
tumour types often having widely different genetic backgrounds. For this reason 
therapies which target upstream signalling pathways are often effective in only a 
small subset of patients, and are highly susceptible to the evolution of drug-resistant 
tumour clones. At the convergence point of these signalling pathways is the 
commitment to initiate DNA replication, a critical step in growth control. Unlike the 
branched, parallel and redundant signal transduction pathways, there appears to be 
only a single mechanism of initiation of DNA replication that is highly conserved in
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all eukaryotic species studied, making this pathway a potentially attractive target for 
therapeutic intervention.
In the work of this thesis I have analysed the regulation of DNA replication initiation 
in examples of normal human tissues to predict how these tissues might respond to 
therapeutic agents targeting this pathway. In addition I have investigated mechanisms 
by which DNA replication initiation could be inhibited and, using an in vitro DNA 
replication assay, I have biochemically characterised two potential protein candidates 
for the development of lead compounds: an endogenous inhibitor of DNA 
replication, geminin, and a pathogenic viral inhibitor, HPV1 E4. Finally, I have 
exploited a novel delivery system to investigate the differential effect of inhibiting 
DNA replication initiation in normal and transformed mouse and human cell lines. 
Taken together these studies provide compelling evidence for the concept that 
inhibition of the DNA replication initiation pathway provides a potent anti­
proliferative strategy. In this Chapter the literature relevant to this work is reviewed, 
focussing in the first part on current strategies for chemotherapy and in the second 
part on the DNA replication initiation pathway and its potential as a therapeutic 
target.
1.1. Treatment of cancer
In the developed world about one in three people will develop cancer over their life 
time and approximately one in four will die from the disease (Jemal et al., 2006). 
The mainstays of cancer treatment are surgery, radiotherapy and chemotherapy, with 
successful treatment generally involving a multidisciplinary approach, integrating 
these treatments to take advantage of the strengths of each one. Surgery is the longest
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established treatment for cancer, and the principle hope of cure for most solid 
tumours. It is primarily used when cancer is localised but, in combination with other 
therapies, can also play an important role in treatment of tumours which show 
metastasis on presentation. Radiotherapy, like surgery, is most successful for 
treatment of localised tumours. Chemotherapy is a systemic treatment which can be 
used to kill tumour cells throughout the body. It is therefore an essential mode of 
treatment for metastatic disease. The success of chemotherapy is inversely related to 
the tumour cell burden, and it therefore can prove most effective when used as an 
adjuvant therapy after eradication of bulk tumour masses with surgery or 
radiotherapy. Chemotherapeutic treatments have developed significantly since their 
first introduction into clinical use in the 1940’s. However since 90% of cancer deaths 
are a result of metastases (Spom, 1996), the continued enhancement of 
chemotherapeutic regimes is critical to improving cancer mortality rates.
1.2. The origins of chemotherapy
While the modem era of cancer chemotherapy began following World War n, the 
origins of cancer treatment can be traced back to ancient times. Both the Ebers 
papyrus and the Edwin Smith papyrus describe malignant diseases and their 
treatments, whilst Celsus and Leonides reported the use of mastectomy in Roman 
times. In the first century A.D. Dioscorides compiled a list of herbs and botanicals 
for treatment of tumours and carcinomas, many of which remained in use until the 
16th century (Reviewed in Papac, 2001). The first demonstration of effective 
chemotherapy for malignant disease is considered to be the use of potassium arsenite 
to treat chronic myelogenous leukaemia in 1865 by Lissauer (Papac, 2001), a 
strategy which remained in use until the 1930s (Forkner, 1938) and, more recently,
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was established as an effective treatment for acute promyelocytic leukaemia (Shen et 
al., 1997; Soignet et al., 1998). The beginnings of the modem era of chemotherapy 
can be traced directly to the discovery of nitrogen mustard as an effective treatment 
for cancer in 1942 (Gilman, 1963). The effects of nitrogen mustard were first noted 
in autopsy findings from soldiers dying of exposure to sulphur mustard gas during 
World War I (Krumbhaar, 1919), with subsequent studies on animal models 
indicating the potential use of nitrogen mustard for cancer therapy (Adair and Bagg, 
1931). However, it wasn’t until May 1942 that the first chemotherapy clinical trial 
began with nitrogen mustard treatment of a patient suffering from non-Hodgkin’s 
lymphoma. The response of the patient was striking and although the remission only 
lasted a few weeks before disease again progressed, the principle was established that 
drugs could be administered systemically to induce tumour regression (Gilman, 
1963). The pioneering work of Alfred Gilman with nitrogen mustard led to the 
clinical use of the first chemotherapeutic alkylating agent and ultimately to the 
production of a range of compounds with similar modes of action. This breakthrough 
catalysed the search for other strategies to treat cancer and over the following 50 
years many new 'classical’ chemotherapeutic strategies were developed, the majority 
acting by inhibiting nucleic acid synthesis or function. More recently, as our 
understanding of the biological, molecular and genetic aspects of neoplastic disease 
has increased, a new chemotherapeutic strategy has emerged in the form of targeted 
therapy.
1.3. Classical chemotherapeutic strategies
‘Classical’ chemotherapeutic agents have provided the mainstay of cancer treatment 
during the last 50 years (Table 1.1). In general, these agents act by targeting
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Table 
1.1. 
Classical 
chem
otherapeutic 
strategies. 
Overview 
of 
the 
classes 
of 
classical 
chem
otherapeutic 
agents, the 
com
pounds 
in 
clinical 
use, 
their 
mode 
of 
action, principle toxicities and 
m
echanism
s of resistance.
Class of 
compound
Examples of compounds in clinical use Mode of action Principle toxicities Mechanisms of resistance
Alklyating agents Nitrogen mustards e.g. Mechlorethamine 
Nitrosoureas e.g. Carmustine 
Aziridines e.g. Thiotepa
DNA alkylation leading to 
DNA interstrand cross­
links
Nausea, vomiting, alopecia, bone 
marrow depression, renal damage, 
development of secondary 
malignancies
Increased chug inactivation, 
enhanced repair of drag-induced 
defect
Anti-metabolites Anti-folates e.g. Methotrexate 
Anti-purines e.g. 6-mercaptopurine 
Anti-pyrimidines e.g. Ftorafur, cytarabine
Inhibition of nucleotide 
synthesis, incorporation 
into DNA and RNA
Neurotoxicity, bone-marrow 
depression, renal failure
Overexpression/mutation of target 
enzymes (e.g. DHFR, thymidylate 
synthase), altered drag transport
Anti-tumour 
antibiotics
Actinomycins e.g. Dactinomycin 
Anthracyclins e.g. Doxombicin, Bleomycin 
Anthraeenediones e.g. Mitoxantrone
DNA intercalation, 
inhibition of 
topoisomerase II, 
generation of free radicals
Cardiotoxicity, myelosuppression, 
immunosuppression, nausea, 
vomiting, secondary neoplasms
P-glycoprotein amplification, 
decreased topoD activity, increased 
DNA repair, increased glutathione 
peroxidase activity
Topoisomerase
inhibitors
Topoisomerase I inhibitors e.g. topotecan 
Topoisomerase n inhibitors e.g. etoposide
Inhibition of 
topoisomerase I/II
Myelosuppression, nausea and 
diarrhoea, mucositis
Decreased intracellular drag 
accumulation, overexpression or 
mutation of topoisomerase
Platinum agents Cisplatin, carboplatin Formation of intrastrand 
crosslinks
Nephrotoxicity, peripheral 
neuropathy, ototoxicity, 
mylosuppression
Increased drag inactivation, 
enhanced repair of drag-induced 
defect
Microtubule
inhibitors
Vinca alkaloids e.g. vinblastine, vincristine 
Taxanes e.g. paclitaxel, docetaxel
Destabilisastion/ 
stabilisation of 
microtubules
Neurotoxicity, myelosuppression P-glycoprotein amplification, 
alterations in microtubule-polymer 
levels and dynamics, dysregulation 
of the mitotic spindle checkpoint
Endocrine therapy Anti-oestrogens e.g. Tamoxifen 
Progestins e.g. Medroxyprogesterone acetate 
Glucocorticoids e.g. Cortisol
Stimulation/inhibition of 
hormone-mediated cellular 
activities
Tumour flare, impotence, 
gynecomastia, secondary 
neoplasms
Reduced intra-cellular drag levels, 
induction of growth factor receptors 
and second messenger systems 
allowing transcription in the presence 
of low level hormones
Immunotherapy Microorganisms e.g. Bacillus Calmette- 
Gu&in (BCG)
Interferons, Interleukins, Tumour necrosis 
factor
Activation of immune 
responses
Sepsis, leukopenia, respiratory 
failure, hypertension, toxic 
fatalities in up to 10% of patients, 
angina, multi-organ malfunction, 
thrombocytopenia, CNS toxicity, 
impairment of renal function,
Impairment of adaptive immune 
response, for example by blocking 
the maturation and function of APCs 
and causing alterations in T-cell 
signal transduction and function. 
Expression of membrane 
complement regulatory proteins
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physiological processes that are essential for cell proliferation, in particular DNA 
synthesis. For example, the anti-cancer activity of nitrogen mustards and other 
alkylating agents is coupled to the ability of these compounds to covalently interact 
with DNA and induce DNA damage (Roberts et al., 1968; Thomas et al., 1978; 
Erikson et al., 1980; Garcia et al., 1988; see also Appendix A, Table A.1). Other 
agents which inhibit tumour growth by interfering with nucleotide synthesis or 
function include anti-metabolites (Farber et al., 1948; Weiss and Pitot, 1974; 
Ahluwalia et al., 1990; Allegra et al., 1990; Chu et al., 1990; Schweitzer et al., 1990; 
Iwaniec et al., 1991; Jonsson and Kamen, 1991; Montford and Weichsel, 1997; 
Szekeres et al., 1997; Uribe-Luna et al., 1997; Danenberg et al., 1999; see also 
Appendix A, Table A.2), anti-tumour antibiotics (Reich et al., 1962; Lown et al., 
1984; Tewey et a l , 1984; Twentyman, 1984; Bowden et al., 1985; Glisson et al., 
1986; Wang et al., 1987; see also Appendix A, Table A.3), topoisomerase inhibitors 
(Liu, 1989; Schneider et al., 1990; Lorence and Nessler, 2004), and platinum 
compounds (Rosenberg et al., 1965; Pinto and Lippard, 1985; Ozols and Young, 
1991; Rice et al., 1988). In addition, further strategies for inhibiting tumour growth 
were developed in the form of microtubule inhibitors (Jordan et al., 1996; Jordan and 
Wilson, 2004), endocrine therapies (MacGregor and Jordan, 1998; Smith and 
Dowsett, 2003; Swinnen et a l, 2004; Dowsett et al., 2005; Nicholson and Johnston, 
2005; see also Appendix A, Table A.4) and immunotherapies (Masui et al., 1984; 
Vollmers et al., 1985; Roth and Weller, 1999; Tagawa et a l, 2000; see also 
Appendix A, Table A.5). However despite these advances in chemotherapy, the 
impact on mortality has been modest (Landis et al., 1998). This failure to 
dramatically improve survival rates is linked to two common problems associated 
with classical chemotherapeutic strategies: lack of specificity and development of
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resistance.
The objective of cancer chemotherapy is the selective killing or inhibition of growth 
of neoplastic cells, leaving normal cells undamaged. In general, however, anti-cancer 
drugs lack specificity due to the dearth of consistent biochemical differences between 
normal cells and cancer cells that can be exploited for therapeutic intervention. The 
majority of classical chemotherapeutic strategies act by damaging DNA, based on 
the concept that sufficient amounts of DNA damage will inevitably kill cancer cells 
(Haince et al., 2005). Treatment with these agents relies on two assumptions; firstly 
that tumour cells proliferate more rapidly than normal cells and therefore incur 
higher levels of DNA damage, and secondly that tumours have defective checkpoint 
pathways and are thereby less able to respond to and repair DNA damage. However 
the assumption that all tumour cell populations proliferate more rapidly than normal 
cells does not always hold true. Tumours characterised by low growth fractions, for 
example chronic lymphocytic leukaemia, cycle considerably more slowly than many 
normal cell populations, particularly those in the gastrointestinal and haemopoetic 
systems which proliferate very rapidly (Keyomarsi and Pardee, 2003). These normal 
cell populations are therefore more sensitive to treatment than the tumour cell 
population, leading to loss of the therapeutic index. This results in debilitating side 
effects which may escalate to dose-limiting toxicities, including gastrointestinal 
toxicity, nausea, vomiting, and diarrhoea when the epithelial lining of the intestine is 
affected, alopecia when the hair follicles are affected, and marrow suppression and 
neutropenia when the haematopoetic precursors are affected (Ramirez et al., 1972; 
Legha et al., 1976; Wilson, 1978; Smith, 1989). In addition, these agents are 
frequently associated with the development of secondary neoplasms due to sublethal
University College London 24
Evaluation of the DNA replication licensing machinery as an anti-proliferative target. Sarah Kingsbury
DNA damage in healthy tissue (Haince et al., 2005). Limiting the dose of 
chemotherapeutic agents to reduce these side-effects can allow tumour cells to 
escape treatment and develop drug resistance, for example by the upregulation of 
DNA repair mechanisms (Cleton, 1995). The problems of toxicity and resistance can 
be illustrated by examining the activity of some classical chemotherapeutic agents.
Alkylating agents are so-called due to their ability to react in a manner such that an 
alkyl group or a substituted alkyl group becomes covalently linked to cellular 
constituents, a process called alkylation (Price, 1975; see also Appendix A, Table 
A.1). The most common sites for alkylation are the N7 and O6 positions of guanine, 
often leading to the formation of DNA interstrand cross-links. Although alkylation of 
DNA decreases its ability to act as a template for DNA synthesis (Ruddon and 
Johnson, 1968; Roberts et al., 1971), the cytotoxicity of alkylating agents directly 
correlates with the ability of the agent to form interstrand crosslinks (Roberts et al., 
1968; Thomas et al., 1978; Erikson et al., 1980; Garcia et al., 1988). Alkylating 
agents can react with the DNA of both proliferating and resting cells, but they are 
most cytotoxic to rapidly proliferating cells (van Putten and Lelieveld, 1971), 
presumably because resting cells have an extended period in which to repair the 
DNA damage. They are generally considered to be cell-cycle-phase non-specific 
although there is some evidence to suggest that the cytotoxic effects are more severe 
when exposure occurs during S phase (Roberts et al., 1968). As a result, alkylating 
agents are extremely toxic to rapidly proliferating normal tissues, invoking a number 
of side effects including nausea, vomiting, bone marrow depression and alopecia 
(Ramirez et al., 1972; Legha et al., 1976; Wilson, 1978; Smith, 1989). Alkylating 
agents are also associated with the production of secondary malignancies, most
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commonly acute leukaemia (Penn, 1976; Tucker et al., 1988), due to errors in the 
repair of DNA damage (Allan and Travis, 2005).
A second class of classical chemotherapeutic compounds which show severe 
cytotoxic effects is the anti-tumour antibiotics (see also Appendix A, Table A.3). As 
with alkylating agents, anti-tumour antibiotics exert their effects by interacting with 
DNA, with reduction in DNA binding linked to a loss or reduction of anti-tumour 
activity. Since anti-tumour antibiotics can interfere with the DNA strand breakage- 
reunion reaction of topoisomerase II (Tewey et al., 1984), cytotoxicity is also 
directly linked to topoisomerase II activity (Glisson et al., 1986; Pommier et al., 
1986). In addition some anti-tumour antibiotics, in particular the anthracylines, can 
precipitate the formation of active oxygen species that can cause single-strand DNA 
breakages (Muindi et al., 1985). Unlike alkylating agents, anti-tumour antibiotics are 
generally cytotoxic to cells in any phase of the cell cycle, and are equally toxic to 
cycling and resting cells (Bhuyan et al., 1977). Consequently extremely severe 
adverse effects are associated with their use, including nausea, vomiting, ulceration 
of the oral mucosa and gastrointestinal tract, alopecia and severe acneiform skin 
lesions (O’Bryan et al., 1977). The major and dose-limiting toxicity is usually 
myelosuppression which is manifested as leukopenia (Frei III, 1974). Anti-tumour 
antibiotics can also potentiate the effects of irradiation (Cassady et al., 1975), and are 
immunosuppressive, carcinogenic and mutagenic agents (Svoboda et al., 1970; 
Marquardt et al., 1976; Vecchi et al., 1976). Both the cytotoxicity and 
carcinogenicity of anti-tumour antibiotics can be attributed to the generation of DNA 
double-strand breaks (DSBs). These adducts are particularly difficult to process and 
can be repaired incorrectly, resulting in mutational events that can contribute to
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therapy-induced carcinogenesis (Allan and Travis, 2005). In addition, the inhibition 
of topoisomerase activity often creates DSBs that are capable of participating in gene 
translocation (Richardson and Jasin, 2000). A further side effect associated with 
some anti-tumour antibiotics, particularly anthracyclines, is severe cardiotoxicity 
(Lenaz and Page, 1976). This heart failure has been linked to myocardial cell 
degeneration, which is probably a result of the drug-induced production of reactive 
oxygen species (Lefrak et al., 1973).
The reaction of cancer patients to chemotherapy can be highly influenced by variable 
genetic backgrounds, with approximately 7% of patients affected by extreme adverse 
drug reactions (Marsh and McLoed, 2004; Candelaria et al., 2005). For example, 
tolerance of the anti-purine agents azathioprine, methotrexate and other 
mercaptopurines, which are mainly used for the treatment of childhood leukaemia 
(Relling et al., 1999), is directly linked to the genetic background of the patient. 
Anti-purines, a sub-class of the anti-metabolite compounds, block the synthesis of 
ribo- and deoxyribonucleotides through inhibition of de novo purine synthesis, and 
can be incorporated into both RNA and DNA (Weiss and Pitot, 1974; Maybaum et 
al., 1987; Iwaniec et al., 1991; Uribe-Luna et al., 1997). Thiopurines are sometimes 
referred to as “self-limiting” drugs, since incorporation into DNA is decreased when 
total DNA synthesis is inhibited by a reduction in purine synthesis (Matsumura et al., 
1983). Due to the increased activity of the purine synthesis pathway in cycling cells 
(Jackson et al., 1975), thiopurines demonstrate toxicity in normal proliferating 
tissues and are typically associated with nausea, vomiting and bone-marrow 
depression. Severe liver damage, haematuria and crystalluria (Shorey et al., 1968; 
Duttera et al., 1972), and the development of secondary malignancies due to loss of
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DNA-mismatch repair (DNA-MMR) (Sobulo et al., 1997) have also been reported. 
Interestingly the expansion or retraction of microsatellite sequences (microsatellite 
instability), which is diagnostic of abrogated DNA-MMR, is detected in up to 90% of 
therapy-related leukaemias, but is very rare in de novo leukaemias (Ben Yehuda et 
al., 1996; Zhu et al., 1999; Sheikhha et al., 2002; Worrilow et al., 2003). Severe 
adverse reaction to thiopurines is governed by the activity of the thiopurine 
methyltransferase enzyme (TPMT), which inactivates the drug (McLeod et al., 
2000). TPMT activity is highly variable and polymorphic in all large populations 
studied to date: approximately 90% of individuals have high activity, 10% have 
medium activity and 0.3% have low or no detectable enzyme activity (Weinshilboum 
and Sladek, 1980; McLeod et al., 1995). Patients with TPMT deficiency have higher 
intracellular levels of thiopurine nucleotides, leading to the development of severe 
and often fatal haematopoietic toxicity when treated with conventional doses of 6- 
mercaptopurine (6-MP; Lennard et al., 1989; Evans et al., 1991; McLeod, 1995; 
Black et al., 1998; Relling et al., 1999). However, these patients can be safely treated 
with lower doses of 6-MP. In contrast, patients with very high levels of TPMT form 
suboptimal levels of intracellular thioguanine nucleotides and hence the therapeutic 
effects are compromised. The introduction of pharmacogenetic screening has 
provided a strategy for overcoming this problem (Roses, 2001; McLeod and Siva, 
2002; Marsh and McLeod, 2004; Lee et al., 2005). The reaction of patients to 
thiopurine treatment can be predicted by either assaying TPMT activity in 
erythrocytes (Weinshilboum et al., 1978) or by determining the TPMT genotype 
using genomic DNA (Ottemess et al., 1997), thereby allowing safe starting doses to 
be established. There is however still some debate as to the logistical and economical 
viability of routine testing. Only one in 300 individuals are homozygous for TPMT
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deficiency and thus genotyping of 300 patients is needed for the detection of a single 
null carrier (Sadee and Dai, 2005).
Although the toxic side effects of classical chemotherapeutics can potentially be 
managed by lowering the dosage of the drug that is used for treatment, in reality this 
only serves to exacerbate the second problem associated with these agents, namely 
the evolution of drug-resistant tumour clones (Cleton, 1995). Drug resistance can be 
defined as a state of insensitivity, or decreased sensitivity, of a population of 
neoplastic cells to drugs that ordinarily cause cell death (Wooley and Tew, 1988). 
This resistance can be either intrinsic, i.e. the tumour is insensitive to the drug at first 
presentation, or acquired. It is generally accepted that acquired drug resistance is the 
most common reason for the failure of drug treatment in cancer patients with initially 
sensitive tumours (Skipper and Schabel, 1978; Kim and Tannock, 2005). Resistance 
to chemotherapeutic agents may occur either by mutational events or by gene 
amplification, and can confer resistance to a single agent or to multiple drugs.
Multi-drug resistance (MDR) is normally the result of amplification of the MDR1 
gene, which encodes the membrane transporter protein P-glycoprotein (Pgp) (Gros et 
al., 1986a,b; Ueda et al., 1987). Pgp is expressed at low levels in a variety of tissues, 
and at higher levels in kidney, liver, pancreas, small intestine, colon and adrenal 
gland, with these latter tissues displaying an intrinsic resistance to some classical 
chemotherapeutics (Cordon-Cardo et al., 1990; Thiebaut et al., 1987; Chaudhury and 
Roninson, 1991). Cancers derived from tissues which normally show low expression 
of Pgp can acquire increased levels of the protein following treatment (Kohno et a/., 
1989), particularly when treatment involves anti-tumour antibiotics (Diddens et al.,
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1987), topoisomerase inhibitors (Rasheed and Rubin, 2003) and microtubule 
inhibitors (Geney et al., 2002). Overexpression of Pgp results in increased drug 
efflux, thereby lowering the intracellular concentration of the drug and reducing 
sensitivity to treatment (Endicott and Ling, 1989; Gottesman and Pastan, 1993).
Multi-drug resistance can also occur if different drugs, through perhaps different 
mechanisms, influence a common enzymatic reaction that is required for their killing 
effect. In this instance, alterations in the activity or level of that enzyme may yield 
resistance to multiple drugs. For example, a number of anti-cancer drugs rely on 
topoisomerase-II activity for their killing effects. Anti-tumour antibiotics (e.g. 
doxorubicin, daunorubicin) interfere with the DNA strand breakage-reunion reaction 
of topoisomerase II (Tewey et al., 1984), whilst topoisomerase-II inhibitors [e.g. 
etoposide (VP-16), teniposide (VM-28) and amsacrine (m-AMSA)] act by inhibiting 
the relegation of cleaved DNA complexes, leading to DNA double-strand breaks, 
illegitimate recombination and enhanced mutational rates (Schneider et al., 1990). 
Resistance to both classes of drugs can therefore be caused by decreased 
topoisomerase activity (Pommier et al., 1986) or expression of topoisomerase 
isoforms with altered catalytic activities (Sullivan et al., 1989).
Similarly, the cytotoxicity of several classes of drugs (e.g. nitrosoureas, nitrogen 
mustards, platinum compounds) is coupled to their ability to form covalent adducts 
with DNA (Roberts et al., 1968, 1971; Ruddon and Johnson, 1968; Thomas et al., 
1978; Erikson et al., 1980; Pinto and Lippard, 1985; Garcia et al., 1988; Rice et al.,
1988). Mammalian cells repair these adducts using the excision repair pathways 
(Regan and Setlow, 1974), the activities of which may be a significant factor in the
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development of resistance to these agents (Ewig and Kohn, 1977; Eastman and 
Schulte, 1988; Hampson et al., 1997). In addition to increased excision repair 
activity, tumour cells may also develop resistance to these agents through increased 
drug inactivation due to reaction with cellular thiols (Meister, 1988). Glutathione 
reacts with the electrophilic derivatives of these agents and detoxifies them (Behrens 
et al., 1987), thereby preventing the delayed formation of DNA cross-links from 
drug:DNA monoadducts (Micetich et al., 1983). Consequently increased levels of 
glutathione-S-transferase, which catalyses the conjugation of electrophilic 
compounds with glutathione (Arrick and Nathan, 1984), or increased glutathione 
content (Behrens et al., 1987), confers resistance to these agents.
In addition to the mechanisms of resistance described above, reduced sensitivity to 
chemotherapy can occur in a variety of ways, including decreased conversion of drug 
to an active form, decreased affinity of target enzyme or receptor for drug, increased 
drug inactivation, decreased intracellular drug levels, and failure to apoptose (Table 
1.2; Kessel et al., 1965; Wolpert et al., 1971; Ewig and Kohn, 1977; Sirotnak et al., 
1981; Washtien, 1982; Micetich et al., 1983; Arrick and Nathan, 1984; Goldenberg 
and Begleiter, 1984; Pommier et al., 1986; Behrens et al., 1987; Berger et al., 1988; 
Eastman and Schulte, 1988; Meister, 1988; Sinha et al., 1989; Srimatkandada et al., 
1989; Dicker et al., 1990; Grem, 1990; Rasheed and Rubin, 2003). One class of 
compounds which is associated with the development of many different types of 
drug resistance, and for which resistance has emerged as a particular problem, are the 
anti-metabolites (Baneijee et al., 1995). Anti-metabolites act by interfering with the 
normal cellular metabolism of nucleic acids and fall into three categories: anti­
folates, anti-purines and anti-pyrimidines (Allegra et al., 1990). Resistance to anti-
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Table 
1.2. M
echanism
s 
of drug 
resistance 
to 
classical chem
otherapeutic 
agents.
Summary 
of 
the 
m
echanism
s 
by 
which 
resistance 
to 
classical 
chem
otherapeutic 
agents 
can 
develop, and 
exam
ples of agents for which 
these 
m
echanism
s have 
been 
dem
onstrated.
Mechanism of resistance Examples of classes of drug for which mechanism has been demonstrated
Decreased intracellular drug level 
due to increased drug efflux
Anti-tumour antibiotics, 
microtubule inhibitors, 
topoisomerase inhibitors
Amplification of P-glyCOprotein (Diddens etal., 1987; Geney et al., 
2002; Rasheed and Rubin, 2003)
Decreased intracellular drug level 
due to decreased inward transport
Anti-metabolites (Kessel eta l., 1965; Sirotnak et al., 1981)
Alkylating agents (Goldenberg, 1975)
Increased drug inactivation Alklyating agents Increased levels of glutathione-S-transferase (Arrick and Nathan, 
1984; Meister, 1988)
Anti-tumour antibiotics Increased glutathione activity (Sinhaeta l., 1989)
Platinum compounds Increased glutathione content (Micetich eta l., 1983; Behrens et al., 1987)
Decreased conversion of drug to an 
active form
Anti-metabolites Deficiency of thymidine kinase (Grem, 1990)
Altered amount of target enzyme or 
receptor
Anti-pyrimidines Increased expression (Washtien, 1982) or structural alterations 
(Berger eta l., 1988) of thymidylate synthase
Anti-purines Deletion of HPRTase (Woipert et al., 1971)
Decreased affinity of target enzyme 
or receptor for drug
Anti-metabolites, 
topoisomerase inhibitors
Structural mutations that diminish drug binding (Snmatkandada et 
al., 1989; Dicker et al., 1990; Rasheed and Rubin, 2003)
Enhanced repair of drug-induced 
defect
Alkylating agents, 
platinum compounds
Increased excision repair activity (Ewig and Kohn, 1977; Eastman and 
Schulte, 1988)
Decreased activity of enzyme 
required for killing effect
Anthracyclines, 
microtubule inhibitors
Decreased topoisomerase activity (Pommiereta l., 1986)
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metabolites can take the form of either inherent or intrinsic cellular resistance, with 
tumours presenting with low drug sensitivity at the start of treatment or acquired 
resistance, with both having a major impact on treatment failure (Moscow, 1998; 
Mader et al., 1998). One of the first anti-metabolites to be developed for clinical use 
was methotrexate, (4-amino-10-methyl-folic acid, MTX), an anti-folate compound 
which is used for the treatment of a range of neoplastic diseases including breast 
cancer, osteogenic sarcoma and leukaemias (Jonsson and Kamen, 1991; Stoller et al., 
1977). MTX is a potent inhibitor of dihydrofolate reductase (DHFR), a key enzyme 
for intracellular folate metabolism. Inhibition of DHFR results in depletion of the 
tetrahydrofolate pool and cessation of de novo purine and thymidine nucleotide 
production, ultimately causing impairment of DNA synthesis and repair, and the 
accumulation of DNA strand breaks (Allegra et al., 1990; Schweitzer et al., 1990). 
The effectiveness of MTX treatment is dependent upon decreased intracellular 
accumulation and alterations to DHFR, with at least four different resistance 
mechanisms known to occur (Bertino et al., 1996; Gorlick et al., 1997). MTX is 
primarily transported into cells via the same specific, saturable system as natural 
reduced folates (Goldman et al., 1968), a pathway which is often altered in MTX 
resistant cells both in vitro (Kessel et al., 1965) and in in vivo animal tumour models 
(Sirotnak et al., 1981). Moreover, alterations to this pathway have been identified in 
acute lymphocytic leukaemia patients, indicating that decreased transport of MTX 
into cells is a common resistance mechanism (Trippett et al., 1992; Gorlick et al.,
1997). Reduced intracellular accumulation of MTX has also been coupled to 
impaired polyglutamylation. Long-chain polyglutamates of MTX have an equal 
affinity for DHFR, but are transported out of the cell more slowly than MTX 
monoglutamates (Goldman and Matherly, 1985). Tumours displaying an intrinsic
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resistance to MTX, including acute nonlymphoblastic leukaemia (Gorlick et al., 
1996), commonly show reduced levels of MTX polyglutamates compared to 
sensitive tumours (e.g. acute lymphoblastic leukaemia), suggesting that impairment 
of polyglutamylation is a significant factor in the development of clinical MTX 
resistance (Lin et al., 1991; Goker et al., 1993; Goker et al., 1995). Aside from 
reduced intracellular drug concentration, resistance to MTX has also been linked to 
alterations to the target enzyme DHFR. Amplification of the DHFR gene, which may 
be catalysed by loss of wild-type p53 function (Livingstone et al., 1992; Yin et al., 
1992; Goker et al., 1995) has been linked to MTX resistance both in vitro (Carman et 
al., 1984; Ozols and Cowan, 1986; Schimike, 1988) and in relapsed acute 
lymphoblastic leukaemia (Goker et al., 1995). In addition, structural mutations that 
diminish methotrexate binding to DHFR have been identified in vitro 
(Srimatkandada et al., 1989; Dicker et al., 1990).
The lack of specificity of classical chemotherapeutic agents and the evolution of drug 
resistance have prevented these compounds from having a high impact on cancer 
survival rates. Indeed, although a large percentage of patients with disseminated 
disease experience at least relief from symptoms, classical cancer chemotherapies are 
only curative for a small subset of human cancers. Furthermore, despite the advent of 
supportive measures, such as the use of antibiotics to prevent infections in 
neutropaenic patients (Pizzo, 1984) and platelet transfusion to ameliorate the lethality 
of bone-marrow suppression (Freireich et al., 1959; Gaydos et al., 1962), the 
potential of some cytotoxic drugs to cause leukaemia, in addition to long-term effects 
on the lungs, heart and reproductive organs, remain formidable barriers and have 
become increasingly important as patients are cured of their primary tumours
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(Burstein and Winer, 2000). There is therefore a profound need to identify novel 
targets or strategies to treat cancer whilst protecting the host. Two approaches to 
protect normal cells against the toxic effects of chemotherapeutics can be envisioned. 
Firstly, normal proliferating cells can be targeted by cytostatic agents to inhibit their 
proliferation. Tumour cells with defective checkpoint pathways should be refractory 
to these agents and will continue cycling, leaving them susceptible to other agents 
(Blagosklonny and Pardee, 2001; Keyomarsi and Pardee, 2003). Secondly, tumour 
cells can be targeted differentially by the identification of novel targets that are 
specific to the cancer cell population.
1.4. Targeted therapy
Over the last decade our understanding of the biological, genetic and molecular 
aspects of neoplastic disease has vastly increased, leading to the establishment of 
targeted therapy (Ross et al., 2004; Bell and Ryan, 2005; Thiery-Vuillemin et al., 
2005). However this is a far from straightforward concept. As summarised recently 
by Hahn and Weinberg: “For those who believe in the simplification and 
rationalization of the cancer process, the actual course of research on the molecular 
basis of cancer has been largely disappointing. Rather than revealing a small number 
of genetic and biochemical determinants operating within cancer cells, molecular 
analyses of human cancers have revealed a bewilderingly complex array of such 
factors” (Hahn and Weinberg, 2002). As a result, identifying novel targets for 
chemotherapy is a complicated process, and these targets must fulfil a number of 
criteria. The ideal cancer target can be defined as a macromolecule that is crucial to 
the malignant cancer phenotype but is not expressed significantly in vital organs and 
tissues (Ross et al., 2004). In addition the target should have biological relevance
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that can be measured reproducibly in clinical samples, be definably correlated with 
clinical outcome, and when therapeutically targeted yield a significant clinical 
response in patients expressing the target but not in those patients whose tumours do 
not express the target (Ross et a l , 2004).
Despite the vast array of mutations which can result in tumour progression, 
ultimately the successive accumulation of mutations provides cells with six 
characteristics that collectively dictate malignant growth and have been defined as 
the ‘hallmarks’ of neoplastic disease: self-sufficiency in growth signals, insensitivity 
to growth-inhibitory signals, evasion of programmed cell death (apoptosis), limitless 
replicative potential, sustained angiogenesis, and tissue evasion and metastasis 
(Hanahan and Weinberg, 2000). Consequently, the majority of targeted therapies 
have been developed to interfere with these processes and thereby selectively inhibit 
the growth of cancer cells (Table 1.3; Ross et al., 2004; Bell and Ryan, 2005; Thiery- 
Vuillemin et al., 2005). However despite the development of a large number of 
targeted therapies, the impact on cancer mortality has been modest, and many of 
these agents have proved disappointing due to poor efficacy, limited response, toxic 
side effects, and the development of resistance.
A limitation of many targeted therapies is the requirement for a particular tumour 
genotype for toxicity. Cancer is a highly complex disease with the genetic status of 
malignant cells covering a very broad spectrum, and human tumours of any given 
histological type having great genetic diversity. Therefore, although directly 
targeting physiological processes that are dysregulated in tumour cells (e.g. cell cycle 
regulation, growth signalling pathways, apoptosis) appears to overcome the problem
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Targeted 
chem
otherapeutic 
strategies. 
Table 
showing 
the 
six 
m
ain 
classes 
of 
targeted 
chem
otherapeutic 
strategies, designed 
to 
interfere 
with 
the 
six 
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arks of neoplastic 
grow
th.
Class of 
compound
Example of 
Target
Drug Drawbacks
Cell cycle 
inhibitors
CDK Flavopiridol Low anti-tumour activity, severe side effects (Losiewicz e ta l., 1994; 
Senderowicz, 2000; Knockaeit et al., 2002)
Kinesin-like 
spindle protein
SB-715992 Poor selectivity (Burris et al., 2004; Chu et al., 2004)
Aurora A VX-680, hesperidin Loss of function mutations in Aurora A can cause centrosome 
amplification and tetraploidisation and therefore risk of secondary 
neoplasms (Anand et al., 2003; Hauf et al., 2003; Harrington et al., 2004)
Signal transduction 
inhibitors
EGFR Gefitinib, erlotinib Narrow efficacy, high incidence of resistance (Lynch et al., 2004; Paez et 
al., 2004; Pao and Miller, 2005)
ERBB2 Herceptin Narrow efficacy, high incidence of resistance, severe cardiac 
toxicity (Hudelist et al., 2004; Emens, 2005)
Bcr-Abl Gleevac Limited response, high incidence of resistance (Kantaijian et al., 2000; 
Sawyers et al., 2000; Talpazef al., 2000; Drucker, 2001; Drucker et al., 2001a,b; 
Gone eta l., 2001)
Apoptosis
modulators
Bcl-2 Oblimersen sodium 
(Genasense)
Modest responses to treatment, major relapses, severe toxicities 
(Chapman et al., 1999; O’Brian et al., 2001; Rai et al., 2004; Chanan-Khan et al., 
2004; Gleave and Monia, 2005)
p53 ONYX-015, Ad5CMV-p53 Poor clinical response (Reid et al., 2001; Vasey et al., 2002; Hamid et al., 2003; 
Hecht et al., 2003; Zeimet and Marth, 2003)
Angiogenesis
inhibitors
VEGF/VEGFR Bevacizumab, DC 101 Severe toxicity, high incidence of resistance due to expression of 
multiple angiogenic proteins (Relfer al., 1997; Eggert et al., 2000; Keibel and 
Folkman, 2002; Uehara, 2003; Abdollahi et al., 2005; Folkman, 2005)Integrin Vitaxine
Anti-invasive
agents
MMP Marimastat, col-3, batimastat Poor efficacy, dose-limiting toxicities (Coussens et al., 2002; Elvin and 
Gamer, 2005)
Inhibitors of 
immortalisation
hTERT/hTR BIBR1532, GRN163L Poor Specificity (Kim et al., 1994; Rezler et al., 2002; Masutomi et al., 2003; 
Kelland, 2005)
Telomerase AS1410
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which may account for the differential response in patients. As a result of the 
response in this subset of patients, gefitinib has been approved for the treatment of 
NSCLC patients, whilst trials are ongoing for treatment of head and neck small cell 
carcinoma (HNSCC), gastrointestinal cancer and breast cancer. However, even with 
the correct genetic background many patients still prove unresponsive. Further 
targeted therapies which show a limited spectrum of action include Gleevac™ (also 
known as Glivac, imatinib mesylate and ST 1571), an inhibitor of the activated 
tyrosine kinase activity of the Bcr-Abl protein (Druker et al., 1996; Druker and 
Lydon, 2000), and Herceptin (trastuzamab), a recombinant monoclonal antibody that 
targets the human epidermal growth factor receptor-2 (HER-2) and which relies on 
overexpression of HER-2/neu (Slamon et al., 2001; Emens and Davidson, 2004; 
Hudelist et a l , 2004; Emens, 2005; Neyt et al., 2005).
In addition to illustrating the problem associated with the narrow range of efficacy of 
many targeted therapies, tyrosine kinase inhibitors are also a prime example for the 
development of drug resistance which has emerged as a major clinical problem for 
targeted therapies (Hynes and Lane, 2005). As discussed for classical 
chemotherapeutic strategies, drug resistance can occur through a variety of different 
mechanisms. However, a particular problem with many targeted therapies is the 
position of these targets on complex signalling pathways. The signal transduction 
network that drives cellular growth and proliferation is extremely complex with 
many branched, redundant, and parallel pathways. Consequently drug resistance can 
rapidly develop, allowing the circumnavigation of blocked pathways by the 
activation of redundant, parallel signalling pathways (Dai et al., 2004). Moreover, 
just as sensitivity to some kinase inhibitors requires a mutation within the kinase
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domain (Pao et al., 2005b), resistance to kinase inhibitors can be incurred by a single 
mutation in the active site of the kinase which prevents the drug from inhibiting 
kinase activity. For example, acquired resistance of lung adenocarcinomas to 
gefitinib is associated with a second mutation in the EGFR kinase domain (Pao et al., 
2005a). Therefore in addition to the small proportion of patients who are initially 
responsive to these therapies, there is also a significant clinical problem with the 
rapid development of resistance to tyrosine kinase inhibitors, with nearly all patients 
who initially show remission following treatment eventually suffering progression of 
the disease (Kantaijian et al., 2000; Talpaz et al., 2000; Drucker, 2001; Drucker et 
al., 2001a,b; Gorre et al., 2001; Kute et al., 2004; Lan et al., 2005; Pao and Miller, 
2005).
Cyclin Dependent Kinase inhibitors (CDKIs) are another example of a targeted 
therapy which was expected to have a huge impact on cancer treatment, but which 
has shown disappointing results in clinical development. Aberrant expression of 
cyclins has been causally linked to the development of a variety of tumours (Schauer 
et al., 1994; Lonardo et al., 1999; Buolamwini, 2000), suggesting that agents 
targeting these proteins may give tumour specificity (Cohen, 1999; Sausville, 2000; 
Knockaert et al., 2002; Senderowicz, 2003; Vermeulen et al., 2003; Schwartz and 
Shah, 2005). However since CDKs are involved in many physiological processes 
with many different substrates (S&nchez and Dynlacht, 2005), CDKIs lack specificity 
and invoke severe toxic side effects (Sausville et al., 1998, 2001; Fuse et al., 1998). 
This is further exacerbated by the significant cross-talk that occurs between signal 
transduction pathways, so that targeting one cascade may block or stimulate an 
unrelated cascade and therefore have multiple and unpredictable effects on cell cycle
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modulation (Senderowicz, 2004). A CDK inhibitor that is currently undergoing 
clinical trial is flavopiridol, a flavonoid that interacts with the ATP-binding pocket of 
CDKs (Losiewicz et a l, 1994). Although flavopiridol inhibits the proliferative 
potential of a broad range of different cell lines, human tumours, leukaemias and 
lymphomas (Drees et al., 1997; Parker et al., 1998), and showed some activity in 
phase I trials of patients with Hodgkin's lymphoma, renal, colon and gastric 
malignancies (Senderowicz et al., 1998, 1999; Tan et al., 2002), it did not show 
significant anti-tumour activity as monotherapy in phase II trials in several epithelial 
tumours (Senderowicz, 2000). In addition, the specificity of flavopiridol, and other 
synthetic CDKIs (e.g. UCN-01, CYC202, BMS-387032, roscovitine) remains a 
limiting factor, with patients in phase I and II clinical trials experiencing severe side- 
effects (Sausville et al., 1998, 2001; Fuse et al., 1998). Other questions have been 
raised about the validity of targeting CDKs as a therapeutic strategy. For example, 
the activity of several of these agents depends on the expression of critical 
downstream regulators that must be present to induce cell cycle arrest (e.g. an intact 
pRb pathway is required in the case of a CDK4 inhibitor; Fry et al., 2001), whilst 
recent studies have suggested that inhibition of single CDKs may not be sufficient to 
induce cell cycle arrest (Tetsu and McCormick, 2003). So on the one hand decreased 
specificity may be important for improving cytotoxicity, but on the other hand this 
decreased specificity is likely to cause increased side-effects and lower the dose- 
limiting toxicity threshold.
The success of chemotherapy relies on the ability of cytotoxic agents to induce 
apoptosis in target cells. Alteration of the components of the apoptotic machinery can 
dramatically affect the dynamics of tumour progression (Kerr et a l, 1972), whilst
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aberrant cell death is a presumptive mechanism of resistance to current neoplastic 
therapy where the desired result, apoptosis of malignant cells, does not occur 
(Hickman, 1996). Strategies for restoring the apoptotic machinery may therefore 
provide a mechanism to induce tumour cell apoptosis and tumour regression, and to 
overcome resistance to current cytotoxic therapies (Senderowicz, 2004; Ghobrial et 
a l, 2005). The pro-apoptotic regulator p53 is the most frequently inactivated gene in 
human cancers (Olivier et a l, 2002), with mutations present in more than 50% of 
human cancers (Hollstein et a l, 1994). Since loss of p53 has been linked to the 
development of resistance, restoration of p53 function may provide a mechanism for 
overcoming drug resistance (Perona and S&nchez-P6rez, 2003). Currently a number 
of p53-gene therapies are under clinical development including ONYX-015 and 
Ad5CMV-p53. ONYX-015 (dll520), a replication competent adenovirus that lacks 
the ELB 55K gene which neutralises p53, is only able to replicate in cells with 
deficient p53 activity. Interactions between ONYX-015 and the p53 pathway cause 
cancer cells lacking p53 to induce viral replication and apoptose (Heise et a l, 1997). 
However the specificity of ONYX-015 for p53-deficient cells remains controversial 
(Goodrum and Omelles, 1998; Rothman et a l, 1998; Harada and Berk, 1999; Tumell 
et a l, 1999; Dix et a l, 2001), whilst phase I/II trials in a range of tumours have 
proved unsuccessful, with no objective clinical response seen in any patient treated 
with ONYX-015 as a single agent (Khuri et a l, 2000; Nemunaitis et a l, 2001; Reid 
et a l, 2001; Vasey et a l, 2002; Hamid et a l, 2003; Hecht et a l, 2003). Similarly 
disappointing results were obtained in phase I/II clinical trials of Ad5CMV-p53, with 
no improvement in effectiveness and increased toxicity compared to traditional 
treatments (Zeimet and Marth, 2003). Failure of p53 gene therapy may occur for a 
number of reasons, including inoptimal gene transfer, insufficient p53 expression
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leading to cell cycle arrest as opposed to induction of apoptosis (Vousden and Lu,
2002), requirement for downstream factors (e.g. Bax, Fas, PTEN) (Wolf et al., 2001) 
and inhibition of exogenous wild-type p53 by endogenous mutant p53 (de Vries et 
al., 2002).
Despite the development of a large number of novel chemotherapeutic strategies 
during the last decade, there are still many hurdles in cancer treatment that have yet 
to be overcome. The agents presented here represent some of the more successful 
and more highly developed chemotherapeutic strategies currently in 
preclinical/clinical development and in clinical use. In addition many other 
chemotherapeutic strategies are currently undergoing investigation and evaluation, 
and new targets are continually sought. Examples of such strategies include 
angiogenesis inhibitors (Relf et al., 1997; Eggert et al., 2000; Kerbel and Folkman, 
2002; Uehara, 2003; Abdollahi et al., 2005; Folkman, 2005), anti-invasive agents 
(Coussens et al., 2002; Nakajima et al., 2003; Sattler et al., 2003; Ertongur et al., 
2004; Lombardo et al., 2004; Elvin and Gamer, 2005), inhibitors of immortalisation 
(Kim et al., 1994; Neidle and Parkinson, 2002; Rezler et al., 2002; Shay and Wright, 
2002; Masutomi and Hahn, 2003; Hsu and Lin, 2005; Kelland, 2005), DNA damage 
response modifiers (e.g. PARP inhibitors; Bryant et al., 2005; Farmer et al., 2005; 
Graziani and Szabo, 2005; Haince et al., 2005; Madhusen and Middleton, 2005) heat 
shock protein 90 (Hsp90) inhibitors (Neckers, 2002; Sreedhar et al., 2004), 
proteasome inhibitors (Adams, 2002a,b), histone deacetylase inhibitors (Das and 
Singal, 2004; Thiery-Vuillemin et al., 2005), statins (Thiery-Vuillemin et al., 2005) 
and carbohydrate ligands (e.g. modified pectin; Nangia-Makker et al., 2002). The 
majority of these strategies are currently only in very early stages of development
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and hence a more comprehensive discussion of these agents is beyond the scope of 
this introduction.
1.5. The DNA replication licensing pathway -  a novel diagnostic 
and therapeutic target?
The initiation of DNA replication is a crucial decision point in cell proliferation that 
lies at the convergence point of all oncogenic and mitogenic signalling transduction 
pathways that drive proliferation, and hence is of fundamental importance in 
tumourigenesis. The DNA replication licensing pathway can therefore be regarded as 
a relay station providing a molecular switch to couple growth regulatory pathways 
with the initiation of chromosomal replication. Tumour progression can be catalysed 
by a vast array of activating and inactivating mutations occurring at all levels of 
these signal transduction pathways, presenting a major challenge for the development 
of effective diagnostic and therapeutic strategies due to the complexity of addressing 
multiple individual mutations for each tumour type and subtype. However the 
position of the DNA replication licensing pathway at the convergence point of 
growth transduction pathways may provide a reductionist solution to this problem. 
At a diagnostic level it can be postulated that the initiation of DNA replication 
should provide a set of cancer biomarkers that are applicable to a broad range of 
tumours independent of genetic background. Similarly, the initiation of DNA 
replication may provide an attractive therapeutic anti-cancer target since the 
mutational status of upstream signalling components should have no implication on 
the action of agents targeting this highly evolutionary conserved process. Such 
agents therefore have the potential to provide an effective therapeutic strategy for a 
wide range of tumour types and subtypes with varying genetic backgrounds.
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Moreover, targeting DNA replication initiation should prove less susceptible to the 
evolution of drug resistant clones that can arise due to the branched, parallel and 
redundant nature of growth regulatory pathways. Importantly, inhibiting the initiation 
of DNA synthesis should minimize collateral damage to the DNA, eliminating the 
risk of genomic damage and therefore circumventing the problems of infertility and 
further neoplastic transformation associated with the use of DNA damaging agents 
and drugs which interfere with elongation DNA synthesis. A further criterion which 
must also be considered is the specificity of therapeutic agents targeting DNA 
replication initiation, especially given that DNA replication is essential to all 
dividing cells and that agents targeting elongation DNA synthesis are known to 
invoke severe toxic effects in normal cells. However, prior to addressing this issue I 
will first provide an overview of the DNA replication licensing pathway.
1.5. h  Licensing o f  DNA
The precise duplication of DNA once, and only once, during each cycle of cell 
proliferation is central to maintaining eukaryotic genome integrity. The initiation of 
chromosomal replication is therefore tightly regulated by the DNA replication 
licensing pathway. During late M and early G1 phase DNA is ‘licensed’ for 
replication by the ordered assembly of DNA replication licensing factors (ORC, 
Cdc6, Cdtl and Mcm2-7) into pre-replicative complexes (pre-RCs), so termed 
because they generate a characteristic footprint prior to replication initiation (Diffley 
et a l , 1994), at origins of replication (Figure 1.1). These licensed origins are 
subsequently fired at different times during S phase by the concerted action of S- 
phase promoting CDKs and the Dbf4ASK-dependent Cdc7 kinase (DDK), leading to 
the initiation of chromosomal replication (Figure 1.1).
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Figure 1.1. The DNA replication licensing pathway. During late M phase and 
early G1 phase pre-replicative complexes (pre-RCs) are assembled in a stepwise 
manner at origins of replication. The origin recognition complex (ORC) recruits 
Cdc6 and Cdtl, which in turn load multiple copies of the Mcm2-7 complex onto 
chromatin forming the pre-RC. During the G l-S phase transition the pre-RC is 
converted to a pre-initiation complex (pre-IC) allowing DNA replication to be 
initiated. Phosphorylation of MCM proteins by Cdc7-Dbf4 and S phase-promoting 
CDKs triggers a conformational change in the MCM complex that is required for 
unwinding of DNA and allows recruitment of further initiation factors Mem 10 and 
Cdc45. The MCM loading factors Cdtl and Cdc6 are removed from the origin and 
the origin licensing repressor geminin, which interacts with Cdtl, is expressed to 
prevent re-loading of pre-RCs. Finally replication protein A (RPA) and DNA 
polymerase a-primase are recruited to the origin and DNA replication is initiated.
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Replication origins are determined, at least in part, by the binding of the six subunit 
origin recognition complex (ORC), which is conserved in evolution from yeast to 
humans (Bell and Stillman, 1992; Diffley et al., 1994; Bell et al., 1995; Gavin et al., 
1995; Gossen et al., 1995; Muzi-Falconi and Kelly, 1995; Carpenter et al., 1996; 
Leatherwood et al., 1996; Rowles et al., 1996). In budding yeast, ORC binds 
specifically to the S. cerevisiae ACS (ARS [automonously replicating sequence] 
consensus sequence) (Bell and Stillman, 1992), an 11 bp AT-rich sequence element 
which together with two or three stimulatory elements (B1-B3) forms the core of the 
replicator (Marahrens and Stillman, 1992). ORC binding is also mediated by short 
AT-rich elements in S. pombe (Okuno et al., 1999; Segurado et al., 2003), although 
no well-defined consensus sequence has been identified (Kim and Huberman, 1998). 
No consensus sequences for ORC binding have been identified in higher eukaryotes 
either, with human ORC capable of binding functionally to any DNA sequence 
(Vashee et al., 2003; Schaarschmidt et a l, 2004). Instead origin selection in higher 
eukaryotes appears to be influenced by chromatin and nuclear structure, with no 
requirement for specific sequence information (DePamphilis, 1999; Lucas et al., 
2000; Blow et al., 2001; Aggarwal and Calvi, 2004; Remus et al., 2004). In Xenopus 
egg extracts, for example, initiation occurs at regular intervals of approximately 10 
kb (Lucas et al., 2000; Blow et al., 2001) whilst in Drosophila ORC binds 
preferentially to negatively coiled DNA (Remus et al., 2004). In mammalian cells 
replication can occur within replication ‘zones’ that vary in size from 6 to 55 kb 
(Dijkwel and Hamlin, 1995) and are dependent on chromatin and nuclear structure, 
sharing little sequence similarity except for the presence of AT-rich elements and 
DNA unwinding elements (DUE) (DePamphilis, 1999). This definition of origins by 
chromatin structure and epigenetic factors has been proposed to provide an
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evolutionary advantage since the genome can sustain genetic alterations without 
concern for losing origins in the process (Gilbert, 2001). Moreover, the epigenetic 
specificity of origins may provide a mechanism by which different programmes of 
gene expression can be established and controlled during development (Mechali, 
2001).
Approximately 30,000 origins are postulated to exist in the mammalian genome 
(Todorovic et al., 1999); however the number of licensed origins exceeds the number 
of origins activated in each cell cycle due to the assembly of pre-RCs at both active 
and silent origins (Santocanale and Diffley, 1996; Walter and Newport, 1997). This 
acts to ensure that the entire genome is replicated even if some origins fail to initiate, 
with silent origins activated if neighbouring origins fail to fire (Santocanale et al., 
1999; Vujcic et al., 1999). In the absence of these secondary origins failed initiation 
events would likely result in replication errors, in particular replication fork stalling 
due to forks having to traverse much larger distances. In S. cerevisiae, for example, 
removal of ARS elements eventually results in chromosome loss, presumably 
because replication is not completed during S phase (Dershowitz and Newlon, 1993). 
The mechanism that determines which origins fire is not clear, and is likely 
influenced by a combination of factors including chromosomal context and 
epigenetic elements (Gilbert, 2001).
Although the process of origin selection is vastly different amongst eukaryotes, the 
process of licensing is highly conserved. During G1 ORC acts as a landing pad for 
the recruitment of Cdc6 and Cdtl to origins of replication, which in turn load the 
Mcm2-7 heterohexameric complex onto chromatin. The helical structure of Mcm2-7,
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and its location around the DNA has led to speculation that ORC and Cdc6 might act 
as an ATP-dependent clamp-loader. This is supported by the presence of ATP 
binding sites (Walker A motifs) in Orel, Orc4, Orc5 and Cdc6, and ATP hydrolysis 
sites (Walker B motifs) in Orel, Orc4 and Cdc6 (Bell et al., 1995; Loo et al., 1995; 
Klemm et al., 1997; Perkins and Diffley, 1998; Weinreich et al., 1999). Mutagenesis 
studies indicate that ATP binding is required for the association of ORC and Cdc6 
with DNA (Chesnokov et al., 2001; Klemm and Bell, 2001), whilst ATP hydrolysis 
is essential for loading of the Mcm2-7 putative helicase (Gillespie et a l, 2001; 
Harvey and Newport, 2003).
Several lines of evidence suggest that Mcm2-7 acts as the replicative helicase during 
S phase. Studies in Xenopus and mammalian cells have established that MCMs are 
present on chromatin during G l, are displaced during DNA replication and are 
absent from chromatin during G2 (Chong et al., 1995; Kubota et al., 1995; Madine et 
al., 1995a,b). Although recruited by ORC, Cdc6 and Cdtl, MCM proteins do not 
remain associated with ORC once bound to the chromatin (Aparicio et al., 1997) and 
probably move away from the origin after firing (Ritzi et al., 1998; Labib et al., 
2000). Indeed once the Mcm2-7 complex has been loaded at origins of replication 
ORC, Cdc6 and Cdtl are no longer required for the initiation of DNA replication 
(Donovan et al., 1997; Hua and Newport, 1998; Rowles et al., 1999; Maiorano et al., 
2000; Harvey and Newport, 2003). This indicates that as well as being involved in 
the initial binding and melting of replication origins (Borowiec and Hurwitz, 1988), 
Mcm2-7 may also act as a helicase at the elongation forks (Stahl et al., 1986). 
Further evidence supporting this hypothesis is provided by the conserved NTPase 
motif shared by all MCM proteins, which has sequence similarity to members of the
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DNA helicase family (Koonin, 1993), the weak in vitro helicase activity identified in 
a complex comprised of Mcm4, 6 and 7 (Ishimi et al., 1997; You et al., 1999; Lee 
and Hurwitz, 2000), and the helicase activity observed for the single MCM of the 
archeon Methanobacterium thermoautotrophicum (Kelman et al., 1999; Chong et al., 
2000; Shecter et al., 2000). Initial models for Mcm2-7 activity suggested that two 
complexes were loaded at each origin for bi-directional replication. However, recent 
findings in Xenopus have proposed that multiple MCM complexes are loaded at each 
origin and spread out over the DNA during S phase (Edwards et al., 2002), consistent 
with the observation that the majority of MCM proteins are associated with 
unreplicated DNA (Madine et al., 1995; Krude et al., 1996; Dimitrova et al., 1999).
Precise regulation of pre-RC assembly is ensured through a lack of redundancy 
between pre-RC components and through the strict cell cycle dependent regulation of 
each replication licensing factor. Each pre-RC constituent is essential for the 
initiation of DNA replication, with reduced levels of any component leading to loss 
of replicative capacity and an inability to progress into S phase (Sinha et al., 1986; 
Gibson et al., 1990; Chen et al., 1992; Yan et al., 1993; Kimura et al., 1994; Ray et 
al., 1994; Todorov et al., 1994; Fox et al., 1995; Liang et al., 1995; Madine et al., 
1995; Carpenter et al., 1996; Coleman et al., 1996; Fujita et al., 1996; Rowles et al., 
1996; Detweiler and Li, 1997; Kubota et al., 1997; Lei et al., 1997; Thommes et al., 
1997; Perkins and Diffley, 1998; Yan et al., 1998; Madine et al., 2000; Maiorano et 
al., 2000; Nishitani et al., 2000; Petersen et al., 2000; Tada et al., 2001; Rialland et 
al., 2002; Higa et al., 2003; Cook et al., 2004). Although the process of replication 
licensing is highly conserved from yeast to vertebrates, the regulation of replication 
licensing factors throughout the cell cycle is species dependent. In yeast, for
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example, all ORC subunits remain bound to chromatin through all phases of the cell 
cycle with some subunits undergoing CDK-dependent phosphorylation in S phase 
(Weinreich et al., 2001). In contrast, ORC-chromatin association in mammalian cells 
is highly dynamic. Orel, for example, undergoes ubiquitin-mediated degradation 
during S phase in human cells (Li and DePamphilis, 2002; Mendez et a l , 2002; Li et 
al., 2004) whilst Orc2 relocates to centromeric heterochromatin in mitosis (Prasanth 
et al., 2004). Both Cdc6 and Cdtl accumulate during late mitosis and early Gl, 
producing a peak in nuclear Cdc6 and Cdtl levels prior to pre-RC assembly, (Muzi- 
Falconi et al., 1996; Stoeber et al., 1998; Coverley et al., 2000; Nishitani et al., 2001; 
Rialland et al., 2002). However as with ORC the precise regulation of these proteins 
is species dependent, with protein levels controlled by degradation, inactivation or 
nuclear exclusion (Drury et al., 1997, 2000; Jallepalli et a l, 1997; Saha et al., 1998; 
Elsasser et al., 1999; Fujita et a l, 1999; Petersen et al., 1999; Pelizon et al., 2000; 
Coverley et a l, 2000, 2002; Mendez and Stillman, 2000; Okuno et al., 2001; 
Biermann et al., 2002; Tanaka and Diffley, 2002; Alexandrow and Hamlin, 2004).
Interestingly in addition to their role in co-ordinating the initiation of DNA 
replication, a number of pre-RC components appear to be involved in other processes 
throughout the cell cycle. ORC proteins have been implicated in the silencing of 
gene expression in budding yeast, drosophila and vertebrates (Bell et al., 1993; Fox 
et al., 1995; Huang et al., 1998; Iizuka and Stillman, 1999; Pak et al., 1997) and in 
the co-ordination of chromosome segregation and cytokinesis (Prasanth et al., 2002), 
whilst Cdtl has been implicated in a Gl checkpoint which induces Cdtl proteolysis 
in response to DNA damage (Higa et a l, 2003) and MCM proteins have been 
suggested to be important for damage response, transcription and chromatin
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remodelling (Forsburg, 2004).
In addition to the core pre-RC components, ORC, Cdc6, Cdtl and Mcm2-7, a further 
MCM protein, Mem 10, is also essential for the initiation of DNA replication 
(Solomon et a l, 1992; Merchant et a l , 1997; Aves et al., 1998; Izumi et al., 2000; 
Wohlschlegal et al., 2002; Christensen and Tye, 2003). McmlO interacts with 
Mcm2-7 (Merchant et al., 1997; Homesley et al., 2000; Izumi et al., 2000; Kawasaki 
et al., 2000), as well as Orc2 and Cdc7-Dbf4, and has been suggested to facilitate 
phosphorylation of Mcm2-7 by Cdc7-Dbf4 (Lee et al., 2003). In addition, McmlO is 
required for the loading of Cdc45 onto chromatin (Wohlschlegal et al., 2002b; 
Gregan et al., 2003; Sawyer et al., 2004) and, like Mcm2-7, is essential for 
elongation DNA synthesis (Kawasaki et al., 2000).
1.5.2. Initiation o f DNA replication
Once the components of the pre-RC have been assembled, activation is mediated by 
the concerted action of S-phase specific CDKs and DDK. CDKs act as global S- 
phase promoting factors whilst DDK acts more specifically and has been shown to 
phosphorylate various members of the MCM family in vitro (Lei et a l, 1997; Sato et 
al., 1997; Brown and Kelly, 1998; Jiang et al., 1999; Kumagai et al., 1999; Takeda et 
al., 1999, 2001; Kihara et al., 2000; Masai et a l, 2000; Ishima et a l, 2001), a 
process that may alter the conformation of the MCM complex and allow unwinding 
of the origin DNA structure. Like the pre-RC components, Cdc7 and Dbf4 are 
essential for the initiation of DNA replication (Jares and Blow, 2000; Walter, 2000; 
Kim et a l, 2002) and are subject to precise cell cycle regulation. Cdc7 is expressed 
at constant levels throughout the cell cycle, whilst Dbf4 is expressed during the Gl/S
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transition under the control of the MBF transcription factor (Moll et al., 1992; Iyer et 
al., 2001) and undergoes anaphase-promoting complex (APC)-dependent 
degradation (Oshiro et al., 1999; Weinreich and Stillman, 1999; Ferreira et al., 
2000). Protein synthesis is no longer required for completing S phase once Cdc7 
function has been executed, suggesting that it is the ultimate factor required for the 
initiation of DNA replication.
There is some confusion as to whether DDK or CDK is the first to act during the G l-  
S transition with experiments in different organisms giving conflicting data and some 
even suggesting that CDK may in fact be required to function twice, first to generate 
a pre-activated pre-RC for Cdc7 action and second to activate the replication 
machinery (Jares and Blow, 2000; Masai et al., 2000; Nougerade et al., 2000; 
Walter, 2000). The mechanism by which Cdc7-Dbf4 activates the pre-RC has been 
postulated from the results of two mutations. The mcm5-bobl (Hardy et al., 1997) 
mutation bypasses Cdc7 function whilst a mutation in mcm2 (Lei et al., 1997) which 
prevents its interaction with Dbf4, is suppressed by the dbf4-6 mutation. These 
results suggest that the only essential function of Cdc7-Dbf4 in initiating DNA 
replication is mediated through the MCM complex and that Mcm2 may be the only 
essential target of regulation for Cdc7-Dbf4. It is likely that the MCM complex is 
inactive until it comes into contact with Cdc7-Dbf4, and most probably until Mcm2 
is phosphorylated, and that this phosphorylation causes a conformational change that 
leads to the activation of the MCM complex. The mcm5-bobl mutation may 
therefore alter the structure of Mcm5 in such a way that it constitutively activates 
MCM without the need for Cdc7-Dbf4.
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Phosphorylation of the MCM complex by CDK and DDK results in the recruitment 
of Cdc45 to the origin. Cdc45 is essential for the unwinding of DNA (Walter and 
Newport, 2000; Pacek and Walter, 2004), potentially by inducing a conformational 
change in the MCM complex which leads to activation of its DNA helicase activity 
(Masuda et a l, 2003). Cdc45 has also been implicated in the recruitment of DNA 
replication proteins RPA and DNA polymerase a  (Mimura and Takisawa, 1998; 
Uchiyama et al., 2001) to origins and appears to associate with moving forks 
suggesting that, like MCM, Cdc45 may be essential for elongation as well as 
initiation of DNA replication (Aparicio et al., 1997; Tercero et al., 2000).
The final step in replication initiation is the loading of the replicative polymerases 
DNA pol a, DNA pol 5 and DNA pol e (Waga and Stillman, 1998; Kawasaki and 
Sugino, 2001; Hubscher et al., 2002), which occurs after origin unwinding has been 
stimulated by Cdc45 and RPA binding (Mimura et al., 2000; Walter and Newport, 
2000). A number of factors are necessary for the recruitment of the replicative 
polymerases to replication origins including McmlO (Kawasaki et al., 2000), Cdc45 
(Mimura and Takisawa, 1998; Uchiyama et al., 2001), Sld3 (Kamimura et al., 2001), 
Dpbll (Masumoto et al., 2000; Van Hatten et al., 2002; Hashimoto and Takisawa, 
2003) and GINS (Kubota et al., 2003; Takayama et al., 2003). Once these factors 
have been assembled at replication origins the conversion of pre-RCs to active 
replication forks is complete and DNA replication can commence.
1.5.3. Prevention o f re-replication and genomic instability
In addition to the regulation of DNA replication initiation, tight controls exist to
ensure that each origin is replicated only once during each cycle of cell proliferation,
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with CDKs central to this process (Nguyen et al., 2001). Multiple, redundant 
mechanisms are utilised to achieve the block to origin re-licensing, with many 
components of the pre-RC subject to negative regulation by CDKs. However, the 
precise strategy by which this block is achieved varies between different organisms 
(Feng and Kipreos, 2003). In yeast, for example, Cdc6 undergoes ubiquitin- 
dependent degradation through the SCF complex following CDK-dependent 
phosphorylation (Drury et al., 1997, 2000; Jallepalli et al., 1997; Elsasser et al.,
1999), whilst phosphorylation of MCMs (Labib et al., 1999; Nguyen et a l , 2000) 
and Cdtl (Tanaka and Diffley, 2002) leads to their exclusion from the nucleus and 
phosphorylation of Orc2 prevents it from interacting with Cdc6 (Seki and Diffley,
2000). In metazoans phosphorylated Cdc6 is either transported out of the nucleus 
after S-phase onset (Saha et al., 1998; Fujita et a l, 1999; Petersen et a l, 1999; 
Pelizon et al., 2000) or remains associated with chromatin in an inactive state 
(Coverley et al., 2000, 2002; Mendez and Stillman, 2000; Okuno et al., 2001; 
Biermann et al., 2002; Alexandrow and Hamlin, 2004). Both Cdtl and Orel are 
subject to phosphorylation dependent proteolysis in mammalian cells (Kreitz et al., 
2001; Li and DePamphilis, 2002; Liu et al., 2004; Sugimoto et al., 2004), whilst 
phosphorylation of MCMs decreases their affinity for chromatin (Coue et al., 1996; 
Hendrickson et al., 1996; Fujita et al., 1998) and inhibits helicase activity (Ishimi 
and Komamura-Kohno, 2001). In addition, metazoans have a further mechanism of 
defence in a recently identified endogenous negative regulator of DNA replication, 
geminin (McGarry and Kirschner, 1998).
Geminin is a dual function 23.5 kDa protein that was identified almost 
simultaneously in two separate expression screens; the first for substrates of the APC
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that degraded in mitotic Xenopus egg extracts (McGarry and Kirschner, 1998) and 
the second for proteins involved in neuralisation of Xenopus embryos (Kroll et al,
1998). Geminin is highly conserved in metazoans with homologs identified in 
Drosophila, mouse, humans (Quinn et al., 2001; Yanagi et al., 2002) and 
Caenorhabditis elegans (Yanagi et al., 2005) but none identified so far in yeast. 
Geminin is expressed during S, G2 and M phases of the cell cycle during which time 
it functions to prevent re-replication from fired origins by interacting with Cdtl and 
thereby preventing re-assembly of pre-RCs (Wohlschlegal et al., 2000; Tada et al., 
2001; Yanagi et al., 2002; Cook et al., 2004). At the end of mitosis, geminin 
undergoes CDK-dependent ubiquitination resulting in proteolysis by the 26S 
proteosome and providing a critical geminin-free window in Gl where pre-RC 
assembly can occur (McGarry and Kirschner, 1998) and the next round of replication 
can be initiated (Benjamin et al., 2004).
1.5.4. The DNA replication licensing pathway as an anti-cancer target
As discussed in Section 1.5.1., the constituents of the pre-RC can be regarded as 
relay stations coupling growth regulatory pathways to the initiation of DNA 
replication. The hypothesis that replication licensing factors may be of major 
diagnostic utility is currently being confirmed in a wide range of tumour systems. 
Importantly the DNA replication licensing pathway appears to become dysregulated 
early in multi-step tumour progression. For example, dysregulation of the MCM 
helicase proteins is observed in precursor dysplastic (pre-invasive) lesions of many 
epithelial organ systems including cervix, colon, prostate, oesophagus and bladder 
(Freeman et al., 1999). This is exemplified in Figure 1.2. which shows the expression 
of Mcm2 in normal oesophageal squamous mucosa, oesophageal precursor lesions
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Figure 1.2. Dysregulation of the DNA replication initiation pathway during 
oesophageal tumourigenesis. Oesophageal cancer is divided into two main 
histological subtypes, squamous cell carcinoma and adenocarcinoma, with very 
different risk factors, incidence and molecular biology. Both subtypes of 
oesophageal cancer have precursor lesions. Squamous dysplasia is recognised as a 
premalignant precursor to squamous cell carcinoma and Barrett’s glandular 
metaplasia a precursor for adenocarcinoma. The figure shows indirect 
immunoperoxidase staining of biopsy material from normal oesophageal squamous 
mucosa, oesophageal precursor lesions and the two histological variants of 
oesophageal cancer with an anti-Mcm2 MAb. In normal oesophageal mucosa and 
metaplastic Barrett’s oesophagus, MCM expression is restricted to the proliferative 
compartment with down-regulation occurring as epithelial cells engage the 
differentiation programme and migrate to the surface layers. In contrast the 
dysplastic epithelium characterised by maturation arrest and loss of epithelial 
polarity shows dysregulation of the DNA replication initiation pathway with failure 
to down-regulate the MCM proteins as cells migrate to the superficial differentiated 
compartment. Progression to squamous cancer and adenocarcinoma is characterised 
by strikingly high expression levels of the MCM proteins coupled to development of 
marked nuclear pleomorphism and muclear megaly, the phenotype associated with 
severe aneuploidy.
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and two histological variants of oesophageal cancer. In normal oesophageal mucosa 
and metaplastic Barrett's oesophagus MCM expression is restricted to the 
proliferative compartment. In contrast the dysplastic epithelium shows dysregulated 
MCM expression, whilst squamous cancer and adenocarcinoma show strikingly high 
expression levels of Mcm2. Significantly MCM licensing factors are detected in a far 
greater proportion of tumour cells than conventional proliferation markers such as 
Ki67 or BrdU S phase labelling index, due to the fact that licensing factors can be 
detected in non-cycling cells with proliferative potential (Stoeber et al., 1999, 2001; 
Eward et al., 2004). These unique biomarkers of growth have now been exploited in 
a wide range of tumours, including colorectal cancer (Davies et al., 2002; Scott et al.,
2003), oligodendroglioma (Wharton et al., 2001, 2004), oesophageal squamous cell 
carcinoma (Going et al., 2002; Siriex et al., 2003; Kato et al., 2003; Williams et al., 
2004; Huang et al., 2005), non-small cell lung cancer (Ramnath et al., 2001), renal 
cell carcinoma (Rodins et al., 2002; Dudderidge et al., 2005), cervical carcinoma 
(Williams et al., 1998; Mukheijee et al., 2001), prostate cancer (Meng et al., 2001; 
Ren et al., 2005), genito-urinary tract cancer (Stoeber et al., 1999, 2002), bladder 
cancer (Kruger et al., 2003), ovarian cancer (Scott et al., 2004) and breast cancer 
(Bukholm et al., 2003; Gonzalez et al., 2003; Shetty et al., 2005), as predictive and 
prognostic markers and as molecular tools for cancer screening and surveillance. 
TriPath Imaging®, the leading company in liquid-based cervical screening, is 
currently seeking FDA approval for the use of MCM proteins for automation of 
cervical screening (ProEx™ C) whilst a large CR-UK funded multi-centre trial (UK 
National Cancer Research Network [NCRN] Trial ID 1279) for bladder and prostate 
cancer is currently ongoing.
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Further to their exciting potential as cancer markers, the abundant expression of 
MCM proteins in cancer cells and dysregulation early in tumourigenesis indicates 
that agents targeting the replication licensing machinery may have high efficacy as 
anti-cancer agents. Importantly since aberrant expression of MCM proteins is 
common to a wide range of tumours such agents should provide effective treatment 
for multiple tumour types and subtypes, thus recapitulating the observed extensive 
diagnostic application of MCM proteins. In addition to the potential broad 
application and sensitivity of agents targeting the replication licensing machinery 
these agents should also be non-genotoxic and less susceptible to the evolution of 
resistance than many conventional agents, as discussed in Sections 1.3 and 1.4.
The potential exploitation of the DNA replication licensing pathway as an anti­
cancer target has gained further impetus through a recent study by Shreeram et al, 
which intriguingly suggests that inhibitors of origin licensing may provoke a 
differential response in normal and transformed cell lines (Shreeram and Blow,
2003). In untransformed IMR-90 fibroblast cells, inhibition of origin licensing causes 
a cell cycle arrest associated with elevated p21Cipl levels, low levels of cyclins A and 
E and markedly reduced levels of phosphorylated pRb consistent with cells arresting 
in Gl (Shreeram et al., 2002). In contrast, inhibition of origin licensing in 
transformed Saos2 and U20S cells results in progression into S or G2 phase after 
which cells undergo apoptosis. Transformed U20S cells with intact pRb and p53 
tumour suppressor growth inhibitory pathways undergo early S phase arrest with 
down-regulation of cyclin A and up-regulation of p53 and p21Cipl, consistent with 
activation of an intra-S phase checkpoint. Notably, in a separate study Cdc7 
inhibition by small interfering RNA also revealed a p53-dependent checkpoint that
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appears to be defective in cancer cells (Montagnoli et al., 2004). In contrast, 
transformed Saos2 cells deficient in p53 and pRb undergo a late S and G2/M phase 
arrest with detectable cyclin A, consistent with loss of the intra-S phase checkpoint 
(Shreeram et al., 2002). The differential response to blocking origin licensing in 
these cell lines has raised the hypothesis that a checkpoint may exist in Gl to monitor 
the assembly of pre-RCs at origins of replication. Up to 30,000 origins are postulated 
to exist in the genome (Todorovic et al., 1999), and it can be envisioned that a 
critical number of these must be licensed before cells can proceed into S phase and 
initiate DNA replication (Figure 1.3). Defects in this putative ‘origin licensing 
checkpoint’ may allow the initiation of DNA replication to commence with only a 
subset of these replication origins licensed. In the presence of an origin licensing 
inhibitor cells with a defective checkpoint may move into S phase and attempt to 
replicate their DNA from the few origins which have been licensed (Figure 1.3). In 
these circumstances DNA replication is likely to break down, leading to stalled 
replication forks and in cells with a complete intra-S phase checkpoint inducing an 
apoptotic response, as was observed in U20S cells (Shreeram et al., 2002). However, 
defects in the intra-S phase checkpoint will allow cells to continue through the cell 
cycle, reaching M phase with incompletely replicated DNA. In this circumstance the 
attempt to segregate chromosomes during mitosis will result in the generation of 
DNA double-strand breaks, causing a mitotic catastrophe and the induction of 
apoptosis, as was observed for Saos2 cells (Shreeram et al., 2002). Whether blocking 
origin licensing will generate a similar response in transformed cells with vastly 
different genetic spectrums is currently unknown.
Further to determining the response of transformed cells to origin licensing
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Figure 1.3. A putative origin licensing checkpoint, (a) Under physiological 
conditions cells are able to assemble a sufficient number of pre-RCs at replication 
origins during G l, enabling DNA replication to be initiated in S phase, (b) When 
origin licensing is blocked in normal cells the initiation of DNA replication is 
impeded by activation of a putative 'origin licensing checkpoint' and cells arrest in 
G l. (c) Transformed cells do not arrest in Gl due to a defective 'origin licensing 
checkpoint'. Instead DNA replication is initiated from the few licensed origins, 
leading to DNA damage (e.g. stalled replication forks and double strand breaks 
[DSB]) and apoptosis.
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inhibitors, in order to fully understand how a patient may respond to treatment it is of 
critical importance to ascertain the response of normal cell populations to these 
agents. To this end it is therefore essential to analyse the normal physiological 
regulation of the DNA replication licensing machinery in all normal cell populations, 
including stem/progenitor cell populations, transit amplifying cell populations and 
functional differentiated and quiescent cell populations. Moreover, a further question 
which remains to be answered is whether the Gl arrest observed in normal cells 
following a block to origin licensing is reversible. If normal cells were able to 
recommence proliferation following removal of an origin licensing inhibitor 
cytotoxicity would be significantly reduced and such an agent could be used at much 
higher doses, allowing a greater insult on tumour cells.
Taken together, these combined findings allow the hypothesis to be put forward that 
inhibitors of the replication licensing pathway could potentially provide effective 
non-genotoxic anti-cancer agents for treatment of a wide range of tumours. Notably, 
the existence of a putative origin licensing checkpoint suggests that such agents may 
provide cancer specific cell killing effects.
1.6. Summary and aims of thesis
The DNA replication licensing machinery has recently emerged as a potential target 
for novel therapeutic anti-cancer agents. Dysregulation of the replication licensing 
pathway is an early event in carcinogenesis. However, little is known about the 
regulation of the replication licensing pathway, and in particular the endogenous 
origin licensing repressor geminin, in normal human tissues. In the first part of this 
thesis, I describe a detailed expression analysis of the replication licensing machinery
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in the out-of-cycle states of quiescence and differentiation, which constitute a large 
proportion of normal cells within the body, and in stem cell populations. These 
studies show that withdrawal of cells from cycle into the differentiated and quiescent 
states is tightly coupled to down-regulation of the DNA replication licensing 
pathway, indicating that these cell populations should be refractory to origin 
licensing inhibitors. Extending on these studies, I have carried out early proof-of- 
principle studies to further define the replication licensing machinery as an anti­
proliferative and anti-cancer target. In Chapters Four and Five I describe an in vitro 
biochemical analysis of two potential future lead compounds, mimicking the 
endogenous origin licensing repressor geminin and a pathogenic inhibitor of origin 
licensing, HPVI E4. Finally in Chapter Six, I have utilised a non-degradable 
fragment of geminin and a novel cell delivery system to investigate the differential 
response of normal and transformed cell lines to inhibition of origin licensing. These 
studies show that normal cells respond to origin licensing by reversibly arresting in 
Gl whilst transformed cells proceed through the cell cycle and undergo apoptosis, 
indicating that origin licensing inhibitors should be highly specific anti-cancer agents 
and show little or no toxicity to normal cells. Collectively, the work presented in this 
thesis provides compelling evidence to support the concept that targeting the origin 
licensing machinery provides a potential anti-cancer strategy applicable to a wide 
range of tumour types regardless of their genetic background.
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CHAPTER TWO
MATERIALS AND METHODS
2.1. General
2.1.1. Chemicals and reagents
Unless otherwise indicated all chemicals were obtained from Sigma (St. Louis, MO, 
USA). All solutions were made using deionised water, except where stated, and 
sterilised either by autoclaving at 121°C or passage through a sterile filter (0.22 pm). 
All enzymes and buffers for DNA manipulation were obtained from New England 
Biolabs Inc. (Beverly, MA, USA) or the Promega Corporation (Madison, WI, USA).
2.1.2. Buffers and solutions
4 x  La em lli Sa m ple  B u ffer
Tris-Cl pH 6.8 33 mM
Glycerol
/3-mercaptoethanol 
Bromophenol blue
SDS 3.3% (w/v) 
30% (v/v) 
17% (v/v) 
0.02% (w/v)
5 x  Tr is-G ly c in e  E lec tr o ph o r esis  B u ffer
Tris-base
Glycine
125 mM 
1.25 M 
0.5% (w/v)SDS
C o o m a ssie  B lu e  R-250 S ta in in g  S o lu t io n
Methanol 50% (v/v) 
10% (v/v) 
0.25% (w/v)
Glacial acetic acid
Coomassie Blue R-250
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C o o m a ssie  G el  D e sta in  So lution
Methanol 10% (v/v)
Glacial acetic acid 10% (v/v)
Tr a n sfer  Bu ffer
Tris-base 0.3 M
CAPS 10 mM
SDS 0.02% (w/v)
Methanol 10% (v/v)
G el  Lo a d in g  B u ffer
Glycerol 10% (v/v)
Bromophenol blue 0.025% (w/v)
TE B u f f e r
Tris-HCl pH 8.0 10 mM
EDTA pH 8.0 1 mM
LS B u f f e r
K-HEPES pH 7.8 20 mM
KAc 5 mM
MgCl2 0.5 mM
Dithiothreitol 0.5 mM
SuNaSp
Sucrose 250 mM
NaCl 75 mM
Spermine trihydrochloride 0.5 mM
Spermidine tetrahydrochloride 0.15 mM
20xNPS
(NH4)2S04 0.5 M
KH2P04 1 M
Na2HP04 1 M
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50 x 5052
Glycerol 25% (w/v)
Glucose 2.5% (w/v)
of-lactose 10% (w/v)
Fr a c tio n a tio n /C h ro m a tin -B in ding  Bu ffer  A
HEPES, pH 7.9 10 mM
KC1 10 mM
MgCl2 1.5 mM
Sucrose 0.34 M
Glycerol 10% (v/v)
Triton X-100 0.1% (v/v)
Dithiothreitol 1 mM
Aprotinin 5 pg/ml
Leupeptin 5 pg/ml
Pepstatin A 5 pg/ml
PMSF 0.1 mM
F ractio n a tio n /C h r o m a tin -B in d in g  Bu ffer  B
EDTA 3 mM
EGTA 0.2 mM
Dithiothreitol 1 mM
Aprotinin 5 pg/ml
Leupeptin 5 pg/ml
Pepstatin A 5 pg/ml
PMSF 0.1 mM
E l o n g a t i o n  B u f f e r  A
KC1 60 mM
Tris-HCl pH 7.4 15 mM
NaCl 15 mM
£-mercaptoethanol 1 mM
Spermidine tetrahydrochloride 0.5 mM
Spermine trihydrochloride 0.5 mM
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In  Vit r o  D N A  R e p l ic a t io n  P rem ex B u f f e r
K-HEPES pH 7.8 160 mM
MgCl2 28 mM
ATP 12 mM
GTP 0.4 mM
CTP 0.4 mM
UTP 0.4 mM
dATP 0.4 mM
dGTP 0.4 mM
dCTP 0.4 mM
Biotin-16-dUTP 1 pM
Dithiothreitol 2 mM
Creatine phosphate 160 mM
Phosphocreatine kinase 20 Hg
T o ta l  C ell  Ex tr a c t  B u ffer
Tris-Cl pH 7.5 50 mM
NaCl 150 mM
EDTA 20 mM
NP40 0.5% (v/v)
2,1.3. Culture media
All growth media were sterilised by autoclaving at 121°C for 20 min, and media 
recipes are for 1 litre.
LB b r o t h  T ag arI
Tryptone 10 g
Yeast extract 5 g
NaCl 10g
[Bacteriological (No 1) agar] 15 g
pH 7.0
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2 X TY BROTH TagarI 
Tryptone 
Yeast extract 
NaCl
[Bacteriological (Nol) agar] 
pH 7.0
SOC MEDIUM
Tryptone 
Yeast extract 
NaCl 
KC1
MgCl2.6H20 
MgS04 
Glucose 
pH 7.4
P-0.5G
MgS04
Glucose
20xNPS
ZY
N-Z-amine AS 
Yeast extract
ZYP-5052
ZY
MgS04 
50 x 5052 
20xNPS
University College London
16 g 
10 g
5g 
15 g
2% (w/v) 
0.5% (w/v) 
10 mM 
2.5 mM 
10 mM 
10 mM 
20 mM
1 mM 
40% (w/v) 
5 ml
10 g
5 g
928 ml 
1 mM 
10 ml 
25 ml
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2.1,4. Tissue specimens
Formalin-fixed, paraffin-embedded archival human colon and thyroid tissue blocks 
from diagnostic biopsy or resection specimens were retrieved from the archives of 
the Department of Pathology, University College London, U.K. Ethical approval was 
obtained from the Joint UCL/UCLH Committees on the Ethics of Human Research.
2.2. Molecular biology techniques
2.2.1. Bacterial strains
Genetic manipulations and expression of recombinant proteins were carried out in 
the following strains of Escherichia coli (Table 2.1.):
Table 2.1. Bacterial strains
Bacterial
Strain
Antibiotic
resistance
Partial
genotype
Application Supplier
ToplO - F-recAl endAl DNA cloning Invitrogen
XL 1-Blue Tetracycline F'proAB laclq ZAM15 
TnlO (Tet11)
Site-directed mutagenesis Stratagene
BL21
(DE3)
pLysS
Chloramphenicol F-ompTdcm (DE3) 
pLysS (CamR)
Expression of His^ 
E1AE4, His^ E 1AE4R45A, 
His6ElAE4A44-48
Invitrogen
Rosetta
(DE3)
pLysS
Chloramphenicol Y-ompTdcm lacYl 
(DE3) pLysS pRARE 
(CamR)
Expression of His6- 
fageminin, His$- 
/wgemininANt, H iv  
/wgemininFF
Novagen
2.2.2. Transformation o f E. coli
50 pi aliquots of chemically competent cells were thawed on ice. Purified plasmid 
DNA (1 -  100 ng) was added, mixed gently and incubated on ice for 5 min. Cells 
were heat-shocked in a pre-heated water bath at 42°C for 30 s and chilled on ice for 2 
min. Cells were resuspended in 250 pi of SOC medium, except for XL 1-Blue cells 
where NZY+ broth was used, allowed to recover at 37°C for 1 h with gentle shaking 
and spread over LB agar plates containing the appropriate selection marker(s). Plates 
were incubated overnight at 37°C.
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2.2.3. Plasmid isolation
3-5 ml of LB medium was inoculated with a single bacterial colony and cultures 
grown overnight at 37°C with shaking at 200 r.p.m. Plasmid DNA was isolated using 
the QIAprep spin miniprep kit (Qiagen GmbH, Hilden, Germany) following the 
manufacturer’s protocol and stored in TE buffer at -20°C.
2.2.4. Restriction endonuclease digestion
Digestion of DNA was carried out according to the manufacturer’s protocol for the 
particular restriction endonuclease enzyme. Typically, 50 to 500 ng of DNA was 
digested in a reaction volume of 20 pi containing 10 U of restriction endonuclease 
for 1 h at 37°C.
2.2.5. Dephosphorylation o f linearised vector DNA
Linearised vector DNA was incubated with calf intestinal phosphatase (0.5 U/pg 
vector DNA) for 30 min at 37°C for dephosphorylation of blunt, 3’- or 5’- 
overhanging ends.
2.2.6. Ligation o f DNA
Ligation of insert DNA into plasmid was performed using T4 DNA ligase (Promega, 
Madison, WI, USA). Reactions containing a 3:1 molar excess of insert to vector, 10 
U of T4 DNA ligase and 2 x rapid ligation buffer (Promega) in a final volume of 10 
pi were incubated for 2 h at RT. 5 pi of the reaction mix was transformed into 
chemically competent E. coli.
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2.2.7, Polymerase chain reaction
For cloning PCR products, the 3’-5’ exonuclease proof-reading J^w-ultra DNA 
polymerase (Stratagene, La Jolla, CA, USA) was used to amplify the template. 1-10 
ng of template DNA was mixed in a final reaction volume of 50 pi containing 180 
ng/pl of each oligonucleotide primer, 200 pM dNTPs, 10% lOx DNA polymerase 
buffer and 2.5 U DNA polymerase (2.5 U/pl). Thermocycling was initiated by 
denaturation of the template at 95°C for 3 min, then 30 cycles of template 
denaturation at 95°C for 40 s, primer annealing at 58°C for 40 s and DNA extension 
at 72°C for 25 s. Cycling was completed by a final extension at 72°C for 3 min. 
Blunt-end PCR products were cloned into a pCR-BLUNT II-TOPO vector 
(Invitrogen, Carlsbad, CA, USA), amplified, and subcloned into a pRSETc 
expression vector (Invitrogen). Primer sequences for amplification of His6- 
E1AE4R45A and His6-ElAE4A44-48 are 5 ’-gctagcatggcagataataaagctccc-3 ’ (forward 
nhel primer) and 3 ’-caattgttacacagaccacgggtgg-5 ’ (reverse mfel primer).
2.2.8, Site-directed mutagenesis
Site-directed mutagenesis was performed using the QuikChange XL Site-Directed 
Mutagenesis Kit (Stratagene) according to the manufacturer’s protocol. Briefly, 
reactions were set up containing 5 pi 1 Ox reaction buffer, 100 ng dsDNA template, 
125 ng of appropriate forward and reverse primers, 1 pi dNTP mix, 3 pi 
QuikSolution and DNase/RNase free dl^O to a final volume of 50 pi. Control 
reactions were performed using 10 ng pWhitescript 4.5 kb control template and 
control oligonucleotide primers. 1 pi PJuTurbo DNA polymerase (2.5 U/pL) was 
added to each tube and the reactions cycled using the parameters outlined in Table 
2.2. Following temperature cycling, the reactions were cooled on ice for 2 min and
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parental supercoiled dsDNA digested by incubation with 1 pi Dpn 7(10 U/pl) for 1 h 
at 37°C. Mutagenesis products were transformed into XL 1-Blue competent cells. 
Primer sequences for generation of His6-/wgemininFF are 5’- 
gattaaagaaaatccatcctctcagttttttaaggaagtggcagaaaaacggag-3’ (forward primer; mutated
nucleotides) and 3 ’-ctaatttcttttaggtaggagagtcaaaaaattccttcaccgtctttttgcctc-5 ’ (reverse 
primer).
Table 2.2. Cycling parameters for QuikChange Site-Directed Mutagenesis
Segment Cycles Temperature Time
1 1 95°C 1 min
2 18 95°C 50 s
60°C 50 s
68°C 7 min
3 1 68°C 7 min
2.2.9. Agarose gel electrophoresis
Horizontal gels were cast with agarose concentrations ranging from 0.8 to 1.0% 
(w/v). Solid agarose was mixed with 1 x TAE buffer and heated in a microwave until 
the agarose had fully dissolved. The solution was cooled to about 50°C and 0.075% 
(v/v) gel star (Cambrex Bio Science Rockland Inc., Maine, ME, USA), was added. 
The gel was poured into a gel try, with combs inserted for casting wells, and allowed 
to set for 30 min at RT. Samples were prepared for electrophoresis by mixing with 6 
x gel loading buffer. Electrophoresis was carried out at 1 -  4 V/cm for 30 min. After 
electrophoresis DNA was visualised at 312 nm.
2.2.10. Recovery o f  DNA from agarose gels
DNA fragments were cut from agarose gels using a sterile scalpel. The DNA was 
recovered from the excised gel using the QiaEXII gel extraction kit (Qiagen GmbH) 
following the manufacturer’s protocol.
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2.2.11, DNA sequencing
DNA sequencing was carried out by the Wolfson Institute for Biomedical Research 
Scientific Support Services, UCL, London, UK (http://www.ucl.ac.uk/wibr/services/ 
dna/index.htmO. DNA was sequenced at a concentration of 500 ng/pl and purity of > 
1.8 OD260/OD280 ratio on a Beckman Coulter CEG 8000 DNA Sequencer.
2.3. Protein chemistry methods
2.3.1. Antibodies
Affinity-purified rabbit polyclonal antibodies against /wgeminin (Wharton et al.,
2004) and hsCdtl (Figure 2.1) were generated in-house. Mouse monoclonal antibody 
4.37 against HPV1 E4 proteins (Doorbar et al., 1988) was a kind gift from S. Roberts 
(CR-UK Institute for Cancer Studies, University of Birmingham, UK). The following 
commercially supplied antibodies were used: mouse anti-/tsOrc4 (BD Transduction 
Laboratories, Lexington, KY, USA), mouse anti-/wMcm2/BM28 (BD Transduction 
Laboratories), mouse anti-/«Mcm3 (MBL, Nagoya, Japan), mouse anti-/wMcm5 
(Stoeber et a l , 2002), mouse anti-/zsCdc47/Mcm7 (Neomarkers, Lab Vision, 
Fremont, CA, USA), mouse anti-/wCdc6 (Santa Cruz Biotechnology, Santa Cruz, 
CA, USA), mouse anti-/zsKi67 (Dako, Glostrup, Denmark), mouse anti-/wPCNA 
(BD Transduction Laboratories), mouse anti-mmKipl/p27 (BD Transduction 
Laboratories), mouse anti-raMek2 (BD Transduction Laboratories), rabbit anti- 
AsHistone HI (Santa Cruz Biotechnology), rabbit anti-/wCrml (Santa Cruz 
Biotechnology), mouse anti-His6 (BD Transduction Laboratories), HRP-conjugated 
goat anti-mouse/rabbit IgG (Dako), fluorescein-conjugated goat anti-mouse IgG 
(Dako), fluorescein-conjugated donkey anti-rabbit IgG (Abeam, Cambridge, MA, 
USA), fluorescein-conjugated mouse anti-BrdU (Alexis Biochemicals, Lausen,
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Figure 2.1. Characterisation of a polyclonal Cdtl antibody, (a) Polyclonal 
antibody Cdtl 2660 was raised following inoculation of a rabbit with a fragment of 
Cdtl corresponding to amino acids 237-564. (b) Immunoblot analysis of NIH/3T3 
asynchronous total cell extracts (TCE) and recombinant hsCdtl with ab Cdtl 2660. 
Pre-incubation of the Cdtl 2660 antibody with recombinant Cdtl blocks detection 
of Cdtl in NIH/3T3 and reduces detection of recombinant Cdtl (right panel).
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Switzerland), biotin-conjugated anti-mouse/rabbit ChemMate™ detection kit (Dako).
2.3.2. Protein expression constructs
The following constructs were used for protein expression (Table 2.3):
Table 23. Protein expression constructs
Protein Construct Insert
Size
Cloning
fragment
Expression
system
His6-/tfgeminin pET14b:geminin‘ 1-212 Nhel-BamHI E. coli
His6-/wgemininANt pET 15bTEF: gemininANt2 80-212 Nhel-BamHI E. coli
His6-/wgemininFF pET 14b:gemininFF3 1-212 Nhel-BamHI E. coli
His6-E1AE4 pPRSETc:E 1AE44 1-125 BamHI -  EcoRI E. coli
His6-E1AE4 R45A pRSETc:ElAE4R45A5 1-125 BamHI -  EcoRI E. coli
His6-E1AE4 A44 pRSETc:E 1AE4A44-485 1-121 BamHI-EcoRI E. coli
His6-AreCdc6 pVL1393L-His* 1-554 - Baculoviral
2.3.3. Expression o f recombinant hsgeminin, hsgemininANt and hsgemininFF 
in E. coli
Rosetta (DE3) pLysS bacteria were transformed with the appropriate expression 
construct and grown overnight at 37°C with vigorous shaking in 20 ml of 2 x TY 
medium containing 100 pg/ml ampicillin, 34 pg/ml chloramphenical and 1% 
glucose. The overnight culture was used to inoculate 4 x 500 ml of fresh 2 x TY 
medium, supplemented with 100 pg/ml ampicillin, 34 pg/ml chloramphenical and 
0.25% glucose. Cultures were grown at 30°C with vigorous shaking until the OD600 
reached 0.5. Protein expression was induced with 1 mM IPTG at 37°C for 90 min.
1 A kind gift from A. Dutta, University of Virginia, VA, USA
2 A kind gift from A. Okorokov, Department of Pathology, UCL, UK
3 Generated by site-directed mutagenesis
4 A kind gift from R. Sawa, School of Crystallography, Birkbeck College, London, UK
5 Subcloned from baculovirus expression vectors (kind gifts from S. Roberts, CR-UK Institute for 
Cancer Studies, University of Birmingham, UK)
6 A kind gift from T. Coleman and W. Dunphy (Coleman et al., 1996)
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Cells were harvested by centrifugation at 5,000 g for 20 min, washed in ice cold 
PBS, the wet weight of cells determined and the pellet frozen at -80°C.
2.3.4. Expression o f recombinant HPV1 E1AE4, E1AE4R4SA and E lAE4M4-48 
in E. coli
BL21 (DE3) pLysS bacteria were transformed with the appropriate expression 
construct and grown overnight at 37°C with vigorous shaking in 20 ml of P-0.5G 
medium containing 100 pg/ml ampicillin and 1% glucose. The overnight culture was 
used to inoculate 2 x 500 ml of fresh ZYP-5052 auto-induction medium, 
supplemented with 100 pg/ml ampicillin. Cultures were grown at 37°C for 8-10 h 
with vigorous shaking. Cells were harvested by centrifugation at 5,000 g for 20 min, 
washed in ice cold PBS, the wet weight of cells determined and the pellet frozen at - 
80°C.
Recombinant baculovirus-expressed and purified E1AE4 and AE4 proteins (see 
Chapter 5) were kind gifts from S. Roberts, CR-UK Institute for Cancer Studies, 
University of Birmingham, UK.
2.3.5. Expression o f recombinant XeCdc6 in Sf9 insect cells
Sf9 insect cells were grown in 400 ml of serum-supplemented TMN-FH medium 
(BD Biosciences, San Jose, CA, USA) containing 5 pg/ml gentamycin (Gibco-BRL, 
Invitrogen) in spinner flasks (spin rate 80 to 90 r.p.m.) at 27°C up to a density of 1.5 
x 106 cells/ml. Cells were harvested by centrifugation at 800 g for 5 min, 
resuspended in 50 ml of serum-free Grace’s medium containing 5 pg/ml gentamycin 
and appropriate recombinant baculovirus at 5 M.O.I., and incubated for 2 h at 27°C
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with gentle mixing. The culture was diluted to 400 ml with fresh TMN-FH medium 
and incubated for 48 h at 27°C. Insect cells were harvested by centrifugation at 5,000 
g for 5 min at 4°C, washed in PBS and stored at -80°C.
2.3.6. Purification o f Hise-hsgeminin, Hise-hsgemininANt and Hise- 
hsgemininFF
Bacterial cell pellets were thawed, resuspended in 5 ml Bugbuster protein extraction 
buffer (Novagen, Madison, WI, USA) per gram wet weight, containing bensonase (1 
pl/ml) and 0.02 volumes of complete EDTA-free Protease Inhibitor Cocktail (F. 
Hoffmann-La Roche, Basel, Switzerland), and incubated for 30 min at 4°C. The 
lysate was clarified by centrifugation at 48,000 g at 4°C for 1 h and the supernatant 
filtered through a 0.45 pm syringe filter and loaded via a peristaltic pump onto 2 x 5  
ml NiCb charged HiTRAP chelating columns (Amersham Biosciences AB, Uppsala, 
Sweden). The columns were washed with 5 c.v. of wash buffer (25 mM Tris-Cl pH
7.5, 250 mM NaCl) to remove unbound protein. Non-specifically bound proteins 
were removed with 4 c.v. of 10% elution buffer (25 mM Tris-Cl pH 7.5, 250 mM 
NaCl, 250 mM imidazole) and 8 c.v. of 20 % elution buffer. Geminin was eluted 
with 2 c.v of 100% elution buffer. Protein containing fractions were put through a 
Superose 6 gel filtration column and final protein-containing fractions pooled and 
desalted into 25 mM Tris-Cl pH 7.5,250 mM NaCl, 10% glycerol (v/v) and stored at 
-80°C (Figures 2.2,2.3,2.4).
2.3.7. Purification ofH is6-E lAE4, His6-E1AE4R45A andHis6-E lAE4A44-48 
Bacterial cell pellets were thawed, resuspended in 5 ml lysis buffer (30 mM Tris-Cl 
pH 8, 30 mM imidazole, 30 mM NaCl, 10% glycerol, 1 mM PMSF) per gram wet
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Figure 2.2. Purification of His£-/?5geminin. (a) Elution profile and Coomassie 
Blue stained SDS-PAGE gel ootained from Ni-affinity purification of His^- 
/wgeminin. (b) Superose 6 gel filtration chromatography, (c) Immunoblot of purified 
recombinant Hisz^/wgeminin with rabbit polyclonal anti-geminin antibody. FT - 
flowthrough, Buffer B (B) contained 250 mM imidazole.
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Figure 2.3. Purification of His^-^gemininANt. (a) Elution profile and Coomassie 
Blue stained SDS-PAGE gel obtained from Ni-affinity purification of His^- 
/wgemininANt. (BI - before induction, AI - after induction, Buffer B [B] contained 
250 mM imidazole), (b) Superose 6 gel filtration chromatography, (c) Immunoblot 
of purified recombinant His^-fagemininANt with rabbit polyclonal anti-geminin 
antibody.
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Figure 2.4. Purification of His^/wgemininFF. (a) Elution profile and Coomassie 
Blue stained SDS-PAGE gel obtained from Ni-affinity purification of Hisjc- 
/isgemininFF. (S - soluble crude extract, I - insoluble crude extract, Buffer B [B] 
contained 250 mM imidazole), (b) Superose 6 gel filtration chromatography, (c) 
Immunoblot of purified recombinant His^-fagemininFF with rabbit polyclonal anti- 
geminin antibody.
His6-/wgemininFF
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weight, containing bensonase (1 pl/ml) and 0.02 volumes of complete EDTA-free 
Protease Inhibitor Cocktail. The cells were broken by sonication and conditions 
adjusted according to lysate volume. Typically for a 25 ml suspension, sonication 
was carried out on ice for 6 x 30 s 6-Watt pulses with 30 s rest between each pulse. 
The lysate was clarified by centrifugation at 48,000 g at 4°C for 1 h and the 
supernatant filtered through a 0.45 pm syringe filter and loaded via a peristaltic 
pump onto 2 x 5 ml NiCh charged HiTRAP chelating columns. The columns were 
washed with 5 c.v. of wash buffer (30 mM Tris-Cl pH 8, 30 mM imidazole, 300 mM 
NaCl, 0.1 mM PMSF) to remove unbound protein. Non-specifically bound proteins 
were removed with 4 c.v. of 10% elution buffer (30 mM Tris-Cl pH 8, 300 mM 
imidazole, 30 mM NaCl, 0.1 mM PMSF) and 8 c.v. of 20% elution buffer. E1AE4 
was eluted with 2 c.v of 100% elution buffer and desalted into 20 mM Tris-Cl pH 8, 
50 mM NaCl (Figure 2.5).
2.3.8. Purification o f baculovirus-expressed His6-XeCdc6 
Insect cell pellets were resuspended in 10 ml of hypotonic buffer (20 mM HEPES pH 
7.4,10 mM NaCl, 0.5 mM EGTA, 5% glycerol, 5 pg/ml each of leupeptin, aprotinin, 
pepstatin A, and chymostatin) per ml. Cells were allowed to swell for 10 min and 
lysed by passing through a Dounce homogeniser (Wheaton, Millville, NJ, USA) 
using a tight-fitting pestle. Immediately after lysis, NaCl concentration was restored 
to 150 mM. The lysate was centrifuged at 5,000 g for 5 min at 4°C. The supernatant 
was clarified at 100,000 g for 1 h. The supernatant (cleared lysate) was transferred to 
a fresh tube and bound to 1 ml of Ni2+-NTA agarose (Qiagen), pre-equilibrated with 
binding buffer (20 mM HEPES pH 7.4,150 mM NaCl, 0.5 mM EGTA, 5% glycerol, 
5 pg/ml of each leupeptin, aprotinin, pepstatin A, and chymostatin), for 90 min at
University College London 81
Evaluation of the DNA replication licensing machinery as an anti-proliferative target. Sarah Kingsbury
a Elution fractions b
kDa FT 10% B 20% B 100% B kDa
118
100
75 - 97
50 - ■ 59
37
29
2 5 ^ .B
20 V 21
15 m 14
C Elution fractions d
kDa FT 10% B 20% B 100% B kDa
75
50
37
25
20
15
Elution fractions
kDa FT 10% B 20% B 100% B
I m m m
Figure 2.5. Purification of bacterially expressed wild-type HPV1 His£-E4 and 
mutant His£-E4 proteins. Coomassie Blue stained SDS-PAGE gels showing 
fractions eluted following Ni-affinity purification and immunoblots of purified 
protein with a monoclonal E4 antibody (4.37). (a and b) wild-type E4 (c and d) E4 
R45A and (e and f) E4 A44-48. FT - flowthrough, Buffer B (B) contained 300 mM 
imidazole._______________________________________________________________
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4°C with gentle shaking (200 r.p.m. on a rotary shaker). One wash and three elution 
steps were performed at 4°C with 20 mM HEPES pH 7.4, 150 mM NaCl, 0.5 mM 
EGTA, 5% glycerol, 5 pg/ml of each: leupeptin, aprotinin, pepstatin A, and 
chymostatin containing 10 mM, 20 mM, 50 mM, and 100 mM imidazole respectively 
(Figure 2.6).
2.3.9. Coupling o f proteins to SMoC
Coupling of proteins to SMoC was carried out as described by Pierce protocol 21341 
for EZ-Link™ Biotin-HPDP (Pierce, Rockford, EL, USA). Briefly, protein was 
dialysed into 0.1 M sodium phosphate buffer, 5 mM EDTA pH 6.0 and concentrated 
to 1 mg/ml using a Vivaspin concentrator (Sartorius AG, Goettingen, Germany). To 
reduce free cysteine residues, 2 mg protein was treated with 14 mg 2- 
mercaptoethylamine.HCl at 37°C for 90 min. Following reduction, excess 2- 
mercaptoethylamine.HCl was removed by buffer exchange through a PD-10 
desalting column (Amersham Biosciences). Protein was eluted into PBS-EDTA (20 
mM sodium phosphate pH 7.4, 150 mM NaCl, 1 mM EDTA) and concentrated to 1 
mg/ml. Reduced protein was incubated with 0.1 mg SMoC for 90 min at RT and 
coupled protein was isolated by buffer exchange as before.
2.3.10. Assaying for efficiency o f SMoC-protein coupling
Efficiency of coupling of SMoC to proteins was assessed by quantitation of 
sulfhydryl groups using Ellman’s Reagent (Pierce) according to Pierce protocol 
22582. Briefly, 250 pi of sample before and after coupling was mixed with 50 pi of 
Ellman’s Reagent Solution and 250 pi of reaction buffer (0.1 M sodium phosphate 
pH 8.0,1 mM EDTA) and incubated at room temperature for 15 min. Absorptivity of
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Figure 2.6. Purification of baculovirus-expressed His6-^eCdc6. (a) Coomassie 
Blue stained SDS-PAGE gels showing fractions eluted following Ni-afFinity 
purification of His^-2feCdc6. Wash buffer contained 10 mM imidazole, (b) 
Immunoblot of purified recombinant His^-A^Cdc6 with a monoclonal Cdc6 
antibody.
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each sample was measured at 412 nm.
2.3.11. Peptide synthesis
Peptides were synthesised on a Gilson Automated Multiple Synthesiser AMS 422 
according to standard operating procedures. The AMS 422 employs standard Fmoc- 
chemistry with in situ activation of the amino acids by the hydroxybenzotriazole 
derivative PyBOP. Double coupling with N,N,Dimethylformamide (DMF) was 
employed to ensure complete elongation of the peptides at each step. Following 
synthesis, the peptides were cleaved from the resin by treatment with trifluoracetic 
acid (TFA) and analysed by reverse phase HPLC and mass spectroscopy. The 
peptides were purified using a C l8 column and freeze dried. For use in in vitro DNA 
replication reactions, peptides were resuspended in water at a final concentration of 
20 pM.
2.3.12. SDS-polyacrylamide gel electrophoresis
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was performed using pre-cast 
Novex 4-20% Tris-glycine gels and the XCell SureLock™ Mini-Cell Electrophoresis 
System (Invitrogen). Prior to loading, protein samples were mixed with 4x laemlli 
buffer, heated to 90°C for 3 min, and pulse centrifuged. Samples were resolved in lx 
Tris-glycine running buffer at 125 mV for approximately 90 min. After 
electrophoresis, gels were stained with Coomassie Blue R-250 or immunoblotted.
2.3.13. Coomassie Blue staining o f SDS-PAGE gels
For visualisation of recombinant protein, SDS-PAGE gels were stained with 
Coomassie Blue R-250 for 1-2 h with gentle shaking. The gels were destained with
University College London 85
Evaluation of the DNA replication licensing machinery as an anti-proliferative target. Sarah Kingsbury
Coomassie gel destain solution, with gentle shaking, until the background was 
colourless.
2.3,14, Concentrating protein solutions
Protein solutions were concentrated in ultrafiltration centrifugation cartridges with an 
appropriate molecular weight cut-off. Cartridges were centrifuged at 3,500 g at 4°C 
until the desired concentration was reached by the reduction in volume of the protein.
2.4. Immunological techniques
2.4.1. Immunoblotting
For immunoblotting, protein was transferred from polyacrylamide gels onto 
nitrocellulose membranes (Amersham Biosciences) by semi-dry electroblotting in 
transfer buffer. Non-specific binding was blocked by incubating the membrane in 
PBS, 5% skimmed milk powder, 0.1% Tween-20 overnight at 4°C. Membranes were 
incubated in primary antibody in PBS, 5% skimmed milk powder, 0.1% Tween-20 
for 2 h at RT, except for some polyclonal antibodies for which PBS, 10% skimmed 
milk powder, 1% Tween-20 was used, followed by six 5 min washes in PBS, 0.1% 
Tween-20. Membranes were then incubated with the appropriate secondary antibody 
in PBS/milk/Tween-20 as before for 1 h at RT followed by six 5 min washes prior to 
visualisation. Immunoreactive bands were visualised on Hyperfilm ECL (Amersham 
Biosciences) by enhanced chemiluminescence (ECL, Amersham Biosciences).
2.4.2. Immunofluorescence
For immunofluorescence analysis, cells were grown on sterile coverslips. Coverslips 
were briefly rinsed in PBS and cells fixed in 4% paraformaldehyde for 5 min at RT. 
Following fixation, cells were permeabilised with PBS, 0.1% Triton X-100, 0.02%
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SDS for 5 min at RT. Coverslips were blocked for 10 min in PBS, 2% BSA and 
incubated with an appropriate dilution of primary antibody for 1 h at 37°C. 
Coverslips were then washed twice in PBS, 0.1% Triton X-100, 0.02% SDS and 
twice in PBS, 2% BSA and incubated with the appropriate fluorescein isothiocyanate 
(FITC)-conjugated secondary antibody, propidium iodide (PI; 50 ng/ml) and RNase 
A (50 ng/ml) for 1 h at 37°C. Coverslips were washed and slides were mounted in 
Vectorshield (Vector Laboratories, CA, USA). For detection of chromatin and/or 
nuclear matrix associated proteins, cells were treated with 0.1% Triton X-100 for 30 
s prior to fixation with 4% paraformaldehyde. Confocal fluorescence microscopy 
was performed on a Leica TCS DMRE confocal microscope (Leica Microsystems 
AG, Wetzler, Germany). Merged pictures of the different channels were obtained 
using Adobe Photoshop Version 7.0 with standardised brightness and contrast 
enhanced operations. ImageJ (http://rsb.info.nih.gov/iii was used for quantification 
of fluorescence intensity.
2.4.3. Immunohistochemistry
Three pm sections of formalin-fixed, paraffin-embedded tissues were cut onto 
DAKO Techmate™ S2024 slides, baked in a 60°C oven overnight to maximise 
section adhesion, dewaxed in xylene and rehydrated through a series of alcohol to 
water. For antigen retrieval, tissues were pressure-cooked for 2 min in 0.1 M Citrate 
Buffer pH 6.0. Immunostaining was performed manually using a standard protocol. 
After antigen retrieval, slides were washed twice in TBS, 0.1% Tween and 
endogenous peroxidase activity was quenched with peroxidase blocking solution 
(DAKO) for 10 min. Primary antibodies were applied for 1 h at RT, and detected 
with a biotin-free polymer-based detection system (ChemMate DAKO EnVision).
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Sections were incubated with peroxidase-labelled secondary antibody for 1 h at RT, 
and the immunostain developed with 3,3-diaminobenzidine tetrahydrochloride 
(DAB) for 10 min. Sections were counterstained in Mayer’s Haematoxylin, 
differentiated in 1% acid alcohol, dehydrated, cleared in xylene and coverslips 
applied using Leica CV Mount (Leica, Nussloch, Germany). Primary antibodies were 
omitted in negative controls and appropriate tissue sections were used as positive and 
negative controls.
2.5. Cell biology techniques
2.5.1. Cell culture and synchronisation
NIH/3T3 (Stoeber et al., 1998), WI-38 (CCL-75, ATCC®, LGC Promochem, 
Middlesex, UK), Hela S3 (CCL-2.2, ATCC®) and U20S (HTB-96, ATCC®) tissue 
culture cells were grown in Dulbecco’s modified Eagle’s medium (Gibco-BRL) 
supplemented with 10% foetal calf serum (FCS, Gibco-BRL), 100 U/ml penicillin 
and 0.1 mg/ml streptomycin. Cell cycle synchronisation was performed essentially as 
described (Krude et al., 1997). Briefly, for preparation of cells in Gl/S, cells were 
synchronised in very early S phase by two sequential 25 h blocks in 2.5 mM 
thymidine separated by a 12 h interval without thymidine (Rao and Johnson, 1970). 
For preparation of cells in G2/M phase, cells were released from the second 
thymidine block for 3 h, followed by adding 40 ng/ml nocodazole for an additional 
12 h to arrest them in mitosis (Johnson et al., 1993). For preparation of cells in mid 
G1 phase, these mitotic cells were released into fresh culture medium for 6 h prior to 
collection. To prepare nuclei from NIH/3T3 cells, cells were driven into quiescence 
by density-dependent growth arrest and after five days were released back into cycle 
by subculturing 1 in 4 into fresh growth medium. Progress through G1 into S phase
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was monitored by BrdU incorporation and FACS (flow assisted cell sorting) analysis 
(Stoeber et al, 1998). To prepare S phase HeLa S3 cytosolic extracts, HeLa S3 cells 
were synchronised in S phase by a single block in culture medium containing 2.5 
mM thymidine for 25 h (Rao and Johnson, 1970), followed by release into fresh 
culture medium for 2 h. Sf9 (ECACC, Wiltshire, UK) cells were cultured in TMN- 
FH media (BD Biosciences) supplemented with 5 pg/ml gentamycin for normal 
growth and protein expression and in Grace’s medium (Gibco-BRL) supplemented 
with 5 pg/ml gentamycin for baculovirus infection.
2.5,2. Bivariate flow cytometric analysis
For cell cycle analysis of DNA content and bromodeoxyuridine (BrdU) 
incorporation, NIH/3T3 fibroblasts were pulse labelled with BrdU for 1 h and cell 
samples fixed in 80% ethanol for a minimum of 12 h. After fixation, cells were 
washed in dPBS and DNA was denatured by incubation in 4 N HC1 for 20 min. 
Subsequently cells were washed twice in dPBS, incubated for 1 h with a FITC- 
conjugated BrdU antibody (1:50 dilution; Alexis Biochemicals) (Dolbeare, 1983; 
Lacombe, 1988) in the dark at 4°C and for 20 min with 0.5 ml PI (20 pg/ml) and 
RNase A (50 pg/ml) (Helmstetter et al., 2003) and 0.5 ml dPBS at RT. To prevent 
clumping of cells and loss of sample, 100 pi of 1% BSA was added at each step and 
unautoclaved pipette tips were used. Analyses of light-scatter properties and 
DNA/BrdU incorporation were performed using a FACSCalibur flow cytometer (BD 
Biosciences). Cell doublets were excluded by gating on a dot plot of the width vs the 
area of DNA fluorescence intensity (Erlanson and Landberg, 1998). In most samples, 
104 cells were examined and data were analysed using CellQuest™ software (BD 
Biosciences) and WinMDI (V 2.8).
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2.5.3. Assaying fo r cell proliferation
Cell proliferation was monitored by either continuous or pulse labelling with 50 pM 
BrdU and antibody staining. Cells on coverslips were washed in PBS, fixed for 5 min 
in 4% paraformaldehyde, and washed two times with PBS. Following fixation, cells 
were permeabilised for 5 min in 0.2% Triton X-100 and washed in PBS. DNA was 
denatured by incubation in 2 M HC1 for 1 h followed by three washes with PBS. 
Coverslips were incubated for 1 h with FITC-conjugated mouse anti-BrdU MAb 
(1:20 dilution) and with the DNA stain PI/RNase A (both at 50 ng/ml), washed again 
and mounted in Vectorshield. Confocal fluorescence microscopy of random fields of 
nuclei was performed on a Leica TCS DMRE confocal microscope. Images were 
collected, and merged pictures of the PI channel (red) and FITC channel (green) 
were obtained using Adobe Photoshop Version 7.0 with standardised brightness and 
contrast enhanced operations for all samples. Images were printed and the number of 
cells incorporating BrdU (yellow) and non-replicating cells (red) were counted. 
Proliferating (BrdU-incorporating) cells were quantitated as percentages of the total 
number of cells.
2.5.4. Assaying fo r apoptosis
TdT (terminal deoxynucleotidyl transferase)-mediated dUTP-x nick end labelling 
(TUNEL) assay to detect apoptotic cells was performed using the ApopTag 
Fluorescein Direct in Situ Apoptosis Detection Kit (Chemicon International, 
Temecula, CA, USA) according to the manufacturer’s protocol. Briefly, cells were 
fixed in 1% paraformaldehyde for 10 min at RT, washed twice in PBS, post-fixed in 
ethanol:acetic acid 2:1 for 5 min at -20°C, and washed a further two times in PBS. 
Fixed, permeabilised cells were incubated with Equilibration buffer (Chemicon
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International) for 10 s at RT, incubated with TdT enzyme for 1 h at 37°C and finally 
the reaction was stopped by incubation with Stop/wash buffer (Chemicon 
International) for 10 min. Coverslips were mounted in Vectorshield containing DAPI 
(4’6’-diamidino-2-phenylindole), and visualised by confocal fluorescence 
microscopy.
2.5.5. Preparation o f total cell extracts
To prepare whole cell extracts, cells were harvested by treatment with trypsin, 
washed in PBS and resuspended in lysis buffer (50 mM Tris-Cl pH 7.5, 150 mM 
NaCl, 20 mM EDTA, 0.5% NP40) at 5 x 106 cells/ml. After incubation on ice for 30 
min the lysate was clarified by high speed centrifugation (13,000 g, 15 min, 4°C) and 
stored at -80°C.
2.5.6. Biochemical subcellularfractionation
Cells were pelleted and resuspended in fractionation buffer A at 4 x 107 cells/ml, and 
incubated on ice for 10 min. Nuclei were pelleted by low speed centrifugation (1,300 
g, 5 min, 4°C) and the supernatant (cytosolic fraction) further clarified by high speed 
centrifugation (14,000 g, 15 min, 4°C) to remove cell debris and insoluble 
aggregates. Nuclei were washed twice in fractionation buffer A, resuspended in 
fractionation buffer B, and incubated for 45 min at 4°C. Insoluble chromatin-bound 
proteins were obtained by centrifugation (1,500 g, 5 min, 4°C), and the supernatant 
(nucleosolic fraction) further clarified by high speed centrifugation (14,000 g, 15 
min, 4°C). Chromatin was washed twice in fractionation buffer B, resuspended in 
fractionation buffer A plus 1000 U/ml DNase I (Invitrogen) and incubated for 30 min 
at RT, and a further 30 min at 4°C with 1 v/v 0.5 M NaCl. Solubilised chromatin-
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bound proteins were obtained by high speed centrifugation (14,000 g, 5 min, 4°C).
2.6. In vitro DNA replication reactions
2.6.1. Preparation o f nuclei and cytosolic extracts
Cytosolic extracts and nuclear preparations were produced by hypotonically 
swelling, scrape harvesting, and Douncing essentially as described (Heintz and 
Stillman, 1988; Krude et al., 1997; Stoeber et al., 1998). Briefly, cells were washed 
once with ice-cold LS buffer and all subsequent steps carried out at 4°C. Cells were 
allowed to swell for 10 min in 20 ml LS buffer per plate, and excess buffer was 
removed. Interphase cells attaching to the substratum were scraped off the plates and 
disrupted with 25 strokes in a Dounce homogeniser (Wheaton Science Products, 
Millville, NJ, USA) using a loose-fitting pestle. Nuclei were centrifuged at 1,500 g 
for 3 min, washed once in 1 ml of ice-cold SuNaSp/3% BSA, resuspended in an 
equal volume of SuNaSp/3% BSA and stored at -80°C. The cytosolic supernatant 
from the first separating spin was clarified at 18,000 g for 15 min. Supernatant 
fractions were aliquoted, snap-frozen, and stored in liquid N2.
2.6.2. Assaying for DNA synthesis in vitro
In vitro DNA synthesis reactions were performed essentially as described (Krude et 
al., 1997; Stoeber et al., 1998). Briefly, reactions contained 30 pi of cytosolic 
extracts (250-300 pg of protein), 10 pi of premix buffer, 1 x 105 nuclei and, where 
indicated, up to 10 pi of recombinant protein(s). When smaller volumes were used, 
the remaining volume was adjusted to the final 10 pi by addition of nuclear 
extraction buffer or of the relevant buffer for recombinant protein(s). Nuclei were 
incubated with recombinant protein, or control buffer, for 15 min prior to addition of
University College London 92
Evaluation of the DNA replication licensing machinery as an anti-proliferative target. Sarah Kingsbury
premix buffer and cytosolic extract. Reactions were then incubated for 3 h at 37°C. 
His6-XeCdc6 protein in 20 mM HEPES pH 7.4, 150 mM NaCl, 5% glycerol, 1 mM 
DTT was added to in vitro replication reactions at a final concentration of 0.65 pM, 
baculovirus-expressed E4/AE4 proteins (Roberts et al, 1994b) in 10 mM phosphate 
buffer pH 7.4, 0.1 mM DTT at 3 pM, bacterially-expressed His6-E1AE4 proteins in 
40 mM Tris-HCl pH 7.6, 30 mM NaCl at 3 pM, and His6-/wgeminin proteins in 25 
mM Tris-Cl pH 7.5,250 mM NaCl, at 4 pM where indicated.
2.6.3. Analysis o f in vitro DNA synthesis products by confocal fluorescence 
microscopy
For analysis of in vitro DNA synthesis reactions by confocal fluorescence 
microscopy, reactions were stopped by diluting with 500 pi of PBS and nuclei fixed 
for 5 min by adding 500 pi of 8% paraformaldehyde at RT. After fixation, nuclei 
were spun through a 30% sucrose/PBS cushion onto poly-L-lysine coated coverslips. 
All subsequent washing and staining steps were carried out in PBS, 0.2% Triton X- 
100, 0.04% SDS. Coverslips were washed, stained for incorporated biotin-16-dUTP 
with fluorescein-linked streptavidin (1:100 dilution, Amersham) and for DNA with 
propidium iodide/RNase A (both at 50 ng/ml), washed again, and mounted in 
Vectorshield. Confocal fluorescence microscopy of random fields of nuclei was 
performed on a Leica TCS DMRE confocal microscope and merged pictures of the 
PI channel (red) and FITC channel (green) were obtained using Adobe Photoshop 
Version 7.0 with standardised brightness and contrast enhanced operations for all 
samples. Images were printed and the number of nuclei incorporating biotin-16- 
dUTP in vitro (yellow) and non-replicating nuclei (red) were counted. Routinely 
800-1000 nuclei were scored for each reaction and quantitated as percentages of the
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total number of nuclei that synthesised DNA in vitro.
2.6.4. Chromatin-binding assay
1 x 105 NIH/3T3 nuclei were incubated in 30 pi of cytosolic HeLa S phase extract 
(250-300 pg of protein), a buffered mix of NTPs, dNTPs, and an energy 
regeneration system as described in Section 2.6.2. After 3 h, nuclei were pelleted by 
low speed centrifugation (1,300 g, 5 min, 4°C), resuspended in fractionation buffer B 
and incubated for 45 min at 4°C. Insoluble chromatin was obtained by centrifugation 
(1,500 g, 5 min, 4°C), washed twice in buffer B, resuspended in fractionation buffer 
A and 1000 U/ml DNase 1 and incubated for 30 min at RT, and a further 30 min at 
4°C with 1 v/v 0.5 M NaCl. Solubilised chromatin-bound proteins were obtained by 
high speed centrifugation (14,000 g, 5 min, 4°C).
2.7. Computing
Unless stated otherwise, all image processing and quantitation were performed with 
Adobe Photoshop Version 7.0 (Adobe Systems Inc., USA) using only standard 
contrast and brightness adjustment functions. Graphs were produced in MSExcel, 
(Microsoft Corporation, USA). The text of this thesis was written in MSWord, 
(Microsoft Corporation, USA) and figures were assembled in Adobe Illustrator 
Version 10.0 (Adobe Systems Inc., USA).
2.7.1. Bioinformatic and database resources 
DNA sequences
Entrez nucleotide: http://www.ncb.nlm.nih.gov/entrez/querv.fcgi?db=Nucleotide 
Protein sequences
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Entrez protein: http://www.ncb.nlm.nih.gov/entrez/querv.fcgi?db=Protein 
DNA and protein sequence homology
BLAST: http://www.ncbi.mln.nih.gov/BLAST/
Multiple sequence alignments
ClustalW: http://www.ebi.ac.uk/clustalw.html 
Restriction enzyme site identification
NebCutter 2: http://www.neb.com/nebcutter.html 
Oligonucleotide primer design
Netprimer: http://www.premierbiosoft.com/netprimer.html 
Protein molecular weight, pi, and extinction coefficient 
ProtParam: http://ca.expasdv.org/tols/protparam.html 
Atomic co-ordinates of protein structures 
RCSB Protein Data Bank:
http://www.rcsb.org/pdb/Welcome.do:isessionid=fV2A2Avl6oGwCepMMGt9GO** 
Protein structure visualisation
Pymol: http://pvmol.sourceforge.net/
Densitometry analysis
ImageJ: http://rsb.info.nih.gov/ii/
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CHAPTER THREE
REGULATION OF THE ORIGIN LICENSING 
REPRESSOR GEMININ DURING QUIESCENCE
3.1. Introduction
The response of normal tissue to chemotherapy regimes is a fundamental 
consideration in the development of novel therapeutic strategies. A major constraint 
of many classical chemotherapeutic agents is their toxicity to normal tissues; 
particularly the rapidly proliferating populations of the gastrointestinal and 
haemopoietic systems (see also Chapter 1, Section 1.3.). As a result, these agents 
cause debilitating side-effects in cancer patients that may escalate to dose-limiting 
toxicides. Lowering the dose of chemotherapeutic agents to reduce these side-effects 
can allow tumour cells to escape treatment and to develop drug resistance (Cleton, 
1995). Therapeutic regimes which specifically destroy tumour cell populations are 
therefore continually sought after.
The putative existence of an origin licensing checkpoint implies that inhibiting the 
DNA replication licensing pathway may provide a strategy for cancer specific killing 
(see also Chapter 1, Section 1.5). Preliminary studies by Shreeram et a l suggest that 
transformed cells respond to inhibition of DNA replication licensing by committing 
apoptosis, whilst normal cycling cells respond by arresting in G1 (Shreeram et al., 
2002). However in mammalian tissues the majority of cells reside in out-of-cycle 
states, having either temporally withdrawn into the quiescent state ready to re-enter 
the cell cycle upon the appropriate mitogenic stimulation, or permanently withdrawn 
into the terminally differentiated state. In order to predict how these different normal
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cell populations may respond to agents targeting the DNA replication licensing 
pathway, the regulation of the replication licensing machinery in normal human 
tissues must be understood. During the mitotic cell cycle the components of the 
replication licensing pathway are tightly regulated, ensuring that replication can 
occur once and only once during each round of cell division (see also Chapter 1, 
Section 1.5.). However, little is known about the regulation of the replication 
licensing machinery, and in particular the origin licensing repressor geminin, upon 
withdrawal from the cell cycle into the out-of-cycle states of quiescence, 
differentiation and senescence.
Human tissues can be divided into three separate classes: self-renewing, conditional 
renewal, and permanent (Leblond, 1963). Self-renewing systems (e.g. skin, 
gastrointestinal mucosa and the haemopoetic system) are characterised by rapid and 
continuous turnover of cells and show a typical hierarchy of cellular development 
from stem cells to terminally-differentiated mature cells via transient amplifying 
cells. Separate from self-renewing systems are tissues with little or no replacement of 
lost cells; permanent tissues (e.g. nerve or skeletal muscle) are composed of static 
cell populations, whereas conditional renewal tissues (e.g. liver or thyroid), although 
normally showing little cell replacement, are capable of extensive proliferation in 
response to a stimulus (Leblond, 1963; Hall and Watt, 1989). In order to determine 
the likely response of normal tissues to agents targeting the replication licensing 
machinery the regulation of replication licensing factors (RLFs) was evaluated in a 
typical conditional renewal tissue, thyroid, and a typical self-renewing system, the 
colonic crypt. To provide support for these immunohistochemical analyses, an in 
vitro quiescence model system was established to allow the generation of a detailed
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molecular map of the replication licensing machinery during exit from and re-entry 
into the mitotic cell cycle.
Of particular importance in these studies is an analysis of the regulation of the origin 
licensing repressor geminin. The ability of geminin to prevent pre-RC assembly and 
block the initiation of DNA replication suggests that compounds mimicking geminin 
activity could prove successful as anti-proliferative agents. In order to evaluate this 
hypothesis it is therefore essential to understand the regulation of geminin during 
tissue maintenance in the adult; specifically in the three classes of human tissues 
described above. The role of geminin as a negative regulator of DNA replication has 
led to speculation that geminin may act as a classic tumour suppressor protein and 
may therefore be mutated or suppressed in human cancers (Lygerou and Nurse, 
2000). However, analyses of geminin expression in human cancers suggest that 
geminin expression is positively correlated with cell proliferation (Wohlschlegal et 
al., 2002; Wharton et al., 2004). These studies may therefore also provide further 
evidence as to whether geminin acts as a classic tumour suppressor protein or a 
marker of cell proliferation.
3.2. Materials and Methods
For Antibodies (2.3.1.), Immunoblotting (2.4.1.), Immunohistochemistry (2.4.3.), 
Cell culture and synchronisation (2.5.1.), Bivariate flow cytometric analysis (2.5.2.), 
Assaying for cell proliferation (2.5.3.), and Biochemical subcellular fractionation 
(2.5.6.) refer to Chapter Two (Materials and Methods).
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3.2.1. Protein expression profile analysis in colon and thyroid
Colonic crypts
In this study protein expression analysis for Ki67, Mcm2 and geminin was performed 
on distal colonic tissue samples only. Haematoxylin and eosin (H&E) stained 
sections were carefully assessed to exclude the presence of paneth cells. Slides were 
examined and images captured with an Olympus BX51 microscope/CCD camera 
setup using ANAlysis software (SIS, Munster, Germany). Captured images were 
printed and cells expressing the protein of interest counted. Epithelial cells in the 
basal proliferative compartments (BC, lower third of colonic crypts) and 
differentiated compartments (DC, upper two thirds of colonic crypts) were evaluated 
separately. The basal proliferative compartments were further segregated into stem 
cell (SCC) and transit amplifying (TAC) compartments (Potten, 1986).
Thyroid
For Ki67, Mcm2 and geminin protein expression profiling, six cases of follicular 
adenoma and five cases of Graves Disease were selected. On histological 
examination cases of follicular adenoma also contained surrounding normal thyroid 
tissue. Slides were examined with an Olympus BX51 microscope/CCD camera setup 
and scanned at low magnification to identify areas of high expression for each 
marker. Three to five fields were captured from selected areas at x400 magnification 
and processed using ANAlysis software (SIS, Munster, Germany). Captured images 
were printed and within fields a labelling index was determined for a minimum of 
300 cells.
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3.3. Results
3.3.1. Reversible growth arrest o f NIH/3T3 fibroblasts in quiescence 
In order to define the replication licensing phenotype of quiescent cell populations, 
the expression of the replication licensing machinery was first analysed in an in vitro 
quiescence model system. The aim of these detailed in vitro studies was to generate a 
molecular map describing the regulation of replication licensing factors during exit 
from and re-entry into the mitotic cell cycle, which can be extrapolated for the 
analysis of conditional renewal and self-renewing tissues.
NIH/3T3 fibroblasts are widely accepted as an immortalised but non-transformed 
cell line of highly contact-inhibited cells (Jainchill et al., 1969), which can be used as 
an in vitro model for replicative quiescence (Holley and Kieman, 1968). NIH/3T3 
diploid fibroblasts cease proliferating and enter a viable state of growth arrest, 
quiescence (GO), following contact-inhibition at high cell densities (density- 
dependent growth arrest). Cell cycle re-entry can be stimulated by sub-culturing at 
lower density, relieving the contact-inhibition and producing a tightly synchronised 
cohort of cells progressing into S phase.
To monitor exit of NIH/3T3 fibroblasts from cycle into quiescence, 
bromodeoxyuridine (BrdU) cell proliferation assays were performed on 
asynchronously proliferating cultures and on contact-inhibited cells. In an 
asynchronously proliferating population 45% of cells incorporated BrdU during a 
one hour pulse (Figure 3.1). In contrast, the BrdU labelling index dropped to 2.4% 
one day post contact-inhibition and to 0% five days post contact-inhibition, 
confirming that the NIH/3T3 fibroblasts used in this study can be synchronised in
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Figure 3.1. NIH/3T3 fibroblasts undergo density-dependent growth arrest and 
enter the reversible resting state of quiescence. Cell proliferation of NIH/3T3 
fibroblasts was monitored by pulse-labelling with BrdU during the transition from 
asynchronous growth (AS) into quiescence, by growth of cells to confluence and 
subsequent density-dependent growth arrest (SC - semi-confluent, C l/5- confluent 
day 1/5). Cells were stained with propidium iodide (red) for total DNA and 
fluorescein-AbBrdU (green) to detect BrdU incorporation. 5 days post confluency 
incorporation of BrdU had ceased indicating that cells were no longer progressing 
through the cell cycle.
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quiescence by density-dependent growth arrest.
Re-entry of NIH/3T3 fibroblasts into the cell cycle was monitored by continuous 
BrdU labelling following sub-culturing at lower density five days after contact- 
inhibition. The percentage of cells incorporating BrdU remains low for 
approximately 16 hours after the release (Figure 3.2a), consistent with cells re­
entering the cell cycle with a prolonged G1 period. The percentage of cells 
incorporating BrdU begins to increase between 16 and 18 hours after release with 
cells reaching S phase between 18 and 20 hours. These data correlate with flow 
cytometric analysis of propidium iodide stained NIH/3T3 nuclei, which indicates that 
at 15 hours cells are in G1 phase with a DNA content equivalent to the DNA ploidy 
index 1.0. Transition into S phase occurs between 18 and 20 hours after release 
(Figure 3.2b). Taken together these data confirm that NIH/3T3 fibroblasts 
synchronously re-enter the cell cycle from quiescence with a prolonged ‘G l’ phase 
following removal of contact-inhibition.
3.3.2. Repression o f origin licensing in GO ensures loss o f proliferative capacity 
independently o f the origin licensing inhibitor geminin
To generate a molecular picture of origin licensing during exit into and re-entry from 
GO, and to determine whether geminin is required for maintenance of the quiescent 
state as may be expected for a putative tumour suppressor protein, a published sub- 
cellular fractionation protocol (Mendez and Stillman, 2000) was followed to separate 
the total protein content into cytosolic, nucleosolic and chromatin-bound fractions 
(Figure 3.3a). To validate this protocol, distribution of several marker proteins was 
assessed following biochemical fractionation of asynchronous NIH/3T3 fibroblasts
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Figure 3.2. NIH/3T3 fibroblasts synchronously re-enter the cell cycle following 
release from density-dependent growth arrest, (a) Re-entry of NIH/3T3 
fibroblasts into the cell cycle by subculturing of cells five days post contact- 
inhibition was monitored by continuous BrdU labelling. Cells were stained with 
propidium iodide (red) for total DNA and fluorescein-AbBrdU (green) to detect 
BrdU incorporation. Cells become competent to replicate 16-18 hours after release, 
(b) FACS analysis of propidium iodide stained NIH/3T3 nuclei for DNA content 
indicates that cells enter S phase approximately 20 hours after release from 
quiescence.
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into cytosolic, nucleosolic and chromatin-bound protein fractions (Figure 3.3b). 
Mek2, a cytosolic serine threonine kinase involved in the MAPK signal transduction 
pathway (Zheng and Guan, 1994), was recovered exclusively in the cytosolic 
fraction, indicating that extraction of soluble cytosolic proteins after cell lysis was 
complete. Chromosomal Region Maintenance 1 protein (Crml) was recovered in 
both the cytosolic and nucleosolic fractions but not in the chromatin-bound fraction. 
This is consistent with its role as a nuclear export receptor for leucine-rich nuclear 
export signals (Fomerod et al., 1997) and confirms that full extraction of nuclear 
proteins was achieved after nuclear lysis. Histone HI was detected exclusively in the 
chromatin-bound fraction, excluding release of chromatin-bound proteins into the 
nucleosolic fraction during nuclear lysis.
To investigate the regulation of origin licensing during exit into and re-entry from 
GO, and the role of geminin in this process, protein fractions were prepared during 
asynchronous growth, at various time points following density-dependent growth 
arrest (C), and during release back into the mitotic cell cycle by sub-culturing five 
days after the cells had undergone growth arrest (C5). Proteins in all three fractions 
were resolved by gel electrophoresis and probed for the RLFs Orc4, Cdc6, Cdtl, 
Mcm2, Mcm3, Mcm5 and Mcm7, the origin licensing repressor geminin, the CDK 
inhibitor p27 and the cytoskeletal filamentous protein actin to control for protein 
levels. Exit into GO (Figure 3.4a and b) and re-entry into cycle (Figure 3.5a and b) 
were monitored by bi-variate flow cytometric analysis of DNA content and BrdU 
incorporation.
Fifty-one percent of asynchronously proliferating NIH/3T3 fibroblasts incorporated
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Figure 3.3. Subcellular biochemical fractionation, (a) Scheme showing the 
biochemical fractionation protocol used to separate cytosolic (CF), nucleosolic (NF), 
and chromatin-bound (CBF) protein fractions, (b) In sub-cellular fractionations from 
asynchronously proliferating NIH/3T3 fibroblasts, Mek2, a cytosolic kinase 
involved in signal transduction, was recovered exclusively in the CF, indicating that 
cell lysis was complete. The nuclear transport factor Crml was recovered in both the 
CF and NF, but not in the CBF, indicating that nuclear lysis was complete and 
excluding spill-over into the CBF. Histone HI was found exclusively in the CBF, 
excluding release of chromatin-bound proteins during nuclear lysis.
CF NF CBF
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BrdU after a one hour pulse, as determined by FACS analysis. After one day of 
density-dependent growth arrest, BrdU incorporation had dropped to 4% and by day 
10 less than one percent of cells were synthesising DNA (Figure 3.4b). The CDK 
inhibitor p27, required for establishment and maintenance of the quiescent state 
(Resnitzky et al., 1995), was up-regulated and found in all three fractions upon the 
onset of density-dependent growth arrest (SC) (Figure 3.4c). Up-regulation of p27 
coincided with rapid down-regulation of the MCM loading factor Cdc6 within 48 
hours and its complete removal from chromatin by the time cells were contact- 
inhibited (C). Protein levels of Cdtl also began to drop at the onset of density- 
dependent growth arrest, but down-regulation was significantly slower than Cdc6 
and protein could still be detected in all three fractions 15 days post-confluency. 
Interestingly, geminin protein levels were not up-regulated during entry into 
quiescence as might be expected for a putative tumour suppressor protein, but were 
down-regulated with similar kinetics to those observed for Cdc6. Protein levels of the 
DNA helicase subunits Mcm2-7 began to drop with the onset of density-dependent 
growth arrest in all three fractions, with complete removal from chromatin occurring 
by day 10 of contact inhibition (CIO). The Orc4 subunit of the origin landing pad 
was also down-regulated as cells progressed into GO, although to a much lesser 
extent than Mcm2-7 and was still present in significant quantities in all three 
fractions by day 15 of contact inhibition (Cl5). In contrast, Orel and Orc2 were not 
down-regulated and remained chromatin-bound during entry into GO (Madine et al., 
2000; Stoeber et al., 2001), suggesting differential regulation of ORC subunits as 
cells exit from cycle. Taken together, these data show that loss of proliferative 
capacity upon exit into quiescence is a two-step process. The immediate response of 
fibroblasts to density-dependent growth arrest is a block to pre-RC assembly
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Figure 3.4. Regulation of replication licensing factors during withdrawal from 
cycle into quiescence. Exit of NIH/3T3 fibroblasts into quiescence by density- 
dependent growth arrest was monitored by bi-variate flow cytometric analysis of (a) 
DNA content and (b) BrdU incorporation. An asynchronously proliferating 
population (AS) showed a normal DNA content distribution and 51% incorporation 
o f BrdU. One day post contact-inhibition the DNA profile showed a strong G1 peak 
and the percentage of cells incorporating BrdU dropped to 4%. (c) Immunoblot 
analysis of Orc4, Cdc6, Cdtl, Mcm2, Mcm3, Mcm5, Mcm7, geminin (Gem), p27 
and actin in cytosolic, nucleosolic, and chromatin-bound protein fractions prepared 
from NIH/3T3 cells during transition from asynchronous growth into GO (AS - 
asynchronous, SC - semi-confluent, C - confluent, C l-15 - days in density-dependent 
growth arrest).
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mediated through rapid down-regulation of the master regulator Cdc6 and induction 
of the global CDK inhibitor p27. The late response involves complete down- 
regulation and removal from chromatin of the replicative Mcm2-7 helicase (Figure 
3.4c) (Kingsbury et al., 2005; see Appendix D).
After five days of density-dependent growth arrest, cells were released back into the 
proliferative cell cycle and DNA synthesis was monitored by bi-variate flow 
cytometric analysis of DNA content and BrdU incorporation (Figure 3.5a and b). The 
percentage of cells synthesising DNA increased to 11% at 15 hours, 30% at 18 hours 
and 51% at 21 hours after release from GO. Chromatin-bound levels of Orc4 
increased two-fold by 9 hours and three-fold by 12 hours after release from contact 
inhibition (relative to protein levels in resting cells) (Figure 3.5c). The MCM loading 
factor Cdc6 was de novo synthesised during re-entry into the mitotic cell cycle and 
bound to chromatin by 9 hours. Although a small proportion of Cdtl was already 
bound to chromatin at 0 hours, an increase in binding was detected between 6 and 9 
hours with a continual accumulation until 18 hours and removal from chromatin at 
21 hours. Binding of Cdc6 and Cdtl was followed by recruitment of Mcm2, Mcm3, 
Mcm5 and Mcm7 from the soluble fractions to the chromatin-bound fraction 
between 9 and 21 hours after the release (Figure 3.5c). Like Cdc6, geminin was de 
novo synthesised during re-entry, however, notably, synthesis and association with 
chromatin did not occur until late in the GO-S transition post pre-RC assembly (18-21 
hours after the release). Interestingly, the CDK inhibitor p27 accumulated in the 
nucleus and was detected in the chromatin-bound fraction during the permissive 
window of pre-RC assembly consistent with the recent finding that p27 interacts with 
Mcm7 and may act to prevent premature firing of origins in late G1 (Nallamshetty et
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Figure 3.5. Regulation of replication licensing factors during re-entry into the 
cell cycle from quiescence. Re-entry of NIH/3T3 fibroblasts into the cell cycle from 
quiescence by density-dependent growth arrest was monitored by bi-variate flow 
cytometric analysis of (a) DNA content and (b) BrdU incorporation. Between 0 and 
15 hours after release from quiescence cells have a DNA content equivalent to the 
DNA ploidy index 1.0, with transition into S phase occuring between 18 and 20 
hours after release. The percentage of cells incorporating BrdU remains low for 
approximately 15 hours after the release, increasing to 11% at 15 hours, 30% at 18 
hours, and 51% at 21 hours after release from GO. (c) Immunoblot analysis of Orc4, 
Cdc6, Cdtl, Mcm2, Mcm3, Mcm5, Mcm7, geminin (Gem), p27 and actin in sub- 
cellular fractions from NIH/3T3 cells following release from density-dependent 
growth arrest.
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al., 2005). These data demonstrate that pre-RC assembly precedes reacquisition of 
proliferative capacity and that the origin licensing repressor geminin, which bans re­
replication in mitotically active cells, is not required to suppress proliferative 
capacity in GO (Figure 3.4c) (Kingsbury et al., 2005; see Appendix D).
3.3.3. Conditional renewal tissues have an unlicensed replication licensing 
phenotype
To determine whether the down-regulation of RLFs during withdrawal from cycle 
into the quiescent state in vitro (Figure 3.4c) extends to conditional renewal tissue 
systems, regulation of Ki67, Mcm2 and geminin protein expression was analysed 
using immunohistochemistry on normal adult thyroid tissue obtained from surgical 
resection specimens (n=6)1. Representative immunostained tissue sections are 
illustrated in Figure 3.6 and mean labelling indices (percentage of positive cells) for 
each protein are shown in Figure 3.7. Expression of the standard proliferation marker 
Ki67 and Mcm2 was detected in a small proportion of thyrocytes (0.5% [95% CI=0- 
1.1%] and 1.3% [CI=0-3.7%] respectively), consistent with most follicular cells 
being in a replication-incompetent quiescent state. Importantly, geminin protein 
expression is restricted to a minute proportion of thyrocytes (0.1% [CI=0-0.3%]), 
indicating that loss of proliferative capacity in human stable tissues is independent of 
this origin licensing repressor, which appears to be redundant following down- 
regulation of the MCM replicative helicase subunits.
Graves Disease and thyroid adenoma are hyper-proliferative disorders of the thyroid
technical assistance in the staining and analysis of histological sections was provided by Marco 
Loddo (Department of Pathology, UCL) and Ellen Obermann (visiting scholar, supported by Dr. 
Mildred Scheel Stiftung fur Krebsforschung/Deutsche Krebshilfe). Guidance in the statistical analysis 
of data was provided by Thomas Fanshawe (University of Cambridge).
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Figure 3.6. Expression of replication licensing factors is induced in stable tissues 
following re-entry into the mitotic cell division cycle. Indirect immunoperoxidase 
staining of normal thyroid, Graves Disease, and follicular adenoma with anti-Mcm2, 
anti-geminin and anti-Ki67 antibodies. Normal thyroid shows very low expression 
of Ki67 and Mcm2 with almost undetectable levels of geminin. In both hyper- 
proliferative conditions (Graves Disease and follicular adenoma) Ki67, Mcm2 and 
geminin protein expression levels are increased 10-30 fold (x!25).
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and represent in vivo correlates of re-entry into the mitotic cycle from GO, through a 
physiological and oncogenic stimulus respectively. In Graves Disease, stimulation of 
thyroid follicular cells by TSH receptor auto-antibodies results in thyroid growth 
through stimulation of the TSH-dependent mitogenic pathway (Chistiakov, 2003). 
Alternatively, oncogenic mutations in TSHR, ras or gsp can result in epithelial 
thyroid follicular tumourigenesis, follicular adenoma representing an early step in 
thyroid tumour progression (Moretti et al., 2000). To test whether acquisition of 
proliferative capacity following re-entry of quiescent thyrocytes into the mitotic cell 
cycle is linked to induction of RLFs, as shown in the in vitro fibroblast model 
(Figure 3.5c), regulation of Ki67, Mcm2 and geminin protein expression was 
immunohistochemically analysed in thyroid follicular adenoma (n=6) and Graves 
Disease (n=5). Increased expression of Ki67 and Mcm2 was detected in both hyper- 
proliferative conditions (Graves Disease: Ki67 [6.4%, CI=2.3-10.5%], Mcm2 
[14.3%, 0=3.4-25.2%]; follicular adenoma: Ki67 [8.1%, 0=2.9-13.3%], Mcm2 
[38.5%, 0=21.5-55.5%]), indicating re-entry of thyrocytes into the mitotic cell 
cycle, whilst increased geminin protein expression was also observed. Notably, 
geminin protein expression was detected in a subpopulation of thyrocytes (Graves 
Disease: 1.7% [0=1.2-2.2%]; follicular adenoma: 2.2% [O=0.7-3.7%]), a fraction 
less than Ki67 which is present throughout all phases of the mitotic cell cycle, in 
keeping with restriction of geminin protein expression to S, G2 and M phase in 
cultured human cells (Wharton et al., 2004). Taken together these data indicate that 
withdrawal of cells from cycle into the quiescent state in vitro and in vivo is coupled 
to down-regulation of the replication licensing machinery and the origin licensing 
inhibitor geminin. The repression of origin licensing may therefore act as a powerful 
downstream mechanism which contributes to loss of proliferative capacity in
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Figure 3.7. Expression of replication licensing factors in normal thyroid, Graves 
Disease and follicular adenoma. Histogram summarising the percentage of nuclei 
expressing Ki67, Mcm2 and geminin in normal thyroid, Graves Disease and 
follicular adenoma (mean ± SD). Geminin identifies a growth fraction less than 
Ki67, consistent with an S-G2-M phase labelling index.
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quiescence/conditional renewal tissues independently of the origin licensing inhibitor 
geminin.
3.3.5, Prolonged cell cycle times of gut stem cells are due to exit o f progenitor 
cells from cycle into an unlicensed quiescent state
In order to define the replication licensing phenotype in self-renewing tissues, the 
data obtained for quiescence/conditional renewal tissues was extrapolated to the 
colon, a typical self-renewing system. As discussed above, self-renewing tissues are 
comprised of three cell populations: a terminally differentiated compartment 
containing functional cells, a transit amplifying compartment and a stem/progenitor 
cell compartment. To determine the replication licensing phenotype of these cell 
populations regulation of Ki67, Mcm2 and geminin protein expression was analysed 
using immunohistochemistry on normal distal colonic crypts obtained from surgical 
resection specimens (n=10).
Application of 3HTdR radioautography, vincristine mitotic accumulation (VCA) and 
per cent labelled mitosis (PLM) techniques has helped to define the cell cycle 
kinetics of stem cell hierarchies in gut epithelial cell populations (Figure 3.8, 
diagram) (Wright and Alison, 1984; Potten and Loeffler, 1987). These studies 
suggest that the stem cells of the gastrointestinal tract have unusually prolonged cell 
cycle times, about twice as long as committed progenitor cells of the transit 
amplifying populations (Potten, 1986). Two cell kinetic models are consistent with 
these observations, either stem cells are traversing through the mitotic cycle with a 
markedly prolonged G1 phase or, alternatively, have reversibly withdrawn from the 
proliferative cycle into GO. Since down-regulation of origin licensing factors and
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Figure 3.8. Gut stem cells reside in an "unlicensed" quiescent state. Ki67, Mcm2 
and geminin protein expression in colonic mucosa (x200 and x350). The schematic 
drawing of a colonic crypt shows the basal proliferative compartment (BC) 
containing the putative stem cell compartment (SCC) [4th position and below], and 
the transient amplified compartment (TAC). The luminal compartment contains 
differentiating mucus-secreting goblet cells that have lost proliferative potential 
(DC). A large fraction of cells in the BC express Ki67, Mcm2 and geminin. A subset 
of differentiating cells express Mcm2, with Ki67 and geminin rapidly down- 
regulated during the proliferation-differentiation switch. In contrast to the majority of 
cells in the BC, very low levels of Ki67, Mcm2 and geminin expression are observed 
in the putative SCC, indicating that the majority of these cells are unlicensed.
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geminin defines the quiescent state in vitro and in vivo, it may be postulated that the 
dynamics of origin licensing can be exploited to distinguish between these two 
models.
The gastrointestinal tract is a well characterised model for studying stem cell 
populations with the stem cells thought to reside in the base of the crypt with 
unidirectional flux of differentiating cells to the surface (Figure 3.8, diagram). The 
precise position and number of stem cells in gut epithelium is based on 
circumstantial evidence, but the consensus opinion is that stem cells are located at 
the base of distal colonic crypts. The ‘unitarian hypothesis’ postulates that the 
epithelial cell lineages of the gastrointestinal tract are clonal populations derived 
from a single stem cell (Ponder et al., 1985; Griffiths et al., 1988), but opposing 
reports have suggested from 4-6 stem cells per crypt (Hendry et al., 1989; Potten & 
Loeffler, 1990) while others suggest up to 16 stem cells per crypt (Brittan and 
Wright, 2004). Stem cell number has also been shown to fluctuate throughout the 
crypt cycle (Loeffler et al., 1997) and throughout different regions of the 
gastrointestinal tract (Cai et al., 1997). An additional problem when considering stem 
cells is the definition of the term itself, since many different interpretations have 
been proposed in the literature. It has been put forward by Potten and Loeffler that 
‘sternness’ is not necessarily a single property, but a number of properties which a 
cell has the capability of executing depending on the circumstances (Potten & 
Loeffler, 1990). From this definition of sternness it can be postulated that in addition 
to the presence of true (or actual) stem cells in the crypt base there may also exist a 
number of potential stem cells, most probably the first progeny of actual stem cells 
that are capable of stem cell function if necessary. Furthermore the concept of
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complex stem cell niches has recently been invoked, niches that are characterised by 
their ability to support multiple stem cells, thus allowing the generation of multiple 
product cells (i.e. pleoclonal or polyclonal) (Ohlstein et al., 2004).
For this study, analysis of the distal colonic crypts was divided into three 
compartments (Figure 3.8, diagram). The luminal (differentiated) compartment (DC) 
lies in the upper two thirds of the crypt and contains the functionally-differentiated 
mucus-secreting goblet cells. The lower third of the crypt contains the basal 
proliferative compartment which is separated into the transit amplifying 
compartment (TAC) and the putative stem cell compartment (SCC). Based on 
published evidence (Hendry et al., 1989; Potten and Loeffler, 1990; Brittan and 
Wright, 2004), the stem cell compartment in the distal colonic crypts was defined as 
the 4th position and below. Representative immunostained tissue sections are 
illustrated in Figure 3.8 and mean labelling indices (percentage of positive cells) for 
each protein are shown in Figure 3.9. The labelling indices for Ki67, Mcm2 and 
geminin are highest for cells occupying the transient amplifying compartment (Ki67 
[77.8%, 0=65.6-90.1%], Mcm2 [89.6%, CI=85.1-94.2%], geminin [28.2%, 
0=20.4-36.0%]) with marked reductions in all three biomarkers of growth as cells 
lose their proliferative capacity, migrate into the differentiated compartment and 
adopt the terminally-differentiated phenotype (surface functional cells) (Ki67 
[11.4%, 0=8.2-14.5%], Mcm2 [36.8%, 0=28.9-44.8%], geminin [3.0%, 0=1.6- 
4.5%]). Taken together these data confirm previous findings that engagement of the 
differentiation programme is coupled to down-regulation of RLFs and that geminin 
does not appear to function as an inducer or regulator of differentiation in somatic 
self-renewing systems (Stoeber et al., 2001; Eward et al., 2004).
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Figure 3.9. Expression of replication licensing factors in distal colonic crypts, 
(a-b) Labelling indices (expressed as the percentage of Ki67, Mcm2 and geminin 
immunostained cells) in relation to stem cell (SCC), transient amplified (TAC) and 
differentiated (DC) anatomical compartments. Note that SCC and TAC together 
make up the basal proliferative compartment (BC). The proliferation-differentiation 
switch and loss of DNA replication competence as cells migrate from the BC to the 
DC are coupled to down-regulation of Ki67, Mcm2 and geminin. Terminally- 
differentiated cells are unlicensed. The SCC compartment contains unlicensed cells 
characterised by low level expression of Ki67, Mcm2 and geminin. Migration of 
cells from the SCC to the TAC is associated with a dramatic increase in expression 
of Ki67, Mcm2 and geminin, indicative of cell cycle re-entry. The quiescent (GO) 
and terminally-differentiated states (SCC v DC) show identical unlicensed 
replication phenotypes, indicative of withdrawal from cycle.
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Intriguingly, the labelling indices for cells occupying the putative stem cell niche are 
indicative of a different origin licensing state compared to other cells of the basal 
proliferative compartment. In comparison with the transit amplifying compartment, 
there is down-regulation of Ki67 (26.8%, CI= 16.9-36.7%), Mcm2 (52.1%, CI=41.5- 
62.8) and geminin (8.1%, 0=5.4-10.7%). In fact, the origin licensing state of the 
putative stem cell niche more closely resembles that of the differentiated 
compartment than that of the transit amplifying compartment (Wilcoxon signed-rank 
test: Ki67 [/N).005], Mcm2 [P=0.005], geminin [P=0.005]). These data argue in 
favour of a cell kinetic model for gut stem cells in which a significant proportion of 
the progenitor cells in the stem cell niche are unlicensed and have therefore 
reversibly withdrawn from the mitotic cell cycle. Furthermore, the detection of a 
number of unlicensed cells in the putative stem cell zone supports models and 
experimental data pointing to the presence of multiple stem or stem-like cells in these 
zones (Ohlstein et al., 2004).
3.4. Discussion and Conclusions
The success of chemotherapeutics depends on their ability to kill tumour cell 
populations whilst causing minimal damage to normal cells. Therefore in the design 
of new therapeutic strategies it is critical to evaluate how agents may affect both 
normal and tumour cell populations. The DNA replication licensing machinery has 
recently emerged as a novel target for anti-cancer therapy, and the presence of an 
endogenous origin licensing repressor, geminin, raises the prospect that agents 
mimicking the activity of this protein may provide such therapeutic compounds. A 
comprehensive understanding of how these proteins are regulated during normal 
tissue maintenance and development is therefore crucial.
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Down-regulation of the RLFs Cdc6 and Mcm2-7 has been linked to exit from the 
mitotic cell cycle into GO (Stoeber et al., 1998, 2001; Yan et al., 1998; Berger et al., 
1999; Petersen et al., 2000; Sun et al., 2000). The data presented here show that loss 
of proliferative capacity in GO is a two step-process, and importantly is independent 
of the origin licensing repressor geminin (Figure 3.4c) (Kingsbury et al., 2005; see 
Appendix D). The immediate early response of fibroblasts to density-dependent 
growth arrest is a block to pre-RC assembly mediated through rapid down-regulation 
of the MCM loading factor Cdc6 and induction of the global CDK inhibitor p27 
(Figure 3.4c). These data add further evidence to the emerging picture of Cdc6 as a 
“master regulator” of cell proliferation control in somatic cells (Kubota and 
Takisawa, 2003; Lea et al., 2003; Pelizon, 2003) and primary oocytes (Lemaitre et 
al., 2002; Whitmire et al., 2002). The late response involves complete down- 
regulation and removal from chromatin of the replicative Mcm2-7 helicase (Figure 
3.4c). In recent years several levels of cellular proliferation control have been 
identified during exit from the mitotic cell cycle, illustrating the extensive measures 
to which metazoa go to prevent illegitimate DNA replication and cell division in 
organs with dormant growth potential such as liver and thyroid (Stoeber et al., 2001; 
Blow and Hodgson, 2002). It may therefore be expected that an additional 
mechanism to ensure loss of replicative capacity during exit into GO may include the 
“inhibitory” presence of an antagonist of replication licensing coinciding with the 
observed down-regulation of key origin licensing factors. However consistent with 
the recent observations by Xouri et al. (Xouri et al., 2005), the data presented here 
show that geminin levels are not up-regulated during withdrawal of fibroblasts from 
cycle into GO as might be expected for a putative tumour suppressor protein, but are 
down-regulated with similar kinetics to those observed for Cdc6 (Figure 3.4c). The
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more rapid down-regulation of Cdc6 and geminin may reflect the fact that both 
molecules are targets for APC/C-mediated ubiquitin-dependent proteolysis (McGarry 
and Kirschner, 1998; Petersen et al., 2000) in contrast to MCM expression which is 
most likely regulated at transcriptional level (Schulte et al., 1996). Upon re-entry into 
the mitotic cell cycle and progression into S phase, Cdc6 and Mcm2-7 are re­
synthesised and pre-RCs sequentially re-assembled onto chromatin (Figure 3.5c), in 
keeping with previous reports (Stoeber et al., 1998,2001; Yan et al., 1998; Berger et 
al., 1999; Petersen et al., 2000; Sun et al., 2000). The CDK inhibitor p27 
accumulates in the nucleus at the time of pre-RC assembly (Figure 3.5c), consistent 
with its main role in preventing activation of Cyclin A-associated kinase (Resnitzky 
et al., 1995), and is also associated with chromatin at this time, supporting recent 
findings that p27 can block premature origin firing through its interaction with 
Mcm7 (Nallamshetty et al., 2005). Geminin is de novo synthesised during re-entry 
but, importantly, synthesis and association with chromatin do not occur until late in 
the G0-S transition post pre-RC assembly (Figure 3.5c). Taken together, these data 
demonstrate that withdrawal of the “license” to replicate is sufficient for loss of 
replicative capacity during exit into GO and that geminin is not required to suppress 
proliferative activity during this transition. Therefore, geminin does not appear to 
behave as a classic tumour suppressor protein. However the possibility does exist 
that geminin may play a role in the dissociation of pre-RCs during early stages of cell 
cycle exit. Acquisition of replication competence during re-entry is critically 
dependent on de novo expression of RLFs and re-assembly of pre-RCs onto 
chromatin. Importantly, geminin expression is delayed until late in the G0-S 
transition, suggesting that its absence during the permissive window of pre-RC 
assembly is a prerequisite for re-issuing of the replication license (Kingsbury et al.,
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2005; see Appendix D).
How geminin expression during re-entry into the mitotic cell cycle is temporally 
coordinated with pre-RC assembly is currently unclear. Interestingly geminin and 
Cdtl constitute targets for various members of the E2F family of transcription factors 
and expression of geminin has been linked to the Rb/E2F pathway (Markey et al., 
2004; Yoshida and Inoue, 2004). However, Cdtl expression needs to precede 
geminin expression for pre-RC assembly to be completed before geminin protein 
levels reach an inhibitory threshold, suggesting additional levels of regulation for 
geminin expression.
It is not known whether the observed dynamics in origin licensing and the spatio- 
temporal regulation of geminin expression during GO also apply to quiescent human 
cells in vivo. Expression profiling in thyroid shows that reversible loss of 
proliferative capacity is coupled to repression of origin licensing through down- 
regulation of Mcm2, and that the licensing repressor geminin is not required for GO 
arrest in vivo (Figures 3.6 and 3.7). Graves Disease and thyroid adenoma are hyper- 
proliferative disorders of thyroid in response to inappropriate growth stimuli and 
represent in vivo correlates of cell cycle re-entry from GO. Upon escape from 
quiescence the standard proliferation marker Ki67, Mcm2 and geminin are re­
synthesised in both conditions (Figure 3.7) with striking similarity to the fibroblast 
model system (Figure 3.5c). Taken together, these combined in vitro and in vivo data 
provide a unifying picture for the dynamics of origin licensing during reversible 
growth arrest in GO. Repression of origin licensing through down-regulation of key 
RLFs is a powerful downstream mechanism that contributes to loss of proliferative
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capacity in GO independent of the licensing antagonist geminin (Kingsbury et al., 
2005; see Appendix D). Importantly, the down-regulation of RLFs and geminin 
during withdrawal of cells from cycle into GO, in conjunction with the absence of 
these factors in normal thyroid tissue suggests that conditional renewal tissues should 
be refractory to therapeutic origin licensing inhibitors.
Self-renewing tissue systems are comprised of three cell populations: a terminally- 
differentiated population at the luminal surface of the crypt, a transient amplifying 
population and a stem-cell population at the base of the crypt. Cells of the transient 
amplifying compartment display a replication phenotype predicted for cycling cells 
with expression of Ki67, Mcm2 and geminin. These data indicate that cells within 
this compartment would be sensitive to the action of a therapeutic origin licensing 
inhibitor, an issue which will be addressed in more detail in Chapter Six. Migration 
of cells into the terminally-differentiated compartment, where they obtain a 
functional phenotype and lose their proliferative capacity, is coupled to a marked 
reduction in expression of Ki67, Mcm2 and geminin. These data are consistent with 
previous reports that differentiation and DNA replication licensing are mutually 
exclusive processes in self-renewing and permanent tissues (Stoeber et al., 2001), in 
keeping with the concept of antagonism between the cellular circuits that control 
proliferation and differentiation (Olson and Spiegelman, 1999). In addition, the 
down-regulation of geminin during the differentiation process is consistent with an 
earlier report from our laboratory that geminin does not appear to function as an 
inducer or regulator of differentiation in somatic self-renewing systems (Eward et al.,
2004). Importantly these results also suggest that differentiated cell populations in 
self-renewing tissues, and most likely in permanent tissues, should be refractory to
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therapeutic origin licensing inhibitors.
Intriguingly Ki67, Mcm2 and geminin are also down-regulated in cells occupying the 
putative stem cell niche indicating that these primitive cells may reside in GO. 
Importantly as predicted from the in vitro data (Figures 3.4 and 3.5), these cells also 
do not express the licensing repressor geminin. These data suggest that 
stem/progenitor cells may be distinguished from cycling committed progenitors of 
the proliferative compartment by absence of origin licensing factors and the 
antagonist geminin. This data is supported by recent findings that circulating CD34+ 
haemopoietic progenitor stem cells have an unlicensed phenotype (G.H. Williams 
and K. Stoeber, Department of Pathology, UCL, UK; personal communication). 
Recent studies have demonstrated that stem cells undergo asymmetrical divisions 
and that by discarding newly synthesised DNA which is more prone to replication 
induced mutation, the stem cell utilises an innate mechanism of genome protection 
(Caims, 2002). The data presented here argue that genome protection may also be 
further ensured through withdrawal of stem cells into an “unlicensed” GO state, thus 
restricting the potentially hazardous process of genome duplication and providing 
extended periods for DNA repair. Furthermore, these data suggest that 
stem/progenitor cell populations should be refractory to origin licensing inhibitors. 
Since self-renewing tissue systems, including the gut, are prime targets for cytotoxic 
damage in response to classical chemotherapeutic regimes, the preservation of self- 
renewing stem/progenitor cell populations is extremely important when considering 
the development of novel therapeutic strategies.
In summary, the data presented in this chapter can be exploited to predict how
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normal cell populations may respond to the presence of a therapeutic origin licensing 
inhibitor, such as a geminin mimetic. Functional cells, including quiescent, 
differentiated and stem/progenitor cell populations, have an unlicensed phenotype 
and should therefore be refractory to inhibition of DNA replication initiation. This 
contrasts with normal cycling cell populations which have a licensed phenotype and 
therefore present a target for therapeutic origin licensing inhibitors. However recent 
studies suggest that the putative origin licensing checkpoint may protect normal 
cycling cells from the effects of origin licensing inhibitors whilst transformed cells 
remain susceptible and are therefore killed (Shreeram et al., 2002). In order to 
validate the origin licensing checkpoint as a potential therapeutic target and to further 
investigate the differential response of normal and transformed cells to inhibition of 
DNA replication initiation, I have exploited the endogenous origin licensing 
repressor geminin (see Chapter 6). In addition to providing a molecular tool for early 
proof-of-principle studies, geminin may also provide a useful starting point for the 
development of mimetic compounds as anti-proliferative agents. In order for such 
compounds to be designed, a comprehensive molecular blueprint of geminin’s 
structure and the regions critical for mediating its activity must be established. In 
Chapter Four, I describe a dual approach to define the structure-function relationship 
of geminin and identify regions within the protein that are critical for mediating 
geminin’s activity as an origin licensing inhibitor.
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CHAPTER FOUR 
STRUCTURE-FUNCTION ANALYSIS OF GEMININ
4.1. Introduction
In the previous chapter I showed that withdrawal of cells from cycle into the 
quiescent and differentiated states is coupled to down-regulation of the replication 
licensing machinery. Moreover down-regulation of replication licensing factors in 
stem/progenitor cell populations indicates that these cells may reside for most of the 
time in an out-of-cycle, quiescent (GO) state. Taken together these findings raise the 
exciting prospect that therapeutic licensing inhibitors should not affect these cell 
populations in human tissues, thus ensuring that the majority of normal cells within 
the body are protected from potential cytotoxic effects of such agents. These data 
therefore further validate the replication licensing pathway as a potential anti-cancer 
target and raise the question as to how replication licensing could be inhibited 
therapeutically.
Theoretically, licensing inhibitors could act by interfering with protein-DNA 
interactions (e.g. ORC binding to DNA), protein-protein interactions (e.g. MCM 
helicase assembly), kinase activity (e.g. Cdc7-Dbf4), or phosphatase activity (e.g. 
protein phosphatase 2A), or by mimicking the activity of endogenous (e.g. geminin) 
or exogenous (e.g. HPVI E4, see Chapter 5) replication licensing regulators. Small 
molecule inhibitors of CDKs have already shown some success in clinical 
development, but are compromised by the wide spectrum of action of these global 
cell cycle regulators and the rapid development of resistance (Blagden and de Bono, 
2005; see also Section 1.4.). Current knowledge of Cdc7-Dbf4 suggests that this
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related kinase complex has a much narrower spectrum of action (Masai and Arai, 
2002; see also Section 1.6.) and may therefore provide an attractive therapeutic 
target. As a result, development of Cdc7 kinase inhibitors is in progress in the 
commercial arena as well as in our laboratory. Whilst the screening for Cdc7 kinase 
inhibitors is ongoing, I have sought to exploit geminin for proof-of-principle studies 
evaluating the potential of the replication licensing machinery as an anti-proliferative 
target.
Human geminin is a highly conserved 212 amino acid, 23.5 kDa nuclear protein with 
known homologs in Xenopus (McGarry and Kirschner, 1998), Drosophila (Quinn et 
al., 2001), mouse (Yanagi et al., 2002) and Caenorhabditis elegans (Yanagi et al.,
2005) (Figure 4.1a). Analysis of deletion mutants of geminin has identified three 
almost independent functional regions of the protein (Kroll et al., 1998; McGarry 
and Kirschner, 1998) (Figure 4.1b). The N-terminus of geminin contains a 
destruction sequence (DEAD box, RRTLKMIQP, amino acid residues 23-31) which 
mediates ubiquitin-dependent degradation via the APC/C-26S proteosome pathway 
during mitosis (McGarry and Kirschner, 1998). Deletion/mutation of this sequence 
generates a geminin molecule that is resistant to ubiquitin-dependent degradation 
(McGarry and Kirschner, 1998). Adjacent, and partially overlapping with the DEAD 
box, is a neuralisation domain (aa 28-79) that is necessary for geminin’s function in 
neuronal development (Kroll et al., 1998). Within the neuralisation domain are 
several clusters of basic amino acids (aa 50-62) that serve as a nuclear localisation 
signal (Benjamin et al., 2004). The central region of geminin consists of a highly 
conserved coiled-coil motif of 35 amino acid residues (aa 112-147) with 5 heptad 
repeats (Lupas, 1996; Burkhard et al., 2001), flanked by an N-terminal sequence rich
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Mouse geminin LFKRKLWDDQLA--SQTSSCG PEANENKDV GDLTQEAFDLISKENPSSQYWKE 98
Rat geminin LSKRKLWDDQLT--SKISSCG PEANENNSV GDLTQEACDLMTKENPSSQYWKE 98
H u m g e m i n i n  LSKRKHRNDHLT--STTSSPGVIV-PESSENKNL---GGVTQESFDLMIKENPSSQYWKE 101
X g e m i n i n H  STKRKLWNDQLT- - SKKAKVEVAVDPEHRENK DCSSEAYDLMVKETPTCLYWKE 109
X g e m i n i n L  STKRKLWNDQLT--SKKAKVEVAVDPEHQENK DCPSEAYDLMVKETPTCLYWKD 109
D a n i o r e r i o  MPKRKMWSAEQVKGSKRVKAEVAVKSTNAENENQP--EGVTQEAYELMIKETPGSSYWKE 114
D_mel_geminin VQVAPKYGKRKCVDTAPAISTKDADTQTDAEAVPLGNADKPITAEDLTSTAE PGENYYKL 120
: . :
M o u s e geminin VAEQRRKALYEALKENEKLHKEIEQKDSEIARLRKENKDLAEVAEHVQYMAEVIERLSN- 157
R a t g e m i n i n  VAEQRRKALYEALTENEKLHKEIEQKDSEIARLRKENKDLAEVAEHVQYMAEVIERLSN- 157
H u m g e m i n i n  VAEKRRKALYEALKENEKLHKEIEQKDNEIARLKKENKELAEVAEHVQYMAELIERLNG- 160
X_geminin_H VAEERRKALYEALQENEKLHKEIELKDEEIARLKQENDELMELAGHVQYMANMIERLTGN 169
X g e m i n i n L  VAEERRKALYEALQENEKLHQEIELKDEEIARLKQENDELMELAGHVQYMANMIERLTGN 169
D a n i o r e r i o  VAEERGKALFSVLQENEKLHKDIEAKDEQ1AQLKTENEELQELAQHVQHMADMIERLTGK 174
D m e l g e m i n i n  LAEQRRLALEDSLTENRHLHERIEGLEEEMDTMRQELDEAKNLVEVLKEICE.......   172
Mousegeminin --EPLDNFESP---- DSQEFDSEEEAVEYSELEDSGAGTCAEETVSSSTDARPCT  206
R a t g e m i n i n  --EPLDNFESP---- DSQEFDSEKETVEYSEPEDSDTGTCAEETVSSSSDGTACT...... 206
Hum geminin - -EPLDNFESL---- DNQEFDSEEETVEDSLVEDSEIGTCAEGTVSSSTDAKPCI 209
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Figure 4.1. Amino acid sequence and structural domains of geminin. (a) Amino 
acid sequence alignment of mouse, rat, human, Xenopus, Zebrafish (.Danio rerio) 
and Drosophila (Djnel) geminin. Highly conserved (*) and partially conserved (: 
and .) residues are indicated. The coiled-coil domain (shaded), and surrounding 
regions, show the highest inter-species homology, (b) Diagram illustrating the 
structural and functional domains of /wgeminin (NLS - Nuclear Localisation 
Sequence).
University College London 128
Evaluation of the DNA replication licensing machinery as an anti-proliferative target. Sarah Kingsbury
in basic amino acid residues and a C-terminus predicted to form a helix (Thepaut et 
al., 2004). Crystallisation of a synthetic peptide of this domain revealed that it forms 
a dimeric parallel two-stranded coiled-coil (Thepaut et al., 2002), whilst mutational 
analyses indicate that it is essential for inhibition of DNA replication (McGarry and 
Kirschner, 1998; Thepaut et al., 2002).
Geminin is expressed in S, G2 and M phase of the cell cycle (McGarry and 
Kirschner, 1998) and functions to prevent re-replication from fired origins by 
interacting with Cdtl thus preventing re-assembly of pre-RCs (Wohlschlegal et al., 
2000; Tada et al., 2001; Yanagi et al., 2002; Cook et al., 2004). Expression of 
geminin interferes with the interactions between Cdtl and Mcm6, Cdtl and Cdc6 
(Cook et al., 2004) and Cdtl and chromatin (Yanagi et al., 2002), whilst 
overexpression of Cdtl reverses the block on licensing imposed by geminin and 
restores DNA replication (Wohlschlegal et al., 2000; Tada et al., 2001). It has 
recently been suggested that two pools of geminin-Cdtl may exist in the cell. 
Geminin and Cdtl bind chromatin at identical or closely adjacent sites (Kulartz and 
Knippers, 2004), with geminin remaining on chromatin after Cdtl has dissociated 
(Maiorano et al., 2004). In addition, soluble geminin-Cdtl complexes are present 
during late S and G2 phase, possibly as a means of protecting newly synthesised 
Cdtl from degradation (Ballabeni et al., 2004). Ubiquitin-mediated degradation of 
geminin in mitosis would therefore release this new Cdtl fraction and enable pre-RC 
assembly in early Gl. This model is supported by knockdown experiments which 
demonstrate that whilst silencing of geminin expression in S phase results in re­
replication (Melixetian et al., 2004), knockdown of geminin in M phase results in 
impaired pre-RC formation during the ensuing cell cycle (Ballabeni et al., 2004).
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The importance of geminin in preventing re-replication during S phase is 
demonstrated by overexpression studies and the expression of non-degradable forms 
of geminin. Addition of geminin to in vitro replication reactions containing Xenopus 
egg extracts and sperm DNA prevents DNA replication (McGarry and Kirschner, 
1998), whilst overexpression of Drosophila geminin results in DNA replication 
inhibition, induction of ectopic neuronal differentiation and apoptosis (Quinn et al., 
2001). Adenoviral-induced overexpression of non-degradable human geminin in 
normal IMR90 diploid fibroblasts blocks origin licensing in G1 and thereby prevents 
transition of cells into S phase (Shreeram et al., 2002). In transformed cell lines the 
block to origin licensing does not impede transition into S phase, DNA replication is 
initiated from a few licensed origins and ultimately an apoptotic response is triggered 
either in S phase or G2/M phase depending on the genetic status of the cell 
(Shreeram et al., 2002; see also Section 1.5.4.).
Interestingly geminin has also been shown to play an essential role in allowing entry 
into mitosis, with geminin depletion resulting in centrosome overduplication, mitotic 
defects (Tachibana et a l , 2005), and accumulation of Chkl in its active 
phosphorylated form (McGarry, 2002; Melixetian et a l , 2004). Geminin may also 
provide an intriguing link between the co-ordination of development and 
proliferative control. Geminin is essential for early neuronal specification in Xenopus 
(Kroll et a l , 1998) and Drosophila (Quinn et a l , 2001) with a loss of neural 
patterning in the presence of a putative dominant negative geminin lacking the 
neuralisation domain (Kroll et a l , 1998) and Dm geminin mutants showing defective 
neural differentiation (Quinn et a l, 2001). Recently geminin has been shown to 
directly interact with transcription factors of the Hox and polycomb protein families,
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inhibiting their transcriptional activity (Del Bene et al., 2004; Luo et a l, 2004), and 
to regulate neuronal differentiation by antagonising the activity of Brgl, a catalytic 
subunit of the SWI/SNF chromatin remodelling complex (Seo et al., 2005). It is 
possible therefore that competition for geminin binding results in the establishment 
of an equilibratory system which governs the decision to proliferate or differentiate 
(Luo and Kessel, 2004).
The role of geminin as a repressor of origin licensing and the fact that geminin is a 
relatively small molecule suggest that compounds mimicking geminin activity may 
provide therapeutic origin licensing inhibitors. Since the normal physiological 
activity of geminin does not induce any damage to the DNA, it can be postulated that 
an agent mimicking geminin activity should be non-genotoxic. In addition, the 
disruption of protein-protein interactions as a therapeutic strategy may be more 
robust than inhibiting kinase activity which can lack specificity and be susceptible to 
resistance. Furthermore no suppressor phenotype is known for geminin, whereas the 
requirement for Cdc7 activity is bypassed by the mcm5-bobl mutant (Hardy et al., 
1997). However, in order for therapeutic geminin mimetics to be developed, the 
mechanism by which geminin inhibits origin licensing, the protein-protein 
interaction(s) involved and the regions within the protein which are critical for 
mediating this activity must first be fully understood.
The geminin molecule also represents a powerful molecular tool that can be 
exploited to study the response of normal and cancer cells to inhibition of origin 
licensing. In this chapter I am going to discuss the development of a molecular 
blueprint of geminin for future design of geminin mimetics and the generation of a
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small, non-degradable, biologically active fragment of geminin for use in proof-of- 
principle studies (see Chapter 6). To this end a dual approach was taken to study the 
structure-function relationship of geminin: working as part of a team to resolve the 
structure of geminin by transmission electron microscopy and complementing these 
structural studies with in vitro activity studies. For the latter a 'loading assay’ was 
developed which, in conjunction with an established cell-free DNA replication assay, 
enabled the recruitment of replication licensing factors onto chromatin, and thus the 
ability of geminin and geminin derivatives to block pre-RC assembly, to be 
monitored.
4.2. Materials and Methods
For Transformation of E. coli (2.2.2.), Plasmid isolation (2.2.3.), Site-directed 
mutagenesis (2.2.8.), DNA sequencing (2.2.10), Antibodies (2.3.1.), Expression of 
recombinant /jsgeminin and /wgeminin-FF in E. coli (2.3.3.), Purification of His6- 
/tfgeminin and His6-/isgemininFF (2.3.6.), Peptide synthesis (2.3.11.), SDS- 
polyacrylamide gel electrophoresis (2.3.12), Coomassie Blue staining of SDS-PAGE 
gels (2.3.13.), Immunoblotting (2.4.1.), Immunofluorescence (2.4.2.), Preparation of 
total cell extracts (2.5.5.), Preparation of nuclei and cytosolic extracts (2.6.1.), 
Assaying for DNA synthesis in vitro (2.6.2.), Analysis of in vitro DNA synthesis 
products by confocal fluorescence microscopy (2.6.3.), Chromatin binding assay 
(2.6.4.) and Bioinformatic and database resources (2.7.1.) refer to Chapter Two 
(Materials and Methods). For Chemical crosslinking of recombinant geminin 
proteins (B.I.I.), Electron microscopy (B.1.2.) and Image processing and molecular 
modelling (B.1.3.) see Appendix B.
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4.3. Results
4.3.1. Characterisation o f an in vitro cell-free DNA replication assay 
As discussed in Chapter Three, in cultured NIH/3T3 fibroblasts chromosomal 
replication origins are licensed for DNA synthesis during a defined “window of 
opportunity” between 16 and 18 hours after release from density-dependent growth 
arrest (Figure 3.5c). It has previously been established that nuclei prepared by 
dounce homogenisation during this window show tight synchrony and are capable of 
initiating a single round of semi-conservative DNA replication in a mammalian cell- 
free DNA replication system (Stoeber et al., 1998). In this assay, nuclei are incubated 
with S phase cytosol prepared from synchronised Hela cells along with 
ribonucleoside and deoxyribonucleoside triphosphates and an energy regeneration 
system to allow initiation of DNA replication in vitro (Krude et al., 1997; Stoeber et 
al., 1998) (Figure 4.2). Replication reactions contain biotin-16-dUTP as a marker to 
allow detection of DNA synthesised during the in vitro incubation by confocal 
fluorescence microscopy. The proportion of nuclei replicating is determined from 
printed images of nuclei stained for the presence of DNA by propidium iodide and 
for synthesis of DNA in vitro by fluorescein-linked streptavidin.
Since geminin’s biological role is to inhibit re-replication by blocking pre-RC 
assembly, I first developed an alternative readout to the cell-free system that allows 
the binding of replication licensing factors onto chromatin to be monitored (Figure
4.2). Chromatin-bound protein fractions are obtained by treatment of insoluble 
chromatin with DNase I and salt extraction following nuclear lysis and are resolved 
by SDS-PAGE. Following incubation in a physiological elongation buffer (Buffer A) 
G1 nuclei, prepared 16.25 hours after release from quiescence, have low levels of
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Figure 4.2. A dual readout mammalian cell-free DNA replication system.
Synchronised murine NIH/3T3 nuclei (N) prepared following release of cells from 
quiescence by subculturing into fresh serum are incubated with S phase HeLa 
cytosol (SC) or an elongation buffer (Buffer A/BA) which supports elongation, 
together with NTPs (0.1 mM each), dNTPs (0.1 mM each), an energy regeneration 
mix and biotin- 16-dUTP for 3 hours. Recombinant proteins, antibodies, small 
molecules etc. can be titrated into reactions (x). To monitor DNA synthesis nuclei 
are washed, fixed in paraformaldehyde and stained with propidium iodide to reveal 
DNA (red) and with fluorescein-streptavidin (green) to detect biotin incorporation 
resulting from DNA synthesis. To monitor recruitment of replication licensing 
factors onto chromatin, chromatin-bound protein fractions are isolated by nuclear 
lysis followed by extraction with NaCl and DNasel. Proteins are resolved by SDS- 
PAGE gel electrophoresis and immunoblotted for replication licensing factors and 
Histone HI as a loading control. Nuclei incubated in Buffer A have low levels of 
Mcm2 associated with chromatin, as a result of the small numbers of nuclei which 
have assembled pre-RCs prior to isolation in the G1 nuclear preparation. Incubation 
in S phase cytosol allows active recruitment of Mcm2 to chromatin in vitro.
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chromatin-bound Mcm2, consistent with the small proportion of nuclei that have 
already assembled pre-RCs prior to preparation of the nuclear templates. These 
include both S phase contaminants that have already initiated DNA replication from 
licensed origins, and late G1 nuclei which have completed pre-RC assembly but have 
not yet initiated DNA replication. Chromatin-bound Mcm2 levels are significantly 
increased following incubation in S phase cytosol due to the completion of pre-RC 
assembly by early G1 nuclei. It was previously unclear whether pre-RCs are being 
actively assembled in vitro or, alternatively, whether the initiation of DNA 
replication in this system is dependent on assembly of pre-RCs prior to nuclear 
preparation. These data demonstrate that initiation of DNA replication in the cell-free 
system is dependent to a large extent on dynamic in vitro pre-RC assembly in 
addition to origin firing by CDKs and Cdc7-Dbf4. Since geminin inhibits DNA 
replication by blocking pre-RC assembly, active assembly of pre-RCs in vitro is 
critical for analysis of geminin activity. An assay in which the initiation of DNA 
replication in vitro is solely reliant on CDK/Cdc7-Dbf4 activity, as is true for 
alternative cell free systems (Krude, 2000), would be of no use for such studies. The 
in vitro cell-free DNA replication system coupled to the chromatin-binding assay 
therefore provide a methodology for studying the activity of geminin, and derivatives 
thereof, in vitro.
To assess the replication capacity of nuclei during the Gl-S phase transition, nuclei 
were prepared at various timepoints after release from density-dependent growth 
arrest and incubated in HeLa S phase cytosol. Nuclei prepared from cells within 15 
hours of release failed to initiate DNA synthesis in S phase cytosol (Figure 4.3). 
However, between 16 and 18 hours after release nuclei become competent to
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Figure 4.3. NIH/3T3 nuclei become competent to replicate 15 hours after 
release from quiescence. Synchronised NIH/3T3 nuclei prepared at the indicated 
time after release from quiescence were incubated with HeLa S phase cytosol, which 
induces initiation in competent nuclei, or an elongation buffer (Buffer A), which 
only supports elongation DNA synthesis in nuclei that are already in S phase 
(Stoeber et al., 1998) along with NTPs, dNTPs, and an energy regeneration mix. 
After incubation for 3 hours with biotin-16-dUTP, nuclei were washed, fixed in 
paraformaldehyde and stained with propidium iodide (red) for the presence of DNA 
and with fluorescein-streptavidin (green) to detect biotin-16-dUTP incorporation 
resulting from DNA synthesis in vitro. Replicating nuclei appear yellow in merged 
images. Nuclei prepared within 15 hours after release fail to initiate DNA replication 
in S phase cytosol. Nuclei become competent to initiate replication at 15 hours and 
by 23 hours have entered S phase and show equivalent levels of replication in S 
phase cytosol or Buffer A.
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replicate in S phase cytosol, consistent with the observation in Chapter Three that 
pre-RC assembly occurs at this time (Figure 3.5c). A small proportion of nuclei 
prepared between 16 and 18 hours are able to replicate DNA in Buffer A, which 
supports elongation DNA synthesis but does not allow initiation of DNA synthesis 
(Stoeber et al., 1998). These nuclei represent a small population of cells which have 
progressed back into cycle more rapidly following release from quiescence. At the 
point of nuclear preparation these S phase contaminants contain origins which have 
already fired, enabling DNA synthesis to continue at established replication forks. At 
21 hours after release from quiescence the majority of cells have initiated DNA 
replication and equivalent levels of replication are observed in co-incubations with 
either S phase cytosol or Buffer A. These data demonstrate that competence of G1 
nuclei to replicate in vitro corresponds to the binding of replication licensing factors 
onto chromatin, as has been previously suggested (Stoeber et al., 1998).
4.3.2. Establishment o f assay conditions for the evaluation o f geminin activity in 
vitro
The in vitro cell-free DNA replication system and chromatin-binding assay (Figure
4.2) provide a ‘dual-readout’ for studying the structure-function relationship of 
geminin. Prior to analysing the activity of geminin with this assay, the approximate 
physiological concentration of endogenous geminin was determined. Total cell 
extracts were prepared from 2.5 x 104 NIH/3T3 fibroblasts 12 hours (G1 phase) and 
23 hours (S phase) after release from density-dependent growth arrest, resolved by 
SDS-PAGE and immunoblotted with a geminin antibody (Figure 4.4a). Comparisons 
with increasing amounts of recombinant geminin (see Chapter 2, Figure 2.2) indicate 
that 2.5 x 104 S phase NIH/3T3 fibroblasts contain approximately 1 ng of
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Figure 4.4. Recombinant His^-/i5geminin enters NIH/3T3 nuclei, (a) To
determine the physiological concentration of endogenous geminin, total cell extracts 
(TCE) were prepared from NIH/3T3 fibroblasts 12 hours (G1 phase) and 23 hours 
(S phase after release from density-dependent growth arrest. Extracts from 2.5 x 10^ 
cells were resolved by SDS-PAGE against known auantities of recombinant 
geminin, and immunoblotted for geminin. 1 x 105 S phase cells contain 
approximately 1 ng of endogenous geminin. (b & c) NIH/3T3 nuclei were incubated 
with recombinant His^-Zisgeminin or a control buffer on ice for 30 minutes. 
Transport across the nuclear membrane was assessed by (b) immunofluorescence 
and (c) immunoblotting. For (b) nuclei were stained with an anti-His primary 
antibody and FITC-conjugated secondary antibody and counterstained with 
propidium iodide. For (c) nuclei were pelleted and the supernatant, containing 
untransported geminin, was removed. Nuclei were washed three times with PBS, 
and nuclear extracts were prepared and immunoblotted with an anti-His antibody.
Propidium Iodide
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endogenous geminin, which equates to approximately 106 molecules per cell. This is 
approximately ten times higher than the number of MCM molecules per cell, which 
has been estimated at about 105 (Kearsey and Labib, 1998). To achieve physiological 
concentrations of geminin in cell-free DNA replication reactions containing 1 x 105 
nuclei, 4 ng of recombinant geminin would be required giving a final concentration 
of4nM .
I next sought to determine whether recombinant His6-/wgeminin can enter NIH/3T3 
nuclei prepared for in vitro replication reactions. Although geminin is a small protein 
of 23.5 kDa, published data suggest that it may oligomerise (Thepaut et al., 2002) 
which could impede its uptake into nuclei. To determine that recombinant geminin 
can enter nuclei in vitro, nuclei prepared by dounce homogenisation were incubated 
with 4 pM His6-/tfgeminin on ice for 30 minutes. Nuclei were spun onto coverslips, 
stained with a monoclonal anti-His primary antibody and a FITC-conjugated anti­
mouse secondary antibody, counterstained with DAPI and analysed by confocal 
fluorescence microscopy (Figure 4.4b). Strong FITC staining was detectable in 
nuclei incubated with recombinant geminin, but not in nuclei which had been 
incubated with a control buffer (25 mM Tris pH 7.5, 250 mM NaCl, 10% glycerol). 
To independently confirm these results, nuclei were incubated with His6-/tfgeminin 
as above, washed three times with PBS, and nuclear extracts prepared by incubation 
in a whole cell extract lysis buffer. Extracts were immunoblotted for geminin and 
anti-His, revealing that approximately 50% of the recombinant His6-/isgeminin had 
entered the nuclei (Figure 4.4c). Taken together these data indicate that recombinant 
geminin can enter NIH/3T3 nuclei in vitro.
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To determine the optimal time at which to prepare nuclear templates for assessing 
geminin activity in the cell-free replication system, the effect of geminin on the 
replication capacity of nuclei prepared during release from GO was examined (Figure 
4.5a). Nuclei prepared between 15 and 23 hours after release from GO were 
incubated with 4 pM His6-/wgeminin and S phase cytosol. A 64% reduction in 
replication was observed in nuclei prepared 16.25 hours after release from GO in the 
presence of geminin (Figure 4.5a). This inhibition was reduced to 21% at 18.25 
hours and 4% at 23 hours. The reduction in inhibition at later time-points can be 
explained by the increased proportion of nuclei with assembled pre-RCs in the 
nuclear preparations. Since geminin inhibits the assembly of pre-RCs, it is unable to 
block DNA replication from licensed origins. As the largest reduction in replication 
was observed in nuclei prepared 16.25 hours after release from GO, these nuclear 
templates were used in all subsequent experiments unless otherwise stated.
To determine the geminin concentration that causes maximum inhibition of DNA 
replication in vitro, and to provide evidence that replication inhibition is a direct 
result of geminin activity, His6-/*sgeminin was titrated into replication reactions with
16.25 hour nuclei. His6-/wgeminin was purified to approximately 95% homogeneity 
(see Section 2.3.4, Figure 2.2b, fraction 27) and thus any titratable effect should be a 
result of geminin activity. A replication signal of 24% was observed upon incubation 
in S phase cytosol alone, with no reduction in replication in the presence of a control 
buffer (25 mM Tris pH 7.5, 250 mM NaCl, 10% glycerol). With increasing geminin 
concentrations there was a linear decrease in the percentage of nuclei replicating 
from 13.5% with 0.5 pM geminin to 6.4% with 4 pM geminin, suggesting that the 
inhibition is specific to geminin activity (Figure 4.5b). For all subsequent
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Figure 4.5. Evaluation of recombinant geminin activity in the cell-free DNA 
replication system, (a) Synchronised NIH/3T3 nuclei prepared at the indicated 
time after release from quiescence were incubated with HeLa S phase cytosol or 
Buffer A and recombinant His6-/*sgeminin. The addition of recombinant geminin 
caused a 64% reduction in replication at 16.25 hours. However, addition of geminin 
23 hours after release caused only a 4% reduction in replication, indicating that 
geminin can not interfere with DNA replication in vitro once pre-RCs have been 
assembled, (b) His^-fogeminin was titrated into replication reactions with 16.25 
hour nuclei. Addition of control buffer had no effect on replication. As the 
concentration of recombinant geminin increased, the percentage o f nuclei 
replicating linearly decreased.
University College London 141
Evaluation of the DNA replication licensing machinery as an anti-proliferative target. Sarah Kingsbury
experiments 4 pM recombinant geminin was used, which is approximately 103 times 
the physiological concentration of endogenous geminin.
4.3.3. Recombinant full-length geminin blocks initiation o f DNA replication and 
assembly o f  pre-replication complexes in vitro
Having established optimal conditions for analysing geminin activity in vitro, I next 
sought to determine that exogenous geminin retained its expected physiological 
function in the in vitro assay. Since geminin inhibits DNA replication by blocking 
pre-RC assembly, addition of geminin to nuclei in which pre-RCs have already been 
assembled or in which origins have fired prior to preparation of nuclear templates 
(i.e. entered S phase) should have no affect on DNA replication. In order to test this 
hypothesis, the ability of geminin to block DNA synthesis in G1 nuclei prepared
16.25 hours after release from quiescence (GO), a proportion of which should be 
competent to assemble replication complexes in vitro, and in S phase nuclei prepared 
23 hours after release from GO was assayed. Incubation of G1 nuclei in Buffer A 
resulted in 2.8% of nuclei synthesising DNA (Figure 4.6a). In comparison, 22% of 
the G1 nuclei replicated DNA upon incubation in S phase cytosol, the difference to 
the elongation control representing true initiation in vitro (Figure 4.6a). Addition of 
recombinant geminin to the reaction resulted in 7% of the nuclei replicating, 
indicating that 67% of replication-competent nuclei failed to synthesise DNA in 
vitro. Elongation of DNA replication was sufficiently supported upon incubation of S 
phase nuclei in either Buffer A (67% of nuclei replicating) or S phase cytosol (67%) 
(Figure 4.6b). Importantly, elongation was not affected by addition of recombinant 
geminin (64% of nuclei replicating). Taken together these data demonstrate that 
recombinant full-length geminin inhibits initiation of DNA replication in vitro, but is
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Figure 4.6. Geminin blocks initiation but not elongation of DNA replication in
vitro. NIH/3T3 fibroblasts were driven into density-dependent growth arrest to 
induce GO and nuclei were isolated at (a) 16.25 hours (G1 phase) and (b) 23 hours 
(S phase) after release from contact-inhibition. A small percentage o f S phase 
contaminants are detected in the G1 nuclear preparation (2.8%). Addition of 
recombinant geminin (final concentration: 4 pM) to co-incubations of G1 nuclei in S 
cytosol inhibits initiation of DNA replication in 67% of replication-competent 
nuclei, whilst S phase elongation DNA synthesis is refractory to the presence of 
recombinant geminin. Results are expressed as the percentage of nuclei replicating 
and summarised in the histograms (mean ± SD).
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unable to inhibit elongation DNA synthesis, consistent with the physiological role of 
eminin in blocking re-assembly of pre-RCs (McGarry and Kirscher, 1998; 
Wohlschlegal et a l , 2000; Tada et al., 2001).
To confirm that the loss of replicative capacity of G1 nuclei seen in the presence of 
recombinant geminin is due to inhibition of pre-RC assembly, identical replication 
reactions to those described above were performed, after which chromatin-bound 
protein fractions were resolved by gel electrophoresis and probed for Mcm2, 
recombinant geminin and Histone HI as a loading control. Analysis of the 
chromatin-bound protein fraction of G1 nuclei incubated in Buffer A shows a small 
amount of Mcm2 bound to chromatin (Figure 4.7a), in keeping with a small 
proportion of nuclei which have assembled pre-RCs prior to preparation of nuclear 
templates. Incubation of G1 nuclei in S phase cytosol results in recruitment of Mcm2 
protein to chromatin indicative of pre-RC assembly in vitro and corresponding to an 
8-fold increase in the percentage of nuclei synthesising DNA in vitro (Figure 4.6a). 
Addition of recombinant geminin to co-incubations of G1 nuclei in S phase cytosol 
bans the replication license by blocking loading of Mcm2 to chromatin, 
corresponding to a 67% reduction in replication-competent nuclei. Notably, the block 
to pre-RC assembly in vitro coincides with binding of recombinant geminin to 
chromatin (Figure 4.7a) as has been reported by others for embryonic cell cycles (Li 
and Blow, 2004; Maiorano et al., 2004) and in somatic cells (Kulartz and Knippers, 
2004). Consistent with the failure of geminin to inhibit elongation DNA synthesis, 
addition of recombinant geminin to co-incubations of S phase nuclei in S phase 
cytosol does not affect the level of Mcm2 protein bound to chromatin (Figure 4.7b). 
Taken together these data demonstrate that recombinant geminin inhibits initiation of
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Figure 4.7. Geminin inhibits initiation of DNA replication in vitro by blocking 
recruitm ent of replication licensing factors onto chromatin. Immunoblots of 
Mcm2, recombinant His^-Zwgeminin and Histone HI in chromatin-bound protein 
fractions prepared from nuclei taken through in vitro replication reactions. 
Incubation of G1 nuclei in S cytosol results in recruitment of Mcm2 to chromatin, 
indicative of pre-RC assembly in vitro. Addition of recombinant geminin blocks 
loading of Mcm2 to chromatin, coinciding with binding of recombinant geminin to 
chromatin. Mcm2 is already bound to chromatin in S nuclei isolated post pre-RC 
assembly in vivo and its levels are unchanged in the presence of recombinant 
geminin.
S NucleiG1 Nuclei
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DNA replication, but not elongation DNA synthesis, by actively blocking the 
assembly of pre-RCs, and that this inhibition is associated with the recruitment of 
recombinant geminin onto chromatin.
4.3.4. An N-terminal deletion mutant o f geminin is fully functional at inhibiting 
origin licensing
To enable the future design of anti-proliferative agents mimicking geminin activity 
for testing in mouse tumour models, it is first necessary to understand the mechanism 
by which geminin inhibits the assembly of pre-RCs and to identify the regions within 
the protein that mediate this inhibitory activity. It has been reported for Xenopus 
geminin that the replication inhibition domain is comprised of residues 87 to 168, 
including the coiled-coil domain (McGarry and Kirschner, 1998). The data suggest 
that integrity of the coiled-coil motif is essential but probably not sufficient, and it 
has been postulated that adjacent N- and/or C-terminal sequences are required for 
inhibition of DNA replication. The minimal region of /^geminin required for 
inhibition of origin licensing is unclear. I therefore sought to identify a small 
fragment of geminin that retains biological activity. A number of strategies are 
available for producing protein fragments that can be assayed for activity. These 
include crude mechanisms such as shotgun cloning and more refined mechanisms 
such as limited proteolysis. In the work of this thesis, the latter option was used since
it allowed the rapid generation of a small number of geminin fragments (Dr. A. 
Okorokov; personal communication). Full-length recombinant His6-fogeminin was 
proteolytically cleaved with enterokinase, resulting in two geminin fragments. 
Enterokinase recognises the site DDDDK where D represents a negatively charged 
residue and generally contains one or more serine residues. Analysis by
University College London 146
Evaluation of the DNA replication licensing machinery as an anti-proliferative target. Sarah Kingsbury
a
kDa
100
75
£  *
< r
50
37
Full length geminin
N
25
20
<— 15 kDa
10
5 <4— 9 kDa 3 =  7 kDa
231 =.31 NLS
28i
I
15 kDa 
9 kDa 
7 kDa
□  = DEAD Box Domain
□  = Neuralisation Domain
■  = Five Coiled-Coil Domain
Figure 4.8. Production of two geminin fragments by enterokinase cleavage, (a)
Geminin fragments produced by enterokinase cleavage were resolved by SDS- 
PAGE gel electrophoresis and stained with Coomassie Blue, revealing a longer 15 
kDa fragment and a shorter 9 kDa fragment with a 7 kDa degradation product, (b) 
Mass spectrometry analysis identified the 15 kDa fragment as amino acids 77-212 
and the 9 kDa fragment as aa 77-160, with the 7 kDa fragment degradation product 
containing aa 94-160.
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SDS-PAGE (Figure 4.8a) and mass spectrometry confirmed that the proteolysis 
products were a 15 kDa fragment containing amino acids 77 through to 212 and a 9 
kDa fragment consisting of amino acids 77 to 160 that underwent degradation to 
produce a 7 kDa fragment (amino acids 94-160) (Figure 4.8b). The ability of these 
fragments to inhibit DNA replication initiation in vitro was assayed using the cell- 
free assay. In co-incubations of G1 nuclei with S phase cytosol 22% of nuclei were 
capable of DNA synthesis (Figure 4.9a), whilst incubation with full-length 
recombinant geminin resulted in a reduction in replicative capacity to 7%. A similar 
reduction in replication was observed with the 15 kDa proteolytic fragment (8% of 
nuclei replicating). However, no reduction in replication was observed following 
incubation with the 9,7 kDa fragments. Furthermore, as with full-length geminin 
(Figure 4.7a), a reduction in Mcm2 recruitment to chromatin was observed in the 
presence of the 15 kDa fragment (Figure 4.9b), whilst no reduction could be detected 
in the presence of the 9,7 kDa fragments. Taken together these data suggest that the 
coiled-coil motif is essential but not sufficient for inhibition of DNA replication, with 
N- and/or C-terminal sequences additionally being required.
4.3.5. Analysis o f the molecular structure o f geminin by transmission electron 
microscopy
In order to further understand the structure-function relationship of geminin and the 
active 15 kDa fragment, the structures of the two molecules were analysed using 
transmission electron microscopy (EM) combined with single particle analysis.
I wish to clearly state that the single particle EM, angular reconstitution image 
analysis and chemical cross-linking experiments described in 4.3.5. are entirely the
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Figure 4.9. The N-terminal 80 amino acids of geminin are not required for 
inhibition of DNA replication, (a) Addition of the 15 kDa fragment to replication 
reactions containing G1 nuclei resulted in an inhibition of DNA replication almost 
identical to that achieved with full length geminin (7.65% and 6.8% respectively). 
Addition of the 9,7 kDa fragments had no effect on the replication signal indicating 
that the region between the coiled-coil and the C-terminus (aa 160-212) may play a 
critical role in the inhibition of DNA replication. Additionally aa 77-94 may be 
important since these are lost when the 9 kDa fragment degrades, (b) Addition of 
the 15 kDa geminin fragment to G1 nuclei prevents recruitment of Mcm2 onto 
chromatin, whilst the 9,7 kDa fragments have no effect on pre-RC assembly.
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work of A. Okorokov (Department of Pathology, UCL, UK). These data are included 
here as part of the connected argument because they provide critical information to 
complement the functional studies described in 4.3.3., 4.3.4., 4.3.6., and 4.3.7. 
performed entirely by myself in the work of this thesis and enable an understanding 
of the structure-function relationship of geminin. In addition, they provide the 
rationale for the mutational analysis described in 4.3.7.
Since geminin has been reported to aggregate at acidic pH (Th6paut et al., 2002), 
alkaline conditions permissive for protein activity were used. EM raw images of full- 
length geminin appear as a homogenous dispersion of small elongated particles with 
a bulk at one end. A total of 3,300 molecular images were selected manually from 
negatives and subjected to image analysis using angular reconstitution to determine 
the orientations of characteristic views (van Heel et a l , 1996). The structure of full- 
length geminin was refined by iterative procedures of alignment and classification to 
give a final three-dimensional (3D) map of geminin at a resolution of 17.5 A at 0.5 
threshold of Fourier shell correlation (Figure 4.10). The overall shape of the full- 
length geminin molecule resembles a ‘key’ of 175 A in length with four visually 
defined parts: ‘tail’, central ‘body’, two ‘necks’ and a ‘head’ (Figure 4.11). The tail 
domain is -45 A long and ~22 A in diameter at its widest cross-section. In the 
original images it appears longer and seems to be flexible, and is therefore not 
resolved in the reconstruction. The central body domain has a flattened conical shape 
which progresses from tail to head with a size of -44 A at the widest point, ~35 A at 
the narrowest point and a length of -70 A. The overall volume of the body domain 
can accommodate -28 kDa of protein mass assuming a unique density for the protein 
of 0.84 D/A3. The top of the body domain splits into two sleeve-shaped ‘necks’
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Figure 4.10. Three-dimensional reconstruction of geminin. Representative class 
averages together with the corresponding 3D surface representations at different 
'tilt' angles p and y. (i) Class averages (representative views) of geminin particles 
obtained by multi-reference alignment and classification, (ii) 3D structure of 
geminin reprojected in the Euler angle directions found for the class averages in (i). 
The quality of the 3D reconstruction can be assessed by comparison between 
images in rows (i) and (ii). (iii) Surface representation of the 3D reconstruction 
viewed from directions identical to the Euler directions assigned to the 
corresponding class averages shown in (i). The bar represents 175 A. (Figure 
adapted from Okorokov et al., 2004; see Appendix E).
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Figure 4.11. Surface representation of the 3D reconstruction of geminin 
determined at a resolution of ~17.5 A. The 'key'-shaped geminin molecule at 
different angle views. From left to right: main view, top view and side view with 
domain boundaries and their dimensions indicated accordingly. (Figure adapted from 
Okorokov et al., 2004; see Appendix E).
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which enclose a large opening with -26 A between them and -31 A between the 
head and the central body. The neck domains support a large head which is also 
slightly flattened and measures 79 A at its widest and 60 A at its narrowest sides. The 
overall volume of the head is -123 nm3 and can accommodate -64 kDa of protein. 
The overall volume of the molecule is large enough to be fitted with 103 kDa of 
protein mass corresponding well to four geminin monomers of 23.5 kDa each.
To further confirm the tetrameric organisation suggested by the structural analysis, 
chemical cross-linking was performed with increasing concentrations of two 
different cross-linkers (BS3 and EGS). Analysis of the reaction products by SDS- 
PAGE shows that the cross-linked species of geminin predominantly migrate as 
dimeric and tetrameric forms of the protein (Figure 4.12). This supports previous 
data indicating that the coiled-coil domain of geminin has a dimeric organisation 
(Thepaut et al., 2002). Taken together with the structural information, these data 
suggest that the main structural organisation of geminin is a dimer that further 
oligomerises into tetramers or dimers of dimers, suggesting that full-length geminin 
has as additional level of spatial organisation.
It is unclear from the overall organisation of the full-length geminin molecule how to 
assign the amino- and carboxy-terminal domains. However, by resolving the 
structure of the 15 kDa fragment (gemininANt) it should be possible to distinguish 
between different structural domains of the protein. Moreover, structural analysis of 
the 15 kDa fragment should shed further light on the structure-function relationship 
of geminin as a repressor of origin licensing and may enable the design of smaller 
active peptides or mimetic molecules. GemininANt appeared as small thread-like
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Figure 4.12. Chemical cross-linking of recombinant geminin. Full-length 
recombinant geminin was cross-linked with BS^ or EGS and analysed by SDS- 
PAGE. Geminin protein concentration was fixed at 10 mg/ml and concentrations of 
BS3 and EGS were increased from 0.5 to 5 mM as indicated by the ascending 
triangle. Cross-linked geminin species predominantly migrate as dimeric and 
tetrameric forms o f the protein. (Figure adapted from Okorokov et al., 2004; see 
Appendix E).
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elongated particles which were missing the head-like bulk observed for the full- 
length protein (Figure 4.13a). Approximately 300 molecular images were selected 
and subjected to multivariate statistical analysis (Serysheva et al., 1995; van Heel et 
al., 1996). GemininANt particles were uniformly shaped as short filaments o f-170 A 
in length and -25 A in diameter. Since these particles were lacking the head domain 
observed for full-length geminin it can be concluded that this domain must contain 
the amino terminal part of geminin which is missing from gemininANt. The smaller 
diameter of gemininANt suggests that this fragment may have a dimeric rather than a 
tetrameric organisation. To confirm this hypothesis, gemininANt was cross-linked 
with increasing concentrations of BS3 and EGS. Analysis of the reaction products by 
SDS-PAGE shows that the cross-linked species of gemininANt predominantly 
migrates as a dimer (Figure 4.13b). Taken together with the structural data, this 
suggests that residues in the N-terminus of full-length geminin may mediate tetramer 
assembly.
In order to further understand the structural organisation of the geminin molecule, 
structural homology modelling was exploited to determine the location of the coiled- 
coil domain. Since the structure of the coiled-coil domain was unavailable, the 
potential dimeric coiled-coil domain was modelled using SwissModel structural 
homology modelling software using 1GK6 atomic structure as a template (Herrmann 
et al., 2000). This structure, originally used by Th6paut et al. for the molecular 
replacement method (Th6paut et al., 2002), was identified by the Threader 3 program 
(Jones et al., 1992) as a potential match for the geminin sequence. The resulting 
structural model is a leucine/isoleucine zipper (O’Shea et al., 1989; Struhl, 1989) that 
is coordinated into a parallel dimer of of-helices with the majority of hydrophobic
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a
Figure 4.13. Three dimensional reconstruction of gemininANt. (a) Representative 
averages o f gemininANt particles and their sum obtained by multi-reference 
alignment and classification. The bar represents 200 A. (b) GemininANt forms a 
dimer in solution. Recombinant gemininANt was crosslinked with BS^ or EGS and 
analysed by SDS-PAGE. Protein concentration was fixed at 10 Jig/ml and 
concentrations o f BS^ and EGS were increased from 0.5 to 5 mM as indicated by the 
ascending triangle, (c) Space-filled representation o f geminin's dimeric coiled-coil 
domain based on molecular modelling. Hydrophobic residues such as Leu, lie and 
Val are shown in green. (Figure adapted from Okorokov et al., 2004; see Appendix 
E).
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amino acid residues forming the interface between monomers (Figure 4.13c). The 
diameter of the dimer is ~22 A, consistent with the diameter of gemininANt. To 
determine the location of this dimer within the full-length geminin tetramer, the 
atomic model was fitted interactively into the 3D map of geminin using O software 
(Jones and Kjeldgaard, 1997). This docking procedure indicated that the body 
domain of geminin could accommodate two dimeric coiled-coil domains, forming a 
4-helix bundle domain that consists of two 2-strand parallel coiled-coils with their 
amino termini facing up towards the head of the molecule (Figure 4.14). The two 
dimeric coiled-coils form a ‘bouquet’-like shape, at the bottom of which the four 
helices form a rectangular configuration resembling a classic 4-strand coiled-coil 
(Walshaw and Woolfson, 2003). As the coiled-coils twist upwards, the two dimers 
move apart, with the formation resembling two conjoined parallel 3-strand coiled- 
coils. At this point one Of-helix from each dimer appears to interact with the helix 
from the second dimer, potentially through the formation of salt bridges between 
glutamine and lysine residues of the coiled-coil domains. At the top of the central 
body domain the four helices lie almost flat in one plane, consistent with the 
observed flattened shape of the geminin tetramer. These data therefore allow the 
central body part of the 3D map of geminin to be assigned to the coiled-coil domain, 
with a tetrameric, or rather dimer of dimers formation of of-helices. At the top of the 
body the two dimers diverge to form two neck domains with a large opening between 
them that is potentially large enough to accommodate DNA. This opening is closed 
by the two co-joined head domains, containing the amino-terminal residues of 
geminin that are essential for geminin’s function in neuronal development (Kroll et 
al., 1998). The tail domain, which contains the carboxy-terminal domains of 
geminin, appears to be flexible and could not be sufficiently resolved for
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Figure 4.14. Structural organisation of the human geminin tetramer. (a) Slice 
views of the 3D map of human geminin with fitted atomic coordinates of two 
coiled-coil dimers shown as cartoon a-helices. Left, the horizontal cross-section 
depicts the internal organisation within the 4-helix bundle domain. Middle, sliced 
side views on the right side of the panel show the positions of a-helices from each 
dimer within the molecule's shell. Right, position of the dimer within the molecular 
envelope, (b) Schematic representation of protein density divided into the 
independent domains with the protein sequence bar coloured accordingly to the 
right side. (Figure adapted from Okorokov et al., 2004; see Appendix E).
University College London 158
Evaluation of the DNA replication licensing machinery as an anti-proliferative target. Sarah Kingsbury
unambiguous separation of chains.
I wish to reiterate that the experiments described in the previous three pages were 
performed by A. Okorokov (Department of Pathology, UCL, UK) and that they are 
included to complement the functional studies described in 4.3.4., 4.3.4., 4.3.6., and 
4.3.7., which are entirely the work of this thesis.
4.3.6. The coiled-coil domain may mediate oligomerisation o f geminin monomers
Since the structural and cross-linking data indicate that full-length geminin has a 
tetrameric organisation whilst the 15 kDa fragment has a dimeric structure, it can be 
postulated that tetramer assembly is mediated by the N-terminus of geminin and that 
dimerisation may be mediated by residues in the C-terminus of the protein. This 
hypothesis is further supported by crystallisation studies of the coiled-coil domain 
which indicate that this domain alone is capable of dimerisation (Thepaut et al., 
2002), suggesting that it is residues within the coiled-coil domain that are important 
for mediating dimerisation. In order to try to elucidate the region within the coiled- 
coil domain which may mediate this oligomerisation, peptide walking was used to 
design peptides spanning the coiled-coil domain and their ability to interfere with 
geminin activity was assayed using the cell-free DNA replication system. Four 
overlapping peptides were synthesised, encompassing the coiled-coil domain and 
short surrounding sequences (Figure 4.15). Incubation of G1 nuclei with each of the 
peptides had no significant effect on DNA replication (Figure 4.16a), consistent with 
previous findings that the coiled-coil domain is insufficient for inhibition of DNA 
replication (McGarry and Kirschner, 1998). Incubation of G1 nuclei with 
recombinant full-length geminin resulted in an approximate 75% reduction in
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Figure 4.15. Synthesis of coiled-coil domain peptides. Design of four 20mer 
peptides containing overlapping regions of the coiled-coil domain.
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Figure 4.16. Oligomerisation of geminin may be mediated by the C-terminal 
region of the coiled-coil domain, (a) Addition of the coiled-coil domain peptides 
B l, C l, D l, and El to replication reactions containing G1 nuclei and S cytosol had 
no significant effect on the replication signal. However in the presence of 
recombinant geminin (Gm), peptides Dl and El restored replication to 85% of that 
achieved with S cytosol and (b) restored recruitment of Mcm2 to chromatin to a 
similar level to that obtained with S cytosol. These data suggest that the C-terminal 
region of the coiled-coil domain may be involved in oligomerisation of geminin and 
peptides Dl and El may act in a dominant-negative manner to disrupt 
oligomerisation, thereby eliminating the inhibitory activity of geminin.
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replication compared to S phase cytosol alone (Figure 4.16a). This decrease in 
replication was maintained when nuclei were incubated with either peptide B1 or Cl 
in conjunction with recombinant geminin. However, addition of either peptide Dl or 
El to replication reactions containing full- length geminin restored the replication 
signal to 85% of that obtained with S phase cytosol alone, indicating that the peptides 
are able to block the inhibitory action of recombinant geminin. Furthermore, addition 
of peptides Dl and El in conjunction with recombinant geminin resulted in a partial 
rescue of the recruitment of Mcm2 to chromatin, close to that observed with S 
cytosol alone (Figure 4.16b). Taken together these data suggest that the region 
encompassed by peptides Dl and El, the C-terminal region of the coiled-coil 
domain, may be critical in mediating the interaction between geminin monomers. In 
addition these results suggest that dimerisation of geminin may be essential to the 
ability of geminin to inhibit pre-RC assembly.
4.3.7. The neck region o f geminin is critical for mediating inhibition o f origin 
licensing
To identify residues that may be important in mediating geminin’s activity as an 
origin licensing inhibitor, the sequence and structural data available for geminin were 
analysed. Based on our 3D structural model of geminin (Figure 4.14; Okorokov et 
al., 2004; see Appendix E), two potential binding interfaces for Cdtl can be 
postulated, the narrow side of the central body domain and the neck region. The 
narrow side of the central body domain has multiple negative charges on its surface 
and is equivalent in size to the DNA double helix. It may therefore be able to mimic 
DNA and occupy the DNA binding pocket of Cdtl. This hypothesis is supported by 
the finding that the geminin-binding and DNA-binding domains of Cdtl overlap
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Figure 4.17. Identification of a putative Cdtl binding site in the neck region of 
geminin. (a) Amino acid sequence alignment of the neck region of geminin in mouse, 
rat, human, Xenopus, Zebrafish (Daniorerio) and Drosophila (Djnel). Sequence 
analysis identified two highly conserved residues, Y98 and W99 (blue and shaded), 
which may be involved in mediating the interaction of geminin with Cdtl. (b) 
Structure of a truncated mouse geminin-Cdtl complex (Lee et al., 2004) highlighting 
amino acid residues Y98 and W99. Cdtl (aa 179-365) is shown in blue, two geminin 
monomers (aa 79-157) are shown in yellow and green, residues 95 and 96 are 
highlighted in orange and blue. Note that for full-length geminin two additional 
geminin monomers would be present to form a tetrameric structure. The Y98 and 
W99 residues labelled in orange protrude into the opening between the neck regions, 
whilst the two residues labelled in blue protrude outwards from the loop region, 
potentially enabling interaction with Cdtl.
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Figure 4.18. The neck region of geminin is critical for inhibition of origin 
licensing, (a) Addition of gemFF to co-incubations of NIH/3T3 G1 nuclei and HeLa 
S cytosol had no effect on the replication capacity of the nuclei, whereas in control 
reactions containing wildtype geminin a 50% reduction in replicative capacity was 
observed, (b) Consistent with its inability to block DNA replication gemFF had no 
significant effect on chromatin-bound Mcm2 levels compared to S phase cytosol 
whilst wildtype geminin was able to block Mcm2 binding to chromatin. Interestingly 
gemFF was still recruited to chromatin to the same extent as wildtype geminin.
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(Yanagi et al., 2002). The neck region of geminin is spaced out from the rest of the 
molecule and therefore well positioned to engage in protein-protein interactions. 
Analysis of the sequence homology data for this region of the protein revealed a 
highly conserved YW motif at residues 98 and 99 (Figure 4.17a). Analysis of the 
structure of this region of geminin, based on the predicted tetrameric organisation 
(Okorokov et al., 2004; see Appendix E), indicate that for two geminin monomers 
these residues protrude into the opening within the geminin molecule, whilst for the 
other two monomers they protrude outwards (Figure 4.17b), potentially enabling 
contact with another protein. The presence of aromatic hydrophobic residues on the 
surface of a protein often indicates an involvement in protein function, for example 
in protein-protein interactions, since such residues lacking any functional 
involvement are generally not conserved through evolution. In addition, the 
structural data indicate that these residues lie in a loop region and are unlikely to 
interact with each other, suggesting that they may be involved in mediating the 
interaction of geminin with Cdtl. To determine whether Y98W99 are critical for 
geminin’s ability to repress origin licensing, site-directed mutagenesis was used to 
create a double phenylalanine mutant at these residues (gemininFF; see Chapter 2, 
Figure 2.4). The use of phenylalanine residues in the mutant ensures that the 
hydrophobic nature of the region is maintained and thus geminin should remain 
structurally intact. However, by removing the hydroxyl and amine groups of tyrosine 
and tryptophan respectively, there are no longer any functional groups for bonding 
available and therefore any interaction with Cdtl that is mediated by this region of 
geminin may be impeded. To determine whether gemininFF is still functional at 
inhibiting origin licensing, its activity was analysed using the cell-free replication 
system. Incubation of G1 nuclei with gemininFF had no effect on the percentage of
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nuclei replicating compared to S phase cytosol alone (Figure 4.18a). Furthermore, no 
reduction in Mcm2 recruitment to chromatin could be detected in the presence of 
gemininFF (Figure 4.18b). Interestingly however, a similar quantity of gemininFF 
could be detected on chromatin as wild-type geminin. Taken together these data 
indicate that the neck region of geminin (in particular residues Y98W99) plays a 
critical role in mediating the inhibition of origin licensing.
4.3. Discussion and Conclusions
The DNA replication licensing machinery represents an attractive, novel anti-cancer 
target. The existence of an endogenous inhibitor of origin licensing, geminin, 
provides a powerful molecular tool to carry out early proof-of-principle studies to 
validate this target in cell cultures for therapeutic intervention. Moreover, since 
geminin is a relatively small protein it may provide a useful starting point for the 
development of small mimetic compounds for use as therapeutic licensing inhibitors. 
The design of such compounds rests on a detailed biochemical understanding of the 
mechanism of geminin activity and the identification of the regions of the protein 
involved in mediating this activity. In this chapter I have analysed the structure- 
function relationship of geminin in order to further dissect the geminin molecule and 
identify regions critical for mediating inhibition of origin licensing. To analyse the 
activity of geminin in vitro, an assay was developed to monitor the recruitment of 
replication licensing factors onto chromatin. In conjunction with an established in 
vitro cell-free DNA replication system (Stoeber et al., 1998), the chromatin binding 
assay provides a highly sensitive ‘dual readout’ assay for analysing geminin activity 
in vitro. Moreover it has the potential for use as a secondary screen to identify 
compounds which mimic the activity of geminin as an inhibitor of origin licensing.
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The cell-free nature of this assay allows the screening of both cell-permeable and 
cell-impermeable compounds with straightforward addition of reaction components 
and no background from cytotoxic compounds. In addition this assay is amenable to 
automation and has the potential to identify compounds which inhibit DNA 
replication initiation either by mimicking geminin activity (i.e. inhibition of pre-RC 
assembly) or by acting at different points in the pathway, for example Cdc7 kinase 
inhibitors (i.e. blocking origin firing).
Interestingly the ability of geminin to repress origin licensing in nuclei prepared 
during the GO-S transition provides further evidence to support the observation in 
Chapter Three that the absence of geminin in GO may be critical for the re­
acquisition of DNA replication competence during re-entry into the cell cycle. 
Geminin is absent in GO and is expressed post pre-RC assembly approximately 18-21 
hours after release from quiescence (Figures 3.4c and 3.5c). The ability of ectopic 
geminin to block Mcm2 loading onto chromatin in G1 nuclei prepared from 
fibroblasts traversing through the GO-S transition, and the resulting failure of these 
nuclei to initiate DNA synthesis in a cell-free replication assay, suggests that the 
delayed expression of geminin is critical for successful escape from quiescence. The 
presence of geminin in quiescence, or its expression early in the GO-S transition prior 
to pre-RC assembly, would inhibit pre-RC assembly and prevent the re-entry of cells 
from quiescence back into the cell cycle.
The structural and biochemical analyses of geminin indicate that the full-length 
protein assembles into a tetrameric ‘ dimer-of-dimers ’ resembling an elongated 
inflated key with a large opening between the conjoined amino-terminal domains
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(Okorokov et al., 2004; see Appendix E). This structural organisation of geminin is 
in keeping with previous reports of its ‘heavy molecular weight’ behaviour on gel- 
filtration columns (Hodgson et al., 2002). The tetrameric organisation of full-length 
geminin is lost upon removal of the N-terminal region of the protein, with the 15 kDa 
N-terminal deletion mutant forming a dimeric structure (Okorokov et al., 2004; see 
Appendix E). This mutant provides a particularly useful tool for early proof-of- 
principle studies since it lacks the DEAD box domain that mediates ubiquitin- 
dependent proteolysis (McGarry and Kirschner, 1998), thereby rendering it resistant 
to such degradation. The retention of inhibitory activity by the dimeric fragment of 
geminin indicates that tetramer formation is not required for inhibition of DNA 
replication licensing, although it is possible that this additional level of organisation 
may be required for the protein to act as a neuralisation factor (Kroll et al., 1998). 
The minimum region of geminin required for activity as a neuralisation factor is 
amino acids 28-79 (Kroll et al., 1998). Determination of the oligomerisation status of 
this fragment by cross-linking analysis would therefore allow the minimum level of 
organisation required for geminin to act as a neuralisation factor to be established. In 
addition it is possible that the oligomerisation status of geminin may be cell cycle 
regulated with different complexes present at different stages of the cell cycle. To 
determine whether changes to the oligomerisation status of geminin occur during 
transition through the cell cycle, geminin complexes could be immunoprecipitated 
from synchronised cell populations, separated by gel filtration and analysed by 
immunoblotting.
A number of studies have implicated the coiled-coil domain (residues 112-147) in 
the inhibition of DNA replication licensing (McGarry and Kirschner, 1998; Thepaut
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et al., 2002,2004; Benjamin et al., 2004; Saxena et al., 2004), although it is apparent 
that the coiled-coil domain alone is insufficient for inhibitory activity. This is 
confirmed by retention of inhibitory activity by the 15 kDa fragment, containing 
residues 77-212, and the lack of inhibitory activity observed with the 9,7 kDa 
fragments which in the fully degraded 7 kDa form lacks amino acids 1-94 and 160- 
219 (Figures 4.8 and 4.9). Taken together with recent studies by other groups, which 
indicate that residues 70-152 are critical for geminin’s activity as a repressor of 
origin licensing (Saxena et al., 2004), it is apparent that the region N-terminal to the 
coiled-coil (residues 77-112), and possibly a short C-terminal sequence (residues 
147-152) are critical for mediating inhibition of DNA replication, but that amino 
acids 152-212 may be redundant. The minimum region required to inhibit DNA 
replication licensing can therefore be defined as a 75 amino acid fragment containing 
residues 77-152. The importance of the coiled-coil domain is further supported by 
the loss of inhibitory activity observed in the presence of peptides representing the C- 
terminal region of the coiled-coil (Figure 4.16). The mechanism by which peptides 
Dl and El interfere with geminin activity can only be hypothesised from these 
studies. To elucidate the mechanism by which these peptides block geminin activity, 
further studies are necessary. To determine whether inhibition of geminin activity is 
a result of an alteration to the oligomerisation state of the protein, geminin could be 
synthesised by in vitro transcription-translation in the presence/absence of the 
peptides. Cross-linking of the reaction products followed by resolution by gel 
filtration and identification by immunoblotting should reveal changes in the 
oligomerisation status of geminin in the presence of the coiled-coil domain peptides. 
However the involvement of the coiled-coil domain in the dimerisation of geminin 
has been confirmed by other studies, with dimerisation of geminin abolished by
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deletion of residues 117-160 (Benjamin et al., 2004) and by point mutation of 
residues 120, 124, 131 and 134 (Saxena et al., 2004). Taken together these data 
suggest that residues within this region are critical for mediating interaction between 
geminin monomers and that organisation of geminin monomers into a dimeric 
structure may be essential for inhibition of origin licensing.
Repression of origin licensing by geminin relies on its ability to interact with Cdtl 
(Wohlschlegal et al., 2000; Tada et al., 2001; Benjamin et al., 2004; Saxena et al., 
2004). The structural data presented here (Okorokov et al., 2004; see Appendix E) 
and mutational analyses carried out by other groups suggest that two regions may be 
required for interaction between the two proteins (Benjamin et al., 2004; Saxena et 
al., 2004). Residues 100-140, which lie within the coiled-coil domain, are essential 
for interaction with Cdtl (Benjamin et al., 2004), although structural analysis of the 
interaction between mouse geminin and mouse Cdtl indicates that residues 129-149 
(residues 134-154 of human geminin) are required for inhibition of DNA replication 
but not interaction with Cdtl (Lee et al., 2004). Interestingly a mutant containing 
residues 92-152 is capable of interacting with Cdtl but not inhibiting replication 
(Saxena et al., 2004). This may be due to the requirement of an additional region of 
geminin that does not interact with Cdtl, which acts as a bulky mask to prevent 
access of the MCM complex to Cdtl by steric hindrance (Lee et al., 2004). The 
surface of the coiled-coil domain is highly negatively charged suggesting that the 
interaction between the coiled-coil domain of geminin and Cdtl may be mediated by 
strong electrostatic interaction. Elimination of the negatively charged residues on the 
surface of the coiled-coil domain inhibited the interaction of geminin with a fragment 
of Cdtl, but not with full length Cdtl indicating that a second interaction also takes
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place (Saxena et al., 2004). Interestingly, the interaction between geminin and Cdtl 
was also blocked when dimerisation of geminin was inhibited (Saxena et al., 2004). 
The structural data presented here suggested that the second region of geminin 
required for interaction with Cdtl lies in the region N-terminal to the coiled-coil 
domain (Okorokov et al., 2004; see Appendix E). Consistent with this hypothesis, 
mutation of residues Y98 and W99 in the work of this thesis abolished the ability of 
geminin to inhibit DNA replication licensing in vitro, suggesting that an interaction 
between the two proteins may have been impeded (Figure 4.18). In this mutant both 
residues were substituted with phenylalanine residues thereby ensuring that the 
structural integrity of the protein is maintained, but that any hydrogen bonds between 
the side chains of these two amino acids are abolished. Structural analysis of this 
region suggests that it may form a bulky mass (Figure 4.17a) and could either act as a 
hook to interact with Cdtl or block the interaction of Cdtl with the MCM helicase or 
DNA by steric hindrance. Analysis of the ability of this mutant to interact with Cdtl 
was beyond the scope of this thesis, however recent data suggest that mutation of this 
region does not abolish Cdtl binding, but does eliminate inhibition of DNA 
replication licensing (Benjamin et al., 2004). It is unclear from this study, however, 
whether the binding affinity of this mutant with Cdtl is altered with respect to the 
wild-type protein. The ability of this mutant to interact with Cdtl to some extent is 
further supported by the finding that gemininFF is still recruited to chromatin (Figure 
4.18), whilst additional studies suggest that although two interactions are required for 
inhibition of DNA replication, only one interaction is necessary for association of the 
two proteins (Saxena et al., 2004). Given that similar results are obtained when 
residues 98 and 99 are substituted for either phenylalanine (Figure 4.18) or alanine 
(Benjamin et al., 2004), and that phosphorylation of Y98 is not critical for activity
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(Benjamin et al., 2004), it can be speculated that the functional hydroxyl and/or 
amine groups may be important for the interaction between geminin and Cdtl. 
Without the potential H-bond type interactions mediated by these residues the 
interaction between Cdtl and geminin may be destabilised, thereby eliminating the 
inhibitory activity of the protein.
The thermodynamics of protein-protein interactions can be determined using high- 
sensitivity isothermal titration calorimetry (ITC). This technique allows the binding 
equilibrium between two molecules to be measured directly by determining the heat 
evolved on association of a ligand with its binding partner (Pierce et al., 1999). 
Protein-protein interactions can also be monitored by surface plasmon resonance 
(SPR), a technique in which one interaction partner is conjugated to the surface of a 
sensor chip and the other flows over the surface allowing interactions to be measured 
in real-time. Binding events result in changes in protein mass that, in turn, alter 
surface plasmon resonance, an electromagnetic phenomenon that dampens the 
intensity of light reflected off the surface of the sensor chip at a specific angle 
(Myszka, 1997). It would therefore be of interest in future work to use a combination 
of ITC and SPR to establish whether the Cdtl-geminin interaction is disturbed in the 
gemininFF mutant.
Changes to the stability of the geminin-Cdtl complex may also affect the stability of 
the interaction of gemininFF with chromatin. This could be tested by altering the 
methodology for isolating chromatin-bound proteins from nuclei. For the 
experimental work presented in this chapter, chromatin-bound proteins were 
removed using treatment with DNase I and NaCl, a treatment which removes the
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majority of chromatin-bound proteins including those which are strongly attached. 
However, by using a stepwise approach to remove proteins from chromatin, 
progressing from gentle to more stringent conditions, differences in the stability of 
attachment may be identified.
In summary, these studies have identified a 15 kDa fragment of geminin which 
retains full activity as an origin licensing inhibitor, but which lacks the DEAD box 
domain and should therefore be resistant to ubiquitin-mediated degradation. This 
fragment therefore provides a powerful molecular tool for carrying out further proof- 
of-principle studies evaluating the potential of the replication licensing machinery as 
a therapeutic target (see Chapter 6). However, the observation that a 15 kDa 
fragment of geminin is required for activity, that oligomerisation may also be 
essential for activity and that interaction between geminin and Cdtl may involve 
multiple contacts suggests that the geminin blueprint may not be suited to the design 
of small molecule mimetics using medicinal chemistry approaches. Nonetheless the 
potential for the development of geminin mimetics cannot be completely discarded 
without further dissection of the geminin molecule and the complex that it forms 
with Cdtl. Future work may elucidate a mechanism by which the licensing of DNA 
can be therapeutically inhibited. Furthermore it is also interesting to note that 
although traditionally small molecules have provided the majority of anti-cancer 
agents, the emergence of targeted therapies has led to the expansion of molecules 
utilised for therapy including antibodies (e.g. Herceptin) and oligonucleotides (e.g. 
Oblimersen Sodium) (see also Section 1.4.). Therefore it can be envisioned that with 
the right delivery strategy the 15 kDa fragment of geminin (gemininANt) may 
provide a mechanism for therapeutically inhibiting origin licensing in itself, thereby
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eliminating the need to develop small molecule or peptide mimetics. Further to 
providing a blueprint for the design of origin licensing inhibitors, geminin also 
represents a powerful molecular tool for early proof-of-principle studies evaluating 
the replication licensing machinery as a therapeutic target. In Chapter Six, geminin 
and the non-degradable 15 kDa fragment are exploited to study the response of 
normal and transformed cells to origin licensing repression.
In addition to endogenous regulators of cellular processes (for example geminin) 
exogenous and often pathogenic regulators such as viral proteins also exist. In order 
for viruses to propagate within their host environment, they utilise normal host cell 
activity to their own advantage. As a result, many viral proteins interact with cellular 
proteins and interfere with cellular processes, for example the human papilloma virus 
(HPV) E6 protein interacts with p53 whilst HPV E7 interacts with pRb, resulting in 
uncoupling of cellular growth and proliferation (Cheng et al., 1995). Recently a 
novel interaction between HPV1 E4 and two replication licensing factors, Mcm7 and 
Cdc6, was identified (S. Roberts, CR-UK Institute for Cancer Studies, University of 
Birmingham, UK; personal communication). These findings suggest that HPV1 E4 
may impede cellular DNA replication in order to promote viral genome 
amplification. In Chapter Five I describe a functional analysis of the HPV1 E4 
protein and the effect that its interaction with Mcm7 and Cdc6 has on DNA 
replication licensing. Since E4 is a small protein of only 17 kDa, it can be postulated 
that, like geminin, it may provide a starting point for the development of alternative 
mimetic compounds. It is also intriguing to note that since E4 and geminin target the 
same cellular process, together they represent a dual strategy for inhibition of origin 
licensing which may provide an opportunity for combination therapy.
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CHAPTER FIVE
HPV1 E4 INHIBITS DNA REPLICATION 
LICENSING
5.1. Introduction
Initiation of DNA replication is dependent on sequential assembly of 
macromolecular pre-replicative complexes at origins of replication, resulting in 
chromatin being licensed for replication (see also Chapter 1, Section 1.5.). A key step 
in this process is recruitment of the MCM complex onto chromatin by the replication 
licensing factors Cdc6 and Cdtl (Kelman et al., 1999; Chong et al., 2000; Labib et 
al., 2000; Lee and Hurwitz, 2000, 2001; Shechter et al., 2000; Labib and Diffley, 
2001). Prevention of MCM recruitment to pre-RCs is a potential mechanism by 
which DNA replication initiation could be therapeutically inhibited (see also Section
4.1.). Two strategies by which Mcm2-7 could be prevented from assembling into 
pre-RCs include targeting the two parallel loading pathways, mediated by Cdc6 and 
Cdtl, which act in concert to recruit MCM onto chromatin. In Chapter Four, I 
discussed a biochemical analysis of the endogenous origin licensing inhibitor 
geminin, which blocks pre-RC assembly through its interaction with Cdtl. These 
studies have shed further light on the regions of geminin that are essential for 
interacting with Cdtl and for blocking origin licensing, and suggest that an agent 
mimicking the activity of geminin may have potential as a therapeutic origin 
licensing inhibitor. Although no endogenous proteins are known to directly block the 
activity of Cdc6 in recruiting MCM onto chromatin, recent unpublished work has 
established an association between the human papillomavirus-1 (HPV1) E1AE4 
protein (N.B. from hereon in the E1AE4 protein will be referred to as E4), Cdc6 and 
Mcm7 (Sally Roberts, CR-UK Institute for Cancer Studies, University of
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Birmingham, UK; personal communication).
A key feature of viral infection is the disruption of normal host cell activity for the 
benefit of viral reproduction. The study of viral infection has thus greatly enhanced 
our understanding of normal cellular processes. For example, the tumour suppressor 
protein p53 was first identified as a complex with SV40 T-antigen in SV40- 
transformed cells (Lane and Crawford, 1979) whilst the existence of oncogenes was 
first realised following the identification of the Rous Sarcoma virus protein v-src 
(Rous, 1973). Moreover, in addition to furthering our understanding of biological 
processes, viruses have provided us with molecular tools for the manipulation of 
these processes. By understanding the mechanisms by which viruses disrupt host cell 
behaviour and the underlying protein-protein interactions, these activities may be 
exploited for drug discovery and development. For example, the ability of HIV Tati 
to transduce biological membranes has been harnessed for transportation of 
biomolecules into intact cells (see also Chapter 6 and Appendix B), whilst 
manipulation of viruses for gene transport has led to the emerging field of gene 
therapy as a novel therapeutic strategy (Young et al., 2006). ONYX-015 (dll520), a 
replication competent adenovirus that lacks the ELB 55K gene and is therefore only 
able to replicate in cells with deficient p53 activity, is currently under development 
as a novel chemotherapeutic strategy (Heise et al., 1997; see also Section 1.4.). 
Although initial clinical trials with ONYX-015 have been disappointing (Reid et al., 
2001; Vasey et al., 2002; Hamid et al., 2003; Hecht et al., 2003), these studies 
establish the principle for the manipulation and exploitation of viruses and viral 
proteins as a therapeutic strategy.
Two recent reports argue that viruses may engage with the cellular DNA replication
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licensing machinery in order to support replication of their own genome. Infection by 
cytomegalovirus inhibits assembly of the pre-RC by promoting accumulation of 
geminin in infected cells (Biswas et al., 2003), as well as through the action of a viral 
protein, EE2 (Wiebusch et al., 2003). Although the underlying mechanism of 
repression of licensing by cytomegalovirus is unclear, these findings suggest that 
inhibition of cellular DNA replication could prove advantageous to viruses that 
depend on the host cell for the supply of essential host replication enzymes and 
nucleotides for viral DNA synthesis. Modulation of pre-RC activity has also been 
demonstrated for Epstein-Barr virus, although in this instance the virus has been 
shown to recruit cellular replication proteins, such as ORC and MCM, to its own 
origins in order to replicate its genome (Chaudhuri et al., 2001, Dhar et al., 2001). In 
the context of these studies, the finding that HPV1 E4 associates with Cdc6 and 
Mcm7 suggests that one of the roles of E4 in the viral life cycle may be the inhibition 
of cellular DNA replication licensing. In support of this hypothesis, addition of E4 to 
in vitro replication reactions resulted in loss of replicative capacity whilst 
microinjection of quiescent NIH/3T3 fibroblasts with an E4-expressing plasmid 
blocked transition into S phase (K. Stoeber, UCL, UK; personal communication).
Human papillomaviruses are small DNA tumour viruses that infect squamous 
epithelium and are associated with a broad range of clinical manifestations, including 
common hand and foot warts, genital condylomas and invasive cancers. The HPV 
replication cycle has an intimate relationship with epithelial cell differentiation 
(Fehrmann and Laimins, 2003). Thus, while HPV early gene expression occurs in 
proliferating and differentiating layers of the epithelium, vegetative viral genome 
replication, late gene expression, and assembly of new virions are restricted to 
differentiated cells. To support vegetative viral replication in non-dividing
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differentiated cells, the early HPV proteins E6 and E7, through their interactions with 
p53 and pRb respectively, deregulate cell cycle progression and activate the host’s 
DNA replication machinery (Cheng et al., 1995). Host cell replication fork assembly 
and activation would deplete the nucleotide pool and replication enzymes that are 
required by HPV for viral genome amplification, thereby interfering with the 
productive stages of the viral life cycle. The early E4 protein, produced from a 
spliced messenger RNA product E1AE4 that encodes five amino acids from the El 
open-reading frame (ORF) spliced to the protein encoded by the E4 ORF, 
accumulates to a high level at the onset of vegetative HPV genome amplification and 
persists in cells containing newly synthesised virions (Peh et al., 2002). As the viral 
life cycle progresses the 17 kDa spliced gene product is progressively proteolytically 
cleaved to produce 16 kDa, 11 kDa and 10 kDa species of E4 (Figure 5.1; Doorbar et 
al., 1988; Roberts et al., 1994a). In addition to modification by proteolysis, E4 is also 
modified by phosphorylation and self-multimerisation, with at least eight prominent 
species of E4 detected as protein doublets in HPV1 warts (Croissant et al., 1985; 
Doorbar et al., 1986; Grand et al., 1989). Multiple functions have been proposed for 
the E4 protein including inhibition of terminal differentiation to preserve cellular 
integrity and enhance virus synthesis (Rogel-Gaillard et al., 1993), involvement in 
vegetative viral DNA replication (Jareborg and Burnett, 1991), control of virus 
maturation (Doorbar et al,, 1986; Palefsky et al., 1991) and mediation of virus 
release from the epithelial squames by disruption of the cytoskeleton (Doorbar et al., 
1991). Cells containing papillomavirus genomes that are unable to express full- 
length E1AE4 proteins do not support amplification of the viral genome or S phase 
maintenance following cell differentiation (Peh et al., 2004; Wilson et al., 2005). The 
association of Mcm7 and Cdc6 with E4 and the ability of E4 to inhibit DNA 
replication in vitro raise the hypothesis that one of the roles of E4 in the viral life
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Figure 5.1. Expression and processing of the HPV1 E4 protein throughout the 
viral life cycle, (a) HPV1 E4 is expressed as a 17 kDa spliced gene product 
containing the 5 N-terminal amino acids from the El ORF and is proteolytically 
cleaved during the viral life cycle to produce 16 kDa, 11 kDa and 10 kDa species of 
the protein. Full-length E4 contains 3 domains, an N-terminal leucine rich region 
which may be involved in interfilament interaction, an adjacent proline-rich region 
that is essential for mediating G2 arrest and a C-terminal homology domain, (b) 
HPV1 E4 is initially expressed in the parabasal cells coincident with the onset of 
vegetative viral genome amplification. The 16, 11 and 10 kDa species of the protein 
accumulate in a processive manner through the viral life cycle, with the more 
processed forms abundant in the superficial keratinocytes in which capsid protein 
expression (LI) and virion assembly occurs.
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cycle may be to modulate cellular pre-RC function as a means of promoting viral 
DNA replication. These data suggest that E4-based mimetic compounds could 
potentially provide novel non-genotoxic anti-proliferative agents. In this chapter the 
preliminary studies by K. Stoeber have been extended to evaluate the potential of E4 
as an inhibitor of DNA replication utilising the in vitro cell-free DNA replication 
assay and, in particular, the chromatin-binding assay that was established in Chapter 
Four (see Section 4.3.1; Figure 4.3). In addition, the E4 molecule has been further 
dissected to identify regions of the protein critical for inhibition of DNA replication. 
Where necessary for the connected argument, the genetic, biochemical, and 
immunofluorescence investigations performed by S. Roberts are discussed.
5.2. Materials and methods
For Transformation of E. coli (2.2.2.), Plasmid isolation (2.2.3.), Restriction 
endonuclease digestion (2.2.4.), Dephosphorylation of linearised vector DNA 
(2.2.5.), Ligation of DNA (2.2.6.), Polymerase chain reaction (2.2.7.), Agarose gel 
electrophoresis (2.2.9.), Recovery of DNA from agarose gels (2.2.10.), DNA 
sequencing (2.2.11.), Antibodies (2.3.1.), Expression of recombinant HPV1 E1AE4, 
E1AE4R45A and E lAE4A44-48 in E. coli (2.3.4.), Expression of recombinant 
XeCdc6 in Sf9 insect cells (2.3.5.), Purification of His6-HPV 1 E1AE4, His6- 
E1AE4R45A and His6-ElAE4A44-48 (2.3.7.), Purification of baculovirus-expressed 
Hise-A'eCdcb (2.3.8.), SDS-polyacrylamide gel electrophoresis (2.3.12.), Coomassie 
Blue staining of SDS-PAGE gels (2.3.13), Immunoblotting (2.4.1.), Preparation of 
nuclei and cytosolic extracts (2.6.1.), Assaying for DNA synthesis in vitro (2.6.2.), 
Analysis of in vitro DNA synthesis products by confocal fluorescence microscopy 
(2.5.5.) refer to Chapter Two (Materials and Methods). For Expression and
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purification of recombinant HPV1 E4 proteins (B.2.I.), In vitro binding assays 
(B.2.2.), Infection of keratinocytes and immunoprecipitations (B.2.3.), and 
Immunofluorescence (B.2.4.) see Appendix B.
5.3. Results
I wish to clearly state that the experiments described in 5.3.1. are entirely the work of 
S. Roberts (CR-UK Institute for Cancer Studies, University of Birmingham, UK). 
These unpublished data are included here as part of the connected argument because 
they provide the rationale for the functional studies described in 5.3.2., 5.3.3., 5.3.4. 
and 5.3.5. performed entirely by myself in the work of this thesis.
5.3.1. HPV1E4 associates with DNA replication licensing factors 
To identify cellular targets of HPV E4, a yeast two-hybrid analysis of an HaCaT 
keratinocyte cDNA library (Boukamp et al., 1988) was performed using a fusion 
protein between the DNA binding domain of GAL4 and the HPV1 E1AE4 protein 
(amino acids 2 to 125), GAL4DB-E4, as the “bait”. Eight out of 11 colonies carried 
partial cDNAs encoding a C-terminal fragment (128 amino acids) of the DNA 
replication licensing factor Mcm7.
To establish whether HPV1 E4 interacts with Mcm7 in vitro, baculovirus-expressed 
E4 protein was incubated with in vfrro-translated Mcm7 (amino acids 117 to 719) 
and protein complexes isolated with a HPV1 E4 monoclonal antibody (MAb 4.37; 
Doorbar et al., 1988) bound to protein G-sepharose. Radiolabelled Mcm7 could be 
detected bound to the E4 matrix, while no Mcm7 binding could be detected bound to 
a control matrix without E4 protein (Figure 5.2a), confirming an interaction between
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Figure 5.2. HPVl E4 associates with Mcm7 and Cdc6 in vitro and in human 
keratinocytes. (a) In v//ro-binding assays between [35S]-Mcm7 and recombinant 
HPVl and HPV 16 E4 proteins, (b) Immunoblot of E4 immunoprecipitates prepared 
from nuclear fractions o f SV40 immortalised keratinocytes infected with Ad-1E4 or 
Ad-BGal and blotted for E4, Cdc6 and Mcm7 proteins, (c) Immunofluorescence 
microscopy of Ad-lE4-infected SV40-immortalised keratinocytes, dual-stained for 
E4 (green) and Mcm7 (red) or Cdc6 (red). Nuclei were visualised using DAPI (4', 6’- 
diamidino-2-phenylindole; blue). Individual z-images were electronically merged to 
detect co-localisation (yellow). Mcm7 and Cdc6 co-localise with nucleolar E4 and 
co-localisation is maintained in cells pre-treated (1 min) with 0.1% Triton X-100 
(lower panel). Co-localisation between nucleolar E4 and Mcm7 and Cdc6 following 
Triton X-100 pre-treatment was also detected using different Mcm7 and Cdc6 
antibodies (inset panels). Specificity of anti-E4 is shown by absence of staining in 
cells not infected by Ad-HPV1E4 and by absence of staining in Ad-BGal-infected 
cells (data not shown).
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HPVl E4 and Mcm7 in vitro. To investigate whether this interaction was specific to 
HPVl E4, binding studies were repeated with HPVl6 E4, expressed as a glutathione- 
S-transferase (GST) fusion protein (GST-HPV16E4). GST-HPV16E4 bound 
radiolabelled Mcm7, but no Mcm7 could be detected bound to GST or an irrelevant 
GST-fusion protein (GST-FZA-B). Taken together these data demonstrate that the 
E4 proteins from HPV types 1 and 16 associate with Mcm7 protein in vitro.
The target cell type for infection by HP Vs is keratinocytes. To determine whether E4 
associates with endogenous Mcm7 in intact cells, immunoprecipitations were 
performed in extracts from SV40-immortalised skin keratinocytes (SVJD) (Roberts 
et al., 1993) infected with Ad-1E4 or a control virus expressing /3-galactosidase (Ad- 
jSGal). Mcm7 could only be detected in E4 immunoprecipitates of soluble nuclear 
fractions isolated from cells infected with the E4-expressing virus and not the control 
virus (Figure 5.2b). The interaction of E4 with Mcm7 raises the question as to 
whether E4 may also interact with other replication licensing factors. Further 
analysis of the immunoprecipitates revealed complexes containing the MCM loading 
factor Cdc6. E4-Cdc6 and E4-Mcm7 protein complexes were also 
immunoprecipitated from Ad-HPV1 E4-infected human cervical intraepithelial 
neoplasia (CIN) 612-9E keratinocytes (Sally Roberts, personal communication; 
Meyers et al., 1992). Taken together these data show that HPVl E4 associates with 
the cellular replication initiation factors Cdc6 and Mcm7 in human keratinocytes.
The low levels of Mcm7, and in particular Cdc6, in E4 complexes suggest that only 
subpopulations of E4, Cdc6 and Mcm7 may be associated. This hypothesis is 
supported by immunofluorometric analysis of E4, Cdc6 and Mcm7 protein 
distribution in SV40-immortalised human epidermal keratinocytes following
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infection with a recombinant adenovirus expressing HPVl E1AE4 (Ad-1E4). 
Consistent with previous studies (Roberts et al., 1993, 2003), the E4 protein was 
found in both the nucleus and the cytoplasm and co-localises with the keratin 
cytoskeleton. Although there was no evidence for re-distribution of Mcm7 to E4- 
keratin filaments, Mcm7 was found to be co-localised with E4 in the nucleolus 
(Figure 5.2c, upper panel) and co-localisation between nucleolar E4 and Mcm7 was 
also evident in a small percentage of cells in which E4 expression was restricted to 
the nucleus. Localisation of Mcm7 to the nucleolus in the absence of E4 indicates 
that this subnuclear distribution of Mcm7 is not E4-mediated. Cdc6 was also found 
to co-localise with nucleolar E4 in Adl-E4-infected keratinocytes (but only in a 
small proportion (< 5%) of the E4-positive cells) and this association was maintained 
following extraction of cytoplasmic E4 with 0.1% Triton (Figure 5.2c, lower panel). 
Co-localisation of nucleolar E4 with these replication licensing factors was verified 
by using more than one Mcm7 and Cdc6 antibody (Figure 5.2c, inset in lower panel). 
Taken together these data suggest that subpopulations of E4, Cdc6 and Mcm7 
associate in human keratinocytes.
I wish to reiterate that the experiments described in the previous three pages were 
performed by S. Roberts (CR-UK Institute for Cancer Studies, University of 
Birmingham, UK) and that they are included to introduce the following functional 
studies, which are entirely the work of this thesis.
5.3.2. HPVl E4 inhibits the initiation but not elongation o f DNA replication in a 
cell-free DNA replication system
The association of HPVl E4 with the replication licensing factors Mcm7 and Cdc6 
and the preliminary functional studies performed by K. Stoeber (Department of
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Pathology, UCL, UK) indicate that an activity of E4 in the viral life cycle may be the 
modulation of cellular pre-RC function. To test this hypothesis, the effects of 
baculovirus- and bacterially-expressed E4 on DNA replication were assayed using 
the cell-free DNA replication assay1. As described in Chapter Three, in cultured 
NIH/3T3 fibroblasts chromosomal replication origins are licensed for DNA synthesis 
during a defined “window of opportunity” between 16 and 18 hours after release 
from density-dependent growth arrest (Chapter 3, Figure 3.5c). Nuclei prepared 
during this period of pre-RC assembly have the capacity to complete origin licensing 
and to initiate DNA replication when incubated in HeLa S phase cytosol.
Incubation of G1 nuclei prepared 16.25 hours after release from quiescence (GO) in 
elongation buffer resulted in 2% of the nuclei synthesising DNA (Figure 5.3). In 
contrast 19% of nuclei were able to replicate DNA upon incubation in S phase 
cytosol, and addition of recombinant baculovirus-expressed E4 (final concentration 3 
pM; a kind gift from S. Roberts, CR-UK Institute for Cancer Studies, University of 
Birmingham, UK) had no effect on the replication of G1 nuclei (20%). The co- 
immunoprecipitation and co-localisation data from Ad-HP V1 E4-infected 
keratinocytes (Figure 5.2) show that only a subpopulation of Cdc6 molecules 
associates with E4, suggesting that Cdc6 may be required for a putative E4 function. 
As described in Chapter Three, during the GO to S phase transition Cdc6 protein is 
synthesised de novo and is entirely chromatin-bound in G1 nuclei at the point of their 
preparation (Chapter 3, Figure 3.5c). However, in normal cycling cells Cdc6 can be 
found in both soluble and chromatin-bound protein fractions (Saha et al., 1998; 
Fujita et al., 1999; Jiang et al., 1999; Petersen et al., 1999). Hence to reconstitute
1 Although the work described in 5.3.2. has previously been performed by K. Stoeber (Department of 
Pathology, UCL, UK), it was independently repeated in the work of this thesis since these 
experiments form the groundwork for die studies described in 5.3.3., 5.3.4., and 5.3.5.
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Figure 5.3. HPVl E4 inhibits initiation of DNA replication. Addition o f 
baculovirus-expressed E4 to co-incubations of G1 nuclei and Hela S cytosol had no 
effect on DNA replication whilst addition of recombinant XeCdc6 had a slight 
stimulatory effect. Addition o f both E4 and Cdc6 together resulted in a 50% drop in 
the replication potential o f G1 nuclei. Results are expressed as the percentage of 
nuclei replicating and summarised in the histogram (mean ± SD).
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more closely the microenvironment encountered by HPVs in proliferating cells, His6- 
XeCdc6 (see Chapter 2, Figure 2.6) was added to replication reactions in addition to 
E4. Consistent with previous findings that Cdc6 is a rate limiting factor in the 
initiation of DNA replication (Stoeber et al., 1998), addition of 0.65 pM of Cdc6 
caused a 4% increase in DNA replication in G1 nuclei. Importantly in contrast to E4 
alone, addition of E4 in conjunction with exogenous Cdc6 to co-incubations of G1 
nuclei and S phase cytosol resulted in a 50% reduction in replication from 19% to 
11% (Figure 5.3).
NIH/3T3 fibroblasts progress into S phase 21-23 hours after release from density- 
dependent growth arrest (Chapter 3, Figure 3.5). Once DNA replication has been 
initiated, agents which interfere with origin licensing can no longer prevent DNA 
replication, as demonstrated with the endogenous origin licensing repressor geminin 
in Chapter Four (Figure 4.6b), whilst agents that inhibit elongation DNA synthesis 
still remain effective. Hence by altering the time at which nuclear templates are 
prepared the cell-free DNA replication system can be used to determine whether 
inhibition of replication occurs at the initiation or elongation stage (see also Chapter 
4, Section 4.3.3). To determine whether, as is the case for geminin, E4 is unable to 
prevent elongation DNA synthesis in vitro, replication reactions were repeated using 
NIH/3T3 S phase nuclei prepared 23 hours after release from GO as the source of 
template. Elongation of DNA replication was sufficiently supported upon incubation 
of these nuclei in either elongation buffer (Buffer A; 55.6% of nuclei replicating) or 
S phase cytosol (57.2% of nuclei replicating) (Figure 5.4). Importantly, elongation 
was not effected by addition of recombinant E4 (final concentration 3 pM) either on 
its own (57.3% of nuclei replicating) or in conjunction with Cdc6 (55.8% of nuclei
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Figure 5.4. HPVl E4 fails to arrest ongoing DNA synthesis. Elongation of DNA 
replication in NIH/3T3 S phase nuclei prepared 23 hours after release from GO was 
sufficiently supported in either elongation buffer (Buffer A) or S phase cytosol. 
Addition of E4 on its own or in conjunction with exogenous Cdc6 had no effect on 
the replication potential o f the S phase nuclei. Results are expressed as the 
percentage o f nuclei replicating and summarised in the histogram (mean ± SD).
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replicating). Taken together these data demonstrate that E4 specifically inhibits the 
initiation of DNA replication but fails to arrest ongoing DNA synthesis.
5.3,3, HPVl E4 blocks the recruitment o f replication licensing factors onto 
chromatin
For the future design of E4-mimetic compounds as anti-proliferative agents, it is 
essential to elucidate the mechanism by which E4 inhibits the initiation of DNA 
replication. To determine whether the association of E4 with Cdc6 and Mcm7 blocks 
the recruitment of replication licensing factors onto chromatin, G1 and S phase 
nuclei were taken through in vitro replication reactions as described above, and 
chromatin-bound protein fractions resolved by gel electrophoresis and probed for 
Mcm2, Mcm7, Cdc6, E4 and Histone HI as a loading control (Figures 5.5 and 5.6). 
Consistent with the results obtained for geminin in Chapter Four (Figure 4.7a), a 
small amount of Mcm2 and 7 are detectable bound to chromatin in G1 nuclei 
incubated in elongation buffer, whilst incubation in S phase cytosol results in 
recruitment of replication licensing factors to chromatin in vitro and an approximate 
two-fold increase in chromatin-bound Mcm2 and Mcm7 levels (Figure 5.5). In 
keeping with the findings from the in vitro replication reactions addition of 
recombinant E4 had no effect on the recruitment of replication licensing factors to 
chromatin, whilst addition of Cdc6 resulted in a further increase in recruitment of 
MCM and Cdc6 proteins to chromatin. Importantly addition of both Cdc6 and E4 to 
the reaction resulted in an approximate 50% reduction in recruitment of MCM 
proteins to chromatin, whilst levels of Cdc6 remained unchanged. E4 could not be 
detected associated with chromatin in any of the reactions, indicating that 
interactions between E4, Mcm7 and Cdc6 occur prior to recruitment of these
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Figure 5.5. HPVl E4 blocks recruitment of replication licensing factors to 
chromatin in vitro. Immunoblots of chromatin-bound protein fractions prepared 
from NIH/3T3 G1 phase nuclei taken through in vitro replication reactions. Addition 
of E4 and Cdc6 to co-incubations of G1 nuclei and HeLa S cytosol caused a 3.5-fold 
and 2-fold reduction in chromatin-bound Mcm2 and Mcm7 levels respectively, 
compared to addition o f Cdc6 alone. Addition of E4 alone had no effect on 
chromatin-bound levels of Mcm2 and Mcm7. E4 could not be detected associated 
with chromatin and no changes in the level of exogenous chromatin-bound Cdc6 
could be detected. Densities of protein bands were measured using ImageJ and are 
summarised in the histogram expressed relative to the band intensities for S cytosol.
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Figure 5.6. HPVl E4 is unable to alter levels of chromatin-bound replication 
licensing factors in S phase nuclei. Immunoblots of chromatin-bound protein 
fractions prepared from NIH/3T3 S phase nuclei taken through in vitro replication 
reactions. In S phase nuclei pre-RCs have fully assembled and initiation of DNA 
replication has already occured prior to preparation of nuclear templates. Hence 
similar levels of chromatin-bound replication licensing factors are observed in co­
incubations with Buffer A or HeLa S phase cytosol. Consistent with the inability of 
HPVl E4 to inhibit elongation DNA synthesis, addition of E4 alone, or in 
conjunction with endogenous Cdc6, had no effect on the chromatin-binding status of 
Mcm2, Mcm7 or Cdc6. Densities of protein bands were measured using ImageJ and 
are summarised in the histogram expressed relative to the band intensities for S 
cytosol.
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replication licensing factors to chromatin. An association between soluble Cdc6, 
Mcm7 and E4 is further supported by the requirement for exogenous soluble Cdc6 
for E4’s inhibitory activity and the inability of E4 to affect the level of endogenous 
chromatin-bound Cdc6. Furthermore, protein complexes containing Cdc6 and Mcm7 
were immunoprecipitated by an anti-E4 antibody (Doorbar et al, 1988) from soluble 
extracts of S phase HeLa cells containing exogenous recombinant HPVl E4, 
confirming that the physical interaction between these proteins can occur in the 
absence of chromatin (S. Roberts; personal communication). Consistent with the 
inability of E4 to inhibit elongation DNA synthesis, E4 had no effect on chromatin- 
bound levels of Cdc6, Mcm2 or Mcm7 in NIH/3T3 S phase nuclei (Figure 5.6). 
Taken together these data suggest that E4 inhibits DNA replication licensing by 
blocking MCM loading onto chromatin.
To independently verify the in vitro replication data, identical reactions were carried 
out using bacterially-expressed E4 (see Chapter 2, Figure 2.5). Consistent with the 
results obtained for baculovirus-expressed E4, no reduction in replication was 
observed with E4 alone, whilst a similar reduction in replication was observed in the 
presence of exogenous Cdc6 (Figure 5.7a). Furthermore, addition of bacterially- 
expressed E4 to replication reactions in conjunction with exogenous Cdc6 blocked 
the recruitment of Mcm2 and Mcm7 onto chromatin (Figure 5.7b).
5.3.4. The N-terminal region o f E4 is essential for the inhibition o f DNA 
replication
As a prerequisite for future design of E4 mimetic compounds as anti-proliferative 
agents, it is essential to identify the regions within the E4 protein which are 
responsible for its activity in blocking origin licensing. During the HPV life cycle
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Figure 5.7. Inhibition of DNA replication and recruitment of replication 
licensing factors to chromatin by bacterially-expressed HPVl E4. To demonstrate 
the specificity o f  replication inhibition, bacterially-expressed HPVl E4 was added to 
co-incubations o f  G1 nuclei and S phase cytosol on its own, and with Cdc6. 
Consistent with the results obtained for baculovirus-expressed E4, no reduction in 
replication or in the recruitment o f replication licensing factors to chromatin was 
observed with E4 alone, whilst a similar reduction in replication and Mcm2/7 
recruitment to chromatin was observed in the presence of exogenous Cdc6 and E4.
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E4 undergoes progressive N-terminal proteolysis producing smaller species of the 
protein, mediating different activities either as monomers or through the production 
of different hetero- and homodimers (Doorbar et al., 1988; Roberts et al., 1994a). 
The first such naturally occurring proteolytic cleavage removes the 15 N-terminal 
amino acids of the protein to produce a 16 kDa species of E4 (Figure 5.1). To 
determine whether these 15 amino acids are critical for the activity of E4 as an 
inhibitor of origin licensing, the activity of an N-terminal deletion mutant (AE4, a 
kind gift from S. Roberts, CR-UK Institute for Cancer Studies, University of 
Birmingham, UK), which is equivalent to the 16 kDa species of E4, was analysed 
using the cell-free DNA replication system. As with full-length E4, addition of AE4 
alone to in vitro DNA replication reactions had no effect on the replication potential 
of G1 nuclei (Figure 5.8a). However when added to replication reactions together 
with Cdc6, AE4 failed to inhibit DNA replication initiation and did not prevent the 
assembly of both Mcm2 and Mcm7 onto chromatin (Figure 5.8b). Taken together 
these data indicate that the highly conserved N-terminal region of the E4 protein is 
critical in mediating its activity as an origin licensing inhibitor. Inhibition of DNA 
replication may therefore be specific to the full-length version of E4 which occurs 
earliest in HPV infection and may be turned off later in the viral life cycle by 
proteolytic cleavage of the protein, when capsid expression and virion assembly are 
initiated.
5.3.5. A proline rich sequence in E4 is necessary for inhibition o f origin licensing 
Expression of the 16 kDa form of HPVl E4 in keratinocytes has recently been shown 
to arrest cells in G2 phase of the cell cycle with a small population of cells re­
entering the cell cycle and continuing to replicate their DNA without intervening
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Figure 5.8. The highly conserved N-terminal region of E4 is essential for 
inhibition of DNA replication. Addition of a baculovirus-expressed N-terminal 
deletion mutant (AE4) to co-incubations of NIH/3T3 G1 nuclei with HeLa S phase 
cytosol had no effect on either (a) replicative capacity of the G1 nuclei or (b) 
recruitment of replication licensing factors to chromatin either on its own or in 
conjunction with exogenous Cdc6.
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cytokinesis (Knight et al., 2004). Interestingly, when full-length E4 was co­
expressed with the 16 kDa species, the G2/M arrest was maintained but re-replication 
was repressed. Mutational analysis of full-length E4 suggested that amino acids 44- 
48, and in particular R45, may be important for mediating this repression of DNA 
synthesis (Gillian Knight and Sally Roberts, CR-UK Institute for Cancer Studies, 
University of Birmingham, UK; personal communication). To test whether these 
residues are involved in mediating the block to replication licensing that is observed 
with full-length E4 in vitro, the activity of two E4 mutants, E4A44-48 and E4R45A 
(see Chapter 2, Figure 2.5) were analysed in the cell-free DNA replication assay. As 
with full-length wild type E4 (Figure 5.3), incubation of G1 nuclei with either 
E4A44-48 or E4R45 A had no effect on the percentage of nuclei replicating compared 
to S cytosol alone (Figure 5.9a). Both mutants also failed to inhibit DNA replication 
when added to replication reactions together with exogenous Cdc6. Moreover, no 
loss of Mcm2 and Mcm7 recruitment to chromatin was observed following 
incubation of G1 nuclei with Cdc6 and either E4A44-48 or E4R45A. Taken together 
these data indicate that residues 44 to 48, and in particular R45, are critical in 
mediating the inhibition of DNA replication licensing by full-length E4.
5.4. Discussion and Conclusions
Molecular modelling and computer-aided design have emerged as important tools in 
drug discovery and pharmaceutical research (Zeng, 2000; Kitchen et al., 2004; Dahl 
and Sylte, 2005). These techniques utilise the information provided by structural, 
biochemical and biophysical analyses of target molecules to identify chemical 
compounds or peptides that will inhibit or stimulate the activity of the target, or 
mimic its function (Zeng, 2000). Structure-based design and screening strategies
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Figure 5.9. A proline-rich sequence in E4 is necessary for inhibition of origin 
licensing. Addition of the bacterially-expressed point mutant E4R45A or the 
deletion mutant E4A44-48, either alone or in conjunction with exogenous Cdc6, to 
co-incubations of NIH/3T3 G1 nuclei and HeLa S phase cytosol had no effect on 
either (a) the replicative capacity of the G1 nuclei or (b) recruitment of replication 
licensing factors to chromatin. In contrast bacterially-expressed WTE4 caused a 
50% reduction in replicative capacity and blocked the recruitment of Mcm2 and 
Mcm7 onto chromatin.
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FIGURE 5.9.
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have influenced the development of a number of drugs, including HIV protease 
inhibitors (Rizzo et al., 2002; Kroeger-Smith et al., 2003; Udier-Blagovic et al., 
2003a,b) and CDK inhibitors (Kontopidis et al., 2003; Mclnnes et al., 2003; Wu et 
a l, 2003; Andrews et al., 2004). The experimental data presented in this chapter 
suggest that the HPV E4 protein may provide a molecular scaffold for the design of 
anti-proliferative therapeutic agents. Previous studies have identified an association 
between the HPV1 E4 protein and the replication licensing factors Mcm7 and Cdc6, 
suggesting that E4 may interfere with cellular DNA replication licensing and have a 
negative effect on DNA replication. Addition of E4, together with Cdc6, to in vitro 
DNA replication reactions containing G1 nuclei resulted in a reduction in DNA 
replication (Figure 5.3), coupled to a block to recruitment of replication licensing 
factors to chromatin (Figure 5.5). However, addition of E4 and Cdc6 to replication 
reactions containing S phase nuclei had no effect on DNA replication or recruitment 
of replication licensing factors to chromatin (Figures 5.4 and 5.6). These data 
indicate that E4 blocks the initiation of DNA replication by preventing the 
recruitment of replication licensing factors onto chromatin, but is unable to interfere 
with elongation DNA synthesis. Since E4 is a small protein, of only 125 amino acids, 
these studies suggest that E4-based mimetic compounds may provide a strategy for 
therapeutically inhibiting origin licensing. To enable the design of E4-based mimetic 
compounds it is critical to elucidate the mechanism by which E4 inhibits origin 
licensing, to identify the regions within the E4 protein that are critical for mediating 
this activity and to understand further the nature of the complex that is formed 
between E4, Cdc6 and Mcm7.
The precise mechanism by which E4 inhibits pre-RC assembly is still unclear, 
although a number of conclusions can be drawn. Since E4 could not be detected on
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chromatin, is unable to affect binding of endogenous Cdc6 and requires soluble 
exogenous Cdc6 for its inhibitory activity, it is likely that the association of E4 with 
Cdc6 and Mcm7 occurs prior to their assembly into pre-RCs on chromatin. The 
ability of E4, Cdc6 and Mcm7 to interact in the absence of chromatin is further 
confirmed by the immunoprecipitation of protein complexes containing Cdc6 and 
Mcm7 from soluble extracts of HeLa cells containing exogenous HPV1 E4 (Sally 
Roberts; personal communication). Moreover, the low levels of Cdc6 and Mcm7 
found in E4 complexes, in conjunction with the immunofluorescence data, suggests 
that only a subpopulation of E4, Cdc6 and Mcm7 are associated at any one time and 
that the interaction may therefore be transient. This raises the possibility that Cdc6 
may act as a ‘molecular matchmaker’ allowing E4 to interact with Mcm7 and prevent 
its assembly into the MCM hexamer. Further understanding of the mechanism by 
which E4 inhibits DNA replication licensing may be revealed by a comprehensive 
analysis of the complex that is formed between E4, Cdc6 and Mcm7. Firstly it is 
important to determine whether the interaction between E4, Cdc6 and Mcm7 can 
occur in the absence of other factors. This can be achieved by carrying out 
immunoprecipitation and farwestem blotting analyses with recombinant proteins. In 
parallel with these studies, biophysical methodologies, including isothermal titration 
calorimetry (ITC, Pierce et al., 1999) and surface plasmon resonance (SPR, Myszka, 
1997), can be exploited to provide information on the stoichiometry of the complex 
and the binding affinities of the protein-protein interactions. Coupled to structural 
analyses of E4, both alone and in complex with Mcm7 and Cdc6, these studies 
should provide a blueprint for the molecular modelling of E4-mimetic compounds 
and screening for lead compounds.
Further information regarding the regions of E4, Cdc6 and Mcm7 involved in
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mediating complex formation and origin licensing inhibition can be elucidated by the 
use of the techniques described above in conjunction with mutational analyses and in 
vitro activity studies. The experimental data presented in this chapter have identified 
two regions of E4 which are essential for inhibiting origin licensing and which may 
therefore be involved in protein-protein interactions. The activity of E4 as an origin 
licensing inhibitor is dependent on the N-terminal 15 amino acids of the protein 
(Figure 5.8) and on residues 44-48 (Figure 5.9), or at the very least R45. Intriguingly, 
Mcm7- and Cdc6-containing complexes could be immunoprecipitated from soluble 
HeLa cell extracts containing AE4 (S. Roberts; personal communication), indicating 
that the N-terminal region of E4 is not essential for mediating complex formation. 
However, since this interaction is insufficient to block DNA replication licensing 
(Figure 5.8) it can be postulated that complexes formed between AE4, Cdc6 and 
Mcm7 may be unstable. It would be interesting therefore to analyse the binding 
affinities of the AE4/Cdc6/Mcm7 complex using ITC and SPR and similarly to 
assess the role of amino acids 44-48 in mediating complex formation. In addition 
peptide walking and shotgun proteolysis could be exploited to generate small 
fragments of the E4 protein that can be assayed for inhibitory activity, using the in 
vitro DNA replication system and chromatin-binding assay, and for their ability to 
interact with Cdc6 and/or Mcm7, using immunoprecipitation and biophysical 
techniques. It would also be of interest to use shotgun proteolysis to fragment Cdc6 
and Mcm7 in order to determine the regions within these two proteins which interact 
with E4. Alternatively interacting regions may be determined by cross-linking the 
complex formed by recombinant Cdc6, Mcm7 and E4, removing non-interacting 
regions by proteolysis and identifying the remaining peptides, and hence the 
interacting regions, by mass spectrometry. Such studies will allow the critical
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residues required for mediating complex formation and inhibition of DNA 
replication licensing to be identified. Moreover, by identifying the binding interfaces 
between the three proteins this information can be utilised for the molecular 
modelling of E4 mimetics for use as anti-proliferative agents. The inhibition of 
protein-protein interactions, as opposed to interfering with enzyme function (e.g. 
CDKIs), is an attractive strategy for therapeutic agents since such agents generally 
show higher target specificity and less susceptibility to the evolution of drug 
resistance (see also Chapter 1, Section 1.4.).
It is also of interest to note that the functional effect of E4 mimics the endogenous 
origin licensing repressor geminin, which inhibits the initiation of DNA replication 
by blocking incorporation of MCM proteins into pre-RCs. However whilst geminin 
acts through the MCM loading factor Cdtl, E4 targets the MCM loading factor Cdc6. 
Therefore together E4 and geminin represent a dual strategy for inhibition of origin 
licensing, targeting the two parallel pathways required for recruitment of the MCM 
complex onto chromatin. Consequently, development of E4 and geminin-based 
mimetic compounds provides an opportunity for a non-genotoxic combination 
therapy. The use of two therapeutic origin licensing inhibitors in combination should 
increase tumour cell kill leading to improved overall response of the tumour and 
reduce the opportunity for the development of drug resistance.
In addition to providing support for the development of E4-based mimetic 
compounds as novel anti-proliferative agents, the work discussed in this chapter 
sheds further light on the role of E4 in the viral life cycle. An integral part of the 
HPV viral life cycle is the reactivation of cellular genes required to support DNA 
replication. Early in HPV infections the E6 and E7 proteins are expressed leading to
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uncoupling of cellular growth and proliferation through their interactions with p53 
and pRb respectively. Inhibition of p53 and pRb results in upregulation of S phase 
gene activity (Cheng et al., 1995), creating an environment in the cell that supports 
active DNA replication. Use of these replication factors for replication of the cellular 
genome would deplete the host cell nucleotide pool and replication enzymes that are 
required by HPV for viral genome amplification, thereby interfering with the 
productive stages of the viral life cycle. The genetic, biochemical and functional in 
vitro replication data suggest that E4, through its interaction with Cdc6 and Mcm7 
and subsequent inhibition of host cell DNA synthesis, may play a role in ensuring 
that the virus gets maximum benefit from this replication-supporting environment. In 
support of this hypothesis, the induction of S phase gene activity and the switch to 
vegetative viral replication is associated with induction of high levels of E4 protein 
and suppression of DNA synthesis (Peh et al., 2002; Nakahara et al., 2005). 
Moreover, loss of E4 expression is associated with a defect in vegetative genome 
replication in systems that recapitulate the papillomavirus productive replication life 
cycle (Peh et al., 2004; Wilson et al., 2005; Nakahara et al., 2005). It can therefore 
be postulated that in differentiating keratinocytes E4 allows efficient replication of 
the virus genome by inhibiting the recruitment of host cell replication factors to 
cellular origins of replication. The lack of inhibitory activity in the N-terminal 
deletion mutant of E4 (AE4) (Figure 5.8), representative of the 16 kDa form of E4, 
suggests that inhibition of DNA replication may be confined to the full length 
version of E4 which occurs earliest in HPV infection. Posttranslational modification 
may therefore allow E4 to have a pleiotropic role in productive HPV infections.
One constraint of this study is that the data were generated using a number of 
different model systems. Hence these data constitute a circular rather than a direct
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argument for the biological role of E4 as an inhibitor of cellular replication licensing. 
To confirm that the association of E4, Cdc6 and Mcm7 that was detected by 
immunoprecipitation and immunofluorescent studies in keratinocytes is responsible 
for inhibition of DNA replication licensing, the functional studies could be extended 
into a human keratinocyte cell line, the target cell type for HPV infection. One 
mechanism by which this could be achieved is through use of novel small molecule 
carriers (SMoC; see also Chapter 6), to transport recombinant E4 into human 
keratinocytes. If the association of E4 with Cdc6 and Mcm7 is responsible for 
blocking DNA replication licensing then recruitment of replication licensing factors 
to chromatin and the replicative capacity of the keratinocytes should be impeded in 
the presence of exogenous E4.
In summary, the data presented in this chapter suggest that one of the roles of E4 in 
the viral life cycle may be the inhibition of cellular DNA replication licensing, 
thereby supporting efficient amplification of the viral genome. The ability of E4 to 
block origin licensing suggests that E4-based mimetic compounds may provide a 
molecular scaffold for the design of novel non-genotoxic anti-proliferative agents. 
However, the apparent requirement for interaction with both Mcm7 and Cdc6 for 
inhibition of DNA synthesis indicates that multiple regions of E4 may be required for 
mediating this inhibition. Therefore, as with geminin, mimicking the activity of E4 
with a small molecule or peptide may be complex. Further understanding of E4’s 
mechanism of action is therefore critical to elucidate whether mimicking the function 
of E4 with a small molecule or peptide is viable. However, as with geminin, it can be 
envisaged that with the correct delivery strategy E4 itself may provide a mechanism 
for therapeutically inhibiting origin licensing. Together with the analysis of the 
endogenous origin licensing repressor geminin in Chapter Four, these data further
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validate the prevention of MCM recruitment to chromatin as a potential mechanism 
for the therapeutic inhibition of origin licensing. In the following chapter, these 
studies have been extended to investigate the effects of blocking origin licensing in 
normal and transformed cell lines. To achieve this the endogenous origin licensing 
repressor geminin was exploited as a tool for triggering a block to origin licensing, 
delivering the protein into cells using a novel small molecular carrier (SMoC) which 
can transport biomolecules across cellular membranes.
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CHAPTER SIX
NORMAL AND TRANSFORMED CELLS RESPOND 
DIFFERENTLY TO INHIBITION OF ORIGIN
LICENSING
6.1. Introduction
In Chapter Three, I showed that the replication licensing machinery is down- 
regulated as cells withdraw from cycle into the out-of-cycle states of quiescence and 
differentiation (Figures 3.4, 3.6, 3.7, 3.8, and 3.9). Furthermore, the majority of cells 
in the stem/progenitor compartment of the colonic crypt displayed an unlicensed 
phenotype (Figures 3.8 and 3.9). Taken together these data suggest that therapeutic 
origin licensing inhibitors should have no effect on these cell populations. On the 
contrary, the rapidly proliferating cells in the transit amplifying compartment of 
distal colonic crypts contain high levels of replication licensing proteins. 
Consequently these cells would be expected to be affected by origin licensing 
inhibitors, indicating that such inhibitors could have severe cytotoxic effects, 
particularly in the rapidly proliferating gastrointestinal and haemopoetic systems. 
However, preliminary data presented in a recent report (Shreeram et al., 2002) argue 
against this conclusion and suggest that inhibition of origin licensing may provoke a 
differential response in normal and transformed cells (see also Section 1.8.; Shreeram 
et al., 2002). The authors report that adenoviral-induced overexpression of non- 
degradable geminin in untransformed IMR-90 fibroblasts prevents transition into S 
phase, causing cells to arrest with characteristic traits of a G1 cell population 
(Shreeram et a l , 2002). In contrast, osteosarcoma-derived Saos2 and U20S cells are 
able to progress into S/G2 phase, where they subsequently apoptose. These findings 
point towards the existence of a novel checkpoint in G1 phase that monitors the
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assembly of pre-replication complexes at a critical number of origins in normal cells, 
but that may be defective in transformed cells. Up to 30,000 replication origins are 
spread along the chromosomes (Todorovic et al., 1999), and it can be postulated that 
the number of licensed origins must reach a threshold before cells can proceed into S 
phase and initiate DNA replication. An origin licensing inhibitor could reduce the 
number of origins that are licensed, thus triggering activation of the putative ‘origin 
licensing’ checkpoint and stalling normal cells in Gl. If this checkpoint is defective, 
DNA replication initiation may commence with only a subset of replication origins 
licensed, ultimately leading to impaired DNA synthesis and DNA damage. It may be 
postulated that dependent on the genetic background of the cancer cell, DNA damage 
may trigger intra-S phase and G2/M checkpoint pathways, ultimately resulting in an 
apoptotic response. The induction of apoptosis in S phase, as observed for U20S 
(p53+/pRb+) cells (Shreeram et al., 2002), is likely to be triggered by stalled 
replication forks. Although replication fork stalling is a common occurrence during S 
phase, under normal circumstances replication can be continued from an adjacent 
replication origin. However if an insufficient number of origins are licensed, then the 
space between origins may impede the recovery of stalled replication forks, resulting 
in the generation of an intra-S phase checkpoint signal. Defects in the intra-S phase 
checkpoint will allow the continuation of DNA synthesis in the presence of stalled 
replication forks, as observed for Saos2 (p53-/pRb-) cells (Shreeram et al., 2002), 
and progression into mitosis with large unreplicated stretches of DNA. The attempt 
to segregate incompletely replicated chromosomes during mitosis will result in the 
generation of DNA double strand breaks, triggering the activation of G2/M 
checkpoints and the induction of apoptosis (Shreeram et al., 2002).
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The published report by Shreeram and co-workers had two constraints, both linked to 
the adenoviral delivery system used in the study. Firstly, some of the observed 
responses may have been due to secondary effects of the viral infection. For example 
p53 activation, which was attributed to ATM/ATR checkpoint activity in this study 
(Abraham, 2001), is commonly observed in adenoviral infection (Debbas and White, 
1993; Lowe and Ruley, 1993; Grand et al., 1994; Lomonosova et al., 2005). More 
importantly, the difficulty in removing the block to origin licensing due to the 
irreversible nature of adenoviral infections prevented Shreeram et al. from 
determining whether normal cells can recover from the G1 arrest that results from a 
block to origin licensing. This is critical in the context of therapeutic origin licensing 
inhibitors since if normal cells were able to recover following treatment, cytotoxicity 
would be dramatically reduced. These remaining doubts highlight the need for 
independent experimental verification of the differential response to origin licensing 
inhibition and an investigation of whether origin licensing inhibition is reversible in 
normal cells. To address these points and to characterise the putative origin licensing 
checkpoint as a therapeutic target, a novel delivery system was exploited to 
reversibly deliver geminin at near physiological levels into normal and transformed 
cells.
6.2. Materials and Methods
For Transformation of E. coli (2.2.2.), Antibodies (2.3.1), Expression of recombinant 
/wgeminin, /isgeminin-ANt and /isgemininFF in E. coli (2.3.3.), Purification of His6- 
fageminin, His6-/wgeminin-ANt and His6-/wgemininFF (2.3.6.), Coupling of proteins 
to SMoC (2.3.9.), Assaying for efficiency of SMoC-protein coupling (2.3.10.), SDS- 
polyacrylamide gel electrophoresis (2.3.11.), Coomassie Blue staining of SDS-PAGE
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gels (2.3.12), Immunoblotting (2.4.1.), Immunofluorescence (2.4.2.), Cell culture and 
synchronisation (2.5.1.), Assaying for cell proliferation (2.5.3), Assaying for 
apoptosis (2.5.4.), Preparation of total cell extracts (2.5.5.) and Biochemical 
subcellular fractionation (2.5.6.) refer to Chapter Two (Materials and Methods). For 
Design of small molecule carriers, Synthesis of small molecule carriers and 
Molecular modelling please see Appendix B.
6.3. Results
6.3.1. 4G-SMoC rapidly transports FITC into intact cells
In order to deliver geminin into cells, a novel delivery system in the form of small 
molecule carriers (SMoCs), which are biphenyl, alpha helical mimetics of peptide 
protein transduction domains (PTDs), was exploited (Figure 6.1; see also Appendices 
B and F [Okuyama et al., manuscript submitted] for additional information on 
SMoCs). To study the uptake of SMoCs into cells, the accumulation of a 4G-SMoC- 
FITC conjugate in NIH/3T3 fibroblasts was monitored. Cells were incubated with 10 
pM 4G-SMoC-FITC for 5, 10, 15, 30 and 60 minutes, fixed, counter-stained with 
DAPI and visualised by confocal fluorescence microscopy. Cells incubated with 4G- 
SMoC-FITC showed strong intracellular FITC staining whereas no intracellular 
staining was detectable in cells incubated with unconjugated FITC (Figure 6.2). 
Diffuse cytoplasmic staining and some nuclear staining could be detected after five 
minutes whilst after ten to fifteen minutes the staining could be resolved as being 
predominantly nuclear. These data demonstrate that delivery of FITC into cells by 
4G-SMoC is both rapid and efficient. No morphological features of apoptosis were 
noted, indicating that SMoCs are non-toxic.
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Figure 6.1. Chemical structure of small molecular carriers (SMoC). (a)
Molecular model o f a typical alpha helix showing the similar spatial orientation of 
the i and i + 3 positions with the 2 and 2' positions on the biphenyl ring (purple), (b) 
Chemical structure o f 2G-SMoC-FITC and (c) 4G-SMoC-FITC. (d) A late stage 
4G-SMoC-amine intermediate allows a flexible range of attachment chemistries to 
be simply instituted depending on the application.
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Figure 6.2. 4G-SMoC-FITC rapidly enters intact cells. NIH/3T3 fibroblasts were 
incubated with 10 |iM  4G-SMoC-FITC for the indicated time periods, fixed, 
counterstained with DAPI and visualised by confocal fluorescence microscopy. Cells 
incubated with 4G-SMoC-FITC showed strong intracellular staining whereas no 
staining could be detected in cells incubated with unconjugated FITC.
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The mechanism by which SMoCs transport biomolecules into cells is unclear, and is 
beyond the scope of this thesis. Preliminary studies indicate that uptake of SMoC- 
FITC is not affected by temperature or by the presence of cytochalasin D or 
nocodazole, and hence appears to be an energy- and endocytosis-independent process 
(Laman H and Selwood D, Wolfson Institute for Biomedical Research, UCL; 
personal communication). In contrast uptake of SMoC-geminin appears to be 
temperature dependent, suggesting that SMoC may utilise a number of different 
mechanisms to cross cellular membranes depending on the biomolecule to which it is 
conjugated, as is the case for PTDs (Joliot and Prochiantz, 2004). For a more detailed 
discussion of the SMoC delivery mechanism see Appendices B and F (Okuyama et 
a l , manuscript submitted)
6,3.2. 4G-SMoC transports proteins into intact cells
The linker chemistry of SMoCs can be altered to allow conjugation to different 
biomolecules (Figure 6.Id). Conjugation to proteins can be achieved by synthesising 
SMoC with a thiopyridal derivation (SMoC-SSPyr) which allows coupling to 
proteins via the formation of disulphide bonds at cysteine residues in the target 
protein (Figure 6.3a). Geminin has two cysteine residues in its C-terminus (residues 
193 and 208) which should enable coupling to SMoC. Coupling of geminin to 4G- 
SMoC was achieved by reducing the two reactive thiol groups at residues 193 and 
208 using B-mercaptoethanolamine.HCl and mixing with 4G-SMoC-SSPyr reagent 
resulting in coupling via disulphide bond formation (Figure 6.3a). To determine the 
efficiency of this coupling, free sulfhydryl groups were quantitated after reduction by 
p-mercaptoethanolamine.HCl and conjugation to 4G-SMoC using Ellman’s reagent 
(Figure 6.3b). Following reduction by P-mercaptoethanolamine.HCl geminin showed
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Figure 6.3. 4G-SMoC can be efficiently conjugated to proteins via formation of 
disulphide bonds, (a) Schematic showing protocol for coupling of 4G-SMoC to 
geminin. Following reduction of the reactive thiol groups at cysteine residues 193 
and 208, geminin is coupled to 4G-SMoC-SSPyr via disulphide bond formation, (b) 
Quantification of sulfhydryl groups with Ellman's reagent before and after coupling 
indicates that coupling of geminin to 4G-SMoC approaches 100% efficiency.
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an increased absorbance at 412 nm. After incubation with 4G-SMoC the absorbance 
was reduced to zero, indicating that all free sulfhydryl groups that were present 
following P-mercaptoethanolamine.HC1 treatment were no longer free after 
conjugation with 4G-SMoC and hence that coupling efficiency was close to 100% 
(Figure 6.3b).
To assess whether 4G-SMoC-geminin could enter into live cells, NIH/3T3 
fibroblasts were incubated with 1.5 pM 4G-SMoC-geminin or unconjugated geminin 
eight hours after release from quiescence (GO), prior to expression of endogenous 
geminin (see Chapter 3, Figure 3.5c). Following incubation for one hour, cells were 
fixed and immunostained with a rabbit anti-geminin polyclonal antibody (Wharton et 
al, 2004) and a FITC-conjugated anti-rabbit secondary antibody. Diffuse 
cytoplasmic and nuclear FITC staining could be detected in cells incubated with 4G- 
SMoC-geminin but not in cells treated with unconjugated geminin (Figure 6.4a). To 
further confirm these results, total cell lysates were prepared from asynchronously 
proliferating NIH/3T3 fibroblasts following incubation with 1.5 pM 4G-SMoC- 
geminin or unconjugated geminin for one hour. Proteins were resolved by gel 
electrophoresis and immunoblotted with an anti-His antibody to detect 4G-SMoC- 
geminin (Figure 6.4b). Exogenous recombinant geminin could be detected in cells 
incubated with 4G-SMoC-geminin but not in cells incubated with unconjugated 
geminin. Taken together, these data confirm that 4G-SMoC can be efficiently 
coupled to geminin and that conjugated geminin rapidly enters intact mammalian 
cells in culture (Okuyama et a l, manuscript submitted; see Appendix F).
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Figure 6.4. 4G-SMoC-geminin rapidly enters intact cells, (a) NIH/3T3 
fibroblasts were incubated with 4G-SMoC-geminin for one hour, eight hours after 
release from quiescence, when no endogenous geminin is present, fixed, stained 
with an anti-geminin polyclonal antibody, a FITC-conjugated anti-rabbit secondary 
antibody and DAPI, and visualised by confocal fluorescence microscopy. Diffuse 
cytoplasmic and nuclear FITC staining could be detected in cells incubated with 4G- 
SMoC-geminin but not in cells treated with unconjugated geminin. (b) Detection of 
4G-SMoC-geminin with an anti-His antibody in total cell extracts prepared from 
NIH/3T3 fibroblasts incubated with 4G-SMoC-geminin or unconjugated geminin 
for one hour.
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6.3.3. 4G-SMoC-geminin blocks GO-S progression in mouse fibroblasts in a 
concentration-dependent manner
To first determine that geminin retains its biological activity following conjugation to 
SMoCs, the ability of SMoC-geminin to block origin licensing was tested in our 
characterised in vitro system for the re-entry of quiescent fibroblasts into the mitotic 
cell division cycle (see Chapter 3). In addition, this experiment allows the question of 
whether the putative origin licensing checkpoint is active during re-entry into the cell 
cycle from GO to be addressed. In cultured NIH/3T3 fibroblasts chromosomal 
replication origins are licensed for DNA synthesis during a defined “window of 
opportunity” between 16 and 18 hours after release from density-dependent growth 
arrest (see Chapter 3, Figure 3.5c; Stoeber et al., 1998; Kingsbury et al., 2005) and 
progression into S phase can be easily monitored by pulse-labelling with 
bromodeoxyuridine (BrdU) 21 hours after release from contact-inhibition (Figure 
6.5a). To assess the ability of SMoC-geminin to inhibit origin licensing and activate 
the putative origin licensing checkpoint during re-entry into cycle, 4G-SMoC- 
geminin was added at concentrations ranging from 0.5 pM to 10 pM to NIH/3T3 
cells eight hours after release from GO. Cells were pulsed for one hour with BrdU 21 
hours after release, analysed by confocal fluorescence microscopy and the percentage 
of cells synthesising DNA determined (Figure 6.5b). With increasing concentrations 
of 4G-SMoC-geminin the percentage of cells incorporating BrdU gradually 
decreased from 65% in the control population to 36% at 10 pM 4G-SMoC-geminin. 
Substitution of 4G-SMoC-geminin with uncoupled geminin or an equivalent volume 
of control buffer did not affect BrdU incorporation.
Full-length wild type geminin undergoes ubiquitin-dependent proteolysis in M phase,
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Figure 6.5. 4G-SMoC-geminin blocks G0-S progression in mouse NIH/3T3 
fibroblasts, (a) To determine whether 4G-SMoC-geminin can block re-entry into 
cycle from GO 4G-SMoC-geminin was added to NIH/3T3 fibroblasts 8 hours after 
release from quiescence, prior to pre-RC assembly at 16-18 hours, and entry into S 
phase monitored by pulsing with BrdU at 21 hours. Inhibition o f G0-S progression 
increases with (b) 4G-SMoC-geminin and (c) 4G-SMoC-ANt concentration. Results 
are expressed as the reduction in the percentage of cells incorporating BrdU relative 
to the control population, (d) A 50% reduction in G0-S progression was observed 
following treatment with 10 pM 4G-SMoC-geminin and 4G-SMoC-ANt, but not 
with the loss-of-function mutant 4G-SMoC-gemininFF.
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mediated by the destruction box in the N-terminus of the protein (see Chapter 4, 
Figure 4.1b). The 15 kDa N-terminal deletion mutant of geminin (gemininANt) 
discussed in Chapter Four (Figures 4.8 and 4.9; see also Chapter 2, Figure 2.3) lacks 
this motif and therefore should be resistant to ubiquitin-dependent proteolysis. 
Treatment of NIH/3T3 fibroblasts with increasing concentrations of 4G-SMoC-ANt 
resulted in a similar reduction in BrdU incorporation to that seen with full-length 
geminin (Figure 6.5c). Maximal inhibition for both SMoC-geminin and SMoC-ANt 
was observed with 10 pM, and therefore this concentration was used for all 
subsequent experiments.
To determine that the reduction in BrdU incorporation observed with 4G-SMoC- 
geminin and 4G-SMoC-ANt was dependent on geminin activity and not a non­
specific effect of SMoC, the ability of a loss-of-function geminin mutant 
(gemininFF, see Chapter 4, Figure 4.18) to inhibit BrdU incorporation was assessed. 
No reduction in BrdU incorporation was observed with 4G-SMoC-gemininFF 
(Figure 6.5d) whilst a 50% reduction was observed with both 4G-SMoC-geminin and 
4G-SMoC-ANt. Taken together these results demonstrate that delivery of geminin 
into cells by 4G-SMoC does not affect its activity as an origin licensing inhibitor 
(Okuyama et a l , manuscript submitted; Appendix F). Furthermore, these data 
suggest that by blocking pre-RC assembly with exogenous geminin during re-entry 
into the cell cycle, an as yet unknown checkpoint activity may be triggered 
preventing cells from initiating DNA replication from the few origins which may be 
licensed.
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6,3.4, 4G-SMoC-ANt blocks G 1S progression by repressing origin licensing in 
normal asynchronously cycling cells
The ability of 4G-SMoC-geminin and 4G-SMoC-ANt to inhibit re-entry of NIH/3T3 
fibroblasts into the cell cycle from GO, potentially by activating a putative origin 
licensing checkpoint, raises the question as to whether cell cycle progression could 
also be prevented in normal cycling cells. WI-38 human diploid fibroblasts were 
treated with 10 pM 4G-SMoC-ANt for 24 hours (approximately one doubling time) 
to assess the ability of geminin to block cell cycle progression. During the final hour 
of treatment cells were pulsed with BrdU and the percentage of cells incorporating 
BrdU calculated. A 50% reduction in BrdU incorporation was observed in treated 
populations compared to control populations (Figure 6.6a). Since cells will only be 
sensitive to geminin activity during Gl phase, treatment of cells for one population 
doubling may not be enough to catch all cells, which may explain why cell cycle 
progression was only blocked in 50% of cells. In addition it is possible that 4G- 
SMoC-ANt may be susceptible to degradation independently of the ubiquitin-26S 
proteasome pathway, and therefore after 24 hours the intracellular concentration of 
4G-SMoC-ANt in some cells may have been insufficient to block cell cycle 
progression. Longer time-courses, with replenishment of 4G-SMoC-ANt every 12 or 
24 hours, are therefore necessary to determine whether cell cycle progression can be 
blocked in a higher proportion of cells. However these results still demonstrate that 
exogenous geminin can block cell cycle progression, and activate the putative origin 
licensing checkpoint, in normal cycling cells.
To determine the biochemical mechanism by which DNA replication is inhibited 
upon treatment with 4G-SMoC-ANt, changes in chromatin-bound Mcm2 levels were
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Figure 6.6. 4G-SMoC-ANt blocks G l-S progression by repressing origin 
licensing in normal asynchronously cycling WI-38 human diploid fibroblasts.
(a) Following treatment with 4G-SMoC-ANt for 24 hours a 50% reduction in BrdU 
incorporation was observed in WI-38 human diploid fibroblasts. This reduction in 
proliferation was coupled to a block to Mcm2 chromatin-binding as detected by (b) 
immunofluorescence and (c) immunoblotting. For detection by immunofluorescence 
cells were treated with Triton X-100 prior to fixation to remove soluble proteins and 
stained with an anti-Mcm2 antibody, FITC-conjugated secondary antibody and 
propidium iodide. For detection by immunoblotting, cytosolic (CF), nucleosolic 
(NF) and chrom atin-bound (CBF) proteins w ere prepared, resolved by gel- 
electrophoresis and immunoblotted for Mcm2 and anti-His to detect 4G-SMoC-ANt. 
The reduction in Mcm2 association with chromatin is coupled to recruitment of 4G- 
SMoC-ANt to chromatin.
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analysed using immunofluoresence and alternatively, immunoblotting of subcellular 
protein fractions. Following treatment with 10 pM 4G-SMoC-geminin for 24 hours, 
WI-38 fibroblasts were either treated to remove soluble proteins and immunostained 
for Mcm2 or biochemically fractionated and analysed by immunoblotting. Treatment 
with 4G-SMoC-ANt resulted in a 75% reduction in the relative intensity of Mcm2 
staining (Figure 6.6b) indicating that 4G-SMoC-ANt inhibits Gl-S progression by 
blocking MCM loading onto chromatin. A reduction in chromatin-bound Mcm2 
levels was also observed in the immunoblot data following treatment with SMoC- 
ANt and interestingly, was coupled to increased levels of the protein in the cytosolic 
fraction (Figure 6.6c). Consistent with previous findings that repression of origin 
licensing is associated with the presence of geminin on chromatin (see Chapter 4, 
Figure 4.7), exogenous geminin was clearly detected in the cytosolic, nucleosolic and 
chromatin-bound fractions following treatment with 4G-SMoC-ANt. Taken together 
these data confirm the ability of 4G-SMoC to efficiently enter cell lines of different 
origin and to retain the biological activity of its protein cargo (Okuyama et al., 
manuscript submitted; Appendix F). Furthermore these data suggest that inhibition of 
origin licensing in normal cells may invoke an as yet unknown checkpoint activity 
which prevents cells from initiating DNA synthesis with an insufficient number of 
licensed origins.
6.3.5. 4G-SMoC-ANt triggers a differential response in normal and transformed 
cell lines
To determine whether normal and transformed cells respond differently to origin 
licensing inhibition, as has been previously suggested (Shreeram et al., 2002), the 
response of normal and transformed cells to 4G-SMoC-ANt was analysed. WI-38
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human diploid fibroblasts were chosen as a normal cell line and osteosarcoma- 
derived U20S (p53+/pRb+) cells were chosen as an example for a transformed cell 
line. Since induction of apoptosis may not be detectable after treatment for 24 hours, 
cells were treated with 10 pM 4G-SMoC-ANt for 72 hours, replenishing with fresh 
medium and 4G-SMoC-ANt every 12 hours to ensure that the 4G-SMoC-ANt 
concentration remained constant. After treatment, cells were assayed for cell 
proliferation by monitoring BrdU incorporation and for apoptosis by TUNEL 
staining. BrdU incorporation in both cell lines dropped to less that 10% of the control 
populations following treatment (Figure 6.7). This indicates that the 50% reduction 
in BrdU incorporation observed for WI-38s in the initial experiments (Figure 6.6a) 
was a result of the short period of treatment. Interestingly, when the BrdU images are 
observed more closely differences in the intensities of staining can be noted between 
the different populations. In the control populations of both cell lines and in the 
treated WI-38s, the majority of positive cells show strong FITC staining. In contrast, 
the majority of positive cells in the treated U20S populations, and indeed a 
proportion of cells which would be considered negative, show faint punctuated FITC 
staining (Figure 6.7, white arrow), suggesting that although cells have initiated DNA 
replication they fail to successfully progress through S phase. These findings are in 
keeping with the report by Shreeram et al which suggests that U20S cells arrest in S 
phase prior to committing apoptosis. WI-38 fibroblasts showed none of the 
morphological changes associated with induction of apoptosis, whilst U20S cells 
showed typical changes characteristic of apoptotic cell death, including cell 
shrinkage, cytoplasmic blebbing and chromatin condensation (Figure 6.8). Apoptosis 
is associated with inter-nucleosomal degradation of genomic DNA which can be 
monitored by TUNEL assay (Gavrieli et al., 1992). 72 hrs after treatment, U20S cells
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Figure 6.7. 4G-SMoC-ANt blocks proliferation in normal WI-38 human 
diploid fibroblasts and transformed U20S cells. Treatment of (a) WI-38 human 
diploid fibroblasts and (b) U20S osteosarcoma-derived cells for 72 hours with 4G- 
SMoC-ANt resulted in a 90% reduction in cells stained positive for BrdU 
incorporation in both cell lines compared to control populations. However, 4G- 
SMoC-ANt-treated U20S cells that are positive for BrdU incorporation show much 
fainter, punctuated staining, compared to treated WI-38 fibroblasts, indicative of an 
inability to complete S phase (white arrow). Moreover isolated BrdU foci can be 
detected in some of the treated U20S cells which were recorded as negative, 
suggesting that many U20S cells have attempted to initiate DNA synthesis from the 
few origins which were licensed in the presence of 4G-SMoC-ANt.
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Figure 6.8. 4G-SMoC-ANt induces apoptosis in transformed U20S ceils but not 
WI-38 human diploid fibroblasts. Following treatment of WI-38 human diploid 
fibroblasts and U20S cells with 4G-SMoC-ANt for 72 hours, apoptosis was assessed 
by monitoring morphological features and by TUNEL assay. WI-38 fibroblasts 
retained normal morphological features, although the cell density was significantly 
reduced compared to the control population, and showed no TUNEL staining. U20S 
cells on the contrary showed characteristic features of apoptosis including cell 
shrinkage, cytoplasmic blebbing and abundant TUNEL staining.
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showed abundant TUNEL staining compared to the control population (Figure 6.9). 
In contrast, no TUNEL staining could be detected in treated WI-38 fibroblasts. These 
findings argue that 4G-SMoC-geminin invokes a cell-cycle arrest in normal cells 
which prevents them from initiating DNA synthesis but does not invoke an apoptotic 
response. On the contrary, transformed cells are able to overcome the inhibition to 
origin licensing and progress into S phase where they ultimately undergo apoptosis.
6.3.6. Normal cells continue proliferating upon removal o f the block to origin 
licensing
The finding that exogenous geminin induces cell cycle arrest in normal WI-38 
human diploid fibroblasts whilst transformed U20S cells appear to attempt to enter S 
phase, is indicative of checkpoint activity. A critical question, particularly in the 
context of origin licensing inhibition as a therapeutic strategy, is whether the G1 
arrest observed in normal cells as a result of this checkpoint activity is reversible. To 
address this question, WI-38 fibroblasts were treated with 10 pM 4G-SMoC-ANt for 
72 hours, following which cells were washed and incubated in medium which did not 
contain 4G-SMoC-ANt for 24 hours and DNA replication assessed by monitoring 
BrdU incorporation. Treatment of cells with 4G-SMoC-ANt caused a 70% reduction 
in the number of cells incorporating BrdU compared to control populations. After 
removal of 4G-SMoC-ANt for 24 hours, the percentage of cells incorporating BrdU 
was approaching the levels found in the control population (Figure 6.9). These data 
suggest that upon removal of the block to origin licensing normal cells have the 
capacity to continue pre-RC assembly and proceed through the cell cycle, whilst the 
fate of transformed cell lines is already determined in the irreversible activation of an 
apoptotic response.
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Figure 6.9. Normal WI-38 human diploid fibroblasts continue 
proliferating upon removal of the block to origin licensing.
Following treatment of WI-38 human diploid fibroblasts with 4G- 
SMoC-ANt for 72 hours, cells were washed and incubated in medium 
which did not contain 4G-SMoC-ANt. 24 hours after removal of 4G- 
SMoC-ANt the percentage of cells incorporating BrdU was 
approaching the levels found in the control population.
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6.4. Discussion and Conclusions
The response of normal proliferating cell populations to chemotherapeutic agents is 
critical in determining dose-limiting toxicities. The DNA replication licensing 
machinery, which has been proposed as a potential new therapeutic anti-cancer 
target, is dysregulated early in carcinogenesis suggesting that inhibitors of origin 
licensing may have high efficacy in tumour cells (Shreeram and Blow, 2003; 
Gonzalez et al., 2005). Replication licensing factors are also expressed in normal 
cycling cells, suggesting that such agents may have severe cytotoxic effects in tissues 
containing rapidly proliferating cell populations. However work by Shreeram et al. 
argues that inhibition of origin licensing may induce a differential response in normal 
and transformed cell lines, with normal cells arresting in G1 and transformed cells 
undergoing apoptosis (Shreeram et al., 2002). Due to the nature of the experiments 
conducted these preliminary findings required independent verification and the 
important question of whether the G1 arrest observed following inhibition of origin 
licensing in normal cells is reversible needed to be addressed. To achieve this, a 
novel delivery strategy (SMoCs) was exploited to transport a non-degradable, 
biologically active fragment of geminin (see Chapter 4, Figure 4.9) into normal and 
transformed cell lines to investigate their response to inhibition of origin licensing 
and to determine whether normal cells can recover from this inhibition.
Delivery of recombinant gemininANt into cells by conjugation to 4G-SMoC resulted 
in a block to G0-S transition in NIH/3T3 fibroblasts (Figure 6.5) and to Gl-S 
transition in asynchronously cycling WI-38 human diploid fibroblasts (Figure 6.6). 
Moreover, treatment of transformed U20S cells with 4G-SMoC-ANt resulted in 
induction of a striking apoptotic response, supporting the preliminary data by
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Shreeram et al., with no apoptosis detectable in treated WI-38 fibroblasts (Figure 
6.8). Critically removal of the block to origin licensing in normal cells resulted in 
progression into S phase. These results suggest that the G1 arrest observed following 
inhibition of origin licensing in normal cells may be the result of a checkpoint 
response. Upon removal of the block to origin licensing, stimulation of the putative 
checkpoint response is alleviated and cells can therefore continue proliferating 
normally.
It can be postulated that this checkpoint response acts to monitor the assembly of a 
critical number of replication complexes onto chromatin during Gl, before allowing 
cells to progress into S phase. Two mechanisms by which this could be achieved can 
be envisioned. Firstly, the soluble levels of a replication factor may need to be 
reduced to a certain level, by its assembly into replication complexes, before 
replication can be initiated. Alternatively, assembly of pre-RCs at a critical subset of 
origins (sensor origins) may be required. This latter model is particularly attractive 
since it may provide a direct connection between the inappropriate licensing of 
origins and the inhibition of transition into S phase. Gene transcription and pre-RC 
assembly are intricately linked, with the presence of replication complexes at origins 
of replication having both a negative and positive effect on transcription (Muller et 
al., 2000; Aladjem and Fanning, 2004; Danis et al., 2004; Niedusynski et al., 2005). 
For example, replication licensing factors may compete with transcription factors for 
DNA binding, with the assembly of pre-RCs therefore having a negative effect on 
transcription (Nieduszynski et al., 2005). In addition transcription of some genes, 
potentially including proteins involved in maintaining a checkpoint response, may be 
activated by the absence of pre-RCs. Alternatively licensing of origins may have an
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enhancer effect on promoter regions, leading to increased gene transcription. The 
location of ‘sensor’ origins within the promoters of genes that are essential for S 
phase entry, for example E2F-regulated genes, would therefore allow a direct 
mechanism by which S phase entry could be inhibited in the absence of sufficient 
origin licensing. Interestingly interaction of the retinoblastoma protein (pRb), a 
regulator of E2F transcription complex activity, with Mcm7 has been shown to 
negatively regulate transition into S phase (Sterner et al., 1998). Under normal 
conditions mitogenic stimulation triggers phosphorylation of pRb by Cyclin 
D/CDK4/6 (Gladden and Diehl, 2003) leading to release of E2F and Mcm7, 
transcription of E2F-regulated genes and entry into S phase. However in the absence 
of sufficient origin licensing transcription of E2F-regulated genes will be impeded, 
leading to reduced phosphorylation of pRb and an inadequate supply of S-phase 
promoting factors. Moreover the reduction in pRb phosphorylation may prevent the 
release of Mcm7 for further pre-RC assembly (Gladden and Diehl, 2003), thereby 
reinforcing the block to S phase entry. Further to changes at the transcriptional level, 
activation of the origin licensing checkpoint may also invoke post-translational 
modifications, including phosphorylation, ubiquitination and sumoylation, leading to 
activation/inactivation of proteins and protein degradation.
Whilst activation of the origin licensing checkpoint causes cells to stall in G1 until 
origins are correctly licensed, a defect in this checkpoint would allow the initiation of 
replication to occur from the few origins which were to able to assemble replication 
complexes in the presence of an origin licensing inhibitor. The genome contains 
approximately 30,000 origins of replication (Todorovic et al., 1999), ensuring that 
failure of a few origins to initiate does not impede accurate replication of DNA.
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However if, for example, 60% of origins remained unlicensed upon entry into S 
phase, then the space between licensed origins would likely be such that replication 
complexes would breakdown or stall prior to reaching the next origin, leaving large 
unreplicated stretches of DNA. In addition it has been suggested that if an 
insufficient number of origins are active, DNA replication may occur in the opposite 
direction than under normal circumstances leading to collisions with RNA 
polymerases (Deshpande and Newlon, 1996) and impeding progress through ‘slow 
zones’ (Cha and Kleckner, 2002). In some instances, as observed for U20S cells, this 
stalling of replication forks may invoke a checkpoint response in S phase which 
triggers apoptosis (Osborn et al., 2002; Tercero et al., 2003; Bartek et al., 2004; 
Gottifredi and Prives, 2005). This checkpoint response most likely involves the 
ATM/ATR checkpoint pathway (Hekmat-Nejad et al., 2000; Osborn et al., 2002; 
Lavin, 2005) and appears to be dependent on pRb (Shreeram et al., 2002). However, 
if defects exist in the intra-S phase checkpoint then cells will not respond to the 
presence of stalled replication forks and will complete S phase with large stretches of 
unreplicated DNA. Studies in both S. cerevisiae Mecl mutants (Lopes et al., 2001) 
and in human ATR mutants (Cha and Kleckner, 2002) suggest that the inability to 
respond to stalled replication forks during S phase results in the generation of DSB in 
G2/M phase, consistent with the finding that Saos2 cells commit apoptosis in G2/M 
(Shreeram et al., 2002). An alternative hypothesis suggests that entry into S phase 
with an insufficient number of licensed origins may induce apoptosis independent of 
intra-S phase checkpoint pathways (Burhans et al., 2002; Weinberger et al., 2005). 
Studies with Orc2-l mutants in yeast indicate that apoptosis may be triggered by the 
irreversible collapse of replication forks that occurs when the number of active 
replication origins is below the threshold required to activate checkpoints and/or
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rescue stalled replication forks (Labib et al., 2001; Shimada et al., 2002; Burhans et 
al., 2003; Tercero et al., 2003). In the absence of checkpoint restraint, replication 
proteins are inappropriately phosphorylated leading to their dissociation from 
replication origins (Dimitrova and Gilbert, 2000) and inducing irreversible collapse 
of replication forks (Burhans et al., 2003). This hypothesis supports previous 
findings that proteolytic destruction of Cdc6 has been shown to contribute to 
apoptosis in mammalian cells (Blanchard et al., 2002; Pelizon et al., 2002; Yim et 
al., 2003). In order to distinguish between these two hypotheses, experiments could 
be performed in the presence of inhibitors of key intra-S phase checkpoint proteins, 
including ATM and Chkl. If checkpoint activity is required for the induction of 
apoptosis in U20S cells following inhibition of origin licensing, then these cells 
would be expected to show a similar phenotype to Saos2 cells (Shreeram et al., 
2002), complete S phase and apoptose with a G2/M DNA profile. However, if 
checkpoint activity is redundant for the induction of apoptosis then no change in the 
response to inhibition of origin licensing should be observed. In addition, the levels 
and phosphorylation status of replication licensing proteins can be monitored to 
determine whether they are involved in triggering the apoptotic programme.
The proteins involved in monitoring, activating and maintaining the putative origin 
licensing checkpoint are currently unclear, although increased levels of p21 and p53 
and reduction of pRb phosphorylation have been observed in response to inhibition 
of origin licensing (Shreeram et al., 2002; Montagnoli et a l , 2004). Intriguingly, the 
reduction in chromatin-bound Mcm2 levels observed in response to inhibition of 
origin licensing in WI-38s (Figure 6.6) was coupled to a dramatic increase in 
cytosolic levels of the protein, whilst in the control population no Mcm2 was
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detected in the cytosolic fraction. It can be postulated that activation of the origin 
licensing checkpoint may trigger an increase in cytosolic Mcm2 by two mechanisms. 
Firstly the block to origin licensing may lead to exclusion of Mcm2 from the nucleus, 
thereby removing the pool of Mcm2 available for licensing until conditions are 
permissible for licensing to continue. Alternatively, the cell may respond to 
insufficient origin licensing by de novo Mcm2 synthesis in order to increase the 
cytosolic pool of Mcm2 and ultimately provide a supply of Mcm2 for licensing to 
continue. Other candidates for involvement in the origin licensing checkpoint include 
the checkpoint proteins ATM, ATR, Chkl, Chk2, RPA, y-H2AX and Cdc25 
(Longhese et al., 1996; Abraham, 2001; Feijoo et al., 2001; Shiloh, 2001; Ward and 
Chen, 2001; Gottifredi and Prives, 2005). In addition to their potential involvement 
in the origin licensing checkpoint, many of these proteins may also be involved in 
mediating the induction of apoptosis in transformed cells. The involvement of these 
proteins in mediating the response of cells to inhibition of origin licensing can be 
determined by monitoring changes to protein levels and phosphorylation status 
following treatment of normal and transformed cells with 4G-SMoC-ANt. These 
studies should shed some light on the mechanism by which the putative origin 
licensing checkpoint is mediated, and on the differential response observed in 
transformed cells. In addition, further factors involved in monitoring or co-ordinating 
the response to inhibition of origin licensing can be identified using comparative 
proteomics and transcriptomics. Activation of the origin licensing checkpoint may 
invoke changes in both the transcriptome and proteome, with the latter potentially 
involving changes in protein levels, or post-translational modifications including 
phosphorylation, ubiquitination, sumoylation and neddylation status. Generic 
changes in the transcriptome can be identified by affymatrix arrays whilst changes to
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the proteome can be determined by utilising different comparative proteomic 
techniques. For example to identify alterations in ubiquitination status, cells can be 
transfected with a tagged-ubiquitin construct, treated with 4G-SMoC-ANt in the 
presence of a proteasome inhibitor and ubiquitinated proteins purified and identified. 
In addition to ascertaining changes which occur in normal cells upon activation of 
the origin licensing checkpoint, these techniques can also be utilised to observe the 
differences between normal and transformed cell populations to determine why 
transformed cells fail to arrest in G1 upon inhibition of origin licensing. Furthermore, 
a range of tumour cell lines with varying genetic backgrounds can be screened to 
determine whether the response to inhibition of origin licensing is influenced by 
genotype.
The data presented in this chapter are particularly exciting when considering the 
therapeutic potential of origin licensing inhibitors. Rapidly proliferating cells, for 
example in the gastrointestinal tract and haemopoetic systems, are a prime site for 
cytotoxic damage in response to classical chemotherapeutic agents. However, these 
results suggest that upon administration of a therapeutic origin licensing inhibitor 
these cell populations would arrest in G1 and, following metabolism of the drug and 
removal of the block to origin licensing, would be able to progress into S phase and 
continue their proliferative cycle. Taken together with the evidence presented in 
Chapter Three that functional cell populations, including stem/progenitor cells, have 
an unlicensed phenotype and should hence be refractory to origin licensing 
inhibitors, these results suggest that origin licensing inhibitors should have little, or 
no, cytotoxic effects in normal cell populations and should not cause secondary 
cancers or infertility. Consequently licensing inhibitors should have a high
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therapeutic index, allowing patients to tolerate high doses of the drag which will 
have a greater insult on the tumour cell population and will reduce the risk of the 
evolution of drag-resistant tumour clones. Moreover, these results also reinforce 
previous findings that transformed cells respond to origin licensing inhibition by 
committing apoptosis (Shreeram et al., 2002). It remains to be seen whether this 
response is shared by all transformed cell populations or whether it is dependent on 
genetic background. Collectively, these results further reinforce the concept of the 
DNA replication licensing machinery as an attractive and promising target for the 
development of novel non-genotoxic therapies to combat cancer.
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CHAPTER SEVEN 
CONCLUSIONS AND IMPLICATIONS
In the developed world one in three people will develop cancer over their life time 
and approximately one in four will die from the disease. Despite significant advances 
in chemotherapeutic regimes, a dramatic improvement in mortality rates has not been 
realised (Landis et al., 1998). There is therefore a profound need for identification of 
novel targets, and for continual enhancement of chemotherapeutic regimes.
Cell cycle specific agents targeting DNA synthetic pathways are important 
therapeutic tools; however inhibiting elongation DNA synthesis can invoke genomic 
damage, infertility and neoplastic transformation. To circumvent these problems, the 
DNA replication licensing machinery has been proposed as a novel therapeutic target 
(Shreeram and Blow, 2003). Origin licensing lies at the convergence point of all 
oncogenic signalling and transduction pathways, and can be regarded as a 'molecular 
switch’ coupling these upstream pathways to chromosomal replication. Unlike these 
branched, redundant and parallel pathways, there appears to be only a single 
mechanism of DNA replication initiation which is highly conserved in eukaryotes. 
Notably dysregulation of the DNA replication licensing machinery is an early event 
in tumourigenesis that has already been exploited in diagnostic and prognostic 
clinical applications (reviewed in Tachibana et al., 2005). Licensing inhibitors should 
therefore be of clinical benefit in a wide range of solid and haematopoietic cancers, 
independent of genetic background and histological type, in contrast to agents 
targeting upstream events where great heterogeneity exists between subgroups of 
even single tumour types.
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From a therapeutic perspective targeting the replication licensing machinery may at 
first seem counterproductive. Although early dysregulation of replication licensing 
suggests that licensing inhibitors should have high efficacy in cancer cells, there is 
no obvious rationale for a differential response between normal proliferating cells 
and tumour cells. It is also unclear how germ cells, stem/progenitor cells and 
quiescent or differentiated cell populations would respond to licensing inhibitors, and 
what the long term effects on the patient may be. Moreover the sequential, multi-step 
assembly of functional replication complexes at chromosomal origins provides a 
conundrum as to which step may represent the most promising target. The work of 
this thesis answers some of these questions and has generated data which argue 
strongly for therapeutic targeting of the replication licensing machinery.
The finding that functional cells in self-regenerating, stable and permanent tissues, 
including quiescent, differentiated and stem/progenitor cell populations, have an 
unlicensed phenotype indicates that these cells should be refractory to origin 
licensing inhibitors (see Chapter 3). Hence the vast majority of normal cells within 
the human body do not present a target, minimising potential cytotoxic effects of 
licensing inhibitors. However rapidly proliferating cells, for example cells in the 
transit amplifying compartment of colonic crypts, are a target to such agents.
Tantalising clues have been reported which suggest that normal and transformed 
cells may respond differently to licensing inhibitors (Shreeram et al., 2002). These 
preliminary data however, which have been generated by overexpressing a mutant 
form of geminin, are far from conclusive since protein overexpression often has 
pleiotropic effects, whilst some of the observed responses in normal and transformed
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cells may be attributed to the adenoviral delivery system. Moreover this study did not 
address the critical question of whether normal cells can recover from G1 arrest and 
re-enter the cell cycle upon removal of the block to origin licensing. The data shown 
in this thesis take the concept further and prove that the replication licensing 
machinery is a promising therapeutic target. Cancer cell specific killing was 
observed following treatment with a licensing inhibitor, whereas normal cells 
arrested in G1 retaining the capacity to continue cell cycle progression upon removal 
of the inhibitor (see Chapter 6). The observed differential response to origin licensing 
repression appears to be due to a checkpoint mechanism that monitors assembly of 
replication licensing complexes at a critical number of origins in normal cells, and 
which appears to be defective or lost in cancer cells. Therefore paradoxically, the 
resistance to growth arrest that is one of the hallmarks of malignant cells (Hanahan 
and Weinberg, 2002) can be exploited to achieve selective cancer cell death. Future 
studies on a large set of selected cancer cell lines derived from solid and 
haematopoietic cancers will reveal whether the findings shown in this work can be 
generalised for cancers of different genetic background and histological type.
The arrest of human diploid fibroblasts in G1 phase following origin licensing 
inhibition raises questions about the molecular nature of the putative origin licensing 
checkpoint. A working model favoured by some researchers in the field features so- 
called ‘sensor’ origins located in the vicinity of promoter regions for S-phase 
inducing genes. In an unperturbed cell cycle licensing of these sensor origins could 
have an enhancer-like function for the expression of S-phase inducing genes and thus 
drive the cell into S phase. Blocking origin licensing would result in loss of enhanced 
function and reduced gene expression leading to G1 arrest. To date no experimental
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data have been reported in support of this model and the elucidation of the 
checkpoint pathway will undoubtedly have to await data from transcriptomic and 
proteomic studies.
The sequential assembly of pre-RCs and their dynamic transition to pre-IC structure 
offers a number of different strategies for blocking origin licensing and/or firing. 
Small molecular inhibitors or macrodrugs may act by blocking protein-DNA 
interactions (e.g. ORC binding to DNA), protein-protein interactions (e.g. 
interactions between Mem subunits) and kinase (e.g. Cdc7-Dbf4) or phosphatase 
(protein phosphatase 2A) activity. Detailed structural and molecular investigations 
are required to determine the feasibility of these approaches; however the biology of 
some pre-RC/pre-IC constituents already provides important clues for shortlisting 
potential therapeutic targets. Blocking ORC binding to DNA, for example, may not 
prove to be an optimal therapeutic strategy since ORC has additional roles in 
transcription, chromatin remodelling, chromosome segregation and cytokinesis (Fox 
et al., 1995; Huang et al., 1998; Iizuka and Stillman, 1999; Pak et al., 1997; Prasanth 
et al., 2002; Chesnokov et al., 2003; Prasanth et al., 2004) which may determine side 
effect profiles. Dbf4-dependent Cdc7 kinase has a narrow spectrum of action, its 
only target being the Mcm2-7 complex (Masai and Arai, 2002), and may therefore 
represent an alternative to the recently developed CDKIs for which phase I and II 
clinical trials have shown poor results (Blagden and Bono, 2005). With Cdc7 being 
at the centre stage of current basic and drug discovery research, ongoing and future 
studies will search for as yet unknown targets of this kinase and possible suppressor 
mutations such as the known mcm5-bobl mutant (Hardy et al., 1997) which bypasses 
Cdc7 requirement for replication initiation. Interestingly siRNA knockout of Cdc7
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function in human cancer cells revealed a similar response to that observed for 
geminin, suggesting that origin firing, which is temporally regulated during S phase, 
may also be governed by checkpoint activity (Montagnoli et al., 2004). Interfering 
with the assembly and/or function of the Mcm2-7 replicative helicase, for example 
through blocking interaction with other pre-RC constituents or between MCM 
subunits, may yet prove to be the best strategy. Although MCM proteins have been 
linked to damage response, transcription and chromatin modelling (Forsburg, 2004) 
these functions do not depend on the complete MCM complex (Ishimi et al., 2001; 
Fitch et a l , 2003). Furthermore the tight down-regulation of Mcm2-7 in cell 
populations residing in out-of-cycle states (Madine et al., 2000; Stoeber et al., 2001; 
see Chapter 3) suggests that side effect profiles should be minimal, in contrast to 
ORC, for example, which is not down-regulated due to its additional roles. 
Moreover, inhibiting protein-protein interactions is less susceptible to the evolution 
of drug resistance than, for example, blocking the ATP binding pocket of a kinase 
such as Cdc7, and is more target specific.
In the work of this thesis the endogenous origin licensing repressor geminin (see 
Chapter 4) and a viral pathogen HPVI E4 (see Chapter 5) were exploited in proof-of- 
principle studies aimed at evaluating the potential of inhibiting origin licensing by 
blocking MCM loading. Although both molecules are capable of blocking MCM 
loading in vitro resulting in the inhibition of DNA replication initiation, questions 
remain about their suitability for drug development programmes. Our quaternary 
structure of the geminin molecule, combined with crystal data for geminin fragments, 
indicates that the geminin-Cdtl interaction involves at least two contact patches. 
Thus mimicking geminin function with a small molecule may prove difficult. This
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also seems to be the case for E4, which associates with both Cdc6 and Mcm7 
suggesting that multiple regions of the protein may be required for mediating origin 
licensing inhibition. However, computer-aided design and molecular modelling may 
live up to this challenge and identify chemical compounds or peptides with the 
capacity to mimic the activity of these biological licensing blockers. Alternatively 
with the optimal delivery strategy geminin or E4 polypeptides may themselves find 
use as 'biologies' in treatment regimes. If SMoC-mediated uptake could be adapted 
into humans with the efficacy observed here in vitro, and that has been observed for 
PTDs in in vivo models (Selivanova et al., 1997; Gius et al., 1999; Hollinger et al., 
1999), then SMoC-geminin or SMoC-E4 derivatives may provide potent anti­
proliferative agents for a wide range of applications. To evaluate the potential of 
SMoC-protein conjugates as therapeutic agents the ability of SMoCs to transport a 
variety of cargo across cell layers, into a range of cell types and across the blood- 
brain barrier must be investigated, whilst the stability of SMoC derivatives and 
chemical protection to prolong the half-life of the molecule must also be determined.
Origin licensing inhibitors may find use for a range of applications and could 
potentially be administered systemically or through other administrative routes. For 
example, intraperitoneal infusion would allow treatment of ovarian tumours in which 
morbidity and mortality is linked to transcoelomic spread, whereas cerebrospinal 
fluid (CSF) administration would be used in the treatment of malignant glial 
tumours. Autologous bone marrow transplantation which is compromised by failure 
of engraftment or can be complicated by relapse as a consequence of contaminating 
tumour cells is another possible application. Origin licensing inhibitors could be 
exploited to purge grafts of contaminating tumour cells. Cycling stem cells are
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resistant to engraftment, therefore arresting stem cells with a non-genotoxic agent, 
especially after genetic manipulation which stimulates cell cycle re-entry, could help 
improve engraftment rates. Importantly by targeting components of the assembly 
process whose roles are unique to this process, the possibility of a side-effect profile 
linked to actions in other cellular processes is removed. This has not been the case 
with the majority of other approaches to the inhibition of the cell cycle. This 
approach also circumvents problems associated with cytotoxicity, which is linked to 
hair loss, infertility and suppression of self-renewing tissues such as the 
haematopoietic and gastrointestinal systems. Low blood counts and gut-related 
symptoms, for example gastrointestinal haemorrhage, are rate-limiting side effects 
for conventional cytotoxic agents. In contrast cyclical treatment with origin licensing 
inhibitors should have minimal effects on normal tissues and therefore be associated 
with a much greater tolerance. Levels and activities of replication licensing factors 
and their regulators, as determined by immunohistochemical staining of biopsy 
sections, may have predictive value for such therapeutic interventions. Origin 
licensing inhibitors may also provide powerful tools to enhance the tumour kill of 
classical chemotherapeutic drugs. Both cell cycle-specific and cell cycle non­
specific agents have been shown to have more potent effects on cycling cells. In 
contrast to cancer cell cycles, licensing inhibition in normal cells results in stalling of 
the cell cycle in G1 phase and therefore should provide protection against cytotoxic 
injury.
In conclusion the work presented in this thesis provides a strong rationale for 
therapeutic targeting of the DNA replication licensing machinery in 
hyperproliferative diseases and cancer, independent of genetic background and tissue
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type. The findings discussed above pave the ground for future experimental work 
towards two major goals. Firstly, detailed transcriptomic and proteomic studies of 
untransformed human cells in the presence and absence of origin licensing inhibitors 
will help to characterise the molecular nature of the origin licensing checkpoint and 
shed some light on its mechanism of action. Such studies will further advance our 
understanding of how origin activation is linked to the cellular circuits that control 
proliferation, DNA damage response and apoptosis. With mechanistic knowledge of 
the molecular machinery that triggers the origin licensing checkpoint, comparative 
studies of matched pairs of normal and transformed human cell lines will help to 
understand loss of this checkpoint function in cancer cells. Secondly the 
identification of a promising new therapeutic target will start the process of drug 
development, which involves further additional target validation particularly in 
human tissues and the optimisation of potential lead compounds. Whether SMoC- 
geminin derivatives themselves constitute potent macrodrugs or ‘biologic’ agents for 
the treatment of cancer, will largely depend on their success in in vivo Xenograft 
model systems and their properties in pharmacokinetic and ADMET (absorption, 
distribution, metabolism, excretion, toxicity) screens. Perhaps more straightforward 
than the development of macrodrugs targeting the licensing machinery is the 
screening for small molecule inhibitors of the Dbf4ASK-dependent Cdc7 kinase, a 
joint venture that our group is currently pursuing in collaboration with the Cancer 
Research UK Drug Development group.
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clinical 
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are 
used 
to 
treat, the 
principle 
toxicites 
associated 
with 
treatm
ent 
and 
die 
m
echanism
s 
by 
which 
resistance 
can 
develop.
Class of 
compound
Mode of action Compounds in 
clinical use
Principle tumour 
types treated
Principle toxicities Mechanisms of 
resistance
Nitrogen
mustards
DNA alkylation at N7 
and 06 positions of 
guanine leading to 
DNA interstrand 
cross-links (Thomas et 
al., 1978; Erikson et al., 
1980; Garcia et al., 1988)
Mechlorethamine
Chlorambucil
Melphalan
Ifosphamide
Hodgkin’s 
lymphoma, chronic 
lymphocytic 
leukaemia, multiple 
myeloma, ovarian 
and breast cancer 
(DeVita etal., 1972; 
George et al., 1972; 
Lemer, 1978)
Nausea, vomiting, 
alopecia, bone marrow 
depression, 
development of 
secondary 
malignancies (Van 
Putten and Lilieveld, 1971; 
Harris, 1976; Penn, 1976; 
Tucker etal., 1988)
Drug inactivation 
due to reaction 
with cellular thiols 
(Meister, 1988), 
decreased drug 
uptake, (Goldenberg 
and Begleiter, 1984) 
increased excision 
repair (Ewig and 
Kohn, 1977)
Nitrosoureas Alkylation and 
carbamoylation at 
guanine 06 producing 
interstrand cross-links 
(Reed et al., 1975)
Carmustine
Lomustine
Semustin
Streptozotocin
Chlorozotocin
Central nervous 
system, brain, lung, 
and colorectal 
cancers, myeloma, 
Hodgkins’s 
lymphoma 
(Wassennan et al., 1975)
Delayed and 
cumulative
thrombocytopenia and 
leukopenia, renal 
damage, nausea, 
vomiting (Ramirez et al., 
1972; Smith, 1989)
Increased 
alkyltransferase 
activity (Brent et al,. 
1985; Aida and Bodell, 
1987; Fox et al., 1987; 
D’Incalci et al., 1988)
Aziridines As nitrogen mustards 
(Iyer and Szybalski, 1963 ; 
Dubois et al., 1990)
Thiotepa
Altretamine
Mitomycin
Lymphoma, ovarian 
adenocarcinoma, 
metastatic breast 
cancer, (Crooke and 
Bradner, 1976)
Anorexia, nausea, 
vomiting, bone 
marrow depression, 
neurotoxicity (Legha et 
al., 1976)
As nitrogen 
mustards (Dorr et al., 
1987 ; Dulhanty et al., 
1989; Hoban et al., 
1990)
Alkane
sulphonates
Bifunctional alkylating 
agents that react with 
guanine N7 to form a 
diguanyl derivative 
and DNA interstrand 
cross-links (Tong and 
Ludlum, 1980; Fanner, 
1987)
Busulfan Chronic 
granulocytic 
leukaemia (Galton, 
1969)
Nausea, vomiting, 
bone marrow 
depression, fibrosis, 
sterility, pulmonary 
infiltration, impotence, 
amenorrhea (Sostman et 
al., 1977; Wilson, 1978)
Increased repair of 
DNA cross-links 
(Bedford and Fox,
1982)
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action, 
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com
pounds 
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clinical 
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and 
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types 
they 
are 
used 
to 
treat, 
the 
principle 
toxicites 
associated 
with 
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ent 
and 
the 
m
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s 
by 
which 
resistance 
can 
develop.
Class of 
compound
Compounds in 
clinical use
Mode of action Principle
tumour
types
treated
Principle toxicities Mechanisms of resistance
Anti-folates
Methotrexate,
Trimethrexate
Inhibition of DHFR 
(Schweitzer et al., 1990) and 
thymidylate synthase (Chu et 
al., 1990)
Breast
cancer,
osteogenic
sarcoma
leukemias
(Jonsson and 
Kamen, 1991)
Neurotoxicity, 
bone-marrow 
depression, renal 
failure (Condit e ta l ,  
1969; Dahl etal., 1971; 
Jacobs et al., 1976; 
Bleyer e ta l., 1981)
Overexpression/mutation of DHFR, 
altered drug transport (Gorlick et al., 
1997)
Raltritrexad Inhibition of thymidylate 
synthase (Danenberg et al., 
1999)
Overexpression of thymidylate 
synthase, impaired cellular uptake
Hydroxyurea Inhibition of ribonucleotide 
reductase (Szekeres et al., 1997)
Overexpression of ribonucleotide 
reductase
Anti­
pyrimidines
Ftorafur,
Doxifluridine,
Capecitabine,
Eniluracil
Inhibition of thymidylate 
synthase, incorporation into 
DNA and RNA (Montford and 
Weichsel, 1997; Danenberg et al., 
1990)
Colorectal, 
breast, 
gastric and 
pancreatic 
cancers 
(Gran, 1990)
Nausea, vomiting, 
ulceration of the 
oropharynx and 
bowel, alopecia, 
bone-marrow 
depression
Deficiency of thymidine kinase, (Gran, 
1990) increased expression (Washtien, 
1982) or structural alterations (Berger et 
al., 1988) of thymidylate synthase and 
reduced availability of the folate 
cofactor (Ullman et al., 1970)
Cytarabine,
Gemcitabine
Compete with dCTP for 
incorporation into DNA 
(Gran, 1990)
Nonlympho-
cytic
leukaemia
Leukopenia, 
thrombocytopenia, 
anaemia, nausea, 
vomiting
Deletion of deoxycytidine kinase, 
expansion of dCTP pools, increased 
activity of cytadine deaminase and 
overexpression of anti-apoptotic 
proteins
Anti-purines 6-mercaptopurine,
6-thioguanine,
Pentostatin
Inhibition of nucleotide 
synthesis and incorporation 
in DNA/RNA (Weiss and 
Pitot, 1994; Uribe-Luna et al., 
1997)
Leukaemias Severe liver 
damage, hematuria, 
crystalluria (Shorey et 
al., 1968; Dutteta.etal., 
1972; Jackson et al., 
1975)
Deletion of HPRTase, increased 
activity of membrane-bound alkaline 
phosphatase activity (Wolpert et al., 1971)
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A3. 
Anti-tum
our 
antibiotics. 
Table 
showing 
the 
classes 
of 
anti-tum
our 
antibiotics that have 
been 
developed, their mode 
of action, examples of com
pounds 
that 
are 
in 
clinical use 
and 
the 
principle 
tumour 
types 
they 
are 
used 
to 
treat, the 
principle toxicites associated 
with 
treatm
ent and 
the m
echanism
s by 
which 
resistance 
can 
develop.
Class of 
compound
Mode of action Compounds 
in clinical use
Tumour types 
treated
Principle toxicities Mechanisms of 
resistance
Actinomycin Inhibition of DNA 
synthesis and DNA- 
directed RNA synthesis 
by blocking chain 
elongation (Reich et al., 
1962)
Dactinomycin Paediatric solid 
tumours (e.g. Wilms’ 
tumour, Ewing’s 
sarcoma), lymphoma, 
testicular cancer (Frei 
III, 1974)
Nausea, vomiting, 
myelosuppression, 
alopecia, acneiform 
skin lesions, 
secondary neoplasms 
(Svoboda et al., 1970; Frei 
III, 1974)
Increased drug efflux 
due to P-glycoprotein 
amplification (Diddens et 
al., 1987)
Anthracyclins Interacts with DNA 
preventing strand- 
reunion reaction of 
topoll and causing 
generation of double 
strand breaks (Tewey et 
al., 1984; Glisson et al., 1986; 
Wang etal., 1987)
Doxorubicin,
Daunorubicin
Doxorubicin is used 
for a wide range of 
tumours, daunorubicin 
is used solely for acute 
myelogenous 
leukaemia (Carter, 1975)
Cardiotoxicity, 
myelosuppression, 
immunosuppression, 
nausea, vomiting, 
secondary neoplasms 
(Marquaidt et al., 1976; 
Vecchi et al. 1976; 
O’Biyan et al., 1977)
Decreased topoll 
activity (Pommier et al., 
1986), increased 
glutathione peroxidase 
activity (Sinha et al., 
1989)
Bleomycin DNA fragmentation and 
generation of free 
radicals (Twentyman, 1984)
Bleomycin Squamous cell 
carcinoma, lymphoma 
(Blum, 1973)
Pulmonary toxicity, 
nausea, vomiting, 
stomatitis, alopecia 
(Blum, 1973)
Increased DNA repair 
(Miyaki et al., 1973), 
bleomycin inactivation 
(Sebti et al., 1991), altered 
glutathione S- 
transferase activity 
(Giaccia eta l., 1991)
Anthracene-
dione
Intercalation and 
electrostatic interactions 
with DNA (Lown et al., 
1984; Bowden etal., 1985)
Mitoxantrone Leukaemias, 
lymphomas (Silver ef al., 
1991)
Nausea, vomiting, 
myelosuppression, 
cardiotoxicity (Silver 
etal., 1991)
Increased DNA repair, 
decreased topoll 
activity (Faulds et al., 
1991)
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A.4. Endocrine 
therapy. Table 
showing 
the 
classes of endocrine 
therapies 
that have been 
developed, their mode 
of action, exam
ples of com
pounds that are 
in 
clinical use, the 
principle 
tumour 
types 
they 
are 
used 
to 
treat, and 
the 
principle 
toxicites associated 
with 
treatm
ent.
Class of 
compound
Mode of action Compounds in clinical 
use
Tumour types 
treated
Principle toxicities
Oestrogens Inhibition of leuteinising hormone 
production leading to reduced 
testosterone levels (Bishopetal., 1985; 
Mashchak et al., 1982)
Diethylstilbestrol, 
Ethinyl estradiol
Prostate cancer, 
(postmenopausal 
breast cancer)
Tumour flare, impotence, 
gynecomastia, secondary 
neoplasms (Carteretal., 1977; 
Claiysse, 1985; Bergvisk et al., 1989)
Anti-
oestrogens
Competition for binding of oestrogen to 
oestrogen receptors (Furr and Jordan, 1984; 
MacGregor and Jordan, 1998)
Tamoxifen Advanced breast 
cancer
Tumour flare,
thrombocytopenia, leukopenia, 
nausea
Progestins Promote maturation of secretory 
epithelium of the endometrium, efficacy 
correlates with presence of progesterone 
receptors (Kneale, 1986)
Medroxyprogesterone
acetate,
Megestrol acetate
Advanced
endometrial
carcinoma
Hypercalcaemia, weight gain, 
tumour flare, thrombophlebitis, 
embolism
Androgens Suppression of leuteinising hormone 
production leading to reduction in 
oestrogen synthesis (Swinnen et al., 2004)
Fluoxymestrone Metastatic breast 
cancer
Masculinisation
Anti­
androgens
Competition for binding of 
dihydrotestosterone to androgen receptor 
(Neumann and Topert, 1986)
Cyproterone acetate, 
Flutamide
Prostate cancer Gynecomastia
Aromatase
inhibitors
Inhibition of aromatisation, the final step 
in oestrogen synthesis (Lonning and 
Kvinnsland, 1988; Nemoto eta l., 1989; Smith and 
Dowsett, 2003)
Aminoglutethimide,
Testolactone
Metastatic breast 
cancer
CNS depression, masculinisation
Gluco­
corticoids
Induction of endonuclease activity 
resulting in programmed cell death 
(Melby, 1977)
Cortisol,
Prednisome,
Prednisolone
Leukaemias,
lymphomas
Osteoporosis, congestive heart 
failure, impotence, neurotoxicity
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Class of 
compound
Mode of action Compounds in 
clinical use
Tumour types 
treated
Principle toxicities Principle
drawbacks
Micro­
organisms
Activation of macrophages, T/B 
lymphocytes and type II 
immunological responses, inhibition 
of tumour cell motility
Bacillus
Calmette-Gu6rin
(BCG),
C. parvum
Metastatic disease,
cutaneous
melanoma
Sepsis, leukopenia, 
respiratory failure, 
hypertension
Low activity
Interferons Enhance cytoxicity of 
immunocompetent cells, suppression 
of neovascularisation, enhanced 
expression of MHC I and II
IFN-a, IFN-p, 
IFN-y
Hairy-cell 
leukaemia, chronic 
myeloid leukaemia
Asthenia, neutropenia, 
nausea, vomiting, 
thrombocytopenia
Responses are 
usually only 
partial
Interleukins Enhanced growth of activated T 
cells, proliferation of lymphoid 
cells, lysis of tumour cells, 
regression of distant metastases, 
stimulation of release of other 
cytokines
IL-1, IL-2, IL-3, 
IL-4
Renal cell
carcinoma,
metastatic
melanoma, acute
myeloid
lymphoma
Toxic fatalities in up to 
10% of patients, angina, 
multi-organ 
malfunction, 
thrombocytopenia
Severe toxicity
Tumour
necrosis
factor
Induction of apoptosis, promotion of 
intravascular thrombosis causing 
tumour necrosis, activation of 
immunocompetent cells
TNF- a Advanced
melanoma,
sarcoma
CNS toxicity, 
impairment of renal 
function,
thrombocytopenia,
hepatotoxicity,
Very low 
(<5%) response 
rate, severe 
toxicity
Monoclonal
antibodies
Antibody-dependent cellular 
cytotoxicity (ADCC)
Unconjugated/ 
native mAbs, 
mAbs-enzyme 
conjugates
Haematological
malignancies
HAMA (human anti­
mouse antiglobulin 
response)
Low antibody 
uptake, 
antigenic 
heterogeneity, 
poor stability
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Appendix B: Methods performed in collaboration
All work performed in collaboration and included because it forms part of the 
connected argument has been clearly identified. This appendix describes the methods 
used in that collaborative work.
B.l. CHAPTER FOUR
B. 1.1. Chemical crosslinking o f recombinant geminin proteins
Crosslinking of geminin or gemininANt proteins at 10 pg/ml was performed in 1 ml 
of buffer (20 mM HEPES pH 7.5, 200 mM KC1, 10 mM DTT, 1 mM EDTA) 
containing either bis-[sulfosuccinidmidyl]suberate (BS3) (Sigma) or ethyleneglycol- 
bis-succinimidylsuccinate (EGS) (Pierce). BS3 and EGS concentrations ranged from 
0.5 to 5 mM. Reactions were quenched after 45 min at RT by adding 0.05 ml 1 M 
Tris-HCl pH 8.0. Cross-linked protein was precipitated by adding 0.115 ml 100% 
trichloroacetic acid. Protein was collected by centrifugation at 10,000 g for 5 min, 
washed once with 1 ml of acetone, air dried, resuspended in SDS-PAGE loading dye 
and analysed by 4-20% SDS-PAGE.
B.l.2. Electron microscopy
For structural analysis, 5 pi of purified full-length geminin or gemininANt (0.05 
mg/ml in buffer [25 mM Tris-HCl pH 8.0, 100 mM NaCl]) were applied to carbon- 
coated copper grids (400 mesh, freshly glow-discharged in air). After 2 min excess 
buffer was removed by blotting and specimens were stained twice with 5 pi 2% w/v 
methylamine vanadate, pH 8.0, or 5 pi 2% w/v methylamine tungstate, pH 6.8 
(NanoVan and Nano-W, Nanoprobes Inc., NY, USA) for 1 min. Micrographs were
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recorded on Kodak SOI63 film using a FEI Tecnai T10 transmission electron 
microscope in low-dose mode, operated at an accelerating voltage of 100 kV and 
with a magnification of 44,000x. Negatives were developed in Kodak full strength 
developer D-19 for 12 min and their quality was assessed by optical diffraction.
B. 1.3. Image processing and computer molecular modelling
Micrographs were digitized on a Zeiss SCAI microdensitometer (Z/I Imaging) with a 
step size of 7 pm and images were coarsened by averaging 2x2 pixels corresponding 
to a pixel size of 3.18 A at specimen level. Micrographs were scanned and particle 
images were selected manually. Image analysis was performed using IMAGIC (van 
Heel et a l , 1996). The resulting set of images was normalised to the same sigma and 
filtered: low-resolution cut-off was -100 A to remove uneven background on particle 
images; high-resolution cut-off was -7  A. Images were centered using rotationally 
averaged total sum of images. The following multivariate statistical analysis allowed 
us to find references for multi-reference alignment. The alignment procedure was 
followed by the next round of statistical analysis of images (Serysheva et a l , 1995). 
The first approximate model of the molecule was obtained using angular 
reconstitution from the best 10-15 classes. The model was centered and its 
reprojections were used to refine alignment and classification of images. The final 
reconstruction was calculated out of -200 classes containing 8-15 images each. 3D 
maps were calculated using the exact-filter back projection algorithm (Harauz and 
van Heel, 1986; Radermacher, 1988). Resolution of the map was assessed using the 
0.5 threshold of Fourier Shell Correlation (Saxton & Baumeister, 1986) which 
corresponds to -17.5 A. Multiple sequence alignments between geminin and known 
structures were made using Threader3 (Jones et a l , 1992)
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(http://bioinf.cs.ucl.ac.uk/threaderA. After alignment, the 1GK6 structure previously 
used in X-ray analysis for molecular replacement (Thepaut et al., 2002) was chosen 
as a template for modelling geminin’s coiled-coil domain structure with the 
SwissModel software package (http://swissmodel.expasv.org/) (Schwede et a l , 
2003). Domain fitting by small translational and rotational movements into the 3D 
map of geminin was performed interactively using O (Jones and Kjeldgaard, 1997). 
The secondary structure prediction was performed by using PredictProtein server 
(EMBL, Heidelberg, http://www.embl-heidelberg.de/predictprotein/predictprotein. 
html). Illustrations were generated using Deep View Swiss-PDB viewer (Guex and 
Peitsch, 1997) (http://ca.expasv.org/spdbvA. PyMOL (http://pvmol.sourceforge.netA 
and IRIS Explorer (http://www.nag.co.uk/visual/IE/iecbb/Product.html). Surface 
representations are displayed at a threshold level of la  corresponding to -100% of 
the expected mass. This threshold was determined assuming the mass of the complex 
is -105 kDa and the specific density is 0.833 kDa A'3.
B.2. CHAPTER FIVE
B.2.1. Expression and purification of recombinant HPV1E4 proteins
HPVI E4 proteins were expressed in Sf9 insect cells using recombinant 
baculoviruses and purified using non-denaturing conditions as previously described 
(Roberts et al., 1994b).
B.2.2. In vitro binding assays
[35S]-methionine-labelled Mcm7 protein was synthesised using a TNT T7/T3 
coupled rabbit reticulocyte system (Promega). Recombinant HPV1 E4 (5 pg) was 
incubated with [35S]-Mcm7 for 2 h at 4°C in ICB: 10 mM Tris-HCl pH 7.4, 150 mM
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NaCl, 0.1% NP-40, 100 pg/ml PMSF, 0.5 pg/ml leupeptin and pepstatin A. E4 
protein was collected by incubating with anti-E4 MAb 4.37 (Doorbar et al., 1988) 
bound to protein-G-Sepharose and analysed by SDS-PAGE and fluorography. 
HPV16 E1AE4 cDNA (Roberts et al., 1993) was cloned into pGEX-2T (Amersham) 
and GST-16E4 fusion protein expressed in E. coli. GST fusion proteins bound to 
glutathione agarose beads were mixed with [35S]-Mcm7 for 1 h at 4°C in PBS/ 0.1% 
NP-40, and complexes analysed as described above.
B.2.3. Infection ofkeratinocytes and immunoprecipitations
A recombinant adenovirus expressing HPVI E4 was generated by homologous 
recombination in 293 cells as previously described (Graham and van der Eb, 1973; 
Wilkinson and Akrigg, 1992). Human keratinocyte cell lines were infected with 
recombinant adenoviruses at a multiplicity of infection (m.o.i.) of 50 for 2 h and 
harvested after 24 h. SVJD keratinocytes were infected with a recombinant SV40 
virus (SV40-AE4) as previously described. Total cell lysates were prepared in ICB or 
extraction buffer. Nuclear pellet fractions were prepared and lysed as described 
(Kimura et al., 1994). Soluble extracts from S phase HeLa cells containing 
baculovirus-expressed HPV1 E4 (3 pM) and XeC6c6 (0.65 pM) were incubated at 
37°C for 2 h and diluted in extraction buffer. All lysates and extracts were precleared 
with IgG-protein-G-Sepharose, incubated with antibodies for 1 h and precipitated 
with protein-G-Sepharose. Isolated immune complexes were resolved by SDS- 
PAGE, immunoblotted, and visualised by ECL (Amersham Pharmacia). HPV1 
E4/AE4 proteins were detected by anti-E4 MAb 4.37 and rabbit polyclonal 
antibodies were used to detect Cdc6 and Mcm7 (Fujita et al., 1996).
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B.2.4. Immunofluorescence
Human keratinocytes grown on glass slides were infected with recombinant 
adenoviruses at a m.o.i. of 25 to 50. After 24 h, cells were fixed as described 
(Roberts et al., 1993). HPVI E4 was detected using anti-E4 MAb 4.37 and Cdc6 and 
Mcm7 using rabbit polyclonal antibodies to Cdc6 and Mcm7 (Fujita et al., 1996). 
Immune complexes were detected using Alexa 488-conjugated anti-mouse IgG 
(Molecular Probes, Invitrogen) and Texas Red-conjugated anti-rabbit IgG (Southern 
Biotechnology Associates, Birmingham, AL, USA). Nuclei were counter-stained 
with DAPI. Z-images (0.5 pm) were acquired and digitally deconvolved using 
Openlab (Improvision, Lexington, MA, USA).
B.3. CHAPTER SIX
B.3.1. Design of small molecule carriers
Small molecule carriers (SMoCs) were designed to mimic the structure and activity 
of protein transduction domains (PTDs), which have recently been highlighted as a 
novel mechanism for the transport of biomolecules into cells and a potential new 
drug delivery strategy (Schwarze et al., 2000). Over recent years studies have shown 
that a variety of peptides, many of which are present in viral proteins, have the ability 
to cross biological membranes in various different cell types. Examples include the 
basic region (47-57) of HIV-1-tat (Frankel and Pabo, 1988; Green and Loewenstein, 
1988), the third helix of the Drosophila antennapedia homeodomain (penetratin) 
(Joliot et al., 1991; Derossi et al., 1994) and designed variants such as Pepl. These 
peptides, known as ‘protein transduction domains’ (PTDs), can be linked to a variety 
of molecules with limited bioavailability (e.g. peptides, proteins, DNA), thereby 
enabling them to traverse biological membranes. Unlike traditional based techniques,
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including fusion to receptor ligands (Ng et al., 2002) and packaging into caged 
liposomal carriers (Abu-Amer et al., 2001), protein transduction does not appear to 
be affected by cell type and can efficiently transduce almost 100% of cells both in 
vitro and in vivo with no apparent toxicity (Nagahara et al., 1998). Furthermore 
PTDs can deliver equal amounts of protein to 100% of treated cells, in contrast to 
viral delivery strategies which achieve only 30-50% transduction efficiency with 
highly variable levels of expression within these cells (Barka et al., 2000). In 
addition it has been claimed that some PTDs, for example Tat, have no limit in the 
size of molecule that they can transport into cells (Joliot and Prochiantz, 2004). A 
major hindrance in drug delivery is accessibility of the central nervous system since 
most hydrophilic substances are unable to cross the blood-brain barrier. However 
studies have shown that PTD fusion molecules introduced into mice exhibit delivery 
to all tissues, including traversal of the blood-brain barrier (Schwarze and Dowdy, 
2000; Denicourt and Dowdy, 2003). Taken together, these studies suggest that 
tethering potential drugs to PTDs may circumvent some of the problems associated 
with current drug delivery strategies (Schwarze et al., 2000). However, there are a 
number of drawbacks to the use of PTDs including reduced expression levels of 
PTD-fiision proteins (Cashman et al., 2003), altered biological activity compared to 
the native protein and susceptibility to rapid degradation by cellular enzymes.
Small molecule carriers (SMoCs) were designed to circumvent the problem 
associated with PTDs, and provide a novel strategy for in vitro and in vivo delivery 
of various cargo moieties into cells (D. Selwood, Wolfson Institute for Biomedical 
Research, UCL; personal communication). The design of SMoCs was based on the 
observation that although small peptides (<20 amino acids) generally lack any
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structure in aqueous media, peptides such as the third helix of the antennapedia sub- 
domain adopt a 3,10 helix in trifluoroethanol solution (which is close to the 
hydrophobic nature of a lipid bilayer) whilst HIV-1-tat 47-57 analogues are more 
efficient transporters when their predicted helicity is increased (Ho et al., 2001). 
Furthermore, the first step in translocation of lysine/phenylalanine co-polymers 
across biological membranes involves a conformation transition from a random coil 
form to a helix-rich form (Shibata et al., 2003). It has been postulated from these 
studies that the helical structure may serve to present the amino acid side chains such 
that the overall molecule is amphipathic in nature. Several reports have highlighted 
the ability of polyphenyl systems (Omer et al., 2001) to mimic the display of amino 
acid side chains in a peptide helix. In particular the 2, 2’ positions of a biphenyl 
system are able to closely mimic the spatial orientations of the i, i+3 or i+4 positions 
of an alpha helix (Jacoby, 2002) (Figure 6.1a). SMoCs are comprised of a simple 
biphenyl system displaying guanidine groups at the 2 and 2’ positions (2G-SMoC) to 
mimic display of arginine residues on one face of the helix (Figure 6.1b). A key 
feature of transportation of PTDs across cellular membranes is the formation of 
bidentate hydrogen bonds between the guanidinium head groups of the PTD and 
anionic structures on the cell surface (Rothbard et al., 2005). For this reason 
unsubstituted guanidine groups were used in the design of SMoCs. A further 
analogue displaying 4-guanidine groups (4G-SMoC) was also designed; in this case 
the precise mimicry of the helix is lost though the amphipathicity of the molecule is 
maintained and the molecule displays more guanidine groups per phenyl unit (4 in a 
6 A distance compared to 3 for an alpha helix) (Figure 6.1c). An important feature of 
PTDs is their ability to transport a variety of different cargo. In order to mimic this 
feature in SMoCs the synthesis was designed such that a late stage intermediate
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would contain a free amine group, allowing a very straightforward variation of the 
linking chemistry (Figure 6.Id).
B.3.2. Synthesis o f small molecule carriers
A scheme of the synthesis of 2G-SMoC is shown in Figure A.l. Initial reduction and 
diazotization-halogenation of the 2-nitro group in 1 provides the 2-bromo-5- 
methylanisole 2. The key step in the synthesis is the palladium [0] catalysed Suzuki 
coupling of the 3-methoxyaryl boronic acid to give the biphenyl system 2 in 63% 
yield. Radical bromination of the aryl methyl group using N-bromosuccinimide, 
followed by reaction with potassium phthalimide yields the protected amine 
intermediate 3. Removal of the methyl ethers and alkylation using the Mitsunobu 
reaction provides 4. Removal of the tertbutyloxycarbonyl (Boc) protecting groups 
with trifluoroacetic acid and guanidinylation using the bis-Boc triflate provides the 
Boc protected biphenyl mimic 5. Finally, removal of the pthalimide group may be 
effected using hydrazine and the amine reacted with fluorescein isothiocyanate 
(FITC) which, after Boc removal, gave the required compound 2G-SMoC-FITC. 4G- 
SMoC-FITC and 4G-SMoC-SS-py were synthesised by similar routes.
B.3.3. Molecular modelling
Molecular modelling was carried out using Sybyl 6.5. Peptides were modelled 
starting from the penetratin structure (pdb code lkzO) using the Biopolymer tools. 
The peptides were energy minimised to a gradient of less than 0.05 kcal/A using the 
Kollman all atom forcefield and charges and Powell minimisation algorithm. Non­
bonded cutoffs were applied at 12 A and a distance dependent dielectric of l.Or was 
used. Small molecules were modelled using Chem3DPro and minimised with MM2.
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Figure A.l. Chemical synthesis of 2G-SMoC-FITC. The key biphenyl formation 
is established early in synthesis by means of a Suzuki Pd[0] coupling of 1 and 3- 
methoxy boronic acid. Guanidinylation of the side chains (4 to 5) is achieved 
through use of bis (Boc) triflate.
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Appendix C: Summary of data from in vitro DNA 
replication reactions
Summary of cell free system data
1 2 3
Positive Negative Positive Negative Positive Negative Mean % replicating St Dev
Figure 4.7a
BA 27 1001 30 1156 39 1362 2.66 0.00128
SC 335 1190 328 1145 217 755 22.17 0.00192
Gem 89 1163 63 746 113 1483 7.25 0.004
Figure 4.7b
BA 375 204 358 156 474 307 64.41 0.04485
SC 434 210 463 238 488 351 63.42 0.04985
Gem 460 284 550 279 574 425 61.59 0.04444
Figure 4.8a
SC 275 952 222 748 93 343 22.41 0.00798
Gem 69 767 63 1091 75 953 6.86 0.0142
ISkDa 62 967 56 800 57 699 6.63 0.0077
9.7 kDa 258 1127 138 602 n o 478 18.65 0.00041
Figure 4.12a
BA 20 831 21 950 15 702 2.21 0.00133
SC 282 830 93 343 76 251 24.05 0.02016
SC + B1 214 996 303 867 183 860 20.45 0.04782
SC + C1 148 781 246 765 235 1172 18.79 0.04644
SC + D1 200 735 155 509 137 699 20.21 0.03588
SC + El 142 799 267 993 161 639 18.99 0.03258
Gem 57 974 54 936 45 536 6.00 0.01302
Gem + Bl 78 827 87 803 87 796 9.41 0.00691
Gem + Cl 91 903 98 684 57 785 9.40 0.02895
Gem + D1 97 507 232 748 162 785 19.40 0.04127
Gem + El 138 709 227 679 153 791 19.21 0.05084
Figure 4.14a
SC 192 513 386 1027 212 589 27.06 0.00469
Gem 124 1233 103 997 95 1069 8.89 0.00639
GemFF 217 737 267 820 274 832 24.09 0.01115
Figure S3
BA 15 564 17 693 8 524 2.20 0.00579
SC 249 733 249 1088 311 1112 21.62 0.03367
E4 344 1249 310 1379 381 1428 20.33 0.01738
Cdc6 430 1364 93 306 204 689 23.56 0.00565
Cdc6 + E4 115 915 109 851 74 758 10.56 0.01369
Figure 5.4
BA 800 601 788 668 702 558 55.62 0.01492
SC 453 817 637 440 470 413 48.30 0.1221
E4 684 488 787 600 671 491 57.57 0.00818
Cdc6 1431 946 478 390 623 370 59.75 0.03908
Cdc6 + E4 716 691 733 473 882 707 55.47 0.04949
Figure 5.7a
SC 150 659 265 1106 274 960 20.18 0.01928
E4 259 1258 229 736 168 697 19.60 0.03376
Cdc6 209 809 382 1191 293 913 23.28 0.02171
Cdc6 + E4 227 1961 193 1439 143 999 11.35 0.01095
Figure 5.8a
BA 25 946 10 660 37 1156 2.54 0.0082
SC 175 851 207 801 186 856 18.47 0.01823
DE4 300 1267 158 728 298 1112 19.57 0.01662
Cdc6 71 246 196 680 346 1532 19.96 0.02288
Cdc6 + AE4 190 837 274 1212 189 723 19.07 0.01302
Figure 5.9a
SC 314 934 154 720 385 1016 24.21 0.05155
E4R45A 199 642 174 519 302 968 24.07 0.00803
E4A44-48 228 702 191 671 278 972 22.91 0.01338
Cdc6 345 938 199 563 256 508 28.48 0.04063
Cdc6 + E4 R45A 256 655 267 739 193 512 27.31 0.00781
Cdc6 + E4 A44-48 321 799 351 1041 322 838 27.07 0.01787
Cdc6 + WTE4 80 787 56 577 66 624 9.22 0.00359
Table A.6. Summary of data obtained from the cell-free in vitro DNA replication 
system. Data is expressed as the number of nuclei positive/negative for biotin-16- 
dUTP incorporation. Three individual experiments were performed for each data set 
and the mean percentage of nuclei replicating calculated.
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Appendix D
Kingsbury SR, Loddo M, Fanshawe T, Obermann EC, Prevost AT, Stoeber K and 
Williams GH. 2004. Repression of DNA replication licensing in quiescence is 
independent of geminin and may define the cell cycle state of progenitor cells. Exp. 
Cell Res. 309: 56-67.
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Functional characterisation of recombinant human Geminin
Prior to structural analysis by EM we characterised recombinant Geminin for its DNA 
replication inhibition activity in the cell-free DNA replication assay1. To test the activity of 
recombinant Geminin, in vitro DNA replication reactions were performed in the presence of 
recombinant his-tagged human Geminin (H6-hsGeminin). The purified recombinant Geminin 
was homogeneous and migrated as a single peak corresponding to a molecular weight of -240 
kDa, indicating either an unusual shape of the protein and/or assembly into oligomers. G1 nuclei 
incubated in a physiological buffer supporting DNA elongation resulted in 2.2 % of nuclei 
synthesising DNA, in keeping with a small amount of S phase contaminants1 (Supplementary 
Fig. la,/ online). In contrast, 22% of G1 nuclei synthesised DNA upon incubation in S phase 
cytosol, representing true initiation in vitro (Supplementary Fig. la^i online). Addition of 
Geminin to the reaction resulted in 6.7% of the nuclei replicating, indicating that 66% of 
replication-competent nuclei failed to synthesise DNA in vitro (Supplementary Fig. la^Vi). In 
control reactions, DNA elongation was not affected by addition of recombinant Geminin to S 
phase nuclei with 64% of them continuing to replicate (data not shown). Taken together, these 
data demonstrate that recombinant Geminin is a potent inhibitor of the initiation of DNA 
replication in vitro, but does not arrest DNA elongation from origins that have fired in vivo prior 
to preparation of the nuclear templates from intact cells.
We next analysed chromatin-bound protein fractions from the reactions identical to those 
described above. There was no Mcm2 protein bound to chromatin in fractions prepared from G1 
nuclei incubated in elongation buffer (Supplementary Fig. lb  online). Incubation of G1 nuclei 
in S phase cytosol resulted in recruitment of Mcm2 to chromatin, indicative of pre-RC assembly 
in vitro (Supplementary Fig. lb  online). Addition of Geminin to co-incubations of G1 nuclei in
S phase cytosol banned the replication license by blocking loading of Mcm2 onto chromatin 
(Supplementary Fig. lb online). Importantly, this block to pre-RC assembly coincides with 
binding of recombinant Geminin to chromatin (Supplementary Fig. lb online). This suggests 
that the replication inhibitory activity of Geminin may also be coupled to its potential to bind 
DNA. These data demonstrate that bacterially expressed recombinant Geminin subjected to 
structural analysis is fully functional in repressing origin licensing and blocking initiation of 
DNA replication.
Properties of an amino-terminal truncated form of human Geminin
To distinguish between different structural domains in our model, we analysed a truncated form 
of Geminin with deletion of the amino terminal part of the protein, which is predicted to form an 
independent structural and functional domain (Supplementary Fig. 3a online). In Xenopus it has 
been demonstrated that the first 80 amino acid residues of the frog ortholog are not required for 
Geminin’s replication inhibition activity, suggesting that the truncated protein folds into the 
active form2,3. We therefore engineered a Geminin-ANt truncated derivative of human Geminin 
lacking the first 80 aa residues. Prior to analysis by EM, the Geminin-ANt recombinant protein 
was tested for its biochemical activity in the cell-free replication assay and showed activity 
(inhibition of 65.5% of competent nuclei) almost identical to that of the full-length protein 
(Supplementary Fig.la i^/ online), indicating that overall folding of either the truncated protein 
or domains involved in replication control have not been affected by the deletion.
Next we analysed Geminin-ANt by EM at conditions identical to those employed for full- 
length Geminin. Raw images of Geminin-ANt appeared as small, thread-like elongated particles. 
In contrast to particles of the full-length protein, the head-like bulk at the end was absent. 
Approximately 300 molecular images were selected and subjected to multivariate statistical
analysis4,5. Five typical raw images of Geminin-ANt and one of the class averages are shown in 
Supplementary Fig. 4d online. All particles of Geminin-ANt are uniformly shaped as a short 
filament of -25A in diameter and -170A in length, thinner and slightly longer than we expected. 
Since the molecular images did not show the head-like domain at one end of the filaments, we 
conclude that the head-like part in the structure represents the amino terminal part of Geminin. 
The smaller diameter of Geminin-ANt particles in comparison to particles of the full-length 
protein is indicative of dimeric rather than tetrameric organisation of the molecule. In keeping 
with this observation, crosslinking experiments show that the major crosslinked species of 
Geminin-ANt is a protein band migrating as a dimer (Supplementary Fig. 4b online). This is in 
keeping with crystallographic data on a peptide representing the coiled coil domain of Geminin6.
Domain structure modelling of human Geminin
Since the structure of the coiled coil domain is unavailable at present, we modelled the potential 
Geminin dimer with SwissModel structural homology modelling software using the 1GK6 
atomic structure as a template7. This structure, originally used by Thepaut and co-authors for the 
molecular replacement method6, was identified as a potential match for the Geminin sequence by 
the Threader 3 program8. The resulting structural model is a leucine/isoleucine zipper9,10 that is 
coordinated into a parallel dimer of a-helices, with almost all hydrophobic aa residues forming 
the interface between monomers (Supplementary Fig. 4c online). The diameter of the dimer is 
-22A, consistent with our findings for Geminin-ANt particles. The length of the 37 aa dimer was 
measured as -60A. Considering that Geminin-ANt is 132 residues long, it is plausible to suggest 
that the overall length of the putative long helical structural organisation could be close to -170A 
as determined for Geminin-ANt. The extended length could be explained by the absence of
3
dimer-dimer interactions within the Geminin molecule and thus straightening of the Geminin-
ANt dimer.
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Supplementary Methods
Protein expression and purification
Geminin and Geminin-ANt were expressed using modified pET-15b vector with 
thrombin site substituted for the recognition sequence o f  TEV protease. Rosetta pLysS 
strain (Novagen) was used for protein expression. Target proteins were purified by 
NiNTA chromatography followed by removal o f  the tag using His-tagged TEV protease 
(Invitrogen) and a subsequent second NiNTA purification step. The proteins were further 
purified by gel filtration chromatography on a Superose 6 (Pharmacia) column using 
250mM NaCl, 25 mM Tris-HCl pH 8.5 buffer.
Chemical crosslinking of recombinant Geminin proteins
Crosslinking o f  Geminin or Geminin-ANt proteins at 10 pg m l'1 was performed in 1 ml o f 
buffer (20 mM HEPES pH 7.5, 200 mM  KC1, 10 mM DTT, 1 mM EDTA) containing 
either bis-[sulfosuccinidmidyl]suberate (BS3) (Sigma) or ethyleneglycol-bis- 
succinimidylsuccinate (EGS) (Pierce). BS3 and EGS concentrations ranged from 0.5 to 5 
mM. Reactions were quenched after 45 min at RT by adding 0.05 ml 1 M TrisHCl pH 
8.0. Crosslinked protein was precipitated by adding 0.115 ml 100% trichloroacetic acid. 
Protein was collected by centrifugation at 10,000 g for 5 min, washed once with 1 ml o f 
acetone, air dried, resuspended in SDS-PAGE loading dye and analyzed by 4-20% SDS- 
PAGE (Invitrogen).
Cell culture, in vitro DNA replication and chromatin binding assay
NIH3T3 and Hela S3 tissue culture cells were cultured and synchronised as described1,2,3. 
Nuclei and cytosolic extracts were prepared from synchronised cells as described1,3,4. 
DNA replication in vitro reactions were performed as previously described1,3. H6- 
hsGeminin protein (or Geminin-ANt ) in 50 mM Na-Phosphate was added to a final 
concentration o f 4 pM. An equal volume o f  buffer was added to control replication 
reactions. Confocal fluorescence microscopy o f  random fields o f nuclei was performed 
on a Leica TCS DMRE confocal microscope and images were processed and analysed as 
described1. For chromatin binding assay nuclei were lysed as described5. Insoluble 
chromatin was washed and resuspended in buffer (10 mM KC1, 1.5 mM M gCh, 10 mM 
HEPES pH 7.9, 0.34 M sucrose, 10% glycerol, 1 mM DTT, 0.1 mM PMSF) plus 1000 U 
m l'1 DNase I, incubated for 30 min at RT followed by 30 min incubation at 4°C with 1 
volume o f 0.5 M NaCl. Solubilised chromatin bound proteins were clarified by 
centrifugation, separated by 10% SDS-PAGE and immunoblotted with antibodies against 
Mcm2 (BD Biosciences, #610701), His-tag (BD Biosciences, #631212) and Histone HI 
(Santa Cruz, #10806).
Electron Microscopy
For structural analysis, 5 pi o f  purified full-length Geminin or Geminin-ANt (0.05mg ml’1 
in buffer [25 mM Tris-HCl pH 8.0, 100 mM NaCl]) were applied to carbon-coated 
copper grids (400 mesh, freshly glow-discharged in air). After 2 min excess buffer was 
removed by blotting and specimens were stained twice with 5 pi 2% w/v methylamine 
vanadate, pH 8.0, or 5 pi 2% w/v methylamine tungstate, pH 6.8 (NanoVan and Nano-W,
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Nanoprobes Inc.) for 1 min. M icrographs were recorded on Kodak SO 163 film using a 
FEI Tecnai T10 transmission electron microscope in low-dose mode, operated at an 
accelerating voltage o f  100 kV and with a magnification o f 44,000*. Negatives were 
developed in Kodak full strength developer D-19 for 12 min and their quality was 
assessed by optical diffraction.
Image processing and computer molecular modelling
Micrographs were digitized on a Zeiss SCAI microdensitometer (Z/I Imaging) with a step 
size o f 7 pm and images were coarsened by averaging 2*2 pixels corresponding to a 
pixel size o f 3.18A at specimen level. Micrographs were scanned and particle images 
were selected manually. Image analysis was performed using IMAGIC6. The resulting set 
o f images was normalized to the same sigma and filtered: low-resolution cut-off was 
-100A  to remove uneven background on particle images; high-resolution cut-off was 
~7A. Images were centred using rotationally averaged total sum o f images. Subsequent 
multivariate statistical analysis allowed us to find references for multi-reference 
alignment. The alignment procedure was followed by the next round o f statistical 
analysis o f images7. The first approximate model o f  the molecule was obtained using 
angular reconstitution from the best 10-15 classes. The model was centred and its 
reprojections were used to refine alignment and classification o f images. The final 
reconstruction was calculated out o f  ~200 classes containing 8-15 images each. 3D maps 
were calculated using the exact-filter back projection algorithm8,9. Resolution o f the map 
was assessed using the 0.5 threshold o f  Fourier Shell Correlation10, which corresponds to 
~ 17.5A. Multiple sequence alignments between Geminin and known structures were
3
made using Threader312 (http://bioinf.cs.ucl.ac.uk/threader/). After alignment, the 1GK6 
structure previously used in X-ray analysis for molecular replacement13 was chosen as a 
template for modelling Gem inin’s coiled coil domain structure with the SwissModel 
software package (http://swissmodel.expasy.org/)14. Domain fitting by small translational 
and rotational movements into the 3D map o f  Geminin was performed interactively using
O 11. The secondary structure prediction was performed by using PredictProtein (EMBL, 
Heidelberg, http://www.embl-heidelberg.de/predictprotein/predictprotein.html).
Illustrations were generated using Deep View Swiss-PDB viewer15
(http://ca.expasy.org/spdbv/), PyM OL (http://pymol.sourceforge.net/) and IRIS Explorer 
(http://www.nag.co.uk/visual/IE/iecbb/Product.html). Surface representations are
displayed at a threshold level o f l a  corresponding to -100%  o f the expected mass. This 
threshold was determined assuming the mass o f the complex is -105  kDa and the specific 
density is 0.833 kDa A '3.
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2Abstract
We have designed and synthesized small molecule, biphenyl, alpha helical mimics of 
a peptide protein transduction domain (PTD). These small molecule carriers, which 
we have termed SMoCs, efficiently deliver dye molecules and proteins into a variety 
of cell types and can be easily coupled to recombinant proteins. The SMoCs were 
designed using molecular modelling techniques. As an example of a protein cargo, we 
have applied this new technology to the internalization of the DNA replication 
licensing repressor geminin, in vitro, providing evidence that a SMoC-geminin, 
delivered extra-cellularly, can have an anti-proliferative effect on U20S human 
osteosarcoma cells. The mechanism of uptake of SMoC-geminin was shown to be via 
clathrin mediated endocytosis.
Introduction
A convenient method to deliver exogenous proteins into cells would have 
wide ranging applications in cell biology. Expression of the protein following gene 
delivery is a widely used technique. However, the amount of protein synthesized is 
largely dependent on the ability of the cell of interest to express the protein. The 
currently available methods to deliver native proteins include micro-injection, which 
is time and labour intensive, or complexing the protein with a lipid-membrane 
permeablizing agent, which is inefficient and often toxic to cells.1,2
One solution to the delivery problem is to utilize a protein transduction 
domain (PTD) to internalize the protein. A number of PTDs have been identified, 
mostly small, less than 30 amino acid peptides. Well known examples include the 
basic region (47-57) of HIV-1-tat, the third helix of antennapedia homeodomain 
(penetratin) 3,4 and designed variants such as Pep l 5, which is not covalently linked to 
its cargo. PTDs generally contain multiple basic residues and in many cases adopt an 
amphipathic helical structure in a membrane-like environment. The field was 
galvanised by a report by Schwarze and Dowdy6 on the ability of HIV-1-tat fusion 
proteins to deliver P-galactosidase to multiple sites, including the brain, in mice. More 
recently reports on delivery of functionally active proteins in vivo have started to 
appear.7,8 Despite these notable successes, the use of PTDs to deliver proteins has yet 
to become commonplace in cell biology, as their use necessitates further experiments. 
PTD-fusion proteins must be engineered, expressed and purified from bacteria, and 
PTDs have been reported to reduce expression levels in some cases.9 Reagents based 
on synthetic PTDs share the disadvantages common to all peptides, including high 
cost of manufacture and the potential for biodegradation.
We sought to design a small molecule mimic of an amphipathic helix cell 
penetrating peptide. Ideally a carrier would be of minimal size and molecular weight 
and easily attached to proteins and other cargo for their transport into cells. As the 
carrier is a small molecule, it would not be subject to the same biodegradation 
processes as peptides. Such a carrier would deliver the protein cargo into cells in its 
native form, so there would be no disruption of protein function. Attachment to a 
carrier after a protein’s cloning, expression and purification would allow researchers 
to easily utilise their existing recombinant proteins. In this article we describe the 
design (using molecular modelling techniques), synthesis and biological application 
of biphenyl mimics of peptide PTDs, which we have named small molecule carriers 
(SMoCs). First we demonstrate the effectiveness of these molecules in transporting 
SMoC-dyes into cells; and second, as an example for protein cargos, we show that 
SMoCs deliver the DNA replication licensing repressor protein geminin10 into cells in 
a functionally active native form, suppressing origin licensing and progression into S 
phase.
Materials and Methods
For chemistry synthesis, see supplementary information.
Molecular modelling. Molecular modelling was carried out using Sybyl 6.5 (Tripos 
Inc, St Louis, MO, USA). Peptides were modelled starting from the penetratin 
structure (pdb code lkzO) using the Biopolymer tools. The peptides were energy 
minimised to a gradient of less than 0.05 kcal/A using the Kollman all atom forcefield 
and charges and Powell minimisation algorithm. Non-bonded cutoffs were applied at 
12  A and a distance dependent dielectric of l.Or was used. Small molecules were 
modelled using Chem3DPro (Cambridgesoft Corporation, Cambridge, MA, USA) and 
minimised with MM2. Figures were generated using Accelrys ViewerPro (Accelrys 
Software Inc., San Diego, CA, USA).
Cell Culture. Human U20S, WI-38 human diploid fibroblasts (HDF), HeLa S3, and 
and murine NIH/3T3 fibroblasts were cultured in DMEM supplemented with 10% 
FCS, 100 U/mL penicillin and 0.1 mg/mL streptomycin. NIH/3T3 fibroblasts were 
subjected to density-dependent growth arrest as previously described.11 Human 
peripheral blood mononuclear cells were isolated from whole blood, and CD3+ cells 
were isolated by MACS separation (Miltenyi Biotech, Belgium).
Cell viability assays. Cell viability assays were performed using CellTiter-Glo™ 
(Promega, Southampton, UK). U20S cells were seeded in 96 well dishes and treated 
with 10 pM of each compound, as indicated, and incubated for 24 or 48 h. Samples 
were processed as per manufacturer’s protocol. Four independent experiments were 
performed and replicated twice.
6Protein expression and coupling to 4G-SMoC and AlexaFluor488. Geminin, ANt- 
geminin, a truncated derivative of human geminin lacking the first 80 amino acid 
residues, and Tev protein were expressed and purified as described. 12,13 For coupling 
of proteins to 4G-SMoC 2 mg protein (lmg/mL in 0.1 M sodium phosphate buffer, 5 
mM EDTA, pH 6.00), was treated with 14 mg 2-mercaptoethylamine*HCl, and 
incubated at 37°C for 90 min. Excess 2-mercaptoethylamine. HC1 was removed by 
buffer exchange using an Amersham PD-10 (exclusion limit (Mr) 5 x 103 globular 
protein) desalting column pre-equilibrated with PBS-EDTA buffer. The eluted, 
reduced protein was concentrated to approximately lmg/mL using an ultrafiltration 
centrifugation cartridge (Sartorius AG, Goettigen, Germany) and coupled with 4G- 
SMoC-SS-Py. Coupling was performed for 90 min at rt using 0.1 mg SMoC reagent 
per 2 mg protein. Following coupling 4G-SMoC-geminin was purified by buffer 
exchange using the desalting column as above.
Conjugation of geminin with AlexaFluor488 was performed using the Molecular 
Probe Protein Labeling Kit, according to the manufacturer’s protocol (Invitrogen, CA, 
USA). Geminin-AlexaFluor488 and Tev-AlexaFluor488 were then coupled with 4G- 
SMoC following the procedure described above, which generated 4G-SMoC- 
geminin-AlexaFluor488 and 4G-SMoC-Tev-AlexaFluor488. The efficiency of 
conjugation reactions, protein concentration and absence of unincorporated label in 
the solution were measured and confirmed with spectroscopic and electrophoretic 
methods.
Assay for efficiency of coupling. Efficiency of 4G-SMoC coupling to geminin was 
assessed by quantification of sulfhydryl groups using Ellman’s Reagent (Pierce, 
Rockford, IL, USA) according to Pierce protocol 22582.
Biochemical fractionation and immunoblotting For analysis of subcellular protein 
fractions, WI-38 HDFs were biochemically fractionated as previously described. 14 
Protein fractions were resolved by SDS-PAGE and immunoblotted with antibodies 
against Mcm2 (BD Transduction Laboratories™, Lexington, KY, USA, #610701), 
geminin15 and p-Actin (Sigma Aldrich, Gillingham, UK, #A5441).
Subcellular localization studies. For visualization of SMoC-FITC uptake in live 
cells, U20S cells were cultured on glass coverslips and pulsed with 10 fiM FITC, 
TAT-FITC or 2G- or 4G-SMoC-FITC for 15 min. For analysis of uptake kinetics in 
live cells, cells were incubated with 10 /xM 2G- or 4G-SMoC-FITC for 10-80 min 
prior to immediate visualization. The efficiency and sub-cellular localization of 
SMoC delivery in live cells was assessed by confocal fluorescence microscopy on a 
Leica TCS DMRE confocal microscope or quantified by FACS analysis (FACS 
Calibur, BD Biosciences, NJ, USA), where cells were washed in PBS and treated with 
50 /xg/mL propidium iodide, to enable discrimination of dead cells. 10000 Cells were 
collected for each sample and analyzed using CellQuest™ software (BD Biosciences, 
NJ, USA).
For detection of 4G-SMoC-geminin-AlexaFluor488 and 4G-SMoC-Tev- 
AlexaFluor488 uptake into live cells, exponentially growing cells (WI-38 HDF, 
NIH/3T3, U20S and Saos2) were cultured on glass coverslips. Cells were washed
once in PBS, and incubated with fresh medium containing 10 fiM 4G-SMoC- 
Geminin-AlexaFluor488 or 10 pM 4G-SMoC-Tev-AlexaFluor488. After appropriate 
time incubation, coverslips were washed extensively in PBS, placed in a plate 
containing medium without Red Phenol (Gibco) and observed by live confocal 
fluorescence microscopy (MP-UV, Leica Microsystems, GmbH, Wetzlar, Germany) 
using a 40x and a 63x water immersion objective.
For detection of Mcm2 associated with chromatin and/or the nuclear matrix by 
immunofluorescence, WI-38 HDFs were treated with 4G-SMoC-ANt-geminin for 24 
h. Soluble proteins were detergent extracted by treatment with 0.1% Triton-X 100 for 
30 s, cells were fixed with 4% paraformaldehyde for 5 min, washed in 2x PBS for 10 
min followed by lx PBS for 5 min and permeabilized in 0.1% Triton-XlOO for 5 min. 
Non-specific interactions were blocked with 1% BSA for 15 min and cells stained 
with a monoclonal anti-Mcm2 antibody, a FITC-conjugated anti-mouse secondary 
antibody and counterstained with propidium iodide/RNase A (both at 50 ng/mL, 
Sigma Aldrich, Dorset, UK). Fluorescence intensity was quantified using ImageJ 
(http://rsb.info.nih. gov/ii).
Mechanism of cellular uptake studies. Studies to determine whether uptake of 2G- 
SMoC-FITC or 4G-SMoC-geminin-AlexaFluor488 by WI-38 or U20S cells could be 
affected by inhibitors of trafficking utilized the following compounds: 14 pM 
chlorpromazine, 25 pM nystatin, 25 pM (eip)amiloride, 4 pM cytochalasin D, and 40 
nM nocodozole. Cells were pre-incubated for 1 h prior to the addition of either 2G- 
SMoC-FITC or 4G-SMoC-geminin-AlexaFluor488. To determine whether uptake 
could be affected by decreased temperature, cells were placed either at 37°C or in an
ice bath prior to the addition of either 2G-SMoC-FITC or 4G-SMoC-geminin- 
AlexaFluor488. Incubation continued for an additional hour. Cells were then washed 
extensively with PBS, and either visualised on a fluorescence microscope or 
trypsinized and stained with 33 pg/mL propidium iodide prior to being collected by 
FACS analysis.
Cell proliferation assays. To assess the ability of 4G-SMoC-geminin and 4G-SMoC- 
ANt-geminin to block re-entry into cycle from GO, NIH/3T3 fibroblasts were driven 
into GO by density-dependent growth arrest and after 5 days were released back into 
the cell cycle by sub-culturing into fresh growth medium. Eight hours after release 
from GO, 10 fiM of 4G-SMoC-geminin/4G-SMoC-ANt-geminin or the equivalent 
volume of PBS was added to the cells. At 21 h following release, cells were pulse- 
labelled for 1 h with 50 fiM BrdU. Subsequently, cells were fixed in 4% 
paraformaldehyde, permeabilized with 0.1% Triton X-100, and DNA was denatured 
by treatment with 2 M HC1 to allow detection of incorporated BrdU. Cells were 
stained with FITC-conjugated anti-BrdU (1:20 dilution; Alexis Biochemicals, 
Nottingham, UK) and propidium iodide/RNase A (both at 50 ng/mL). Confocal 
fluorescence microscopy of random fields was performed on a Leica TCS DMRE 
confocal microscope.
To assess the ability of 4G-SMoC-ANt-geminin to block cell proliferation in 
cycling cells WI-38 HDFs were seeded onto glass slides at a density of 1 x 104/mL. 
After 12 h 10 fiM of 4G-SMoC-ANt-geminin was added to the cells and replenished 
after a further 12 h. Twenty-three hours after the initial treatment, cells were pulse- 
labelled for 1 h with 50 fiM BrdU. BrdU incorporation was monitored as described 
above.
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Results
Design o f the amphipathic helix mimics. Although small peptides (<20 amino acids)
generally lack any structure in aqueous media, peptides such as the third helix of the
antennapedia sub-domain can adopt a helical conformation in phospholipid vesicles16
as can the HIV-1 Rev-(34-50) peptide17 in methanol solution. An analogous
conformational switch into a helical form has been reported for lysine/phenylalanine 
18co-polymers. HIV-1-tat 47-57 analogues became more efficient transporters when 
their predicted helicity was increased. 19 Thus the helical structure may serve to 
present the amino acid side chains such that the overall molecule is amphipathic in 
nature (Figure lb). Several reports, notably by Hamilton,20,21 have highlighted the 
ability of polyphenyl systems to mimic the display of amino acid side chains in a 
peptide helix. In a detailed molecular modelling study the 2 ,2 ’ positions of a biphenyl 
system are able to closely mimic the spatial orientations of the i, i+3 or i+4 positions 
of an alpha helix22 (Figure la). We designed a simple biphenyl system displaying 
guanidine groups at the 2 and 2’ positions (2G-SMoC) to mimic display of arginine 
residues on one face of the helix (Figure lc). Unsubstituted guanidine groups were 
used, since bivalent coordination of guanidine by phosphate, which forms a tight ion 
pair, is thought to be essential for the function of cell penetrating peptides.23 The 
amphipathic nature of the antennapedia third helix compared to the designed biphenyl 
compound is shown in Figure lb. Another analogue displaying 4-guanidine groups 
(4G-SMoC) was also designed (Figure Id); in this case the precise mimicry of the 
alpha helix is lost, however, the amphipathicity of the molecule is maintained and the 
molecule displays more guanidine groups per phenyl unit (4 in a 6 A distance 
compared to 3 for an alpha helix). We designed the synthesis such that a late stage
intermediate would contain a free amine group (Figure le). This allows a 
straightforward variation of the chemistry to link the SMoC to the protein cargo. Here 
we utilize the DNA replication licensing repressor, geminin10 as a protein cargo to 
couple to an SMoC. Geminin is a 23.5 kDa protein which blocks DNA replication 
licensing by competitively binding Cdtl to prevent loading of the hexameric MCM 
complex (Mcm2-7) onto chromatin. We employed a thiopyridyl derivative of 4G- 
SMoC to enable its coupling to geminin through a bio-reducible disulfide bond to two 
cysteine residues at amino acids 194 and 208 in the C-terminus of geminin.
Synthesis o f SMoCs, A scheme of the synthesis of 2G-SMoC is shown in Figure 2. 
Initial reduction and diazotization-halogenation of the 2-nitro group in 1 provides the 
2-bromo-5-methylanisole 2. The key step in the synthesis is the palladium [0] 
catalysed Suzuki coupling of the 3-methoxyaryl boronic acid to give the biphenyl 
system 2 in 63% yield. Radical bromination of the aryl methyl group using N- 
bromosuccinimide, followed by reaction with potassium phthalimide yields the 
protected amine intermediate 3. Removal of the methyl ethers and alkylation using the 
Mitsunobu reaction provides 4. Removal of the tertbutyloxycarbonyl (Boc) protecting 
groups with trifluoroacetic acid and guanidinylation using the bis-Boc triflate 
provides the Boc protected biphenyl mimic 5. Finally, removal of the pthalimide 
group may be effected using hydrazine and the amine reacted with fluorescein 
isothiocyanate (FITC) which, after Boc removal, gave the required compound 2G- 
SMoC-FITC. 4G-SMoC-FITC and 4G-SMoC-SS-py were synthesized by similar 
routes (see supplementary information).
SMoC delivery and sub-cellular localization. In order to test the ability of the di- 
guanidine (2G-SMoC) and tetra-guanidine (4G-SMoC) compounds to deliver small 
molecules, they were coupled to fluorescein as described above. Human U20S 
osteosarcoma cells were incubated with 10 /zM of each compound, and live cells were 
visualized by confocal fluorescence microscopy. Delivery was compared to a TAT- 
FITC conjugate and to FITC alone. At lower magnification (10x), cells treated with 
either of the SMoC-FITC compounds or with TAT-FITC appeared strongly 
fluorescent (Figure 3a inset panels), while cells treated with FITC alone were not 
visible. Assessment of sub-cellular localization of the FITC was possible under higher 
magnification (40x). Cells treated with 2G-SMoC-FITC or 4G-SMoC-FITC had both 
nuclear and cytoplasmic fluorescence, however, 4G-SMoC-FITC showed more 
intense nuclear fluorescence (Figure 3a). These results demonstrate the delivery of 
FITC to both the nucleus and cytoplasm of cells by 2G-SMoC and 4G-SMoC. Next a 
time course of 2G-SMoC-FITC uptake in live U20S cells was performed. Cells were 
incubated with 10 /zM 2G-SMoC-FITC for the indicated times and visualized with 
confocal microscopy which revealed that 2G-SMoC-FITC was rapidly transported 
into cells (Figure 3b). Identical results were seen when cells were treated with 4G- 
SMoC-FITC and fixed for visualization (data not shown). After ten minutes, 2G- 
SMoC-FITC showed diffuse cytoplasmic staining that steadily increased in intensity 
up to 80 minutes after addition. Thus delivery of FITC by the SMoCs was rapid, and 
upon higher magnification (60x), the localization appeared to be in vesicles located in 
the cytoplasm of the cell, possibly the Golgi apparatus or the endoplasmic reticulum 
(Figure 3c).
Next the efficiency of SMoC mediated fluorescein delivery was determined by FACS 
analysis. U20S cells were treated with 10 /zM of SMoCs, then analysed for the 
percentage of live fluorescent cells. As can be seen in Figure 3d, >99% of live cells 
treated with either 2G-SMoC-FITC or 4G-SMoC-FITC were fluorescent. These data 
were comparable to TAT-FITC, for which 97% of cells were fluorescent after 
treatment. Similar results were obtained with 293T cells and for primary human cells 
,CD3+ cells, isolated from freshly harvested peripheral blood mononuclear cells (data 
not shown). Thus both primary and cultured human cells were susceptible to the 
delivery of FITC by SMoCs.
SMoCs do not affect the viability o f cultured cells. The experiments described above 
demonstrate the rapid and efficient delivery of SMoC-FITC to cells, which occurred 
within 10 minutes of application. To test the effects of longer exposure on viability, 
cells were incubated for 24 and 48 hours with 2G-SMoC-FITC and 4G-SMoC-FITC, 
ranging in concentration from 0.1 pM  to 10 pM (Figure 3e and data not shown). No 
decrease in viability was seen with SMoC treatment compared to DMSO alone. 
Viability was compared to cells treated with cycloheximide (CHX), a protein 
synthesis inhibitor, where prolonged exposure is toxic to cells. These results indicated 
that 48 hour incubation of cells with SMoCs did not affect their viability.
4G-SMoCs coupled proteins are transported into live cells.
To determine whether SMoCs would deliver a protein cargo to cells, 4G-SMoC-SSPy 
was coupled to the nuclear protein, geminin, a repressor of origin licensing.10 We 
selected 4G-SMoC due to its enhanced ability to deliver FITC to the nucleus (Figure 
3a). Endogenous geminin protein levels are down-regulated during G1 phase, which
allows the licensing of replication origins for DNA synthesis. Geminin levels increase 
during S-G2-M, when the protein binds competitively to the MCM loading factor 
Cdtl, to block the re-licensing of origins.24 The reducing agent 2- 
mercaptoethanolamine was used to ensure that the two reactive thiols (i.e., cysteines 
at amino acid 194 and 208) in geminin were in the free thiol form, and the protein was 
mixed with 4G-SMoC-SSPy reagent (Figure le). The efficiency of coupling full- 
length human geminin or a truncated protein to 4G-SMoC approached 100%, as 
determined by quantification of free sulfhydryl groups before and after the coupling 
reaction with Ellman’s reagent (Figure 4a).
The uptake and the distribution of 4G-SMoC-geminin-AlexaFluor488 in live cells 
was followed in WI-38 HDFs, NIH/3T3 mouse fibroblasts, U20S and Saos2 
osteosarcoma cells by live confocal fluorescence microscopy (Figure 4b, data not 
shown for Saos2). No fluorescence was observed in controls (AlexaFluor488 or 
geminin only) nor in samples treated with geminin-AlexaFluor488, suggesting that 
coupling to SMoC is essential for cellular uptake of geminin. In contrast cells 
incubated with 10 /xM 4G-SMoC-geminin-AlexaFluor488 appeared fluorescent with 
preferential perinuclear and nuclear staining. In order to obtain similar fluorescence 
intensities, WI-38, NIH/3T3 and U20S cells required incubation with the protein 
conjugate for 1,2 and 5 hours respectively.
To confirm that SMoC can deliver proteins other than geminin into cells, we sought a 
protein with free, solvent exposed cysteine and lysine residues (required for SMoC 
and AlexaFluor488 conjugation). We chose Tev-protease, which has 4 cysteines and 
12 lysines on its surface, and no reported toxicity for human cells. 13 WI-38 HDFs
were incubated with 1 0  /nM 4G-SMoC-Tev-AlexaFluor488 as described above for 
4G-SMoC-geminin-AlexaFluor488. Live fluorescence microscopy revealed that this 
conjugated protein was able to enter the cells whereas, Tev-AlexaFluor488 lacking 
SMoC was not. The intensity of fluorescence inside the cells was similar to that 
obtained with 4G-SMoC-geminin-AlexaFluor488.
To independently assess the ability of SMoCs to transport geminin into cultured cells, 
WI-38 HDFs were biochemically fractionated into cytosolic, nucleosolic and 
chromatin-bound protein fractions following incubation with 4G-SMoC-geminin for 
24 hours. Proteins were resolved by gel electrophoresis and immunoblotted for 
geminin. In the treated cell population exogenous geminin can be clearly detected in 
the cytosolic, nucleosolic and chromatin bound fractions, consistent with previous 
findings that repression of origin of licensing is associated with the presence of 
geminin on chromatin.25
Celllular uptake mechanisms fo r  SMoC coupled molecules. In order to determine 
the mechanisms by which SMoCs are taken up by cells, chemical inhibitors were 
employed to block specific endocytotic pathways,. These included chlorpromazine, 
which induces the misassembly of clathrin-coated pits at the plasma membrane;26 
nystatin which sequesters cholesterol and thus inhibits lipid-raft mediated endocytic 
pathways; (epi)amiloride, an inhibitor of the Na+/H+ exchange required for 
macropinocytosis;27 cytochalasin D,28 an F-actin elongation inhibitor; and 
nocodozole, which inhibits microtubule polymerization. Cells were treated with these 
inhibitors prior to the addition of 2G-SMoC-FITC and then visualized by fluorescence 
microscopy. Both untreated and treated cells appeared equally fluorescent (Figure 5a).
This finding was verified by flow cytometric analysis of the m ean fluorescence 
intensity of live cells (Figure 5b), which confirmed that no significant differences 
were observed upon treatment with these inhibitors. These data suggest that either 
2G-SMoC-FITC can be taken up by cells by several distinct entry routes or that 
macropinocytosis, and clathrin-mediated and lipid-raft mediated endocytic pathways 
are not required for 2G-SMoC-FITC.
To determine whether the cellular uptake of 2G-SMoC was energy dependent, the 
effect of reduced temperature was assessed. A large reduction in the mean intensity of 
fluorescence was observed when incubated with 2G-SMoC-FITC at a lower 
temperature (Figure 5c), suggesting that it did utilize energy dependent pathways for 
uptake into cells
To test whether endocytic processes are involved in the uptake of a protein cargo, we 
next tested the effect of reduced temperature on the delivery of 4G-SMoC-geminin- 
Alexafluor488. Cells incubated with 4G-SMoC-geminin-AlexaFluor488 at a lower 
temperature had a significant reduction in the intensity of fluorescence (Figure 5d), 
suggesting that it also used endocytic pathways for uptake. We next tested these 
chemical inhibitors (chlorpromazine, nystatin, epi-amiloride, and cytochalasin D) for 
their ability to inhibit 4G-SMoC-geminin-Alexafluor488 uptake. As shown in Figure 
5e, cells treated with chlorpromazine showed a 70% reduction in fluorescence 
intensity compared to the control cells. Treatment with other inhibitors, did not 
significantly alter the fluorescence intensity of the cells (data not shown). This 
indicates that uptake of 4G-SMoC-geminin-AlexaFluor488 is dependent upon 
clathrin-mediated endocytosis. Moreover, these data together suggest that the SMoCs
are capable of efficiently delivering different cargo, which retain functionality, and 
which use multiple pathways, dependent on the cargo, for uptake into cells.
SMoCs can deliver functionally active protein cargo into cells o f different tissue 
origin. In cultured NIH/3T3 fibroblasts, chromosomal replication origins are licensed 
for DNA synthesis during a defined “window of opportunity” between 16 and 18 
hours after release from density-dependent growth arrest (Figure 6 a11 14). In this in 
vitro model system, DNA synthesis can be monitored by pulse-labelling with 
bromodeoxyuridine (BrdU). To determine whether, SMoC-mediated cell delivery 
affects protein functionality, 4G-SMoC-geminin was added at concentrations ranging 
from 0.5 pM to 10 pM to NIH/3T3 cells at eight hours after release from GO. We then 
examined whether geminin was functional in repressing origin licensing and thus the 
initiation of DNA synthesis by determining the percentage of cells incorporating 
BrdU at 21 hours, which is the time they would normally enter S phase (Figure 6b). 
Both 4G-SMoC-geminin and a truncation mutant of geminin (ANt-geminin) 12 
delivered by 4G-SMoC inhibited GO-S progression in a concentration dependent 
manner with a maximal inhibition of ~50% occurring with 10 pM 4G-SMoC- 
geminin/ANt-geminin (Figure 6 b and Supplementary Figure 1) in keeping with 
geminin's biological function as a repressor of origin licensing.72 However when 4G- 
SMoC was coupled to a geminin derivative with a double point mutation (Y98F, 
W99F) at a predicted Cdtl binding site (4G-SMoC-gemininFF) , 12 no decrease in the 
percentage of cells incorporating BrdU was observed, indicating that inhibition of 
DNA replication in these experiments was dependent on wild-type geminin and not 
linked to a non-specific effect of the SMoC (Figure 6 c). Substitution of 4G-SMoC- 
geminin with equal molar concentrations of uncoupled geminin protein or an
equivalent volume of control buffer did not affect BrdU incorporation. Trypan blue 
exclusion showed no loss of cell viability compared with controls (data not shown). 
These data demonstrate that geminin delivered by 4G-SMoC retained its biological 
activity to block entry into S phase in cells re-entering the mitotic cell division cycle 
from GO.14
To determine whether human cells of epithelial, mesenchymal and haematopoietic 
origin were susceptible to geminin delivered by 4G-SMoC, WI-38 HDFs, HeLa S3 
epithelial adenocarcinoma cells and MOLT-4 leukaemic lymphoblasts were treated 
with 10 pM 4G-SMoC-ANt-geminin for 24 hours. Consistent with the data from 
NIH/3T3 fibroblasts, the percentage of cells synthesizing DNA was reduced by 
approximately 50% compared to control populations in the three different cell lines 
tested, WI-38: 50% [control] vs 26% [treated], Figure 6 c; HeLa S3: 40% vs 17%; 
MOLT-4: 42% vs 22% (data not shown).
To confirm that the reduction in DNA synthesis that occurs following treatment with 
4G-SMoC-ANt-geminin is due to geminin’s biological function as an origin licensing 
repressor, changes in chromatin-bound Mcm2 levels were analysed using 
immunofiuoresence and subcellular fractionation. Following treatment with 10 pM 
4G-SMoC-ANT-geminin for 24 hours WI-38 HDFs were either treated to remove 
soluble proteins and immunostained for Mcm2 or biochemically fractionated and 
analysed by immunoblotting. Treatment with 4G-SMoC-ANt-geminin resulted in a 
75% reduction in the relative intensity of Mcm2 staining indicating that 4G-SMoC- 
ANt-geminin inhibits Gl-S progression by blocking MCM loading onto chromatin 
(Figure 6 d). These results are confirmed by the immunoblot data, which show a
reduction in chromatin bound mcm2 levels following treatment with 4G-SMoC-ANt- 
geminin (Figure 6 e), indicating that 4G-SMoC-Nt-geminin is specifically interfering 
with the recruitment of replication licensing factors onto chromatin in treated cells. 
Taken together these data confirm the ability of 4G-SMoC to efficiently transduce cell 
lines of different origin and to retain the biological activity of its protein cargo.
Discussion
It is significant that 4G-SMoC is capable of delivering its protein cargo in such a way 
that it retains its endogenous cellular function. Specifically, 4G-SMoC conjugated to a 
truncated derivative of human geminin was capable of both inhibiting quiescent cells 
from re-entering the proliferative cycle and of preventing cycling cells from 
progressing through the Gl-S transition. Origin licensing was repressed, by 
prevention of loading of MCM subunits onto chromatin. In addition, the decision to 
utilize 4G-SMoC as the geminin transporter on the basis of the nuclear localization of 
4G-SMoC-FITC was vindicated as the sub-cellular localization of the 4G-SMoC- 
geminin was predominantly nuclear. Currently the reasons for this localization are 
unclear but one intriguing possibility is that 4G-SMoC is mimicking a short highly 
basic nuclear localisation signal such as the SV40 sequence PKKKRKV29 or the vJun 
sequence30 GKKRSKV. This ability to target SMoC cargo to different sub-cellular 
locations is likely to be a useful property. An alternative scenario is that once native 
geminin is generated in the cell (by cleavage of the SMoC-SS-geminin bond) it is 
localised to the nucleus by virtue of its own structure and sequence characteristics. 
4G-SMoC was able to efficiently transduce a number of geminin variants into several 
cell lines of epithelial, mesenchymal and haematopoetic origin. Thus our novel small 
molecule PTD mimics are able to transport proteins into a wide variety of cell types.
The mechanisms of entry of PTDs into cells are a matter of some debate, with both 
energy dependent and non-dependent processes being advanced. In particular the 
mechanism of HIV-1-tat PTD i.e. the short tat peptide, entry has been proposed to be 
via the clathrin mediated endocytotic pathway, while a recent report indicated that the 
process for tat fusion-proteins was in fact macropinocytosis.31 Our experiments using 
fluorescently labelled geminin protein in live cells show that the uptake process is 
inhibited at 4°C and by the presence of chlorpromazine, which induces the 
misassembly of clathrin-coated pits at the plasma membrane and therefore inhibits 
this endocytotic pathway. In contrast nystatin, which sequesters cholesterol and 
blocks lipid raft mediated endocytosis and (epi)-amilioride, which inhibits 
macropinocytosis by blocking the Na+/H+ pump, were ineffective. Similarly 
cytochalasin D (actin elongation) and nocodazole (microtubule polymerisation) were 
without effect. There appears to be a difference in the mechanism of uptake for the 
SMoC-dye molecules, as none of the inhibitors had any significant effect, though 2G- 
SMoC-FITC was still inhibited at 4°C. Our experiments indicate that uptake of the 
SMoC-geminin molecules is via classical clathrin mediated endocytosis. Calveolae 
mediated endocytosis or macropinocytosis, do not appear to be involved. However we 
should caution that at least for PTD’s the uptake pathways are both cargo and cell 
type dependent.32
In summary, we have designed and synthesized a small molecule, biphenyl, alpha 
helical mimic of a peptide PTD. These small molecule PTDs, which we have termed 
SMoCs, efficiently deliver dye molecules and proteins into a variety of cell types and 
can be easily coupled to recombinant proteins. As an example for a protein cargo, we 
have applied this new technology to the internalization of geminin in vitro, providing
evidence that 4G-SMoC-geminin, delivered extra-cellularly, can have an anti­
proliferative effect on tumour cells. Future investigations will establish the utility of 
the SMoCs for other types of cargo such as peptides, antibodies and oligonucleotides.
Supporting information available
Full experimental details of the chemical syntheses are provided.
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Figure Legends
Figure 1. (a) Molecular model of a typical alpha helix showing the similar spatial 
orientation of the i and i + 3 positions with the 2 and 2' positions on the biphenyl ring 
(puiple). (b) The amphipathic nature of the helix mimic 2G-SMoC is shown 
compared to the alpha helix of antennapedia 44-57 (penetratin). Electrostatic potential 
is shown as a wire mesh with blue (positive), red (negative) and grey (neutral). Both 
molecules are drawn to the same scale, (c) Chemical structures of 2G-SMoC-FITC 
and (d) 4G-SMoCo-FITC. (e) A late stage 4G-SMoC-amine intermediate allows a 
flexible range of attachment chemistries to be simply instituted depending on the 
application.
Figure 2. Chemical synthesis of 2G-SMoC-FITC; the key biphenyl formation is 
established early in the synthesis by means of a Suzuki Pd[0] coupling of 1 and 3- 
methoxy boronic acid. Guanidinylation of the side chains (4 to 5) is achieved through 
use of the bis(Boc) triflate
Figure 3. SMoCs are rapid and efficient transporters of FITC in primary and cultured 
cells, (a) Visualization of delivery of 2G-SMoC and 4G-SMoC coupled to FITC 
compared to TAT-FITC and FITC alone in live cells. There is widespread distribution 
of FITC in nuclear and cytoplasmic compartments delivered by SMoCs and TAT, 
compared to minimal uptake of FITC alone, (b) Time course of delivery of 2G- 
SMoC-FITC. Cells were treated for the times indicated prior to visualization. 
Fluorescence is detectable within five minutes of application of 2G-SMoC-FITC, with 
increasing intensity being detected after 80 minutes, (c) Visualization of 2G-SMoC 
uptake at higher magnification in live cells. There is widespread distribution of FITC
in perinuclear, vesicular structures in the cytoplasmic compartment, (d) Efficiency of 
delivery of 2G-SMoC and 4G-SMoC coupled to FITC, TAT-FITC and FITC alone in 
live cultured cells as determined by FACS analysis. Cells were treated for 10 minutes 
prior to washing with PBS and staining with propidium iodide to exclude dead cells, 
(e) Cell viability of cells is not affected by SMoC-FITC. Cells were incubated for 48 
hours with 10 pM of the indicated compounds prior to assaying for viability. 
Cycloheximide (CHX) was included as a positive control for inducing loss of cell 
viability.
Figure 4. Coupling of geminin to SMoC allows rapid transportation of active protein 
into cells, (a) Quantification of sulfhydryl groups with Ellman’s reagent before and 
after coupling indicates that coupling of geminin to 4G-SMoC approaches 100% 
efficiency, (b) Geminin and Tev proteins were coupled with AlexaFluor 488 (AF488) 
and 4G-SMoC. WI-38 HDFs (i), osteosarcoma-derived U20S cells (ii) and mouse 
NIH/3T3 fibroblasts (iii) were treated with 10 pM 4G-SMoC-geminin-AF488 for 1, 5 
and 2 hours respectively and analysed by live confocal fluorescence microscopy. The 
presence of fluorescence inside the cells (particularly localised in perinuclear and 
nuclear areas) proves the internalization of the protein complex, (iv) WI-38 human 
diploid fibroblasts were incubated with 10 pM 4G-SMoC-Tev-AlexaFluor488 and 
cells were analysed after 1 hour, (c) For detection of geminin internalization by 
immunoblotting, cytosolic (CF), nucleosolic (NF) and chromatin-bound (CBF) 
protein fractions were prepared from WI-38 HDFs following treatment with 4G- 
SMoC-geminin. Protein fractions were resolved by gel-electrophoresis and 
immunoblotted for geminin. In the treated population exogenous geminin can be 
clearly detected in the cytosolic, nucleosolic and chromatin-bound protein fractions.
Figure 5. Effect of chemical inhibitors and temperature on uptake of SMoCs with 
different cargo, (a) Images of U20S cells treated with the compounds indicated and 
then incubated with 2G-SMoC-FITC. (b) Histograms of FACS profiles of live cells 
treated with various compounds as indicated prior to addition of 2G-SMoC-FITC. (c) 
Histogram of FACS profile of live cells treated with 2G-SMoC-FITC at 37°C or 4°C. 
(d) Histogram of FACS profile of live cells treated with 4G-SMoC-geminin- 
Alexafluor488 at 37°C or 4°C. (e) Histograms of FACS profiles of live cells treated 
with chlorpromazine prior to addition of 4G-SMoC-geminin-Alexafluor488.
Figure 6 . The biological activity of protein cargo is not affected by SMoC-mediated 
delivery, (a) In cultured NIH/3T3 fibroblasts, chromosomal replication origins are 
licensed for DNA synthesis during a defined “window of opportunity” between 16 
and 18 hours after release from density-dependent growth arrest. Progression into S 
phase can be easily monitored by pulse-labelling with BrdU 21 hours after release. To 
determine whether SMoC-mediated cell delivery affects protein functionality 4G- 
SMoC-geminin was added to NIH/3T3s eight hours after release from GO and re-entry 
into S phase monitored at 21 hours, (b) Treatment of NIH/3T3 fibroblasts with 10 pM 
4G-SMoC-geminin or 4G-SMoC-ANt-geminin eight hours after release from GO 
resulted in a 50% reduction in BrdU incorporation compared to control populations. 
In contrast, no reduction in BrdU incorporation was observed in a geminin derivative 
with a double point mutation (Y98F, W99F) at a possible Cdtl binding site (4G- 
SMoC-FFgeminin). (c) Asynchronous WI-38 HDFs were treated for 24 hours with 10 
pM 4G-SMoC-ANt-geminin and pulse-labelled with BrdU for one hour. Gl/S 
progression was inhibited by approximately 50% in treated cells compared to a 
control population, (d and e) The reduction in DNA synthesis was coupled to a block
to Mcm2 chromatin-binding as detected by (d) immunofluorescence and (e) 
immunoblotting. For detection by immunofluorescence, WI-38 HDFs were treated 
with detergent prior to fixation to remove soluble proteins and stained with a mouse 
anti-Mcm2 MAb, a FITC conjugated secondary anti-mouse antibody and propidium 
iodide. Treatment with 4G-SMoC-ANt-geminin reduced the intensity of fluorescently- 
labelled bound Mcm2 by 75%. For detection by chromatin-bound (CBF) protein 
fractions were prepared from WI-38 HDFs following treatment with 4G-SMoC-ANt- 
geminin. Protein fractions were resolved by gel electrophoresis and immunoblotted 
for Mcm2 and actin as a loading control. Treatment with 4G-SMoC-ANt-geminin 
caused a reduction in chromatin-bound Mcm2 levels, indicating that 4G-SMoC-ANt- 
geminin blocks DNA replication by specifically interfering with recruitment of 
replication licensing factors onto chromatin.
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Chemistry Experimental methods
All starting materials were either commercially available synthesised by methods 
reported in the literature. ’H and 13C spectra were recorded on a Bruker AMX-300 spectrometer. 
Chemical shifts are reported as ppm relative to TMS as internal standard. Mass spectra were recorded 
on either a VG ZAB SE spectrometer (El, FAB) or a Gilson- Finningan AQA LC-mass spectrometer 
using C-18 column (Hypersil BDS 100 x 4.6 mm, 5 pm). Microanalysis was carried out by the 
Analytical Services Section, Department of Chemistry, University College London. Purification was 
by reverse-phase HPLC (Gilson) using preparative C-18 columns (Hypersil PEP 100 x 21 mm, 5 pm). 
Melting points were determined on a Gallenkamp melting point apparatus and are uncorrected.
Synthesis of 2G-SMoC-FITC
See the chemical scheme in the manuscript
2-Methoxy-4-methyl-phenylamine
A solution of 2-methoxymethyl-l-nitrobenzene (3.00 g, 17.9 mmol) and SnCl2*2 H2 0  
(20.2 g, 89.5 mmol) in MeOH (120 mL) was refluxed for 3 h. The solvent was 
removed under vacuum and the residue was dissolved in Ethyl acetate (200 mL). The 
solution was washed with saturated aqueous NaHCC>3 (3 x 200 mL), and dried over 
Na2SC>4 to afford the product (2.37 g, 95% yield).
'H-NMR (CDCIj): <52.27 (s, 3H), 3.84 (s, 3H), 6.56-6.66 (m, 3H).
I3C-NMR (CDC13): <521.0,55.4,111.5,115.1,121.2,128.1,133.5,147.4.
Theoretical Mass: (M + H) 409.30120. Measured Mass: (M + H) 409.30140
Bromo-2-methoxy-4-methyl-benzene (1)
Br
To a suspension of cupric bromide (4.88 g, 21.8 mmol) in CH3CN (20 mL) at rt was 
added tert-butylnitrite (2.13 mL, 17.9 mmol), the mixture was then warmed to 65°C. 
A solution of 2-methoxy-4-methyl-phenylamine (2.24 g, 16.3 mmol) in CH3CN (20 
mL) was then added slowly and stirred for an additional 15 min. The solvent was 
removed under vacuum and the residue was dissolved in cyclohexane (150 mL), 
washed with aqueous ammonia (3 x 150 mL), water (150 mL), and dried over 
Na2SC>4. The solvent was removed under vacuum and the product purified by silica 
gel flash chromatography using CHCI3 as eluent to afford (1) (1.92 g, 59% yield). 
‘H-NMR (CDCI3): <52.32 (s, 3H), 3.86 (s, 3H), 6.64 (dd, J  = 8.0, 1.4 Hz,lH), 6.72 
(d ,J =  1.4 Hz, 1H), 7.39 (A,J= 8.0 Hz, 1H).
,3C-NMR (CDC13): <521.4,56.1,108.3,113.1,122.5,132.9,138.7, 155.6.
Theoretical Mass: (M + H) 199.98313. Measured Mass: (M + H) 199.98387
2 ,3 ’-Dimethoxy-4-methy 1-biphenyl (2)
Ov.
Ov,
To a solution of bromo-2-methoxy-4-methyl-benzene (610 mg, 3.03 mmol) in 1,2- 
dimethoxyethane (12 mL) and EtOH (3 mL) was added 3-methoxy-phenylboronic 
acid (553 mg, 3.64 mmol), followed by 2 M Na2CC>3 solution ( 6  mL) and Pd(PPh3)4 
(176 mg, 0.152 mmol). The suspension was then refluxed for 17 h under nitrogen. 
The reaction mixture was cooled to rt, diluted with hexane/Ethyl acetate (1/1,20 mL), 
washed with water (3 x 20mL), brine (20 mL), and dried over Na2S0 4 . The solvent 
was removed under vacuum and the product was purified by silica gel flash 
chromatography using hexane/dichloromethane (2/1) as eluent to afford (2), (529 mg, 
76% yield).
'H-NMR (CDC13): <52.43 (s, 3H), 3.82 (s, 3H), 3.86 (s, 3H), 6.83-6.91 (m, 3H), 7.11-
7.15 (m, 2H), 7.25 (d, J = 7.6 Hz, 1H), 7.34 (t, J = 7.6 Hz, 1H).
13C-NMR (CDC13): <5 21.6, 55.3, 55.6, 112.3, 115.4, 121.5, 122.1, 127.8, 128.9,
130.6,138.8,140.0,156.4,159.3.
Theoretical Mass: (M + H) 229.1223. Measured Mass: (M + H) 229.14446.
2-(2,3’-Dimethoxy-biphenyl-4-ylmethyl)-isoindole-l,3-dione (3)
To a solution of 2,3’-dimethoxy-4-methyl-biphenyl (529 mg, 2.32 mmol) in CCI4 (48 
mL) was added N-bromosuccinimide (392 mg, 2.20 mmol) followed by AIBN (34 
mg) and the reaction refluxed for 2.5 h. The mixture was then cooled to 0°C; and 
filtered. The solvent was removed under vacuum to afford the crude 4- 
(bromomethyl)-2,5'-dimethoxybiphenyl, which was used without further purification. 
The crude material was dissolved in DMF (7.5 mL) and potassium phthalimide (430 
mg, 2.32 mmol) was added. The mixture was then stirred at 80°C for 1.5 h. The 
suspension was then cooled to rt and diluted with hexane/ethyl acetate (1/1, 20 mL) 
and washed with water (3 x 20 mL), brine (20 mL), and dried over Na2SC>4. The 
solvent was removed under vacuum and the product purified by silica gel flash 
chromatography using hexane/ethyl acetate (3/1) as eluent to afford (3) as a cream 
solid, mp 110-112°C.
IR v Max KBR/cm12940(CH3), 1718 (CO N )
'H-NMR (CDCIj): <53.81 (s, 6H), 4.87 (s, 2H), 6 .8 6  (dd, J = 8.0, 2.4 Hz, 1H), 7.02- 
7.10 (m, 4H), 7.24-7.29 (m, 2H), 7.71 (dd, J=  5.4, 3.0 Hz, 2H), 7.86 (dd, J=  5.4,3.0 
Hz, 2H).
13C-NMR (CDCI3): <541.6,55.2,55.7,111.8,112.6,115.2,121.0,122.0,123.4,128.9,
130.2,131.0,132.2,134.0,137.0,139.5,156.6,159.2,168.1.
Theoretical Mass: (M + H) 347.13923. Measured Mass: (M + H) 347.13891.
Calculated C23H19NO4 : C 73.98%, H 5.13%, N 3.75%, found C 73.36%, H 5.08%, N 
3.86%
2-[2, 3’-Bis(2-tert-butyloxycarbonylamino-ethyloxy)-biphenyl-4-ylmethyl]-
isoindole-l^-dione (4)
® ^NHBoc
® ^NHBoc
2-(2, 3 ’-Dimethoxy-biphenyl-4-ylmethyl)-isoindole-1,3-dione (72 mg, 1.9 mmol) 
was dissolved in dichloromethane (5 mL) and treated with a 1.0 M solution of BBr3 
(1.0 mL) in dichloromethane at 0°C, allowed to warm to room temperature and stirred 
overnight. The reaction mixture was then cooled to 0°C and MeOH (3 mL) was 
added, and the solvent was removed under vacuum. The residue was dissolved in 
ethyl acetate (20mL) and washed with water (3 x 20 mL), brine (20 mL), and dried 
over Na2SC>4 . The solvent was removed under vacuum and the product obtained was 
purified by short silica gel flash chromatography using hexane/ethyl acetate (1 / 1 ) as 
eluent to give 2-[(2,5'-dihydroxybiphenyl-4-yl)methyl]isoindoline-l,3-dione (61 mg). 
To a mixture of the crude bis-phenol (56 mg, 0.16 mmol), 2-tert- 
butyloxycarbonylamino-ethanol (65 mg, 0.41 mmol) and triphenylphosphine (106 
mg, 0.41 mmol) in THF (2 mL) was added diethylazido dicarboxylate (71 mg, 0.41 
mmol) and the mixture stirred at r.t. for 24 h. The reaction mixture was diluted with 
ethyl acetate (20 mL), washed with 1M Na2CC>3 (2 x 20 mL), and dried over Na2 SC>4 . 
The solvent was removed under vacuum and the product purified by silica gel flash 
chromatography eluting with hexane/ethyl acetate (2/1) to afford (4) as a oil (36 mg, 
35% yield).
'H-NMR (CDCI3): £1.41 (s, 9H), 1.43 (s, 9H), 3.41 (m, 2H), 3.52 (m, 2H), 3.99-4.05 
(m, 4H), 4.73 (br s, 1H), 4.85 (s, 2H), 5.02 (br s, 1H), 6.85 (dd, J = 8.0, 2.4 Hz, 1H), 
7.00-7.12 (m, 4H), 7.24-7.32 (m, 2H), 7.72 (dd, 7 =  5.4, 3.0 Hz, 2H), 7.86 (dd, J  = 
5.4,3.0 Hz, 2H).
13C-NMR (CDCI3): £28.40, 40.0, 40.1, 41.5, 67.2, 68.2, 113.0, 113.6, 115.7, 121.7, 
122.3, 123.5, 129.0, 130.5, 131.0, 132.1, 134.1, 137.2, 139.5, 155.5, 155.8, 155.9,
168.1.
Theoretical Mass: (M + H) 632.29718. Measured Mass: (M + H) 632.29602.
2-[2, 3’-Bis(2-tert-butyloxycarbonylamino-ethyloxy)-biphenyl-4-ylmethyl]-isoindole- 
1,3-dione (36 mg, 0.057 mmol) was dissolved in TFA (2 mL) and stirred at rt for 2.5 
h. The solvent was removed under vacuum to give the free amine, which was used 
without further purification. To a solution of the crude material in DMF (0.8 mL), was 
added N, N-di-Boc-N’-trifluoromethanesulfonyl-guanidine (67 mg, 0.17 mmol), and 
/-P^EtN (60 pL, 0.34 mmol) and the mixture stirred at rt for 18 h. The reaction 
mixture was then diluted with ethyl acetate (10 mL) and washed with IN HC1 (3 x 10 
mL), water (lOmL), brine (10 mL), and dried over Na2S(>4. The solvent was removed 
under vacuum and purified by preparative TLC using hexane/ethyl acetate (1/1) as 
eluent, to give (5) as a white solid (47 mg, 90% yield). Mp 100-101 °C
2-{2, 3’-Bis[2-(N^’-bis-boc-guanidino)-ethyloxy]-biphenyl-4-ylmethyl}-
isoindole-l,3-dione (5)
NBoc
X NHBoc
H
NBoc
NHBoc
H
O
IR v Max KBR/cm'11723 (C=0), 1717 (C=ON)
*H-NMR (CDCI3): S 1.47 (s, 18H), 1.49 (s, 18H), 3.74-3.86 (m, 4H), 4.04-4.10 (m, 
4H), 4.85 (s, 2H), 6.87 (dd, J = 8.0, 2.0 Hz, 1H), 6.97 (br s, 1H), 7.04 (s, 1H), 7.09 (d, 
J  = 7.7 Hz, 1H), 7.21 (d, J = 7.7 Hz, 1H), 7.26-7.31(m, 2H), 7.71 (dd, J  = 5.4, 3.0 Hz, 
2H), 7.86 (dd, J = 5.4, 3.0 Hz, 2H), 8.62 (br t, J = 5.6 Hz, 1H), 8.74 (br t, J  = 5.1 Hz, 
1H).
13C-NMR (CDCI3): <528.0, 28.3, 40.1, 40.3, 41.5, 66.3, 66.9, 112.8, 113.3, 115.8, 
121.5, 123.0, 123.5, 128.9, 130.3, 131.2, 132.1, 134.1, 137.0, 139.3, 152.9, 153.0,
155.4,156.38,156.43,158.4,163.30,163.33,168.1.
Theoretical Mass: (M + H) 632.29718. Measured Mass: (M + H) 632.29602.
2-[2, 3,-Bis(2-guanidino-ethyloxy)-biphenyl-4-ylmethyl]-thioureido-fluorescein 
(6)
NH
NH
NH
NH
OH
To a solution of 2-{2, 3’-bis[2-(N, N’-bis-boc-guanidino)-ethyloxy]-biphenyl-4- 
ylmethyl}-isoindole-1,3-dione (22 mg, 0.024 mmol) in EtOH (0.6 mL) was added 
hydrazine monohydrate (12 pL, 0.24 mmol) and the mixture stirred at rt for 18 h. The 
solvent was than evaporated under vacuum, and the residue was dissolved in 
dichloromethane (15mL) and the precipitate removed by filtration. The filtrate was 
washed with brine (lOmL), and the water layer was extracted with dichloromethane (3 
x lOmL). The combined organic layer was dried over Na2SC>4. The solvent was 
removed under vacuum to afford crude amine which was used without further 
purification.
Crude amine was dissolved in DMF (1.0 mL) and fluorescein isothiocyanate isomer I 
(19 mg, 0.048 mmol) and i-P^EtN (17 pi, 0.096 mmol) were added and the reaction 
mixture was stirred in the dark at rt for 20 h. The reaction mixture was diluted with
ethyl acetate (10 mL) and washed with IN HC1 (3 x 10 mL), water (10 mL), brine (10 
mL), and dried over Na2SC>4. The solvent was removed under vacuum. The residue 
was dissolved in THF (1.5 mL) and treated with PS-trisamine (Argonaut 
Technologies Inc., 4.17 mmol/g, 20 mg) to remove the excess of fluorescein 
isothiocyanate. After shaking the mixture at room temperature for 15 min, the resin 
was filtered off and the solvent was removed. The residue was dissolved in TFA (1.5 
mL) and stirred at rt for 2 h. TFA was removed under vacuum, and the crude material 
was purified by HPLC using a gradient of 3-97% acetonitrile in 0.1 aq. TFA over 30 
min at a flow rate of 10 mL/min. Retention time 8.0 min., to afford (6 ) (8  mg, 30 % 
yield).
'H-NMR (MeOH-d4): <53.54 (m, 2H), 3.61 (m, 2H), 4.15 (m, 4H), 4.91 (s, 2H), 6.64 
(d, J =  9.0 Hz, 2H), 6.78-6.83 (m, 4H), 6.93 (d, J  = 7.9 Hz, 1H), 7.05-7.35 (m, 9H), 
7.81 (d ,/=  8.2 Hz, 1H), 8.22 (s, 1H).
MS (MALDI) m/z 774 (calcd), 775 (M + 1, found).
Theoretical Mass: (M + Na) 797.24817. Measured Mass: (M + Na) 797.24955.
Synthesis of 4G-SMoC amine intermediate
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Synthesis of 4G-SMoC-FITC and 4G-SMoC-SS-pv.
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1-Bro mo-2,3-dimethoxy-4-methyl-benzene (S7)
Br
I H
n-BuLi 1.6 M in hexane (18.5 mL, 29.6 mmol) was added dropwise at 0°C to a 
solution of 2, 3-dimethoxytoluene (3.00 g, 19.7 mmol) and TMEDA (2.97 mL, 19.7 
mmol) in anhydrous ether (50 mL) under nitrogen and stirred at room temperature for 
2 h. The reaction mixture was cooled to -78°C and (CBrCl2)2 (9.64 g, 29.6 mmol)
was added. After stirring for a further 10 min, the cooling bath was removed and the 
reaction vessel allowed to warm to rt. The reaction mixture was then diluted with 
ether (50 mL) and washed with water (950 mL), IN HC1 (2 x 50 mL), brine (50 mL), 
and dried over Na2SC>4. The solvent was removed under vacuum and purified by 
silica gel flash chromatography using hexane/dichloromethane (5/1) as eluent to 
afford (S7) as a colourless oil (1.62 g, 36% yield).
'H-NMR (CDCI3): S2.22 (s, 3H), 3.85 (s, 3H), 3.88 (s, 3H), 6.79 (d, J=  8.3 Hz, 1H),
7.16 (d,y= 8.3 Hz, 1H).
I3C-NMR (CDC13): £15.7,60.4,60.6, 114.6,126.7,127.4,132.1,150.4,152.5. 
Theoretical Mass: (M + Na) 252.98346. Measured Mass: (M + Na) 252.98370.
2 ,3 ,2 ’, 3’-Tetramethoxy-4-methyl-biphenyl (S8 )
i
s'
/
To a solution of l-bromo-2, 3-dimethoxy-4-methyl-benzene (SI) (500 mg, 2.16 
mmol) in 1,2-dimethoxyethane (8.7 mL) and EtOH (2.2 mL); was added 2, 3- 
dimethoxy-phenylboronic acid (472mg, 2.59 mmol) and 2M Na2CC>3 solution (4.3 
mL), followed by Pd(PPh3)4 (125 mg, 0.108 mmol). The mixture was refluxed for 18 
h under nitrogen. The reaction mixture was cooled to rt and diluted with hexane/ethyl 
acetate (1/1, 10 mL) and washed with water (3 x 20 mL), brine (20 mL), and dried 
over Na2SC>4. The solvent was removed under vacuum and the product was purified 
by silica gel flash chromatography using dichloromethane as eluent to afford (S8 ) as a 
solid (573 mg, 92% yield). Mp : 30-31 °C
'H-NMR (CDCI3): £2.31 (s, 3H), 3.63 (s, 3H), 3.67 (s, 3H), 3.87 (s, 3H), 3.90 (s, 
3H), 6.85 (dd, J = 7.6,1.3 Hz, 1H), 6.91-6.94 (m, 3H), 7.07 (t, J=  7.9 Hz, 1H). 
13C-NMR (CDC13): £15.9, 55.8, 60.1, 60.4, 60.6, 111.6, 123.3, 123.4, 125.0, 125.7, 
130.8,131.7, 133.0,146.9,150.8,151.3,152.8.
Theoretical Mass: (M + H) 289.14398. Measured Mass: (M + H) 289.1446.
2-(2,3 ,2 ’, 3’-Tetramethoxy-biphenyl-4-ylmethyl)-isoindole-l, 3-dione (S9)
To a solution of 2, 3, 2 \  3’-tetramethoxy-4-methyl-biphenyl (573 mg, 1.99 mmol) in 
CCU (42 mL), was added N-bromosuccinimide (336 mg, 1.89 mmol), and AIBN (29 
mg). After 2 h reflux, the mixture was cooled to 0°C; and filtered. The solvent was 
removed under vacuum to afford crude 4-(bromomethyl)-2, 3, 5', 6 ’-
tetramethoxybiphenyl, which was used without further purification.
A solution of the crude bromomethyl compound and potassium phthalimide (369 mg, 
1.99 mmol) in DMF (6.5 mL) was stirred at 80 °C for 1.5 h. The mixture was then 
cooled to rt and diluted with hexane/ethyl acetate (20 mL, 1/1) and washed with water 
(5 x 20 mL), brine (20 mL), and dried over Na2SC>4. The solvent was removed under 
vacuum and the product was purified by silica gel flash chromatography using 
hexane/ethyl acetate (3/1) as eluent to give (S9) (552 mg, 64% yield). Mp 135-136 
°C
IRvMax KBR/cm'12936(CH3), 1712 (CO N )
' H-NMR (CDCI3): S  3.62 (s, 3H), 3.65 (s, 3H), 3.89 (s, 3H), 3.99 (s, 3H), 4.98 (s, 
2H), 6.81 (dd, J  = 7.6, 1.5 Hz, 1H), 6.90-6.93 (m, 2H), 6.98 (d, J = 8.0 Hz, 1H), 7.06 
(t, J=  7.9 Hz, 1H), 7.72 (dd, 7 =  5.4,3.0 Hz, 2H), 7.86 (dd, J = 5.4,3.0 Hz, 2H). 
13C-NMR (CDC13): S  36.4, 55.8, 60.3, 60.59, 60.63, 111.8, 122.9, 123.1, 123.36, 
123.45, 125.9,129.5,132.2,132.5,132.7,134.0,146.9,151.2,151.4,152.8,168.2. 
Theoretical Mass: (M + Na) 456.1476. Measured Mass: (M + Na) 456.14150.
2-[2, 3, 2’, 3 ’-T etra(2-tert-butyloxycarbonylamino-ethyloxy)-biphenyl-4-
ylmethyl]-isoindole-l,3-dione (S10)
^^NHBoc
q/ \^ N H B oc
BocHN
BocHN______ ____
T
2-(2, 3, 2’, 3’-Tetramethoxy-biphenyl-4-ylmethyl)-isoindole-1,3-dione (250 mg, 
0.577 mmol) was dissolved in dichloromethane (15 mL) and treated with a solution of 
BBr3 in dichloromethane 1.0 M (6.0 mL) at 0 °C. The mixture was then allowed to 
warm to room temperature and stirred overnight. The reaction mixture was than 
cooled to 0 °C and MeOH (3 mL) was added. The solvent was removed under 
vacuum, and the residue was dissolved in ethyl acetate (20 mL), washed with IN HC1 
(2 x 20mL), water (20 mL), brine (20 mL), and dried over Na2SC>4. The solvent was 
removed under vacuum to give the tetramine (248 mg), which was used without 
further purification.
To a solution of the tetramine (105 mg) in DMF (3.0 mL) was added CS2CO3 (654 
mg, 2.00 mmol) and tert-butyl N-(2-tosyloxyethyl)-carbamate (526 mg, 1.67 mmol) 
and the mixture heated to 80 °C and stirred under nitrogen for 4 h. After this time 
additional CS2CO3 (654 mg, 2.00 mmol) and tert-butyl N-(2-tosyloxyethyl)-carbamate 
(526 mg, 1.67 mmol) were added and the mixture stirred for a further 15 h. The 
reaction mixture was diluted with ethyl acetate (15 mL). The organic layer was 
washed with IN HC1 (2 x 10 mL) water (15 mL), brine (15 mL), and dried over 
Na2SC>4. The solvent was removed under vacuum and the product purified by 
preparative TLC (CHCL/MeOH = 10/1). The product obtained, was dissolved in 
DMF (2 mL) and acetic anhydride (0.5 mL) was added and the mixture stirred at 80 
°C for 1 h. The mixture was diluted with ethyl acetate (10 mL) and washed with 
water (3 x lOmL), Na2CC>3 saturated aqueous solution (15 mL), brine (15 mL), and 
dried over Na2SC>4. The solvent was removed under vacuum and purified by 
preparative TLC (ethyl acetate/hexane = 1/1) to afford (S10) (38 mg, 16 % yield).
1 H-NMR (CDCI3): S  1.38 (s, 9H), 1.42 (s, 9H), 1.43 (s, 9H), 1.45 (s, 9H), 3.10 (m, 
2H), 3.19 (m, 2H), 3.58 (m, 4H), 3.78 (m, 4H), 4.11 (m, 2H), 4.23 (m, 2H), 4.64 (br s,
1H), 4.95 (s, 2H), 5.20 (br s, 1H), 5.44 (br s, 1H), 5.78 (br s, 1H), 6.85 (br d, J =  6.7 
Hz, 1H), 6.93 (br d, 7  = 7.4 Hz, 1H), 6.98 (d, 7=  8.0 Hz, 1H), 7.08 (t, 7=  7.9 Hz, 1H), 
7.14 (d, J = 8.0 Hz, 1H), 7.73 (dd, 7  = 5.4, 3.0 Hz, 2H), 7.87 (dd, J  = 5.4, 3.0 Hz, 2H). 
Theoretical Mass: (M + H) 950.47625. Measured Mass: (M + H) 950.47705.
2-{2, 3, 2% 3’-Tetra[2-N, N ’-bis(tert-butoxycarbonyl)guanidino-ethyloxy] -
biphenyl-4-ylmethyl}-isoindole-l,3-dione (SI 1)
NBoc
? ° v^ sNx^NHBoc 
H
o  H
L^N^/NHBocT
o o
A
I L c
2-[2, 3, 2’, 3’-Tetra(2-tert-butyloxycarbonylamino-ethyloxy)-biphenyl-4-ylmethyl]- 
isoindole-l,3-dione (38 mg, 0.040 mmol) was dissolved in TFA (2 mL) and stirred at 
rt for 2 h. The solvent was removed under vacuum to give the unprotected tetramine, 
which was used without further purification. To a solution of the crude tetramine in 
DMF (1.0 mL), was added N, N-di-boc-N’-trifluoromethanesulfonyl-guanidine (94 
mg, 0.24 mmol), and /-P^EtN (84 pL, 0.48 mmol) and the mixture stirred at rt for 15 
h. The reaction mixture was diluted with ethyl acetate (5 mL) and washed with IN 
HC1 ( 3x5  mL), followed by water (5 mL), brine (5 mL), and dried over Na2SC>4. The 
solvent was removed under vacuum and purified by preparative TLC (hexane/ethyl 
acetate 3/2) to give (S ll) (45 mg, 74% yield) as a colourless oil.
1 H-NMR (CDCI3): S 1.36 (s, 9H), 1.41 (s, 9H), 1.44 (s, 9H), 1.45 (s, 18H), 1.48 (s, 
27H), 3.45 (m, 4H), 3.88 (m, 8 H), 4.16 (m, 2H), 4.39 (m, 2H), 4.98 (s, 2H), 6.83-7.03 
(m, 5H), 7.71 (dd, J = 5.4, 3.0 Hz, 2H), 7.86 (dd, J = 5.4, 3.0 Hz, 2H), 8.46 (br s, 1H), 
8.57 (br s, 1H), 8.79 (br s, 1H), 8.89 (br s, 1H).
Theoretical Mass: (M + H) 1518.7731. Measured Mass: (M + H) 1518.78005.
[2, 3, 2% 3’-Tetra(2-guanidino-ethyIoxy)-biphenyl-4-ylmethyl]-thioureido-
fluorescein (S13)
NH
NH
NH
NH
NH
NH
NH
OH
To a solution of 2-{2, 3, 2 \  3’-tetra[2-N, N’-bis(tert-butoxycarbonyl)guanidino- 
ethyloxy]-biphenyl-4-ylmethyl} -isoindole-1,3 -dione (4 5  mg, 0.030 mmol) in EtOH 
(0.7 mL) was added hydrazine monohydrate (15 pL, 0.30 mmol) and the mixture 
stirred at rt for 16 h. The solvent was then evaporated under vacuum, the residue was 
dissolved into dichloromethane (5 mL), and the precipitate filtered off. The filtrate 
was washed with brine (5 mL) and the aqueous layer was extracted with 
dichloromethane ( 3 x 5  mL). The combined organic layer was then dried over 
Na2S0 4 . The solvent was removed under vacuum to afford crude amine (S12), which 
was used without further purification. The crude material from the previous reaction 
dissolved in DMF (1.0 mL) and fluorescein isothiocyanate isomer I (18 mg, 0.045 
mmol) and /-Pr2EtN (16 p, 0.090 mmol) were added and the mixture was stirred in the 
dark for 15 h. To the reaction mixture was added PS-trisamine (Argonaut 
Technologies Inc., 4.17 mmol/g, 25 mg) to remove the excess FITC. After shaking 
the mixture at rt 30 min, the resin was filtered off and the filtrate was diluted with 
ethyl acetate (10 mL), washed with IN HC1 ( 3 x 5  mL) followed by water (5 mL), 
brine (5 mL), and dried over Na2SC>4. The solvent was removed under vacuum to 
give the fully protected product, which was dissolved in TFA (2.0 mL) and stirred at 
rt for 2 h. TFA was removed under vacuum and the residue was purified by reverse- 
phase HPLC using a preparative C-18 column (0.1 % TFA H20  / acetonitrile) to 
afford (S13) (9 mg, 20 % yield).
'H-NMR (MeOH-d4): <53.34 (m, 4H), 3.69 (m, 4H), 3.94-3.97 (m, 4H), 4.22-4.30 (m, 
4H), 4.96 (s, 2H), 6.61 (d, J  = 8.7 Hz, 2H), 6.76-6.78 (m, 4H), 6.90 (d,J =  7.3 Hz, 
1H), 7.04-7.24 (m, 5H), 7.79 (d, J=  8.1 Hz, 1H), 8.29 (s, 1H).
MS (MALDI) m/z 976 (calcd), 977,978,979 (found).
N-{2, 3, 2’, 3’-Tetra{2-[N, N’-bis(tert-butoxycarbonyl)guanidino]-ethyloxy}- 
biphenyl-4-ylmethyl}-3-[2-pyridyl)dithioJpropionamide
NBoc 
NHBoc
HBocHN^NT
NBoc
H | 
BocHN^N^ 1
NBoc
° ^ N ^ -
H
I Hk ^ N ^ N H B o c
0
NH
To a solution of 2-{2, 3, 2’, 3’-tetra[2-N, N’-bis(tert-butoxycarbonyl)guanidino- 
ethyloxy]-biphenyl-4-ylmethyl}-isoindole-1,3-dione (8  mg, 0.005 mmol) in EtOH 
(0.5 mL) was added hydrazine monohydrate (3 pL, 0.06 mmol) and the mixture was 
stirred at rt for 17 h then the solvent was evaporated under vacuum. The residue was 
dissolved into DCM (5 mL) and the precipitate was filtered off. The filtrate was 
washed with brine (5 mL), and the aqueous layer was extracted with dichloromethane 
( 3 x 5  mL). The combined organic layer was dried over Na2SC>4, and the solvent was 
removed under vacuum to afford crude amine (S12), which was used without further 
purification.
To a solution of the crude amine and i-P^EtN (2 pL, 0.01 mmol) in dichloromethane 
(0.3 mL) was added N-succinimidyl-3-(2-pyridyldithio)propionate (3 mg, 0.01 mmol) 
and the mixture was stirred in the dark for 24 h. The solvent was removed under 
vacuum and purified by preparative TLC (ethyl acetate/hexane 1/1) to afford the 
product (4 mg, 50 % yield).
IR v Max KBR/cm'3336 (NH), 1722 (C=0), 1641 (CON )
'H-NMR (CDCU): S  1.43-1.51 (m, 72H), 2.70 (t, / =  7.2 Hz, 2H), 3.11 (t, J =  7.2 Hz, 
2H), 3.45-3.50 (m, 4H), 3.84-3.93 (m, 8 H), 4.15-4.21 (m, 4H), 4.46 (d, J  = 5.6 Hz,
2H), 6.89-6.92 (m, 2H), 6.99-7.08 (m, 4H), 7.57-7.68 (m, 2H), 8.36 (m, 1H), 8.46 (br 
t, 1H), 8.55 (br t, 1H), 8.80 (br t, 2H).
Theoretical Mass: (M + H) 1585.76459. Measured Mass: (M + H) 1585.05043.
N-[2, 3, 2’, 3’-Tetra(2-guanidino-ethyloxy)-biphenyl-4-ylmethyl]-3-[2-
pyridyl)dithio]propionamide (14)
NH
H 2
NH H
H,NA N'— 0 -  k . N Y NH2
H ^  NH
H 9h2n ^ n ^
Sv N v
’I ^
N’-Bis(tert-butoxycarbonyl)guanidino]-ethyloxy}-biphenyl-4-ylmethyl}-3-[2- 
pyridyl)dithio]propionamide (4 mg, 0.0024mmol) was dissolved in TFA (0.8 mL) and 
stirred at rt for 3 h. TFA was removed under vacuum to give (S14), as a colourless oil 
(4 mg).
IR v Max KBR/cm'3376 (br NH, NH2), 1381 (CO N )
!H-NMR (MeOH-d4): 8 2.73 (t, J=  6 .6  Hz, 2H), 3.10 (t, J = 6 .6 Hz, 2H), 3.23-3.30 
(m, 4H), 3.62-3.67 (m, 4H), 3.88 (m, 2H), 3.96 (m, 2H), 4.22 (m, 4H), 4.47 (s, 2H), 
6.87 (dd, J  = 7.4, 1.7 Hz, 1H), 7.02 (d, / =  7.9 Hz, 1H), 7.08-7.24 (m, 4H), 7.76-7.80 
(m, 2H), 8.38 (d, 7=  4.7 Hz, 1H), 8.70 (br t, 1H).
ESMS; m/z calcd; 784, found; 899[(M + 1) + TFA], 785 (M + 1), 507 [(M + 2) + 
2TFA], 450 [(M + 2) + TFA], 393 (M + 2), 338[(M + 3) + 2TFA].
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expressed as the reduction in the percentage of cells incorporating BrdU relative to 
the control population.
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Cellular senescence can result from short, dysfunc­
tional telom eres, oxidative stress, or oncogene expres­
sion, and may contribute to aging. To in vestigate the  
role o f cellu lar senescence in aging it is  necessary to 
d efine the tim e-dependent m olecular even ts by w hich  it 
is  characterized. Here w e investigated  ch an ges in levels  
of key proteins involved in cell cycle regulation, DNA 
replication , and stress resistance in sen escin g  hum an  
fibroblasts follow ing oxidative stress. An im m ediate re­
sponse in  stressed cells w as dephosphorylation  o f reti­
noblastom a (Rb) and cessation  o f DNA synthesis. This 
w as follow ed by sequential induction  o f  p53, p21, and 
p i 6. Increase in hypophosphorylated Rb and induction  
of p53 and p21 by a single stress treatm ent was tran­
sient, w hereas sustained induction  or dephosphoryl­
ation  w ere achieved by a second stress. D ow n-regula­
tion o f the critical DNA replication  in itia tion  factor 
Cdc6 occurred early after stress concurring w ith  p53 
induction, and w as follow ed by a d ecrease in Mcm2 lev­
els. A late event in the stress-induced  m olecular se­
quence w as the induction o f SO D l, catalase, and HSP27 
coincid ing w ith  developm ent o f the fully  sen escen t phe­
notype. Our data suggest that loss of proliferative capac­
ity  in oxidatively  stressed  ce lls  is  a m ultistep  process 
regulated  by tim e-dependent m olecular events that may 
play d ifferentia l roles in induction  and m aintenance of 
cellu lar senescence.
Normal human fibroblasts only have a limited proliferative 
capacity in vitro and will become senescent eventually (1). 
Although cellular senescence is mainly observed with cells in 
culture, several lines of evidence suggest that a similar process 
occurs in vivo and contributes to aging (Ref. 2 and references 
therein). Telomere shortening because of the end replication 
problem is believed to be the prime intrinsic cause that limits 
the cell proliferation capacity because critically shortened te­
lomeres serve to activate the senescence process (3). However, 
various stresses such as DNA damaging agents, oxidative 
stress, and certain oncogene overexpression can also induce 
cellular senescence (4-7). The cell culture condition of 20% 0 2 
might represent an oxidative stress when compared with the
* This work was supported in part by the European Union, the 
National Institutes of Health, the Wellcome Trust, and Cancer Re­
search UK. The costs of publication of this article were defrayed in part 
by the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734 
solely to indicate this fact.
§ To whom correspondence should be addressed. Tel.: 44-1223- 
336784; Fax: 44-1223-330598; E-mail: jhc36@cam.ac.uk.
** Supported by a Medical Research Council research studentship.
much lower in vivo physiological pressure of 0 2 (8-10). Thus 
telomere shortening may be driven to a large extent by stress, 
and telomere shortening by the end replication problem may 
set an upper limit to the replicative lifespan, which might only 
seldom be reached (11).
The free radical theory of aging proposes that reactive oxy­
gen species produced in mitochondria cause damage to cellular 
macromolecules, thus resulting in a decline of cellular function 
and organism aging (12). This theory has gained strong support 
from studies that linked oxidative stress to longevity using 
model organisms including yeasts, nematodes, flies, and ro­
dents (13, 14). Mutations that increase longevity are often 
associated with increased antioxidant activity and improved 
resistance to oxidative stress (15-17).
For the past decade we have studied the long term conse­
quences of poor early growth using rodent models (18). One of 
our most striking observations is that the rate of growth in 
early life has profound effects on longevity. Fetal growth re­
striction followed by postnatal catch-up growth in male rats 
and mice results in reduced longevity (19, 20). Male rats most 
frequently die of renal failure (19). We have shown that the 
reduced longevity of fetally growth restricted, postnatally 
growth caught-up male rats is associated with accelerated 
shortening of telomeres in the kidney (21). We have suggested 
that this shortening is associated with accelerated senescence 
of renal cells with earlier renal failure and death. It seems 
unlikely that replicative senescence alone could lead to the 
degree of shortening observed and therefore telomere shorten­
ing consequent upon oxidative damage may be involved (21, 
22). We have further speculated that telomeres not only func­
tion as a measure of the number of cell divisions undergone by 
telomerase-negative cells but also, by virtue of their GGG con­
tent, monitor oxidative damage by the accelerated telomere 
shortening that results (23).
The present study was undertaken to study a selection of key 
proteins involved in DNA damage response, cell cycle regula­
tion, DNA replication licensing, and stress resistance in oxida­
tively senescing cells by exploiting a model cell line in vitro. 
Knowledge of the molecular markers of oxidative stress-in­
duced cellular senescence will allow us to study the progress of 
cell senescence in vivo. It has been shown that early passage 
human fibroblasts can be induced into senescence prematurely 
by oxidative stress (4, 24, 25). Because the cells develop fea­
tures of senescence within 7 days and the time course for 
developing senescent features is well defined, oxidatively 
stressed human fibroblasts provide a useful experimental 
model to study the underlying mechanism and markers of 
senescence-associated aging. Here we show that oxidative 
stress causes loss of proliferative capacity and induction of
This paper is available on line at http://www.jbc.org 49439
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FlC. 1. Inhibition of DNA synthesis and induction o f SA-0-gal activ ity  in H.20 2-treated hum an fibroblasts. Logarithmically growing 
IMR-90 cells were seeded at a density of 2 x  106 cells in 100-mm dishes and treated with H20 2 for 2 h 24 h after seeding. Cells were split 1:3 4 
days after the first H20 2 treatment and treated for 2 h with H20 2 again 24 h later. A, BrdUrd was added to the cells at the indicated time points 
for a 48-h incubation and its incorporation was detected with fluorescein-conjugated antibody (green). Nuclei are stained with TOTO-3 to reveal 
DNA (red). The inset is a representative BrdUrd incorporation assay of control cells. Data represent the mean ± S.E. of three independent 
experiments. B, SA-0-gal activity was detected by incubating the fixed cells in SA-0-gal solution at 37 °C overnight. The inset is a representative 
SA-/3-gal assay of H20 2-induced senescent cells. The mean ± S.E. of three independent experiments are shown.
senescence in human fibroblasts by well defined sequential 
molecular events.
EXPERIMENTAL PROCEDURES
Cell Cultures and H20 s Treatment—IMR-90 cells at population dou­
bling (PD)1 24.5  were obtained from the America Type Culture Collec­
tion (ATCC). The cells were grown in ATCC modified Eagle’s minimal 
essential medium supplemented with 10% fetal bovine serum. Cells for 
H20 2 treatment were prepared from exponential phase around PD30. 
H20 2 treatment was carried out 24 h after seeding by incubating 2 X 
106 cells in 100-mm dishes in 13 ml of the culture medium containing 
600 fiM H20 2 for 2 h. For a second H20 2 treatment the cells were split 
1:3 after being cultured for 4  days following the first treatment and 
treated again for 2 h with 600 /xM H20 2 24 h after seeding. IMR-90 cells 
reached replicative senescence at PD59.
BrdUrd Labeling and SA-fi-Gal Assay—Cells were seeded and 
treated as described above in dishes containing autoclaved coverslips. 
For BrdUrd labeling, coverslips were transferred into a 6-well plate and 
incubated in 2 ml of the culture medium containing 10 pM BrdUrd for 
48 h. Cells on coverslips were then washed with PBS, fixed in 4% 
paraformaldehyde in PBS, washed twice in PBS, permeabilized in 0.2% 
Triton X-100, and washed in PBS. DNA was denatured by incubation in
1 The abbreviations used are: PD, population doubling; BrdUrd, 
2-bromo-5-deoxyuridine; SA-0-gal, senescence-associated 0-galactosid- 
ase; PBS, phosphate-buffered saline; Rb, retinoblastoma; SOD, super­
oxide dismutase; HSP, heat shock protein; PCNA, proliferating cell 
nuclear antigen; PML, promyelocytic leukemia protein.
2 M HC1 for 1 h followed by three washes with PBS. Coverslips were 
incubated for 1 h with fluorescein-conjugated mouse anti-BrdUrd 
monoclonal antibody (1:20 dilution; Alexis Biochemicals) and with DNA 
stain TOTO-3'-iodide (0.5 /xM; Molecular Probes), washed three times 
with PBS, and mounted in 90% glycerol, 10% PBS containing p-phe- 
nylenediamine (1 mg/ml; Sigma). For senescence-associated /3-galacto- 
sidase (SA-0-gal) assay, cells on coverslips were washed twice in PBS, 
fixed for 5 min in 4% paraformaldehyde in PBS, washed three times in 
PBS, and incubated at 37 °C overnight in flesh SA-0-gal staining solu­
tion (1 mg of 5-bromo-4-chloro-3-indolyl 0-D-galactosidase (stock ^ 100 
mg/ml of dimethylformamide)/ml of 5 mM potassium ferrocyanide, 5 mM 
potassium ferricyanide, 150 mM NaCl, 2 mM MgCl in 40 mM citric 
acid/sodium phosphate, pH 6.0) (26). At least 500 cells from each time 
point were scored under microscope for BrdUrd- or SA-0-gal assay.
Western Blotting—Whole cell lysate was prepared by scraping cells in 
Laemmli buffer (0.12 M Tris, pH 6.8, 4% (w/v) SDS, 20% (v/v) glycerol 
with protease inhibitors (mixture from Sigma)). Protein concentration 
was determined by the bicinchoninic acid (BCA) method (Sigma) with 
bovine serum albumin as a standard. 25 /xg of proteins were separated 
by SDS-PAGE and electrophoretically transferred to nitrocellulose 
membrane. Blots were probed with the following antibodies: anti-p53 
antibody (ab7757, abeam), anti-p21 antibody (H-164, Santa Cruz), anti­
pie antibody (H-156, Santa Cruz), anti-Rb antibody (G3-245, BD 
Pharmingen), anti-Cdc6 antibody (180.2, Santa Cruz), anti-Mcm2 an­
tibody (BM28, Transduction Laboratories), anti-Mcm5 antibody (27), 
anti-PCNA antibody (ab29, abeam), anti-catalase antibody (abl877, 
abeam), anti-SODl antibody (FL-154, Santa Cruz), anti-HSP70 anti­
body (W27, Santa Cruz), and anti-HSP27 (H-77, Santa Cruz). The
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Fig. 2. Changes in leve ls o f cell cy­
cle checkpoint proteins and phos­
phorylation o f Rb in  H20 2-treated  
cells. A, H20.2-treated IMR-90 cells were 
harvested at the indicated time points 
and whole cell lysates (25 pg of proteins) 
were analyzed by Western blotting using 
antibodies against p53, p21, and pl6. 
Loading was revealed by Coomassie Blue 
staining. Indicated on the top are the 
times after H20.2 treatment and the num­
ber of H20.2 treatments. This experiment 
is representative of two independent ex­
periments. B, changes in the phosphoryl­
ation state of Rb in the samples used for 
panel A were analyzed by Western blot­
ting using an antibody against Rb. Hyper- 
phosphorylated Rb and dephosphorylated 
Rb were analyzed by densitometry and 
the ratio of the two is shown.
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bound primary antibodies were detected by horseradish peroxidase- 
conjugated secondary antibodies (Amersham Biosciences), followed by 
enhanced chemiluminesence (Amersham Biosciences). The densities of 
the bands were quantified using an Alpha Imager (Alpha Innotech 
Corporation, San Leandro, CA).
Preparation of Nuclei and Cytosolic Extracts—Nuclear and cytoplas­
mic extracts were prepared by hypotonically swelling cells in ice-cold LS 
buffer (20 mM potassium-HEPES, pH 7.8, 5 mM potassium acetate, 0.5 
mM MgCl2, 0.5 mM dithiothreitol), scrape harvesting, and Dounce ho­
mogenization as described previously (28) with the following minor 
modifications. Cytosolic supernatant was taken from the first spin 
(2,000 X g  in a Whatman Micro-Centrifuge for 2 min) and respun at 
10,000 x  g  for 10 min. Supernatant fractions were then aliquoted, 
snap-frozen, and stored in liquid nitrogen. Nuclear pellets from the first 
separating spin were resuspended in an equal volume of ice-cold 
SuNaSp/bovine serum albumin solution (250 mM sucrose, 75 mM NaCl, 
0.5 mM spermine tetrahydrochloride, 0.15 mM spermidine trihydrochlo­
ride, 3% bovine serum albumin) and respun at 2,000 x g  for 2 min. The 
supernatant was discarded and the packed nuclear pellet was resus­
pended in an equal volume of SuNaSp/bovine serum albumin, frozen, 
and stored at -8 0  °C.
In Vitro DNA Synthesis Assay—DNA replication reactions contain­
ing 30 pi of elongation buffer (60 mM KC1, 15 mM Tris-HCl, pH 7.4, 15 
mM NaCl, 1 mM fi-mercaptoethanol, 0.5 mM spermine tetrahydrochlo­
ride, 0.5 mM spermidine trihydrochloride), a buffered mixture of NTPs, 
dNTPs, and an energy regeneration system (yielding a final concentra­
tion of 40 mM K-HEPES, pH 7.8, 7 mM MgCl2, 3 mM ATP, 0.1 mM each 
of GTP, CTP, UTP, 0.1 mM each of dATP, dGTP, and dCTP, 0.25 pM 
biotin-16-dUTP, 0.5 mM dithiothreitol, 40 mM creatine phosphate, and 5 
pg of phosphocreatine kinase) and 1 x  10s nuclei were performed as 
previously described (28, 29). For detection by immunofluorescence, the
nucleotide mixture was supplemented with a final concentration of 0.25 
pM biotin-16-dUTP (Roche Diagnostics). In vitro DNA replication reac­
tions were incubated at 37 °C for 3 h. Nuclei in the DNA replication 
assays were resuspended in PBS (0.5 ml) and fixed for 5 min by adding 
an equal volume of 8% paraformaldehyde. After fixation, nuclei were 
spun through 30% sucrose/PBS onto polylysine-coated coverslips. All 
subsequent washing and staining steps were carried out in PBS, 0.2% 
Triton X-100, 0.04% SDS. Coverslips were washed, stained for incorpo­
rated biotin-16-dUTP with fluorescein-linked streptavidin (1:100 dilu­
tion, Amersham Biosciences) and for DNA with propidium iodide/ 
RNase A (both at 50 ng/ml, Sigma), washed again, and mounted in 
vectorshield (Vector Laboratories, Peterborough, UK). Confocal fluores­
cence microscopy of random fields of nuclei was performed on a Leica 
TCS DMRE confocal microscope. Images were collected, and merged 
pictures of the propidium iodide channel (red) and fluorescein channel 
(green) were obtained using Adobe Photoshop with standardized bright­
ness- and contrast-enhanced operations of all samples. Images were 
printed, and the number of nuclei incorporating biotin-16-dUTP in vitro 
(yellow) and non-replicating nuclei (red) were counted. Routinely, 800-  
1000 nuclei were scored for each replication reaction and quantitated as 
percentages of the total number of nuclei that synthesized DNA in vitro.
RESULTS
Cessation of DNA Replication and Induction of Senescence in 
the H20 2-treated Cells—To understand molecular mechanisms 
underlying aging, we investigated key cell cycle regulatory 
proteins and stress-resistant factors in normal human diploid 
fibroblasts that were subjected to oxidative stress. We adopted 
H20 2 treatment to induce premature cellular senescence. Dose- 
response experiments showed that the cells could tolerate up to
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Fig. 3. Changes in levels of DNA 
replication and stress-resistance pro­
teins in H20 2-treated cells. A, H20 2- 
treated IMR-90 cells were harvested at 
the indicated time points and whole cell 
lysates (25 pg of proteins) were analysed 
by Western blotting using antibodies 
against Cdc6, Mcm2, Mcm5, and PCNA. 
Loading was revealed by Coomassie Blue 
staining. Indicated on the top are the 
times after H20 2 treatment and the num­
ber of H20 2 treatments. This experiment 
is representative of two independent ex­
periments. B, H20 2-treated IMR-90 cells 
were harvested at the indicated time 
points and whole cell lysates (25 pg  of 
proteins) were analysed by Western blot­
ting using antibodies against catalase, 
SOD1, HSP70, and HSP27. Loading was 
revealed by Coomassie Blue staining. In­
dicated on the top are the times after 
H20 2 treatment and the number of H20 2 
treatments. This experiment is represent­
ative of two independent experiments.
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600 p.M H20 2 for 2 h with very few lethal effects under the 
conditions used in this study (data not shown). A small fraction 
of the cells that received a single H20 2 treatment were able to 
recover and re-enter the cell cycle. This was manifested by the 
gradual increase of cell number after the treatment. Indeed, 
about 20% of the treated cells incorporated BrdUrd 5 days after 
a first H20 2 treatment (Fig. 1A). We therefore reseeded the 
cells at a ratio of 1:3 4 days after the first treatment and 
performed a second treatment 24 h later. The second H20 2 
treatment caused a permanent cell cycle arrest for over 95% 
cells. As shown in Fig. 1A BrdUrd positive cells decreased to 
less than 4% after the second H20 2 treatment and eventually 
became undetectable 4 days later. Cells stressed with H20 2 
twice eventually developed senescence phenotypic features in­
cluding enlarged and flattened morphology and SA-/3-gal activ­
ity. The fully developed phenotypic features appeared 4 days 
after the second H20 2 treatment when over 95% cells displayed 
SA-/3-gal activity (Fig. IB). This result shows that a second 
oxidative stress is necessary to induce a high incidence of 
premature senescence.
Induction of CM Cycle Checkpoint Proteins in the H20 2- 
trcated Cells—Among the cell cycle checkpoint proteins inves­
tigated, p53 was rapidly increased by oxidative stress (Fig. 2A). 
This was followed by the induction of p21, which is a target of 
p53 (Fig. 2A). Both proteins tended to return to basal level if 
the induction was caused by a single H20 2 treatment. Sus­
tained induction of p53 and p21 was seen in the cells that 
received two H20 2 treatments (Fig. 2A). An elevated p!6 level
was only observed in the cells that received two H20 2 treat­
ments and developed senescent phenotypic features (Fig. 2A).
Dephosphorylation of Rb was also induced by H20 2 treat­
ment (Fig. 2B). The ratio of hyperphosphorylated Rb (pRb) to 
dephosphorylated Rb decreased from 53% in control cells to 
43% in cells a half-hour after a 2-h H20 2 treatment (Fig. 2B). 
The ratio returned to the control level 5 days after the treat­
ment. However, the second H20 2 treatment caused a sustained 
decrease in hyperphosphorylated Rb, which eventually became 
undetectable 1 day after the second treatment and remained 
dephosphorylated thereafter (Fig. 2B).
Decrease of DNA Replication Proteins in the H20 2-treated 
Cells—Cdc6, Mcm2, Mcm5, and PCNA are proteins involved in 
DNA replication (30). Apart from Mcm5 that remained largely 
unaffected, they generally decreased in the H20 2-treated cells 
(Fig. 3A). Cdc6 became undetectable in the cells that received 
two H20 2 treatments and had the senescent phenotype fully 
developed (Fig. 3A). However, a residual amount of Mcm2 and 
a substantial amount of PCNA remained detectable in the 
twice H20 2-treated cells (Fig. 3A).
Effects of Oxidative Stress on Antioxidant Enzymes and 
Stress-response Proteins—Levels of antioxidant enzymes SOD1 
and catalase were not immediately affected by H20 2 treatment, 
but an increase in the levels of these two enzyme proteins was 
clearly detected in the stressed cells when senescent pheno­
typic features were fully developed (Fig. 3B). Levels of the 
stress response protein HSP70 did not change noticeably in the 
H20 2-treated cells, whereas HSP27 showed a slight increase
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F ig . 4 . Changes in  levels o f p53, p21, p l6 , and Mcm2 in repli- 
catively  senescing  cells. Whole cell lysates (25 yg  of proteins) from 
IMR-90 cells of early population doubling, near replicative senescence, 
and 4 weeks into replicative senescence were analyzed by Western 
blotting using respective antibodies. Actin is shown as a loading control. 
This experiment is representative of two independent experiments.
Rb
\ lc m 2
Act in
F ig . 5. M olecular events in  the early tim e points after HaOa- 
treatm ent. H20 2-treated IMR-90 cells were harvested at the indicated 
time points and whole cell lysates (25 p.g of proteins) were analyzed by 
Western blotting using antibodies against p53, p21, pl6, Rb, and Mcm2. 
Actin is shown as a loading control. This experiment is representative 
of two independent experiments.
in the treated cells that also showed high SA-/3-gal activity 
(Fig. 35).
Molecular Events in Replicatively Senescing Cells—To con­
firm that molecular events induced by oxidative stress are 
similar to those in replicatively senescing cells, we examined 
changes in p53, p21, pl6, and Mcm2 in cells when they were in 
early population doubling (PD30), in a near senescent state 
(PD57), and in the fully established replicative senescent state 
(4 weeks into replicative senescence). As shown in Fig. 4, p53 
and p21 increased substantially in the near replicative senes­
cent cells but declined in the fully senescent cells. A significant 
increase in p l6  was only observed in the fully senescent cells 
(Fig. 4). On the other hand, Mcm2 decreased substantially in 
the near replicative senescent cells and was undetectable in the 
fully senescent cells (Fig. 4). These data suggest that time-de­
pendent changes in molecular events observed in the oxida­
tively senescing cells occur similarly in the replicatively senesc­
ing cells but over a much longer time frame.
Molecular Events in Early Time Points after H20 2 Treat­
ment—Oxidative stress is a potential source of DNA damage. 
To investigate the immediate consequences of oxidative stress 
in the cells we examined molecular events in earlier time points 
after H20 2 treatment. Induction of p53 can be detected at the 
end of the 2-h H20 2 treatment (Fig. 5). The highest induction 
was observed 2 h later. Thereafter it declined gradually and 
returned to almost the basal level 5 days later. This rapid 
induction of p53 was repeated after a second H20 2 treatment 
(Fig. 5). Induction of p21 was detected 2 h later than that of p53 
with the highest induction being seen 6 h after the 2-h H20 2 
treatment (Fig. 5). Expression of p l6 was not affected by H20 2 
treatment during this early time course (Fig. 5). H20 2 treat­
ment caused a decrease in the ratio of hyperphosphorylated Rb 
to dephosphorylated Rb in the cells. This change was detected 
in the cells that received treatment for only 1 h (Fig. 5). Den­
sitometry analysis showed that the ratio decreased from 60% in 
the control cells to 46% in the 1-h H20 2-treated cells. Further 
decreases were seen in subsequent time points and the hyper­
phosphorylated Rb eventually became undetectable 10 h after 
the 2-h H20 2 treatment (Fig. 5). The hyperphosphorylated Rb 
reappeared a day after the treatment and returned to the 
control level 5 days later (Fig. 5). The second H20 2 treatment 
caused a similar change in the ratio in the cells at the end of the 
treatment (Fig. 5). In contrast, the DNA replication protein 
Mcm2 remained unchanged during the initial 24 h after the 
first H20 2 treatment with a slight decrease only being seen 5 
days later and 2 h after a second H20 2 treatment (Fig. 5). 
Changes in levels of Cdc6 showed a similar pattern to that of 
Mcm2 (data not shown).
Cessation of DNA Replication Is a Rapid Responsive Event in 
the H20 2-treated Cells and Is Because of the Inhibition of DNA 
Elongation—H20 2 treatment caused a rapid cessation of DNA 
replication as demonstrated by a rapid decrease of BrdUrd 
positive cells in the oxidatively stressed cells (Fig. 6A). A 1-h 
H20 2 treatment caused an almost 10-fold decrease in DNA 
synthesis as compared with the untreated cells (83% BrdUrd 
positive cells). At the end of the 2-h H20 2 treatment BrdUrd 
positive cells decreased to 2.7%. A further decrease was ob­
served 2 h later. A slight recovery was observed 4 h after the 
2-h H20 2 treatment (Fig. 6A). Thus cessation of DNA replica­
tion was a rapid responsive event that preceded any detectable 
changes in protein levels of p53, p21, pl6, Mcm2, and Cdc6 (see 
Fig. 5).
Rapid cessation of DNA replication in the H20 2-treated cells 
suggested that any ongoing DNA synthesis during S-phase 
must have been halted by the stress. To test this hypothesis we 
employed a cell-free in vitro DNA replication assay and com­
pared DNA synthesis in elongation buffer using nuclei pre­
pared from control and 2-h H20 2-treated cells. As shown in Fig. 
65, only 1.8% of nuclei prepared from H20 2-stressed cells were 
capable of DNA synthesis in contrast to the control in which 
about 10% of nuclei were synthesizing DNA (Fig. 65). Note that 
the relatively low percentage of replicating nuclei compared 
with that detected by a 48-h BrdUrd labeling (Fig. 6A) is 
because of the short incubation period of the in vitro replication
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Fig. 6. Acute inh ib ition of DNA syn thesis is because o f inhibition of DNA elongation in  H20 2-treated cells. A, control and 
H20 2-treated IMR-90 cells were incubated with BrdUrd for 48 h and its incorporation was detected with fluorescein-conjugated antibody. The data 
represent the mean of two independent experiments. Insets are merged images from a representative BrdUrd incorporation assay for control and 
1-h H20 2-treated cells. B, nuclei were prepared from control and 2-h H20 2-treated cells and incubated for 3 h in elongation buffer substituted with 
ribonucleotide and deoxyribonucleotide triphosphates and an energy regeneration system. Nuclei are stained with propidium iodide to reveal DNA 
(red) and with fluorescein-streptavidin (green) to detect biotin-dUTP incorporation resulting from in vitro DNA synthesis. Merged images are 
shown. Results are expressed as the percentage of nuclei replicating and summarized in the histogram. The data represent the mean ± S.E. of 
three independent experiments.
reaction (3 h). This suggests that elongation during S-phase 
was inhibited by H20 2 treatment.
DISCUSSION
We have established a unique rodent model in which longev­
ity can be significantly increased or decreased by a minor 
manipulation of maternal diet (19, 20). A causative link be­
tween longevity and cellular senescence in vivo remains to be 
established. As a first step toward elucidating the molecular 
mechanisms underlying cellular senescence and such a pro­
found effect of growth rate during fetal and postnatal develop­
ment on aging, we used an in vitro human fibroblast model to 
study key proteins involved in cell cycle control, DNA replica­
tion, and stress resistance in oxidatively stressed cells. We 
demonstrated that around 20% of cells exposed to a single H20 2 
treatment were able to recover and re-enter the cell cycle de­
spite the initial abrupt cessation of DNA synthesis. This is 
consistent with an earlier report that showed that over 30% of 
the BrdUrd positive cells were detected in single H20 2-treated 
IMR-90 cells (24). Presumably this is because these cells were 
able to repair the DNA damage caused by a single H20 2 treat­
ment. It is not clear as to why some cells are able to recover and 
re-enter cell cycle while the majority become permanently ar­
rested and eventually senesce. One possibility is the heteroge­
neity in DNA damage caused by H20 2 treatment. A high inci­
dence of cell senescence was induced only by a second 
subcytotoxic H20 2 treatment. Indeed, cellular senescence in 
vivo is more likely to be induced by repeated oxidative insults. 
Mitochondria are major producers of reactive oxygen species 
and, at the same time, particularly susceptible to oxidative 
damage. In particular, damage to mtDNA results in faulty
mitochondrial proteins, with a consequent decrease of electron 
transfer, leading to further production of reactive oxygen spe­
cies and thus exposing cells to a vicious circle of oxidative stress 
(31).
In our time course study of oxidative senescence, we ob­
served sequential inductions of cell cycle checkpoint proteins 
including p53, p21, and p l6 with the induction of p l6  coincid­
ing with an increase in the activity of SA-/3-gal. Increased pl6  
expression was also observed in replicative senescent cells. 
This is in keeping with cells undergoing replicative senescence 
in that p53 senses stresses, which then activates expression of 
p21 resulting in cell cycle arrest, whereas p l6 is responsible for 
the maintenance of the senescent state (32, 33). The induced 
p53 and p21 by a single H20 2 treatment tended to return to 
basal levels. The transient induction of p53 may be because of 
the regulation of the p53-Mdm2 feedback loop. In the p53- 
Mdm2 feedback loop, elevated p53 induces Mdm2 transcrip­
tion, which in turn binds p53 and promotes p53 degradation via 
the ubiquitin-proteasome pathway (34). Sustained elevations 
of p53 and p21 were observed only after the cells received a 
second treatment. This suggests that the p53-Mdm2 feedback 
loop may be disrupted by repeated oxidative stress. Louria- 
Hayon et al. (35) recently showed that PML (promyelocytic 
leukemia protein) is critical for the accumulation of p53 in 
response to DNA damage. PML protects p53 from Mdm2-me- 
diated ubiquitination and degradation by prolonging the 
stress-induced phosphorylation of p53 on serine 20 (35). PML is 
essential for the formation of a subnuclear structure called 
PML nuclear bodies, which serve as an important meeting 
point for p53 regulation, including phosphorylation, acetyla-
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tion, and de-ubiquitination (36). Several studies have indicated 
that PML is involved in the induction of premature cell senes­
cence (37-39).
These changes in cell cycle checkpoint proteins in human 
fibroblasts in vitro upon oxidative stress could provide markers 
for detection of cells undergoing oxidative damage and thus 
becoming senescent in vivo. Melk et al. (40) recently showed 
that expression of mRNA for pl6 was undetectable in most 
young rat kidneys, but rose 27-fold during growth and a further 
72-fold during aging (40). p l6 protein was localized to the 
nucleus and increased with age. Concomitantly, lipofusin, an 
age-related pigment and SA-/3-gal also increased with growth 
and aging (40). Similarly, strong correlation between the pl6  
level and age was detected in human kidney (41). It is evident, 
therefore, that aspects of molecular changes observed in senes­
cent cells in vitro do occur in animals and humans in vivo.
It is believed that mitochondrial oxidant generation is one of 
many regulated processes that affect aging. Other factors such 
as antioxidant defenses, and the repair of oxidative damage are 
probably equally important (13). Superoxide dismutase (SOD) 
and catalase are antioxidant enzymes that convert superoxide 
to H20 2 and H20 2 to water, respectively (42). On the other 
hand, heat shock proteins are generally induced in response to 
many environmental stresses including heat, oxidizing condi­
tions, and exposure to toxic compounds, making cells resistant 
to stress-induced cell damage (43). We found that increased 
expressions of SOD 1, catalase, and HSP27 were only detected 
in the H20 2-treated cells when senescent features had fully 
developed. Although the underlying mechanism for the delayed 
stress response is not known, these stress responses may ex­
plain why senescent cells have increased tolerance to stresses 
and are resistant to apoptosis (44).
The present study also showed that H20 2-induced cell senes­
cence is accompanied by the decline of several DNA replication 
proteins including Cdc6, Mcm2, and PCNA. Cdc6 and Mem 
proteins are components of the DNA replication licensing com­
plex, which is assembled during the Gx phase, whereas PCNA 
is a DNA sliding clamp for replicative DNA polymerases, which 
is an essential component of the eukaryotic chromosomal DNA 
replisome during S-phase (30). These proteins undergo cell 
cycle-regulated synthesis, chromatin association, and proteo­
lysis, thereby ensuring that DNA is replicated once and only 
once during a single cell division cycle (30, 45,46). The absence 
of Cdc6 and decreased levels of Mcm2 and PCNA in the H20 2- 
induced senescent cells are probably a consequence of cell cycle 
arrest in the Gj phase (24). The sequential down-regulation of 
Cdc6 and Mcm2 in the oxidatively stressed cells suggests that 
repression of DNA origin licensing is responsible for the loss of 
proliferative capacity upon oxidative stress. The presence of 
residual Mcm2 in cells that received two H20 2 treatments but 
its absence in replicative senescent cells again suggests that 
this protein is tightly correlated with cell proliferative capacity. 
Indeed, we observed that a small fraction of cells retained DNA 
replication potential even after receiving two H20 2 treatments 
(data not shown).
DNA damage rapidly activates DNA checkpoint machinery 
that stop a proliferating cell in the Gt, S, or G2 phases of the cell 
cycle, contributing to the maintenance of genome integrity (47). 
Our cell-free in vitro assay indicated that the abrupt cessation 
of DNA replication caused by H20 2 treatment was because of 
inhibition of ongoing DNA elongation. This rapid inhibition 
was not because of the proteolytic degradation of DNA replica­
tion proteins, as the protein levels of Cdc6, Mcm2, Mcm5, and 
PCNA were not significantly affected immediately after H20 2 
treatment. Although H20 2 treatment stabilized p53 and caused 
subsequent induction of p21, these events only occurred after
cessation of DNA replication had already occurred. It is there­
fore unlikely that p21 is directly involved in the inhibition of 
DNA replication under these conditions. Cicchillitti et al. (48) 
showed that a rapid inhibition of DNA synthesis in human 
umbilical vein endothelial cells (HUVEC) by H20 2 treatment 
was correlated with a rapid hypophosphorylation of the retino­
blastoma family proteins Rb, pl07, and pl30 (48). This event 
did not require p53 or p21 and was not associated with cyclin/ 
CDK down-modulation, but was rather dependent on the ac­
tivity of protein phosphatase 2A (48). It was speculated that, 
upon cell treatment with H20 2, Rb family members might bind 
in their dephosphorylated form directly to the DNA replication 
origins thereby inhibiting their firing (48). Indeed, upon DNA 
damage by y-irradiation, Rb binds to selected DNA replication 
origins, inhibiting DNA replication in S-phase (49). In this 
study we observed a decrease in the ratio of hyperphosphory­
lated Rb to hypophosphorylated Rb in the cells at the earliest 
time point (Fig. 5). It is conceivable, therefore, that dephospho­
rylation of Rb may play an important role in the immediate 
inhibition of DNA replication in the H20 2-treated cells. It also 
remains possible that Rb re-location from certain chromatin 
structures to chromatin locations that contain origins of DNA 
replication contributes to the rapid inhibition of DNA synthesis 
upon oxidative damage (49).
In conclusion, our study demonstrated that oxidative stress 
induced an array of molecular events. This involved increases 
and decreases in the levels of various proteins as well as 
changes in phosphorylation status. These events were time 
dependent and resulted in loss of proliferative capacity and 
ultimately the development of a senescent state that was in­
distinguishable from replicatively senescent cells. One of the 
initial events in this multistep process was the immediate 
inhibition of ongoing DNA elongation that is likely to be con­
trolled by dephosphorylated Rb. Down-regulation of Cdc6 may 
contribute to the early response of cells to oxidative stress by 
inhibiting the pre-replicative complex from licensing during 
the G1 phase. In contrast down-regulation of Mem proteins 
appeared to constitute a late response in the process. Sustained 
loss of proliferative capacity and high induction of cellular 
senescence are achieved by a second oxidative stress that is 
presumably necessary to cause irreparable DNA damage in 
human fibroblasts.
REFERENCES
1. Hayflick, L. (1965) Exp. Cell Res. 37, 614 -6 3 6
2. Cam pisi, J . (2001) Exp. Gerontol. 36, 607-618
3. C hiu  C. P., and H arley, C. B. (1997) Proc. Stx\ Exp. Biol. Med. 214, 99 -1 0 6
4. C hen, Q. M., and  Ames, B. N. (1994) Proc. Nall. Acad. Sci. U .S .A . 91,
4130 -4134
5. S errano , M., Lin, A. W., M cCurrach, M. E., Beach, D., and  Lowe, S. W. (1997)
Cell 88, 593-602
6. Robles, S. J., and  Adami, O. R. (1998) Oncogene 16, 1113-1123
7. Zhu, J . ,  Woods, D., McM ahon, M., and  Bishop, J . M. (1998) Genes Deu. 12,
2997-3007
8. S herr, C. J ., and  D epinho, R. A. (2000) Cell 102, 407-410
9. H alii well, B. (2003) FEBS U tt.  540, 3 - 6
10. P arrine llo , S., Sam per, E., K rtolica, A., G oldstein, J ., Melov, S ., and  Cam pisi,
J . (2003) Nat. Cell Biol. 5, 741-747
11. M artin-R uiz, C., S aretzki, G., P etrie , J ., LadhofT, J ., Jeyapalan , J ., Wei, W.,
Sedivy, J ., and  von Zglinicki, T. (2004) J. Biol. Chern. 279, 17826-17833
12. H arm an , D. (2001) Ann. N. Y. Acad. Sci. 928, 1-21
13. Beckm an, K. B., and  Ames, B. N. (1998) Physiol. Rev. 78, 547-581
14. F inkel, T., and Holbrook, N. J . (2000) Nature 408, 239-247
15. Lin, Y. J ., Seroude, L„ and  Benzer, S. (1998) Science 282, 943-946
16. Migliaccio, E., Giorgio, M., Mele, S., Pelicci, G., Reboldi, P ., Pandolfi, P. P .,
Lanfraneone, L., and  Pelicci, P. G. (1999) Nature 402, 309-313
17. H onda, Y„ an d  H onda, S. (2002) Ann. N. Y. Acad. Sci. 959, 4 6 6 -4 7 4
18. H ales, C. N „ and  O zanne, S. E. (2003) J. Physiol. 547, 5-10
19. Jenn ings, B. J ., O zanne, S. E., Dorling, M. W., and  H ales, C. N. (1999) FEBS
Lett. 448, 4 - 8
20. O zanne, S. E., and H ales, C. N. (2004) Nature 427, 411-412
21. Cherif, H., T arry , J . L., O zanne, S. E ., and  H ales, C. N. (2003) Nucleic Acids
Res. 31, 1576-1583
22. T oussain t, O., D um ont, P., R em ade, J ., D ierick, J . F „  P ascal, T., F ripp ia t, C.,
M agalhaes, J . P ., Zdanov, S., and C hain iaux, F. (2002) ScientificWorld J. 2, 
230-247
49446 Molecular Events in Oxidatively Senescing Cells
23. O ikaw a, S ., and K aw anish i, S. (1999) FEBS Lett. 453 , 365-368
24. C hen, Q. M., B artholom ew , J . C., C am pisi, J ., Acosta, M., R eagan, J .  D., and
Ames, B. N. (1998) Biochem. J. 332, 43-50
25. Chen, Q. M., Tu, V. C., and  Liu, J . (2000) Biogerontology 1, 335-339
26. D im ri, G. P., Lee, X., Basile, G., A costa, M., Scott, G., Roskelley, C., M edrano,
E. E., L inskens, M., Rubelj, I., P ere ira-S m ith , O., Peacocke, M., and  
Cam pisi, J . (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 9363-9367
27. S toeber, K., H alsall, I., F reem an , A., Sw inn, R., Doble, A., M orris, L., Colem an,
N., Bullock, N „ Laskey, R. A., H ales, C. N., and  W illiam s, G. H . (1999) 
Lancet 354, 1524-1525*
28. S toeber, K., M ills, A. D., K ubota, Y„ K rude, T., Rom anowski, P ., M arheineke,
K., Laskey, R. A., and W illiam s, G. H. (1998) EM BO ,J. 17, 7219-7229
29. K rude, T., Jackm an , M., P ines, J ., and  Laskey, R. A. (1997) Cell 8 8 ,1 0 9 -1 1 9
30. Bell, S. P., and  D utta , A. (2002) Annu. Rev. Biochem. 71, 333-374
31. G enova, M. L., P ich, M. M., B ernacchia, A., B ianchi, C., Biondi, A., Bovina, C.,
F alasca, A. I., Form iggini, G., C astelli, G. P., and  Lenaz, G. (2004) Ann. 
N. Y. Arad. Sci. 1011, 86 -1 0 0
32. l ta h a n a , K., D im ri, G., and  Cam pisi, J . (2001) Eur. J. Biochem. 268,
2784-2791
33. S te in , G. H ., D rullinger, L. F., Soulurd, A., and  Dulic, V. (1999) Mol. Cell. Biol.
19, 2109-2117
34. O ren, M., D am alas, A., G ottlieb, T., M ichael, D., Taplick, J ., Leal, J .  F,, M aya,
R., M oas, M„ Seger, R., Taya, Y., and Ben-Ze’Ev, A. (2002) Ann. N. Y. Acad. 
Sci. 973, 374-383
35. Louria-H ayon, I., G rossm an, T., Sionov, R. V., A lsheich, O., Pandolfi, P. P ., and
H aup t, Y. (2003) J. Biol. Chcm. 278, 33134-33141
36. Salom oni, P., and Pandolfi, P. P. (2002) Cell 108, 165-170
37. Pearson , M., Carbone, R., S ebastian i, C., Cioce, M., Fagioli, M., S aito , S.,
H igashim oto, Y., A ppella, E ., M inucci, S., Pandolfi, P. P ., and  Pelicci, P. G. 
(2000) N alure  406, 207-210
38. Ferbeyre, G., de S tanch ina , E ., Q uerido, E ., B ap tiste , N., P rives, C., and  Lowe,
S. W. (2000) Genes Dev. 14, 2015-2027
39. Langley, E., Pearson, M., F a re t ta , M., B auer, U. M., F rye, R. A., M inucci, S.,
Pelicci, P. G„ and  K ouzarides, T. (2002) EMBO J. 21, 2383-2396
40. M elk, A., K ittikow it, W., Sandhu , I., H allo ran , K. M., G rim m , P ., Schm idt,
B. M., and H alloran , P. F. (2003) Kidney Int. 63, 2134 -2143
41. M elk, A., Schm idt, B. M., Takeuchi, O., S aw itzki, B., R ayner, D. C., and
H allo ran , P. F. (2004) Kidney Int. 65, 5 1 0 -520
42. Droge, W. (2002) Physiol. Rev. 82, 4 7-95
43. Takayam a, S., Reed, J . C., and  H om m a, S. (2003) Oncogene 22, 9041-9047
44. S asak i, M., K um azaki, T., Takano, H ., N ish iyam a, M., and  M itsu i, Y. (2001)
Mech. Ageing Dev. 122, 1695-1706
45. Blow, J . J ., and H odgson, B. (2002) Trends Cell Biol. 12, 72-78
46. Stoeber, K ,  T lsty , T. D., H apperfie ld , L., T hom as, G. A., Romanov, S., Bobrow,
L., W illiam s, E. D., and  W illiam s, G. H. (2001) J. Cell Sci. 114, 2027-2041
47. Nyberg, K. A., M ichelson, R. J ., P u tn am , C. W., and  W einert, T. A. (2002)
Annu. Rev. Genet. 36, 617 -6 5 6
48. C icchillitti, L., F asanaro , P., Biglioli, P., Capogrossi, M. C., and  M arte lli, F.
(2003) J. Biol. Chem. 278, 19509-19517
49. Avni, D „ Yang, H., M arte lli, F., H ofm ann, F., E lSham y, W. M., G anesan , S.,
Scully, R., and  Livingston, D. M. (2003) Mol. Cell 12, 735-746
